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”Ithaka
As you set out for Ithaka hope the voyage is a long one, full of adventure, full of discovery.
Laistrygonians and Cyclops, angry Poseidon dont be afraid of them: you’ll never find things
like that on your way as long as you keep your thoughts raised high, as long as a rare excitement
stirs your spirit and your body. Laistrygonians and Cyclops, wild Poseidon you won’t encounter
them unless you bring them along inside your soul, unless your soul sets them up in front of
you.
Hope the voyage is a long one. May there be many a summer morning when, with what pleasure,
what joy, you come into harbors seen for the first time; may you stop at Phoenician trading
stations to buy fine things, mother of pearl and coral, amber and ebony, sensual perfume of
every kind as many sensual perfumes as you can; and may you visit many Egyptian cities to
gather stores of knowledge from their scholars.
Keep Ithaka always in your mind. Arriving there is what you are destined for. But do not hurry
the journey at all. Better if it lasts for years, so you are old by the time you reach the island,
wealthy with all you have gained on the way, not expecting Ithaka to make you rich.
Ithaka gave you the marvelous journey. Without her you would not have set out. She has
nothing left to give you now.
And if you find her poor, Ithaka wont have fooled you. Wise as you will have become, so full of
experience, you will have understood by then what these Ithakas mean.”
C.P. Cavafy, Greek poet, 1863-1933
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Abstract
Motor Neuron Diseases (MND) including Amyotrophic Lateral Sclerosis (ALS) and Spinal
Muscular Atrophy (SMA) are neurodegenerative diseases that can cause progressive paralysis
and premature death, while there are no treatments available up to date. Gene therapy us-
ing lentiviruses has been successful at alleviating symptoms and extending survival in murine
models of both. Restricting transduction to specific cells, is critical for safe and efficient gene
therapy. The aim of this study was to generate novel lentiviral vectors with tropism to motor
neurons (MNs) using surface engineering, that involves incorporation of a fusogenic glycoprotein
(mutated sindbis G) and an antibody recognizing a cell-surface receptor, onto the lentiviral sur-
face. Antibodies against rat Thy1.1, rat p75NTR (Low Affinity Nerve Growth Factor Receptor)
and mouse CAR (Coxsackie and adenovirus receptor) receptors expressed on the presynat-
pic terminal of the neuromuscular junction (NMJ) were cloned and used to surface engineer
high titer lentiviral vectors (αThy1.1, αp75NTR and αCAR). These vectors preferentially trans-
duced cell lines expressing these receptors and primary motor neuron cultures compared to
non-targeted controls. The ability of these vectors to be transported retrogradely and trans-
duce MNs was demonstrated in vitro in compartmented microfluidic cultures in fixed and live
imaging experiments. Tropism of these vectors was assessed in vivo in the rat brain following
intrastiatal injections. In vivo intramuscular delivery of CAR targeted lentiviral vectors in
tibialis anterior of mice lead to transduction of motor neurons in ventral spinal cord. Trans-
duction of spinal cord was further demonstrated by in vivo bioluminescence imaging studies
in mice injected intramuscularly with the CAR targeted vectors. This is the first ever demon-
stration that surface engineering can confer novel trafficking and transduction characteristics
to lentiviral vectors. These targeted lentiviral vectors have superior trafficking, transduction
and specificity for MNs than previously used lentiviral vectors, making them good candidates
for non-invasive CNS -targeted delivery of therapeutics in MN diseases.
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Introduction
1.1 General Background
1.1.1 Gene Therapy
Gene therapy is the introduction of a functional gene, the alternation or removal of a defective
one within an individual’s cells and biological tissues to provide a therapeutic advantage [1]. The
original principle of gene therapy is known as ’gene supplementation’, but in recent days it has
been extended to cover any strategy for disease treatment. Human Gene Therapy utilizing viral
vector systems has gained considerable attention over the past two decades. It is considered one
of the most promising approaches developed for disorders that currently lack effective treatment,
including both acquired (i.e. cardiovascular, cancer and AIDS) and inherited (cystic fibrosis) [2].
This has a promising therapeutic advantage compared to the traditional medicine by achieving
long-lasting therapeutic function in target tissue without systemic side effects. Even though the
concept of gene therapy is simple, the success relies substantially on the development of selective
and efficient gene transfer vectors [3]. Gene therapy in the central nervous system (CNS) is
particularly challenging due to the post mitotic nature of the neuronal cells and the restricted
accessibility of the brain. A number of neurological disorders are disseminated throughout the
brain and the spinal cord, posing considerable difficulties in matter of access. The blood-brain
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barrier efficiently prevents the systemic delivery/ access of viral vector molecules; therefore,
invasive brain surgery is often required. Neural architecture itself is promising for designing
therapy. The morphology of each neuron and the interconnected networks they create make the
nervous system particularly appropriate for vector mediated gene transfer; therefore delivery
at one site can lead to effect at a distal site, if retrograde transport is possible [4].
1.1.2 Ex vivo and In vivo gene delivery
In gene therapy there are two primary approaches for gene delivery. Ex vivo gene therapy
relies on the ability to isolate stem, progenitor or differentiated cells from a patient followed by
cultured cell modification [5] and re-implantation of these modified cells to the patient, which
allows establishment of transient or more stable infusion of progeny cells. Whereas, in vivo gene
delivery, allows a simple direct transfer of transgene into target cell of patient, which provides
a better way of treatment. However, toxicity related to the vector needs to be considered and
overcome [6]. Additionally, ex vivo gene therapy application is restricted to certain cell types
(lymphocytes, fibroblasts, myoblasts, stem cell and hepatocytes, etc), therefore it limits the
potential to treat certain diseases that require targeting of specific tissue like heart, brain and
lungs [7].
1.1.3 Ideal gene delivery vehicle
For a successful gene therapy protocol, the exogenous therapeutic gene has to specifically,
efficiently and stably be incorporated into the target cell. An ideal gene delivery vector should
therefore have the following properties, as previously proposed by Verma and Somia [1, 8].
Ideally, the production of a gene delivery vector should be simple. The vector should be able to
be produced in high titers, required for human gene therapy, and preferable have the ability to
be targeted to specific molecules within the host’s cells. Moreover it should have large cloning
capacity, to carry small genes such as insulin (350 bp) and large genes like dystrophin (12 kb).
Upon delivery, it should not elicit any significant immune response which would lead to its
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degradation from the host immune system. The vector should specifically target a tissue or a
cell type limiting any non-specific tissue targeting. Most importantly, the vector should have
the ability to transduce both dividing and non-dividing cells such as neurons, hepatocytes and
myocytes. The transgene carried by the vector needs to be integrated specifically at a defined
locus of host’s chromosomal DNA or maintained in the nucleus as an extrachromosomal episome
dividing and segregating with the cell. Finally, a vector should be able to induce stable and
long-term transgene expression as certain diseases require sustained and lifelong expression of
the therapeutic gene to achieve treatment. Unfortunately, none of the existing viral and non-
viral vectors combine all the above characteristics, consequently tremendous effort are being
made to improve the efficacy, specificity and safety of current vectors aiming to develop an
ideal gene deliver vector for successful disease treatment.
1.1.4 Gene delivery systems: Viral and non-viral vectors
Gene delivery into cells can be achieved utilizing either viral or non-viral vectors. Despite the
fact that gene therapy with viral vectors appears to be the most promising approach, there
are several approaches for delivery of specific gene sequences into target cells which involve
non-viral vectors [9]. A vector, as a gene delivery system, is expected to fulfil certain criteria
including it’s ability to (i) protect the transgene that carries, from degradation by nucleases
and intracellular matrices expressed within the target cell(s), (ii) ensure trangene transport
across the plasma membrane into the nucleus of the target cell(s), and (iii) cause no adverse
effect/ immune response on the host [9].
Non-viral vector
Non-viral vectors are generally considered to be safer than viral vectors, since these vectors do
not elicit a significant immune response and reduce the risk of a possible infection. The simplest
approach of non-viral vector in known as ’naked plasmid DNA’ and it has been demonstrated
that direct injection of naked plasmid DNA, aiming to correct genetic defects, has resulted in
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prolonged transgene expression in a number of mice studies [10, 11, 12, 13]. However, systemic
delivery of naked plasmid DNA can cause problems due to rapid degradation and neutralization
from endogenous DNAnase [14]. In addition, the naked plasmid is naturally restricted to target
cell transfection. The phosphate groups of the deoxyribose rings of DNA set an overall negative
charge, which consequently limits the potential for non-viral vector entry into target cells
because of the electrostatic interaction with the anionic lipid-bilayer of the cell membrane [9].
To address this, naked DNA is coupled to cationic carrier molecules, such as liposomes, in order
to neutralize its negative charge, aiming to improve cell membrane endocytosis and therefore
enhance its transfection efficiency (lipoplex non-viral vector). Moreover, non-viral gene delivery
systems include physical approaches with carrier-free gene delivery including needle injection,
electroporation, gene gun, ultrasound and hydrodynamic delivery (reviewed in [9]). Chemical
approaches also utilize vectors based on synthetic or naturally occurring compounds for the
delivery of the transgene into the nucleus [15].
Unfortunately, the fact that canonical plasmid-based vectors cannot achieve sustained thera-
peutic levels of transgene expression in vivo dramatically limits their gene therapy applications.
However, minicircle (MC) DNA vectors that are devoid of the bacterial backbone (BB) are able
to persistently express the transgene 10-1000-fold more than a conventional plasmid in quies-
cent tissues in vivo [16, 17, 18]. Although a robust system to produce minicircle DNA vectors
has been developed [19], the production method is quite limiting since it involves the use of a
specific plasmid-bacterial host and time consuming compared to conventional plasmid prepa-
ration. Nonetheless, recently it has been proven that silencing is observed when 1kb or more of
DNA is placed outside the transcription unit (between the 5’-end of the promoter and 3’-end
of polyA site) even when the bacterial plasmid DNA sequences are replaced with random DNA
sequences [20]. To overcome this, alternative plasmid propagation processes have been devel-
oped, where the bacterial elements essential for plasmid replication and selection are placed
within the transcritpion unit (e.g. made part of the 3’UTR). In addition, this novel vector
system called ’mini-intronic plasmid’ (MIP), provides 2-10-times higher transgene expression
compared to minicircle vectors bearing the same expression cassette, both in vitro and in vivo.
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Figure 1.1: Schematic diagram of viral vector based gene therapy. Figure modified from
Thomas et al.,2003.
Viral vectors
Viral vectors provide a highly efficient tool for gene delivery to the nervous system, with broad
applications in basic research and genetic therapy. Viral vector technology exploits the natural
features of the virus life cycle to genetically engineer a recombinant virus particle that infects
and introduces desired transgenes into target cells; yet is replication incompetent. Gene therapy
approaches utilizing viral vectors include in vivo and in vitro expression of normal or mutant
proteins within the host cell or inhibition of target protein expression through transcription of
antisense RNA, ribozymes or small inhibitory RNAs [21]. Generally, viral genome consists of
coding regions and cis-acting regulatory elements; the coding sequence encodes viral structural
and regulatory proteins which are essential for the production of infectious viral particles [22].
Furthermore, cis-acting sequences are important in viral genome packaging and integration into
host cell. In order to generate a replication defective viral vector, the coding region can be re-
placed with a therapeutic gene, leaving the cis-acting sequence intact (Figure 1.1). A producer
cell line is used to provide structural viral components in trans, from separate/additional ex-
pression cassettes, which allows the production of non-replicating virus carrying a therapeutic
gene.
Successful gene therapy protocols require specific, efficient and stable incorporation of the ex-
1.1. General Background 7
ogenous therapeutic gene into the target cell. In this respect, there are a large number of
viral vectors with unique characteristics useful for gene therapy, as delivery systems offering
important advantages over standard germ-line transgenic techniques. These vectors can be
used in virtually any mammalian system and administered to adult animals to generate local-
ized disease models. Viral vectors can efficiently express either single or multiple transgenes
and transduction does not seem to interfere with normal function [4]. Since viral vectors can
incorporate a wide variety of regulatory elements, it is possible to achieve short or long-term
transgene expression and to target specific regions of the nervous system. Temporal and spa-
tial control can be achieved by combining transgenic knock-in/knock-out strategies with virus
vectors [23]. Indeed, recombinant viruses such as adenoviruses, adeno-associated viruses, her-
pes viruses, poxviruses, retroviruses and recently lentiviruses have successfully been used in
applications both in clinical trials and laboratories [24, 25, 26, 27].
Integrating and non-integrating viral vectors
Viral vectors are divided in two major groups, the integrating (with the ability to integrate
their genome into host cell chromosomal DNA) and the non-integrating vectors. Most widely
used integrating viral vectors are based on adeno-associated viruses (AAV) and retroviruses
(lentivirus and foamy virus). Non-integrating vectors like adenovirus (Ad) and herpes simplex
virus type 1(HSV-1) and -2 (HSV-2) deliver their genome into the nucleus of the target cell
which remains ’unintegrated’ as an extrachromosomal episome [8].
1.1.5 Choosing the right vector
As mentioned above, an ideal vector for gene delivery should be able to: accommodate the
transgene of interest, mediate gene transfer of the desired efficiency and specificity, induce
long-term and stable expression, mediate regulated expression and elicit small or negligible
immune response in vivo. In other words a vector, which combines the best targeting as well
as the best form of delivery by avoiding toxicity while achieving the strongest efficacy. Since
these characteristics are difficult to find in a single system, the appropriate viral vector system
should be carefully selected for each specific application as they differ in terms of cloning
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capacity, tropism, transgene expression duration, biosafety, immunogenicity and challenges in
production method (Table 1.1).
A large number of viruses exists, bearing unique characteristics particularly useful for gene
therapy. Indeed, recombinant viruses such as adenoviruses, adeno-associated viruses, herpes
viruses, poxviruses, retroviruses and recently lentiviruses have been used in applications both
in clinical trials and laboratories. Vectors based on retroviruses such as MLV were among
the first to be produced [29] and used in gene therapy applications. Despite many of their
advantageous characteristics as gene delivery vehicles that stably integrate into the target cell
genome, they encounter a major drawback, as they can not transfer genes in non-dividing cells
such as neurons.
On the other hand, lentiviral vectors which are based on the single stranded RNA (ssRNA)
lentiviruses (a subgroup of the retrovirus family) are among the most promising approach for
the treatment of neurological disorders as they are able to integrate their genome into both
mitotic cells, such as glia, and post-mitotic cells, such as neurons [30, 31, 32].
Table 1.1: Viral vectors commonly used in neuroscience and their properties
Viruses Features References
Lentivirus Infects dividing and non dividing cells; large cloning
capacity of 8-10 kb; long-term transgene expression
(up to years); flexible tool for many applications (i.e.
pseudotyping, targeting and can incorporate regula-
tory elements); capable of retrograde transport when
pseudotyped with rabies glycoprotein
[4]
Adenovirus Efficiently infects neurons, astrocytes, oligoden-
droglia, ependymal cells, the choroidal epithe-
lium and microglia, retrograde axonal transport
from nerve terminals; transgene capacity 8-30 kb;
trangene expression: week/months
[24]
Adeno-associated virus Various serotypes infect some types of neurones i.e.
purkinje cells of the cerebellum or ependymal cells;
non-pathogenic; no immune response; does not in-
tegrate into the genome but stably persists in ex-
trachromosomal sites; very small cloning capacity of
∼ 4.6 kb; trangene expression: years
[25]
Herpes virus Broad host range; efficiently infects neurons, highly
efficient retrograde and anterograde transport, large
insert capacity (30 kb); trangene expression: weeks-
year
[28]
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1.1.6 Retroviral vectors
Retroviridae is a family of single stranded (ss) RNA viruses [33]. The retroviral particle (100nm)
is comprised of a copy of positive strand RNA, which together with essential enzymes are en-
countered within a capsid protein forming the viral core [34]. A layer surrounding the core is
formed by matrix proteins, which interact with a cell-derived lipid envelope where viral enve-
lope glycoproteins (env) are incorporated, mediating interaction with specific cellular receptors.
Based on genomic structure retroviruses can be subdivided into simple and complex retro-
viruses which consist of three different groups: oncoretroviruses, lentiviruses and spumaviruses
[35](Figure 1.2). Oncoretroviruses have the simplest proviral DNA structure which encodes
only gag (capsid nucleocapsid and matrix protein), pol (reverse transcriptase, integrase (IN)
and protease) and env (viral envelope glycoprotein) structural genes that are highly conserved
in all retroviruses [36]. Lentiviruses, HIV-1 in particular, encode six additional viral proteins
(Vif, Vpr, Vpu, Tat,Rev and Nef), important for viral replication [37]. Tat (mediates transacti-
vation of viral transcription) and rev (nuclear export of unspliced viral RNA) accessory proteins
are conserved in all lentiviruses [38, 39]. Finally, spumaviruses contain three additional open
reading frames (bel-1, bel-2 and bel-3) which act as co-activators for viral transcription [40].
Additionally, the 5’ and 3’-end of proviral DNA in all retroviruses are flanked by long terminal
repeats (LTR) which contain cis-acting sequences that are crucial for viral gene expression (pro-
moter, transcription terminator and polyadenylation signals) (Donald et al,. 2004). Moreover,
the attachment sites (att) located at downstream of LTRs are necessary for viral integration,
whereas additional cis-acting signals are involved in reverse transcription. The polypurine
tract (PPT), primer binding sites (PBS) and encapsidation signal psi (ψ) packaging sequence
are involved in assembly of the viral particle [41].
In retroviral life cycle several steps can be distinguished. However, basic molecular virology
distinguishes two phases in the life cycle of a virus: infection and replication. During infection
upon binding of the vector to a specific receptor on the target cell surface and membrane
fusion, the viral genome enters the cell and starts to express essential viral proteins using the
host cell machinery. During replicative phase all viral proteins produced are packaged into
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Oncoretroviruses
Lentiviruses
Spumaviruses
Figure 1.2: Schematic presentation of the proviral DNA organization of retroviruses. Pre-
sentation of the MLV, HIV -1 and FV proviral genome. (Adapted from Kootstra et al., 2003 )[3]
.
virions. Consequently, what gene therapy utilizes, is transduction, where through infection
functional genetic information is applied into the target cell but compared to the wild type
virus infection; transduction is abortive and non-replicative [32]. In detail, a transgene, in
the form of RNA, is carried in the retrovirus. Upon viral transduction into a target cell the
viral RNA is reverse transcribed into double stranded DNA (dsDNA) by the enzyme reverse
transcriptase (RT). The proviral dsDNA is permanently integrated into host chromosomal DNA
through the viral enzyme integrase (IN) that is directed by LTRs [42]. This provides a stable
and long-term integration and naturally prolongs the expression of the therapeutic gene and
minimizes the chance of gene re-assortment. However, not all retroviruses are able to transduce
non-dividing cells. Active cellular transport mechanisms are required in order to overcome the
barrier of the nuclear membrane and achieve nuclear import of the viral DNA [43]. In contrast
to dividing cells, where disruption of the nuclear membrane provides access to the chromosomes,
passive diffusion through the nuclear pore seams to be the only option for nuclear import in
non-dividing cells [44].
1.1.7 Lentiviral vectors
The major advantage of lentiviruses is their ability to transduce both dividing and non-dividing
cells. This unique characteristic allows lentiviruses to integrate and replicate efficiently in post-
mitotic cells such as neurons [27, 32], and make them particularly attractive tools for gene
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therapy. Upon target cell infection, the fusion event between viral envelope and host membrane
allows the release of nucleoprotein core, which uncoats to deliver its viral RNA into cytoplasm.
In the cytoplasm, DNA synthesis occurs through the reverse transcription complex (RTC)
[45]. For lentiviruses and specifically HIV-1, nuclear import is facilitated by the pre-integration
complex (PIC), which is composed by viral and cellular proteins associated with the viral
DNA. PIC transports through the nuclear pore complex via microtubule trafficking, utilizing
the host’s import machinery. Once PIC enters the nucleus, reverse transcribed proviral DNA
is integrated into host chromosomal DNA by the enzyme integrase (IN) [46] (Figure 1.3A).
A. B.
Figure 1.3: A long way from cell entry to DNA integration. (A) Schematic diagram of the
route of a lentivirus infection pathway. (B) Schematic diagram of HIV-1 interacting proteins and PIC
nuclear import. (Adapted from Suzuki and Craigie, 2007 [46]).
Although the precise mechanism for PIC nuclear entry remains enigmatic, studies have illus-
trated that IN can govern the nuclear transport of PIC in a two step mechanism. Initially by
recruiting karyophilic Vpr and matrix protein into the viral nucleoprotein complex which is rec-
ognized by the cell nuclear import machinery that actively transports PIC through the nuclear
pore [47, 48]. Recent studies have identified two additional cis-acting sequences known as the
central polypurine tract (cPPT) and the central termination sequence (CTS) which are located
in lentiviral genome and are involved in the formation of central DNA flap. The DNA flap
acts as a cis-determinant for the nuclear import of HIV-1 genome. This is further confirmed by
the fact that a cPPT deficient mutant virus results in defective nuclear localization of the PIC
[44] (Figure 1.3B). Therefore, the viral factors matrix (MA), Vpr, integrase (IN) and cPPT are
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considered as karyophilic determinants of HIV-1 for PIC transport across nuclear pore complex
[46].
1.1.8 Lentiviral vectors in gene therapy
Lentiviral vectors combine the advantages of large cloning capacity (8-10 kb) with those of
stable integration of a transgene into the chromosomes of target cells resulting in long-term
expression and an attractive safe profile due to minimal inflammatory response that does not
compromise the viability of their target. This is of high importance for gene therapy applica-
tions for neurodegenerative diseases, since they often require invasive surgery, where repetitive
administration of the vector is impractical. Therefore sustained therapeutic expression is the
key to a successful treatment protocol. Since their initial development, lentiviral vector systems
have constantly been improved, and proven to successfully transduce dividing and non-dividing
cells [49] mediating neuronal gene expression in vivo [50, 51, 52]. Lentiviral vectors can be
divided into two groups, the ones derived from primates such as human and simian immunod-
eficiency viruses (HIV and SIV respectively) and ones derived from non-primate viruses, such
as equine infectious anemia virus (EIAV), feline and bovine immunodeficiency viruses (FIV,
BIV respectively) and others (reviewed in [29]). Although vectors based on HIV-1 are by far
the most extensively used in the nervous system and retina, common gene therapy applications
utilize gene transfer vector systems based on both groups. Modified lentiviral production in
serum-free culture conditions, followed by purification through a sucrose gradient are proven
to reduce lentivirus induced immunogenicity without affecting transduction efficiency [53]. De-
spite their several advantages, there are certain safety issues regarding the use of lentiviral
vectors. The risk of insertional mutagenesis in the host DNA which may lead to oncogene-
sis [54] is of major concern. There are studies reporting increased incidences of oncogenesis
following gene transfer with EIAV derived lentiviral vector in neonatal mice [55]. There is
also concern regarding the possibility to generate replication-competent virus. Vector systems
derived from different lentiviruses have been further refined to very high safety and efficiency
levels [56, 57, 58].
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Lentiviral vectors are particularly useful for mediating temporally and regionally controlled
genetic modifications in the nervous system. Latest generation of lentiviral vectors can accom-
modate large transgenes (up to 10kb) and utilize only up to 1kb of non-coding viral DNA, hence
expressing only the transgene cassette [59]. Lentiviral vectors used in research and clinical ap-
plications are referred to as minimal self inactivating (SIN) vectors. They are typically produced
by co-transfection of cell lines (e.g. human embryonic kidney 293T cells) with (i) the packaging
plasmids encoding the pol, gag, rev and tat viral genes and containing the rev-response element;
(ii) a plasmid encoding the envelope gene; and (iii) the lentiviral vector plasmid containing
the psi (ψ) packaging sequence and the transgene inserted between the lentiviral LTRs to allow
integration into the target cell [21]. The 3’LTR that causes inactivation of the upstream LTR,
is deleted, diminishing the risk of replication-competent lentiviruses and promoter interference
[59]. The entire viral coding regions are removed from the viral genome and the genes es-
sential for production are provided in trans from separate/additional expression cassettes [4].
Optimum efficiency can be obtained by using gag-pol gene that is codon-optimized (altered
to preferred codon usage for efficient expression when introduced into mammalian cells) [60].
Usage of codon optimized trangenes is desirable, since codon-optimisation has not only been
shown to improve translational efficiency [60], but also eliminates various signals/factors affect-
ing RNA transcription control and RNA stability, which can negatively affect gene expression
[61]. Since there are no residual lentiviral promoters or enhancers remaining in the genome in
SIN vectors, the transgene is expressed from an internal enhancer-promoter that can be varied
depending on the application.
The typical expected titer of an unconcentrated vector is about 106-107 TU/ml (transducing
units/ml), which can be increased further to 109-1010 TU/ml upon ultracentrifugation or ultra-
filtration. Despite the fact that this method results in high titer LV, it is challenging to scale up
production which is often required for certainin vivo applications. To overcome this limitation,
stable packaging cell lines have been developed that stably express the essential viral genes
necessary for viral production. However, developing high titer stable producer cell lines for
LV production, has also proven to be challenging, mainly due to intrinsic cytotoxicity of viral
proteins. To overcome this limitation, inducible producer cell lines were recently developed, in
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Figure 1.4: Schematic representation of HIV-1-derived packaging constructs. At the top a
schematic representation of the HIV provirus is shown. First-, second- and third- generation packaging
constructs. All accessory proteins related to virulence and and rev gene are deleted from 2nd and 3rd
generation packaging constructs. ψ, packaging signal; SD, splice donor; SA, splice acceptor. (Adapted
from [32])
which expression of potentially cytotoxic proteins is tightly regulated at transcriptional level by
inducible promoters [62, 63, 64, 65, 66]. These cell lines facilitated large-scale vector production,
however they have not so far been used in clinical trials.
1.1.9 Gene Delivery
Gene delivery via lentiviral vectors requires entry of the virus into the target cell. Lentiviral
vector-mediated gene transfer to specific neuronal populations can be achieved in many ways.
Briefly, by direct injection at the site of interest, by remote delivery using vectors that can
be retrogradely transported, by modification of the vectors capsid (pseudotyping) or by in-
corporation of transcriptional elements that regulate gene expression. Furthermore, lentiviral
vector transduction does not appear to affect the electrophysiological properties of neurons [67].
Many types of therapeutic genes are being evaluated including trophic factors and enzymes,
intrabodies and siRNA targeted to defective intracellular proteins and genes. The versatility
of lentiviral vectors allows ex vivo engineering of stem cells or differentiated cells for trans-
plantation, direct injection at the target site, and remote delivery and targeting via retrograde
transport. Approaches can be broadly grouped into those that aim for widespread delivery of
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the transgene/secreted protein throughout the brain and/or spinal cord and those that target
specific cell populations.
Direct injection
Lentiviral vectors are capable of neuronal delivery in vivo. Transduction is reported to be stable
in different tissues with number of transduced cells limited by volume constrains (dependent on
the target tissue), the titer of the vector and its efficiency of infection [21]. Local administration
can deliver high titers of vector into the target region. Upon direct in vivo injection lentiviral
vectors were proven to transduce most cell types within the central nervous system, including
neurons, astrocytes, glial cells, adult neuronal stem cells and oligodentrocytes [4, 68, 69, 70].
Moreover, transduction resulting from lentiviral vectors remains essentially confined to the
area near the injection site. Implantation of transduced cells into the parenchyma, ventricles or
vasculature of the central nervous system has been attempted [21]. Direct intra-parenchymal
injections of lentiviral vector into the CNS has proven beneficial for some cases of Lysosomal
Storage Diseases (LSD) (reviewed in [69]). However, the widespread pathology of the disease
in combination with the poor diffusion of LVs upon these injections make this strategy an
ineffective approach for clinical use for most LSD.
To overcome the lack of specificity, modification of the viral envelope (altering the vector
tropism) or application of cell-specific promoters were introduced. Examples of effective gene
transfer upon direct spinal cord injections of rabies-G (RabG) pseudotyped lentiviral vectors
into SOD1 mice and rat spinal injury models has also been reported [71, 72]. Nonetheless
direct intraspinal injection in human and especially in ALS patients, could be impractical and
challenging because the numerous injection sites that would be required would greatly increase
the probability of morbidity [73, 74].
1.1.10 Pseudotyping
Alternative approaches utilize specific features of lentiviral vectors such as the ability of retro-
grade transport. Lentiviral vector tropism is determined by their viral envelope glycoproteins,
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Figure 1.5: Four proposed models for viral pseudotyping. (A) Random integration, (B) Similar
targeting, (C) Direct Interaction, (D) Indirect interaction. (Adapted from Jorgenson et al [75])
which upon identification and interaction with specific receptors induce fusion of the viral en-
velope with the target cell membrane. Lentiviral vectors can be targeted to cells by altering the
envelope protein. More specifically, since wild type proteins have restricted tropism, lentiviral
vectors can be targeted to specific cell types by replacing their natural envelope protein with
heterologous glycoproteins, a process known as pseudotyping. Their ability to pseudotype with
a range of non-lentiviral envelope glycoproteins confers to these vectors broad-species tropism.
The precise mechanism of pseudotyping remains controversial, however studies in retrovirus
models have attempted to address this for the first time. Four proposed models exist [75]: The
first model is the ”random incorporation” in which all cellular surface proteins are passively
incorporated into viral particles under non-sterical exclusion environment; in the ”similar tar-
geting” model, microdomains on the plasma membrane act as important assembly sites to allow
viral structural and surface protein recruitment; the third model ”direct interaction” suggests
that there is a direct contact between viral structural protein and viral glycoprotein which
allows them to recruit at the assembly site. In the final model, ”indirect interaction” cellular
intermediates are essential to allow viral structural and viral glycoprotein recruitment at the
assembly site (Figure 1.5).
Among the first and most widely used glycoproteins (GP) for pseudotyping lentiviral vectors
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is the GP derived from vesicular stomatitis virus (VSVG), which interacts with a ubiquitously
expressed receptor, possibly a phospolipid of the membrane [76] rendering the lentiviral vector
pantropic. VSV-G confers on various vectors the ability to deliver genes to a broad range of cells
in vitro and in vivo (e.g. brain, muscle, and liver) and enables the production of stable high titer
vector stocks, withstanding purification and concentration protocols required for their clinical
use [77]. In particular, brain injection of VSV-G pseudotyped EIAV vector resulted in neuronal
transduction with consequent anterograde transport of the expressed protein through the cell
bodies and axons. Same was observed upon intra-striatal injection of VSV-G pseudotyped HIV-
1 vector, where anterograde transport and labeling of axons at distal sites was evident [78, 79].
However, transport of these vectors to the retrograde direction was reported to be inefficient
[80, 81, 82]. In addition, VSV-G can be inactivated by serum complement [83] and has been
shown to cause toxicity following long-term infection of mammalian and non-mammalian cell
lines [84, 77, 85]. VSV-G pseudotypes have become effectively the standard for evaluating the
efficiency of any other pseudotype. Their broad cell tropism, however, does not make these
vectors appropriate for targeting gene delivery to specific sites as they lack the ability to access
difficult to reach areas without invasive delivery methods.
Over the last decade, many glycoproteins derived from other viruses, have successfully been
used for pseudotyping lentiviral vectors including those from rabies virus (RV), Mokola, Lym-
phocytic Choriomeningitis Virus (LCMV) and alpha viruses such as Sindbis virus and Ross
River conferring tropism for the nervous system (reviewed in [85]). It is clear that in gene
therapy applications, the choice of envelope used for pseudotyping a LV is partly determined
by the target cell type of tissue. Additionally, the choice of envelope influences not only on
the tropism but also the trafficking of the LV in the CNS. Pseudotyping of lentivirus with the
envelope glycoprotein of the neurotrophic rabies virus (RV-G) confers both neurotropism and
the ability to mediate retrograde trafficking of vector particles along neuronal axons [82, 86].
There are three major neurotropic receptors for RVG binding: (i) the nicotinic acetylcholine re-
ceptor (nAChR) ([87, 88]), (ii) the p75 neurotrophin receptor [89] and (iii) neural cell adhesion
molecule (NCAM).
Rabies-G pseudotyped lentiviral vectors are useful for distal targeting of neurons in vivo since
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they are retrogradely transported from the synapse via the axon to the nucleus where they
integrate into the host’s genome and express the transgene [82]. Specifically, peripheral muscle
injection of rabies-G pseudotyped EIAV vectors resulted in transduction of spinal cord motor
neurons [90]. This offers the possibility of a less invasive administration of the vector by
targeting the peripheral sites of the neuromuscular synapses in order to reach the affected central
nervous system. Intra-striatal administration, resulted in transport to other areas of the brain
i.e. with transduction within the striatum, and in distal regions including the olfactory bulb,
thalamus, cortex, hypothalamus, substantia nigra pars compacta (retrograde protein transport)
and globus pallidus, pars reticulata (anterograde protein transport and expression)[82, 91].
Different pseudotyped vectors possess useful features for diverse applications, with variation in
terms of tropism, axonal transport characteristics, and titres produced.
As previously discussed, several types of viral vectors are able to traffic retrogradely from the
synapse, via the axon, to the cell body of neurons upon internalization at the axon terminal.
These properties can be advantageous for precise and less invasive gene delivery from more ac-
cessible sites such as muscles or peripheral nerves to inaccessible areas of the CNS and might be
applicable for treatment of a variety of neurodegenerative diseases. Remote access to the spinal
cord via muscle injection can provide a relatively simple palliative treatment to spare key mus-
cle groups such as those that control limb movement, swallowing, and breathing to enhance the
quality of and/or extend life. Direct intra-parenchymal spinal cord injection of vectors able to
transport on the retrograde direction can also provide simultaneous gene delivery to both upper
and lower motor neurons. As mentioned above, rabies-G pseudotyped EIAV vectors resulted
in gene expression in the spinal cord upon intramuscular administration [91, 82]. Nonetheless,
each approach poses limitations and challenges for human application. The high affinity of some
vectors in the muscle, the architecture of nerves innervating the distal extremities, and more
importantly the muscle mass, which vastly exceeds the mouse, make intramuscular approach for
treatment of motor neuron diseases one of the biggest challenges. Alternatively, injections into
the peripheral nervous system have been attempted. Indeed Tanase et al., reported rabies-G
EIAV gene expression in cervical spinal cord motor neurons in a mouse model upon brachial
plexus injection [71]. However, the confined binding affinity at synaptic terminals, which re-
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stricts both neuronal uptake and axonal transport, is a limiting factor for the application of
this method in humans.
1.1.11 Cell specific targeting
A desired gene therapy protocol would be to precisely deliver a gene of interest to specific
cells in vivo using a targeted gene delivery vehicle for administration. As an alternative to
pseudotyping with existing envelopes, various modifications have been employed to improve
the targeting of vectors to specific cell types and regulate transgene expression.
Cell type-specific lentiviral vectors can be generated through surface engineering, by incorpo-
rating cell type-specific ligands or antibodies on a mutated viral envelope. Several attempts
have been made to alter the receptor-recognition attachment function in the envelope glycopro-
tein, without affecting membrane fusion [92]. Such modifications ablate the native tropism of
the vector, so it is no longer able to recognize and bind to its cognate receptor and redirect its
tropism to the corresponding cellular receptors recognized by the ligand or antibody. Targeting
systems available at the moment involve, among others, antibody specific binding methods
based on (i) molecular events of receptor binding and endocytosis followed by fusogen induced
pH dependent membrane fusion [93, 94, 95, 96] or (ii) active membrane fusion [97, 98, 99].
In 2006 Yang et al. [93], have proposed an efficient targeting method. The method involves the
incorporation of an antibody and a fusogenic protein as two distinct molecules on the lentiviral
surface, separating the recognition from the fusion function. The fusogen is modified so it lacks
the ability to bind to it’s natural receptors, but retains the ability to trigger pH-dependent
membrane fusion, thus is binding deficient but fusion competent [100, 96, 101]. The specificity
of this lentiviral vector is solely determined by the antibody chosen to recognise a specific
antigen on the surface of the target cell. Recently these targeted lentiviral vectors have been
optimized by using single chain antibodies (scFV) genetically fused to either Sindbis virus or
Measles virus (MV) hemmaglutinin envelope [95, 98]. Modifications applied to optimize this
method, aimed to overcome limitations such as receptor internalization and endosomal release
[94], which are necessary when vectors are pseudotyped with certain envelopes.
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An additional targeting method involves coating of the viral surface with polymers such as
polyethylene glycol, poly-[N-(2-hydroxylpropyl0 methacrylamide] or biodegradable alignate mi-
croparticles [102, 103, 104]. All these methods are based on the same principle; ablating native
tropism and re-targeting through surface display of ligands (peptide, proteins, or antibod-
ies). One disadvantage of the method is that the two-component nature of these bispecific
molecules adds complications in vector production and in maintaining stable batch-to-batch
homogeneity, as the number of plasmids required for production of these targeted vectors in-
creases (usually 5-6 plasmid co-transfection is required). Other approaches involve the use of
a ligand protein or antibody as a bridge to attach the virus to specific cells [100, 96, 105, 106].
However, this approach requires endocytosis for the pH-dependent fusion and in addition, once
the envelope protein is connected to the one end of the bridge molecule, it fuses inefficiently.
Additionally to targeting through surface engineering, tissue specific promoters [107, 108] or
tissue-specific regulatory elements [109] have been used and might also optimise the targeting
strategy restricting transduction to the tissue of interest. The use of mammalian promoters
can result in long-term physiologival levels of transgene expression [21]. Glial fibrilary acidic
protein (GFAP), synapsin 1 [110, 111, 112], neuronal specific enolase (NSE) [113], tyrosine
hydroxylase/neurofilament [114], and the prion promoters [115] are some examples of powerful
neuronal promoters which have been used in adenoviral and lentiviral systems. CMV, platelet
growth factor and CMV-chicken -actin promoters have also been tested in AAV and lentiviral
systems for CNS targeting, where specificity achieved from each can vary between different
CNS regions [112]. Alternatively, incorporation of drug-inducible systems (e.g. tetracycline,
ecdysone, mifepristone [116, 117]) in lentiviral vectors, can control more efficiently the levels
and timing of gene expression [118]. Such lentiviral systems have been generated and used to
mediate regulated gene delivery in Parkinsons disease [118, 119]. Moreover, it is also possible
to achieve cell type-specific expression through microRNA (miR) regulation [120, 121]. When
shRNA molecules are incorporated into a lentiviral vector are able to inhibit mRNA by RNA
interference [122]. Moreover, control might be exerted by the inclusion of matrix scaffolding
domains which place sequences in transcriptionally favoured regions of the nucleus, and insulat-
ing elements which can protect promoters from the influences of vector and genomic sequences
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[123].
As described, transgene expression can be achieved using both integrating and non-integrating
lentiviral vectors. There is, however, a risk of activation of proto-oncogenes or de-differentiation
following integration, as most transduced neural cells are terminally differentiated [4]. Concerns
associated with random integration and insertional oncogenesis can be alleviated with the use
of integration deficient lentiviral vectors (IDLV) that are deficient in integrase activity, the
enzymatic activity required to catalyse integration into the host cell genome [124]. IDLV can
be used in conjunction with zinc-finger nuclease (ZFNs) hybrid technology to achieve site-
specific gene correction or addition at the targeted chromosomal loci [125] in which integration
is believed to be safe, which could minimize or overcome the risks associated with random
integration. Despite the fact that this technology is promising, it requires further optimization
in terms of both efficiency and safety. Nonetheless, the necessity for introduction of double-
stranded DNA breaks (DSB) can be an issue as there is a potential of off-target effects where
DSBs can be introduced in loci different from the desired one. This could result in accumulation
of ZNFs to these sites and further contribute to ZFN-mediated cytotoxicity [126].
1.2 Project Specific Background
Disorders of the nervous system still remain a major medical challenge, in matters of manage-
ment and cure. It is crucial to investigate and understand the disease mechanisms, identify
therapeutic targets, design and develop strategies for therapy. The ability to transfer genes to
neuronal cells utilizing viral vectors and specifically lentiviruses, allows delivery of therapeutic
genes to the nervous system. Neural architecture itself is promising for designing therapy. The
morphology of each neuron and the networks they create, make the nervous system ideal for
vector mediated gene transfer; thus delivery at one site can lead to action at a distal site, if
retrograde transport is possible [4]. Gene therapy approaches include delivery of trophic factors
to protect neurons from damage, axogenic or regeneration molecules to restore neural function
after injury, siRNA targeted to defective intracellular proteins and genes, or restoring miss-
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ing proteins by gene replacement. Protocols of gene delivery for neurodegenerative disorders
often require invasive surgery and therefore repeated treatments are impractical; long-term,
stable expression at therapeutic levels is essential. The therapeutic potential of viral vector
gene therapy has been illustrated in many studies using animal models for human disease. The
first use of lentiviral vectors for therapeutic gene expression in the CNS was reported in 1998,
delivering Bcl-xL [127]. Since then, effective long-term treatment has been reported in many
animal models of neurological disorders, such as Parkinson’s disease, Alzheimer’s disease, Hunt-
ington’s disease, motor neuron diseases, lysosomal storage diseases and spinal injury (reviewed
in [4, 69]).
1.2.1 Motor Neuron Diseases (MNDs)- Amyotrophic Lateral Scle-
rosis
Motor neuron diseases (MNDs) including amyotrophic lateral sclerosis (ALS) are neurodegen-
erative diseases that cause progressive paralysis and premature death and there are no treat-
ments available up to date [4]. ALS (also known as Lou Gehrig’s diseae) is one of the most
common adult-onset progressive neurodegenerative disorders, mainly resulting from selective
degeneration of upper and lower motor neurons of the spinal cord, brain stem and cortex [128].
Upper motor neurons reside in the motor region of the cerebral cortex, and ultimately they
form synapses with the lower motor neurons, which reside in the brainstem and spinal cord
and innervate muscles of the head and neck, limbs and thorax to control voluntary movement,
speech, swallowing and breathing. Although motor neuron degeneration is the primary and
most prominent feature of ALS, there is increasing evidence suggesting that ALS represents
a multisystem disorder due to involvement of the sensory and spinocerebellar pathways, as
well as neuronal groups within the substantia nigra and the dentate gyru’s granule layer of
the hippocampus [129, 130]. It is a late onset disease, typically affecting individuals in mid
adult life, usually over the age of 40, with the highest incidence occurring between the ages of
50 and 70, leading to paralysis and death typically within 3 to 5 years [131]. Generally the
fatal event is respiratory failure due to denervation of the respiratory muscles and diaphragm.
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The progressive manifestations of upper and lower motor neuron dysfunction include weakness
and wasting usually accompanied by pathologicaly brisk reflexes, involving the limb and bulbar
muscles. However, not all motor neuron groups exhibit the same vulnerability. Motor neurons
in upper brain stem nuclei controlling eye movements and those in Onuf’s nucleus within the
sacral spinal cord controlling the pelvic floor musculature exhibit decreased vulnerability [132].
There are two different hypothesis regarding the progression of the disease; the ’dying forward’
and the ’dying back’ hypothesis. The first one states that abnormalities of the motor cortex
could lead to anterograde neuronal degeneration of the anterior horn cells, since studies in
ALS patients showed that cortical neuron hyperexcitability is an early feature of the disease
preceding the clinical onset. The second hypothesis proposes that retrograde degeneration of
the lower motor neuron axons could lead to impairments in the motor neuron cell bodies of
the muscle cells and neuromuscular junction. Indeed there are findings of synaptic denervation
at the neuromuscular junction prior to motor neuron degeneration which further support this
theory [133, 134].
1.2.2 Genetics
ALS cases are mainly sporadic (SALS) with approximately 5% exhibiting an autosomal dom-
inant mode of inheritance (familial ALS or FALS), clinically distinguishable from SALS. One
fifth of FALS cases (20%) are caused by mutations in the Cu/Zn superoxide dismutase-1 (SOD1)
gene [135] and 5-10% by mutations in TARDBP gene, apart from a newly identified and un-
characterized C90RF2 gene [134, 136]. SOD1 is a ubiquitous, predominantly cytosolic protein
that is abundant in the CNS, accounting for about 1% of brain proteins. This 153-amino acids
protein catalyzes the conversion of intracellular superoxide free radicals- a toxic by-product of
mitochondria oxidative phosphorylation- to hydrogen peroxide through the dismutation (cycli-
cal reduction and oxidation) of copper. More than 120 missense mutations in SOD1 have been
identified both in patients with FALS and in transgenic mouse models for ALS carrying the
human mutant SOD1 gene (reviewed in [137]). There is no clear correlation between enzyme
activity and disease phenotype, and it is suggested that the mutant SOD1 protein acts through
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a toxic gain of function rather than a loss-of-function as studies in SOD1 knockout mice showed
no motor degeneration [138, 139]. Other mutations include a gene encoding the proteins ALSIN,
a guanine-nucleotide-exchange factor that is involved in maintenance of normal cytoskeleton.
It is suggested to play an important role in endosomal dynamics, and in the regulation of
trafficking of signalling molecules essential for both the development and the maintenance of
motor neurons. Other ALS causative genes involved in endosomal trafficking and cell signalling
include dynactin (encoding a regulator of axonal retrograde transport), senataxin (DNA/RNA
helicase), vesicle-associated membrane protein (VAMP)-associated proteins (ER protein regu-
lations), ANG (rRNA transcription), fused sarcoma (FUS; RNA processing) and TAR DNA
binding protein (TDP-43) gene, but all these mutations together still account for less than 5%
of FALS patients (reviewed in [140, 141, 142]).
Axon guidance proteins are instrumental in regulating motor axon path-funding during early
developmental stages but also influence axonal transport and synaptic function [143]. Expres-
sion of several different axon guidance molecules is modified in ALS mouse models .
The molecular basis for the selective vulnerability of the affected neurons remains unknown.
Despite the extensive research on the genetics of ALS, the disease cannot be explained solely by
genetics. However, the presence of a similar pathology in both familial and sporadic ALS cases,
including those without SOD1 mutations, suggests that common pathogenic mechanismscan
lead to the onset of this neurodegenerative disease. Various pathogenic hypotheses have been
proposed for ALS, including protein misfolding and aggregation, defective axonal transport,
excitotoxicity, mitochondrial dysfunction, apoptosis, oxidative stress and even toxicity caused
by non-neuronal cells. There is evidence supporting each hypothesis, and this most likely
suggests that there is not a unifying disease-causing mechanism, but ALS might be the common
end stage phenotype of diverse causes.
1.2.3 Transgenic animals.
Transgenic mice or rats overexpressing a mutated form of human SOD1 (various mutants
with G93A being the most aggressive) have been developed. They develop a severe and
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progressive motoneuron disease closely resembling the human one (FALS-transgenic mice)
[144, 145, 146, 147]. Deleterious effects of the mutant SOD1 protein arise through a novel
and yet unknown process. Several mechanisms by which expression of mutant SOD1 may lead
to chronic motoneuron degeneration have been suggested. Some of these include the following:
(i) nitrotyrosine formation catalysed by the mutant enzyme and leading to damage of essential
proteins [148, 149]; (ii) altered conformation of mutant SOD1 leading to toxic release of copper
and zinc [150]; (iii) increased peroxidase activity of the mutant enzyme leading to oxidative
stress [151]; (iv) toxicity mediated by abnormal folding and aggregation of mutant SOD1 [152];
(v) exitotoxicity through selective inhibition of a glial glutamate transporter by mutated SOD1
[153]. Depolarization of the neuronal membrane after activation of neuronal glutamate recep-
tors activates voltage-dependent Ca2+ channels, allowing Ca2+ entry into the cell. Thus, excess
activation of neuronal glutamate receptors may cause cell death via alterations in cytosolic
Ca2+ homeostasis; (vi) finally, formation of neurofilament inclusion in the perikaryon and axon
of motoneurons [154].
1.2.4 Need for therapy
At present there is an unmet clinical need for potent interventions in ALS. The only FDA ap-
proved therapy is riluzole a sodium channel blocker that indirectly inhibits glutamate receptors,
that results only in moderate lifespan extension [155, 156]. Viral vectors capable of efficient
transduction that can be retrogradely transported along motor neurons would eliminate the
need for invasive surgery and allow targeted gene therapy to sites, which are away from the site
of administration. Lentiviral vectors are shown to integrate reporter genes into the genome of
hematopoietic stem cells, liver cells, retinal photoreceptors, and terminally differentiated neu-
rons leading to stable long-term expression [27, 157, 158, 159, 160, 161, 162, 163, 164]. Lentiviral
vectors have entered clinical trials in diseases such as Adenosine deaminase deficiency, X-linked
severe combined immunodeficiency, Parkinsons disease, X-linked adrenoleukodystrophy and
metachromatic leukodystrophy amongst others (www.clinicaltrials.gov). HIV and EIAV-based
lentiviral vectors, pseudotyped with VSV-G, have shown promising results to be used in gene
26 Chapter 1. Introduction
therapy for targeting motor neurons. Rabies-G pseudotyped EIAV vectors mediate retrograde
transport and transduction of MNs after delivery to muscle [82, 91]. HIV-1 based vectors,
when pseudotyped with selected rabies glycoproteins can be targeted to mouse MNs upon in-
tramuscular injection [86]. It is clear that the specific targeting of neuronal cells with the RV-G
pseudotype opens up the possibility of non-invasive, distal administration of the vector at the
neuromuscular synapses to target cells of the CNS affected by motor neuron diseases such as
ALS and spinal muscular atrophy (SMA). In both cases, unfortunately, gene transfer was not
MN specific since sensory neurons and muscle gets transduced. Rabies-G pseudotyped lentivi-
ral vector injections in the affected muscle of mouse models of ALS (SOD1 mutant mouse) or
SMA (SMNdelta7 knockout mouse), is taken up at the nerve terminals and expressed in the
cognate MNs in the spinal cord. Vectors expressing vascular endothelial growth factor VEGF
[90] or siRNA targeted to mutated SOD1 gene [165] or carrying the normal SOD1 [51] restored
motor defects and extended survival of these animals. Despite therapeutic effects achieved in
mouse models of ALS and SMA, the efficiency of this approach needs to be improved in order
to proceed to clinical translation. Although high efficiency was observed in postnatal animals
(60-70% of MNs transduced) following intramuscular injections of large volumes of vector [51],
this drops to >30% in adult rats [82]. Efficacy with these viral vectors for ALS has not been
reported in primates. It could be mainly due to limitations of gene transfer in NHPs (i.e. RVG
pseudotyped lentiviral and AAV-2 vectors) and/or differential sensitivity to post entry restric-
tion factors, expressed in mammalian cells in a cell-autonomous manner that inhibit retroviral
replication. An example is the tripartite interaction motif 5 alpha (TRIM5a), an acytoplasmic
body component recently demonstrated to block retrovirus infection in primates (for EIAV)
[166, 167]. Another possible reason could also be due to lack of efficacy in mouse SOD1G93A
model despite good gene transfer in rodents and NHPs (i.e. AAV-6 vectors)[168, 169, 170].
1.2.5 The Neuromuscular Junction (NMJ)
In vertebrates, skeletal muscle is composed of multinucleated cells forming fibers that are in-
nervated by MNs, which belong to CNS neurons. The cell bodies of the lower MNs are located
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in the brainstem or the ventral horn of the spinal cord. Each MN cell has a myelinating axon
that extends towards a target muscle passing through a complex of peripheral nerves. Once the
axon reaches and enters its target muscle it branches, innervating many individual muscle fibers.
During branching, axons loose their myelin sheath and further branching continues (it divides
into 20-100 unmyelibated terminal fibers) until the nerve finally reaches the muscle forming the
neuromuscular junction (NMJ)[171]. NMJ is a specialized chemical synapse between terminal
MNs and skeletal muscles, transmitting the electrical impulses by specific neurotransmitters.
As most synapses in the nervous system, NMJ is a chemical synapse that transmits the in-
formation from axon terminal of the neuron to the target cell, which in this case is a muscle
fibre. NMJ is comprised by three major structural compartments: (i) the presynaptic nerve
terminal, capped by a Schwann cell, (ii) the synaptic cleft and (iii) the postsynaptic surface
on the membrane of the muscle (reviewed in [172]). Combination of fluorescent probes with
confocal microscopy allowed visualization of the NMJ both in living tissue and in cells.
Figure 1.6: Schematic organisation of the NMJ Neuromuscular synapses are composed of three
major structural elements: the presynaptic region with the nerve terminal, the synaptic cleft and the
postsynaptic surface. Although overall morphology of the neuromuscular synapse varies among muscle
types and species, most of the molecules involved in differentiation of the synapses are present at all
vertebrate NMJs. (Adapted from [172])
Presynaptic Regions
Presynaptic regions are the terminal parts of the axons. This nerve terminal accumulates
mitochondria (MC) and synaptic vesicles (SV), each of which contains 5,000-1,0000 molecules
of the neurotransmitter acetylcholine (ACh). SVs are located close to the release sites, called
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the active zone (az) formed along the junctional surface, where calcium channels are arranged in
regular parallel arrays. During action potential, calcium channels open, leading to a significant
increase of free Ca2+ within the nerve terminal. Increase of Ca2+ triggers a series of events which
result in fusion of some SVs to plasma membranes of the nerve terminal and the release of ACh
into the synaptic cleft (reviewed in [173, 172]). During the processes of SVs mobilization and
docking, a synaptic core complex is formed that is composed of three SNARE proteins; which are
syntaxin-1 and synaptic vesicle-associated protein 25 (SNAP25) on the presynaptic terminal
membrane and synaptobrevin on the synaptic vehicle membrane, all of which participate in
the formation of a fusion pore. Synaptic vehicle fusion is controlled by Munc18-1 allowing
the formation of the core complex that upon dissociation form syntaxin while synaptophysin
dissociates from synaptobrevin. At the NMJ, terminal Schwann cells (TSCs) (3-5) cap the
motor nerve and have a critical role in synaptic transmission, growth and maintenance of
the nerve terminal, axonal sprouting and regeneration [174, 175], through the synthesis and
secretion of essential trophic factors such as neuregulin and nerve growth factor [176, 177]. TSCs
express axon guidance proteins. The importance of Schwann cells was highlighted in studies
with embryos lacking Schwann cells. In these embryos axons did grow towards the muscles and
formed neuromuscular contacts, though these contacts disappeared quickly, the MNs died and
animals died at or short after birth [176, 178, 179]. Reversely, terminal Schwann cells can be
rescued from degeneration in denervated mice by neuregulin [180]. Finally Schwann cells have
a function in nerve-terminal injury, where upon damage to the nerve terminal they invade the
space between the injured nerve terminal and the muscle fiber, they become phagocytic and
remove nerve terminal debris [175].
Synaptic Cleft
The space between the presynaptic nerve terminal and postsynaptic membrane is called the
synaptic cleft and separates the nerve and myotube membranes. This region contains a basal
lamina. The synaptic basal lamina contains components which organise synaptic specialization
in all three compartments of the NMJ, such as collagen IV, laminin, fibronectin, entactin and
perlecan [181]. In the mature synaptic lamina other proteins can be found: acetylcholinesterase
(AChE), laminin α4 and α5 chains, collagen α3 (IV), α4 (IV), and α5 (IV) chains and neuregulin
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( reviewed in [172]). Its main role is to transmit ACh from the presynaptic terminal to the
postsynaptic membrane (reviewed in [173, 172]).
Postsynaptic Surface
The postsynatic membrane is located on the muscle fibre membranes. The formation of sec-
ondary synaptic clefts creates folds in the postsynaptic membrane, where ion channels, the
acetylcholine receptors (AChR) are asymmetrically anchored at the crests of the folds[182, 183]
and voltage-gated sodium channels are concentrated in the troughs of the folds. AChR is the
most important protein in the NMJ. It is a transmembrane protein consisting of five subunits
in a pentameric unit arrangement, which in adult mammals are designated as α2βδ. On the
synaptic surface they provide sites for binding of ACh. In the absence of ACh the central
pore (formed by the subunits) is closed. Upon release of AChs from the presynaptic region
into the synaptic cleft, two AChs molecules bind to the N-terminal domain of the αδ and α
subunits of the AChR and stimulate it, allowing sodium ions to enter the muscle cell, resulting
in a change of the membrane potential and initiation of a series of events leading to muscle
contraction (reviewed in [184, 173, 172]). During this transmission process, electrical impulses
are converted into chemical signals, prior to being transformed into mechanical signals in the
form of muscle contraction. An important molecule in the postsynaptic organization of the
neuromuscular junction is agrin which is synthesized by the nerve, transported down motor
axons, released from motor nerve terminals and incorporated in to the basal lamina of the
synaptic cleft. Although agrin-deficient knockout mice have normal AChR levels they have low
levels of AChR clusters and other postsynaptic specializations and poor branching of motor
axons [185, 186, 187]. NMJ generation is a multistep process requiring various growth factors,
hormones and cellular structures.
Overall, generation of in vitro NMJ models would be a promising cell biology tool for investi-
gating the involvement of NMJs in many neurodegenerative diseases that can lead to muscle
weakness[188].
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1.2.6 Targeting lentiviral vectors to specific cell types.
It is clear that restricting infection to specific cells, known as ”targeted transduction”, is critical
when it comes to safe and efficient in vivo gene delivery and it may be a possible way of
enhancing therapeutic effects, reducing side effects and lowering the amount of vector required.
Alternatively to pseudotyping with rabies virus, specific entry at the neuromuscular junction
could possibly be achieved by utilizing an established strategy for improving the efficiency
of transduction which is the manipulation of the viral envelope, a process known as surface
engineering [189].
Targeting lentiviral vectors to specific cell types has so far proven to be challenging. A vi-
tal step to achieve efficient targeting through surface engineering is to uncouple/distinct the
steps/functions of receptor recognition/interaction and fusion with the cellular membrane. Cell-
specific targeting strategies have generally concentrated on surface engineering of envelope pro-
teins by mutating the natural receptor sites and inserting cell-specific ligands, such as antibodies
on the viral surface. Attempts in the past focused on modifying the receptor attachment func-
tion to limit (but not ablate) the tropism of the envelope glycoproteins. This resulted allowed
specific gene-transfer but titer yields were compromised due to extensive manipulation in the
fusion domain of the proteins.
Yang et al., [93] have proposed an efficient method to target lentivirus mediated gene transduc-
tion to a desired cell type (Figure 1.7). This approach involves incorporation of an antibody for
receptor recognition/interaction and a fusogenic protein into lentiviral surface as two distinct
molecules. Thus uncoupling the target cell recognition function from the fusion function by
providing them in separate proteins. The specificity of such a lentiviral vector is solely de-
termined by the antibody chosen to recognize a specific surface antigen of the desired target
cell type. Necessary for an exclusive specificity is a binding deficient fusogen. The fusogen
is generated by modifying viral envelope proteins, so that they lack the ability to bind to its
cognate receptor but retain the ability to trigger pH-dependent membrane fusion. Antibody
recognition and binding then induces endocytosis of the surface antigen, bringing the lentivirus
into an endosome. There, the fusogenic molecule (FM), responds to the low pH environment
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Figure 1.7: Antibody targeting strategy Schematic diagram of the antibody targeting methodology
proposed by [93]. The engineered lentivector co-displays a binding determinant (CD20 antibody) and
a fusogenic molecule (SINmu). Specific binding of CD20 to the surface CD20 antigen expressed on
the target cell surface induces endocytosis of the lentivector into an endosomal compartment. In the
endosome, SINmu responds to the low pH and triggers membrane fusion, allowing the endosomal
escape of the viral capsid into the cytosol. (Adapted from Yang et al. [93])
and mediates membrane fusion, allowing the endosomal escape of the virus core into the host’s
cytoplasm. Upon reverse transcription and nuclear transfer of the product, the genome of the
vector is expected to integrate into the target cell genome. Using CD20 as a targeted antigen
for human B cells, they have proven the targeting efficiency of this method both in vitro, on a
panel of cell lines and in a human xenograft mouse model. The advantage of this methodology
is its flexibility as it can be extended to other forms of cell type-specific recognition to mediate
targeting. The only requirement is that the antibody must be endocytosed after interaction
with its cell surface-binding determinant. In other word, the targeting method utilized is based
on receptor mediated endocytosis.
1.2.7 The key players: pH-dependent fusion molecule SINmu
FMs used in the present study had the following characteristics: They were able to incorporate
into the lentivirus envelope and induce membrane fusion at low pH, independent of receptor
binding. There are two classes of FMs [190]. Class I, which trigger membrane fusion through
helical coiled-coil structures and class II fusogens, which trigger fusion with β-barrels. Sindbis
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virus glycoprotein, from the alphavirus family [191], is a class II fusogen, and is designated
as SIN. SIN consists of two transmembrane proteins/domains: E1 which mediates the fusion
between the virus and the target cell and E2, which is responsible for binding of the virus to
the antigen on the target cell surface [192]. SIN can pseudotype both oncoretroviruses and
lentiviruses. Morizono and colleagues managed to generate a fusion-competent and binding-
deficient SIN by inserting a ZZ binding domain into the E2 domain and making several muta-
tions to inactivate the receptor binding sites [96]. Yang et al., have further modified the SIN
by replacing the ZZ-domain with a 10-residue tag (HA tag) sequence, resulting in the protein
designated SINmu [93] (Figure 1.8 top). SINmu was shown to be a good fusion protein to
partner with αCD20 for targeting lentiviral vectors to CD20 expressing cells [51]. Lei et al.,
reported that improved version lentiviral vectors carrying engineered FMs exhibited 8-17 fold
enhanced transduction towards target cells compared to the parental SINmu [94]. Based on Lu
et al. studies on cholesterol dependency of the Sindbis virus glycoprotein, which have shown
that mutations on E1 domain at region 266 resulted in viruses less dependent on cholesterol for
transduction [193], they have incorporated these mutations into SINmu and engineered three
FMs designated as SGM, SGN and AGM (Figure 1.8 bottom). A series of neutralization and
pH-dependent vector transduction assays revealed that engineered FM had a broader pH range
and subsequently enhanced its transduction ability [94].
1.2.8 The key players: membrane bound antibody
For the construction of membrane-bound antibody for targeting, Yang et al., generated a con-
struct encoding a mouse/human chimeric antiCD20 antibody with the human membrane bound
IgG constant region. More specific, light and heavy chain variable regions from the murine anti-
CD20 antibody were amplified and cloned upstream of the corresponding human κ light chain
constant regions. The resulting construct was designated pαCD20. Alongside, genes encoding
human Igα and Igβ were cloned into the construct named Igαβ. Antibody accessory proteins
Igα and Igβ are required for cell surface expression of antibodies into producer cells and trans-
port of membrane immunoglobulins for subsequent incorporation into the viral vector [194].
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Figure 1.8: Schematic representation of SINmu Class II fusogenic molecule (top panel)
The class II fusion protein SINmu derived form SIN. E1 and E2 domains and signal peptide E3 are
presented. A 10 residue HA tag sequence was inserted between amino acids 71 and 74; a4, a5 and
a6 indicate the residues where a series of modifications were introduced to yield the binding-deficient
and fusion-competent SINmu. (bottom panel) Construct encoding the SINmu. For SINmu, SGN,
SGM, AGM constructs, amino acid sequence at E1 226 are shown specific amino acids involved in
generating new FMs underlined in bold. (Modified from [93, 94])
1.2.9 Choosing a target at NMJ to access MNs upon intramuscular
delivery
To design and efficiently utilize a lentiviral vector with tropism to the NMJ aiming to increase
the efficiency/specificity of retrograde transport and subsequent gene transfer to MNs, would
prove an advantageous and ideal non-invasive approach for therapy. This requires careful selec-
tion of the ideal target molecules that will be recognized by the antibody incorporated onto the
lentiviral surface and will allow its efficient retrograde transport to the affected cells, located
in the spinal cord. On this front, receptors expressed and internalized at the presynaptic NMJ
appear ideal targets aiming to achieve a more efficient MN transduction. In addition, recep-
tors that are also associated/activated by molecules proven to undergo retrograde transport
will be further advantageous. Most of the information on the mode of retrograde transport in
motor neurons has been derived from studies of clostridial neurotoxins such as the TeNT and
Botulinum neurotoxin (BoNT) (reviewed in [195]) and will presented later in this section. More-
over, information for potential targets derived also from in vivo studies of RVG-pseudotyped
lentiviral vectors which are proven to be retrodragely transported to spinal cord MN upon in-
tramuscular application can expand the pull of antibodies that can be utilized in this approach.
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As discussed in a previous section (Section 1.1.10), pseudotyping lentiviral vectors with the
envelope GP of rabies virus (RV-G) makes them neurotropic and more importantly confers
upon them the ability to retrogradly traffic along axons to neuronal soma [82]. One major
disadvantage is that, efficient transduction with rabies-pseudotyped lentiviral vectors has not
been observed in non-human primates, which poses a significant barrier to clinical translation.
This could partially be explained by inefficient vector trafficking in non-human primates. The
exact mechanisms involved in in vivo entry and retrograde trafficking of wild-type rabies virus
(and therefore of the RVG-pseudotyped Lentivirus) are unclear. However rhabdoviruses such
as rabies virus and VSV enter cells using a well studied mechanism [196], which can proven to
be informative regarding the choice of the right target molecule.
Following binding to a cell surface molecule (p75 neurotrophin receptor, p75NTR; neural cell
adhesion molecule, NCAM; nicotinic acetylcholine receptor, nAChR; for RV), virus particles
undergo clathrin-mediated endocytosis. Upon uptake, clathrin coated vesicles become asso-
ciated with the small GTPase Rab5 (early endosomal marker), and their lumen undergoes
acidification. Subsequently, a process well known as ”endosomal maturation” promotes an in-
creased association with Rab7 (late endosomal marker; rather than Rab5) and is accompanied
by a further acidification (decrease in pH), before the endosome finally fuses with the lysosome
[197, 198]. Importantly, the viral particles escape from the endosomal lumen before fusion with
the lysosome, a process that is triggered by acidification [199, 200]. This acidic environment in-
duces a conformational change in the viral glycoprotein that initiates membrane fusion between
the viral envelope and the endosomal membrane, allowing escape of the viral capsid through
a newly generated fusion pore. However, it is unclear whether the viral un-coating actually
takes place in nerve terminals or in the cell body after axonal transport. It has been suggested
that retrograde axonal transport is mediated by direct interaction of a rabies virus protein (P
protein) with the cytoplasmic dynein light chain LC8 [201]. However, this had subsequently
been disproved by studies where deletion of the LC8-binding site in the rabies virus P protein
did not affect viral transport from a peripheral site to the CNS [202]. On the other hand, ra-
bies virus glycoprotein (RV- G) appears to play a predominant role in the transneuronal spread
of rabies virus infection. Two studies showed that retroviruses pseudotyped with RV-G are
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retrogradely transported upon peripheral delivery and can reach the CNS in a similar manner
to wt rabies virus [82, 86]. This suggests that long distance, axonal transport of RV depends
on the G protein, and supports another model where the whole virion is transported inside a
vesicle, mediated by the surface G protein. In wild type rabies virus, the capsid then enters
the nucleus, a process enhanced by an interaction of the capsid with the cytoplasmic dynein
motor complex, which promotes transport toward the nucleus [203, 204, 205]. The described
mechanism does not exist for capsids of either HIV1 or EIAV, raising the question of how viral
capsids can reach the nucleus from such distal sites as the neuromuscular junction (NMJ).
A possible explanation would be via association with molecules known to undergo retrograde
trafficking along the motor axon towards the soma. Identification of the receptors associating
with these molecules would be vital for selecting the antibodies to generate lentiviral vectors
targeted to them.
Extensive studies in motor neurons have revealed an elegant process by which proteins within
the distal potion of the axon can undergo retrograde trafficking to the soma. Recently an
axon-specific membrane trafficking pathway has been characterized [124, 206]. This pathway is
utilised by tetanus neurotoxin (TeNT) and allows TeNT to reach the neuron soma from distal
infection sites, such as the neuromuscular junction [207, 208, 209, 210, 211, 212]. This axonal
trafficking pathway also shared by neurotrophins in the CNS [213] (p75NTR), utilises a sequential
Rab5 and Rab7 endosomal pathway, in which endosomal maturation takes place in neutral pH.
In addition to TeNT and p75NTR, this pathway has been shown to mediate the transport of
several cell adhesion molecules (ALCAM, NCAM) [214], and viruses such as canine adenovirus
2 (CAV-2) and its receptor CAR (coxsackievirus and adenovirus receptor) [210] in non-acidified
endosomes. Recent studies of our lab in primary motor neuron cultures, revealed that these
non-acidic enodomes containing RV-G psesudotyped particles undergo trafficking towards the
soma of the MN (Hislop et al, under review). Based on these studies, we have concentrated our
interest to the receptors that these molecules are reported to bind to. The particular antibodies
to presynaptic terminal receptors that will be incorporated on the lentiviral surface to target
MN at the NMJ were chosen to be against the: (1) Thy1.1 receptor, p75NTR receptor and (3)
CAR receptor, for which there is extensive evidence, as presented in the next sections, that
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supports their expression at NMJ and their ability to undergo, upon internalisation, retrograde
trafficking along MN axons.
1.2.10 Target molecule: The Thy1 receptor- Monoclonal anti-Thy1.1
antibody (OX7)
Most of the information on the mode of retrograde transport in motor neurons has been de-
rived from studies of clostridial neurotoxins such as the tetanus toxin (TeNT) and botulinum
neurotoxin (BoNT) [195]. Both of these neurotoxins bind and internalize at the neuromuscular
junction (NMJ). These proteins share a common structure comprised of a heavy (H, 100 kDa)
and a light (L, 50 kDa) chain linked with a disulfide bond. The H chain mediates binding and
internalisation in neurons, while the L, which acts as metalloprotease, selectively cleaves synap-
tic proteins [215]. TeNT enters the axonal retrograde transport pathway and reaches the soma
of motor neurons located in the spinal cord [206]. It is then transcytosed to inhibitory interneu-
rons and blocks the release of inhibitory neurotransmitters in the spinal cord, causing spastic
paralysis [216, 217]. In contrast, BoNTs remains in the periphery, and blocks acetylcholine re-
lease at the neuromuscular junction, inducing faccid paralysis. Recently, a recombinant binding
fragment of TeNT (HcT) has been utilised extensively to monitor internalisation and axonal
retrograde transport in many neuronal types [206], allowing the in vitro and in vivo quanti-
tative analysis of these trafficking processes. A few years ago a (GPI)-anchored glycoprotein
that interacts with the binding domain of TeNT (TeNT Hc), but not with BoNTs, was isolated
[218]. This TeNT-interacting protein has been identified as Thy-1 in differentiated PC12 cells
and spinal cord MNs [219]. It was further shown by immunoprecipitation experiments that
Thy-1 interacts with TeNT Hc and HcC, the domain sufficient for binding, in PC12 cell line
[219].
Thy-1 (CD90) is a 25-37kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein localised
on the external leaflet of the libid bilayer of lipid rafts. It is expressed on many cell types, such
as neurons, thymocytes, fibroblasts and endothelial cells. There are two alleles in mice, the
Thy-1.1/CD90.1 and Thy1.2/CD90.2 which differ by one amino acid. CD90.2 is expressed by
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most strains of mice, while CD90.1 is found only in AKF/J and PL mouse strains [220, 221].
Thy-1 is involved in T cell activation [222]. Among its several non-immunologic functions Thy-
1 is involved in neurite outgrowth. Is highly expressed in adult neurons. In the rat brain it
is detected in high concentrations in the striatum and hippocampus, followed by neocortex,
cerebellum, spinal cord, the retina and optic nerve [223], whereas in the mouse brain is largely
expressed in the cerebral cortex in synaptosomes as compared to mitochondria, neurons and
myelin [224]. It is also involved in apoptotic signaling and is an important regulator of cell-
cell and cell-matrix interactions, with key roles in metastasis, adhesion, migration and fibrosis
(reviewed in [225]).
A monoclonal antibody to rat Thy1.1, clone OX-7 has been produced [226] and was initially
used to visualize, with autoradiographic technique, the distribution of Thy1.1 in the rat brain
[227]. Analysis for Thy1.1 showed that it is widely distributed throughout the rat brain from
the olfactory bulb to brain stem, but it is differentially expressed in neurons from various
regions of the brain. Further western blot and immunohistofluorescence analyses utilizing OX-
7 antibody, revealed strong Thy1.1 expression in brain and thymus, moderate expression in
kidney, lung and spleen, whereas no expression was detected in heart and liver [228]. Direct
brain and peripheral nerve microinjections of the anti-Thy1.1 (OX7) antibody itself revealed its
ability to be axonally transported [229]. Injections of monoclonal anti-Thy 1.1 (OX7 ) antibody
in rat vagus nerve, tongue or caudate nuleus showed by indirect immunoperoxidase staining,
that anti-Thy1.1 antibody is axonally transported both antero-and/or retrogradely from all
injection sites. These results suggest that the OX7 might be a useful carrier to selectively
target molecules to neurons via endocytosis and axonal transport.
1.2.11 Target molecule: the p75NTR receptor -Monoclonal antibody
anti-p75 MC-192
As mentioned in a previous section (section 1.2.9), p75NTR (low affinity neurotrophin receptor)
is reported to be involved in the rabies-G vector internalisation and trafficking, in neuronal
cells, where it internalises upon activation and undergoes retrograde trafficking in specialized,
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non-acidic endosomal compartments [207, 91]. Furthermore, it is reported as one of the two
receptors for RVG (the other one is NCAM) which undergo retrograde axonal transport, towards
the soma, in these Rab7-positive non-acidified endosomes [208, 214].
Neurotrophins are growth factors that play important roles in development, maintenance, sur-
vival and death of the nervous system. These include nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), neuritrophin-3 and 4/5. The nerve growth factor (NGF) family
of neurortophins binds to two classes of cell-surface receptors: (i) Tyrosine kinase receptor
(trk), where it is involved in signalling of differentiation or survival of neuronal cells [230] and
(ii) the shared neurotrophin receptor p75NTR. p75NTR is a non-enzymatic 75kDa transmebrane
protein which has multiple roles in the nervous system, ranging from enhancement of axonal
outgrowth to modulation of cell survival or cell death [231]. Rat PC12 cells, derived from a
pheochromocytoma tumor [232] have become the most widely used model for the study of NGF
action. In the absence of NGF these cells proliferate and resemble chromaffin cells in the way
they synthesize, store and release catecholamines. In presense of NFG, these cells stop dividing
and extend neurites, differentiating into acetylcholinergic cells. Expression of p75NTR at the
extracellular surface of exponentially growing PC12 cells was found to vary in cycle phase spe-
cific manner, where p75NTR is expressed mainly in late G1, S and G2 phases [233]. Bobo et al.,
utilizing a monoclonal antibody against the extracellular domain of p75NTR (monoclonal MC
192-IgG antibody) have suggested that NGF exerts its pro-apoptotic effect exclusively via the
p75NTR receptor in a cell cycle-dependent manner [234]. There are many studies demonstrating
that p75NTR receptor has been found to induce apoptosis in embryonic stages. It has been
shown that p75NTR mediates apoptosis of the developing forebrain neurons [235], and apoptosis
of developing motor neurons in the rat embryonic spinal cord [236].
A monoclonal antibody to rat p75NTR (MC-192-IgG) has been produced and initially reported
to enhance β-NGF binding to PC12 cells [237]. The antibody is produced by 192 hybridoma
which was obtained by fusing Sp2/0-Ag14 myeloma cells with splenocytes from Balb/C mice
[237]. p75NTR is expressed almost exclusively on cholinergic neurons [238]. MC-192-IgG an-
tibody, is strictly directed against p75 low affinity growth factor receptor in rats. Tremere
et al., assessed the cross reactivity of MC-192-IgG in the basal forebrain of rat, human, dog,
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cat, raccoon, pig and rabbit. In this study it was shown that only the rat tissue was im-
munopositive for 192-IgG where is identified cholinergic basal forebrain neurons [239]. Further
characterisation of the binding and retrograde properties of this antibody revealed that upon
intraocular injection in gerbils, hamsters, guinea pigs and mice, there where no evidence of
retrograde transport of p75NTR in these species [240], compared to injections in rat where it
was retrogradely transported in vivo. These results indicated once more that this antibody
does not have a high affinity for its target receptor in any other species but rat. MC-192-IgG
antibody was also utilized to examine ligand induced internalisation of p75NTR in rat PC12
cells. It was reported that p75NTR is internalized to a transferin-positive endosome in a ligand
dependent manner and its internalisation proceeds via clathrin-coated pits to early endosomes
with subsequent transfer to the recycling compartment [241].
The available monoclonal antibodies to p75NTR bind strictly to one mammalian species or other.
For years, a number of monoclonal antibodies were available that bound primate of rat p75NTR
receptor but none that bound across species and detected mouse p75NTR effectively. Rogers et
al., [242], have produced a functional monoclonal antibody that cross reacts with p75NTR in a
wide range of species including the mouse, by immunizing p75NTREXONIII knockout mice with
the extracellular portion of recombinant human p75NTR.
1.2.12 Target molecule: the coxsackievirus and adenovirus receptor
(CAR)
Coxsackievirus and adenovirus receptor (CAR) is a transmembrane protein belonging to the
immunoglobulin superfamily. CAR is composed of an extracellular domain with two Ig-like
disulfide-linked loops and a typical hydrophobic transmembrane domain, with a cytoplasmic tail
[243]. Homologues exist in mouse, rat, pig, dog and zebrafish with highly conserved amino acid
sequences among those species [244]. CAR is a widely expressed cell adhesion protein involved
in tight junction formation in epithelial cells and myocardial cells. It is also highly expressed
in the developing brain (E16.5 mouse hippocampus cultures)[245] and drops off rapidly after
birth [245, 246, 247, 248]. The junctional adhesion molecule is the primary receptor for most
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adenoviruses (AdV) and group B coxsackieviruses (CVB) [243].
CAR is the major receptor for the canine adenovirus serotype-2 (CAV-2) [249]. In order to
determine the role of CAR in viral entry and its expression patterns-the binding, endocytosis
and transport of CAV-2 have been characterized in combination with surface expression of CAR
[210]. In these studies it has been shown that CAV-2 interaction with the neuronal membrane
correlates with CAR surface expression (it is CAR-dependent), followed by endocytosis involv-
ing clathrin [210] and Rab5- Rab7 endosomes. CAV-2 is using an axonal trafficking pathway
where carriers involve tetanus toxin and neurotrophin receptors as well as CAR. Furthermore,
CAV-2 preferentiallly transduces motor neurons (sacral dorsolumbar rachis) and undergoes
efficient retrograde axonal transport following injection into the mouse gastrocnemius [249].
This uptake of receptor-antigen complex by clathrin-dependent endocytosis, prior to endoso-
mal trafficking in cells followed by axonal transport were previously described for trafficking of
neurotropic viruses including the herpes simplex virus type I (HSV-1) and rabies [250, 82].
CAR expression and distribution has extensively been assessed. On differentiating spinal cord
cultures CAR was found to co-localise primarily with the neuronal marker MAO-2. In the rat
olfactory epithelium CAR was significantly expressed in olfactory neurons near the olfactory
receptors, while low level of expression was detected in mouse skeletal muscle. Finally, evidence
of expression of CAR near the neuromuscular junction and on the neurites of innervating motor
neurons enhanced the hypothesis that CAR distribution on the soma and neurites permits
CAV-2 entry and axonal transport to other regions of CNS [249]. Further studies using specific
antibodies against epitopes located at both the N-terminal extracellular domain and the C-
terminal transmembrane intracellular tail, confirmed CAR expression at the NMJ [251].
The expression of the CAR at the NMJ and the retrograde axonal transport of the receptor
upon antigen-binding triggered endocytosis, are ideal characteristics for a receptor to be used
for gene therapy of MNDs.
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1.2.13 Engineering membrane bound antibodies
Immunoglobulin structure
Antibodies, also known as gamma globulins because of their electophoretic mobility profile, are
immune system related plasma glycoproteins. All antibodies share a basic molecular structure.
Each antibody monomer is a Y-shaped molecule with molecular weight of approximately 150
kDa and is composed of four polypeptide chains; two identical heavy (H) chains of about 440
aa and two identical light (L) chains of about 220 aa, covalently bonded by interchain disulfide
linkages (Figure 1.9). H and L chains contain intrachain disulfide bonds that stabilize their
folding into domains, each about 110 aa [252]. These domains are classified into different
categories according to their size and function. Five H chain isotypes have been found: alpha,
gamma, delta, epsilon and mu. The type of heavy chain present defines the class of antibodies
which are named IgA, IgD, IgG, IgE and IgM antibodies respectively and influence the effector
functions of the antibody molecules. There are only two types of L chain, kappa or lambda
[252, 253]. Each heavy and light chain has two regions, the constant (C) and the variable
(V) region. The constant regions (CH and CL) are the same in all antibodies of the same
isotype. The amino acid sequence of the variable regions (VH and VL) vary considerably
and are responsible for the antigen binding diversity of antibodies. The variable domain is
also referred as FV region and is the region that is binding to antigens. Within VH and VL
there are hypervariable loops, three in each of the light and heavy chain which upon folding
they form the antibody complementary determining regions (CDRs), responsible for antigen
recognition and binding. CDRs are supported within the variable domains by less variable
conserved framework regions. Upon proteolitic cleavage of the basic immunoglobulin molecule
two main fragments are revealed. The amino terminal fragments, which are the arms of the
Y, contain sites that can bind two antigens and are called Fab (antigen binding fragments)
region. The carboxyl terminal region, which contains two or three CH (whether secreted or
membrane bound) is called Fc region and contains the complement-binding and Fc receptor
(FcR)-binding sites. It is thereby possible to join the separate segments of the HC and LC
in the Fv by antibody engineering with a flexible peptide linker to generate a single chain
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Figure 1.9: Structure of a typical immunoglobulin (antibody) protein. Two identical heavy
chains and two identical light chains are connected by disulfide linkages. The antigen-binding site is
composed of the variable regions of the heavy and light chains, whereas the effector site of the antibody
is determined by the amino acid sequence of the heavy chain constant region. Bottom: Rearrangement
of the light chain genes during B lymphocyte differentiation. Top: Rearrangement of the heavy chain
genes. A heavy chain gene contains three segments (V, D, and J) that come together to form the
variable region, as well as a constant region. (Reproduced from Gilbert SF, 2000)
antibody (scFv). In the case of membrane-bound Ig there is an additional transmembrane
sequence on the carboxyl terminal CH region. There, the Igα and Igβ transmembrane proteins
form a disulfide-linked heterodimer (Igαβ), which is linked to the CH transmembrane domain
through polar residues [254]. Igαβ is essential for cell surface expression of membrane-bound
immunoglobulins [254, 255].
Gene expression
Antibodies must have enough antigen-binding diversity (determined by the variable (V) region)
in order to recognize and target every possible antigen, while maintaining the biological effec-
tiveness of the constant (C) region. Instead of being encoded by a single contiguous DNA se-
quence, immunoglobulin chains are encoded by sets of gene segments. This is achieved through
somatic recombination, during B-cell development to assemble a functional gene encoding ei-
ther a heavy or a light chain. The region of the chromosome that encodes an Ig H, kappa
and lambda chains are found on three different chromosomes; heavy chain genes are found on
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Figure 1.10: Major steps in synthesis of immunoglobulin variable genes.
chromosome 14 [256] while for lambda and kappa light chains genes are on chromosomes 22 and
2 [257]. As previously mentioned in this section, differences between domains are located on
the 3 complementary determining regions (CDR1, CDR2 and CDR3). Somatic recombination
of the genes between the domains generates a unique immunoglobulin variable region. This
combination is called V(D)J recombination [258]. Ig gene segments in mammals are organized
in groups of variable (V), diversity (D), and joining (J) [259, 258]. V, D, and J are present in
Ig heavy chains, while in Ig light chains only V and J segments are found, each one of which
encodes for part of framework (FR1-4) and complementary determining (CDR1-3) regions. The
immunoglobulin loci also contain regulatory elements; leader (L) sequences are found upstream
of each V region and enhancer elements are present with the segments facilitate transcription.
Multiple copies of the V, D and J gene segments exist and undergo somatic recombination
during the development of B cells (Figure 1.10).
The series of events that lead to the generation of an antibody is as follows: first, a DH and a JH
are randomly rearranged (D-J joining); next, a random VH segment is spliced to generate DJH.
VDJH and CH are transcribed and intervening sequences are spliced out of the primary mRNA
before mature message is translated into H chain (protein). L chain recombination occurs with
V and J and proceeds as for H chain [59, 60, 67]. In both cases L segments encode a leader
(signal peptide) sequence that is used to transport Ig into the endoplasmatic reticulum (ER)
and is not present in the mature Ig protein. Each B cell makes antibody of a single antigen
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specificity, which results from that B cell productively rearranging only one L and one H chain
gene. Productive rearrangement of one allele inhibits the rearrangement of the other. If in a B
cell both H and L chains genes are not successfully rearranged, it undergoes apoptosis [259].
1.2.14 PCR amplification of Antibody genes
Advances in genetic engineering and expression over the past years have provided powerful tools
for analyzing antibody function and producing antibodies with desired functional properties.
Chimeric antibodies can be obtained by joining murine V regions to human C regions. Hybrido-
mas are a major source of monoclonal antibodies. Hybridomas result from the fusion of a spleen
cell and a myeloma cell line. Thus, an immortal, constantly dividing clone of cells is produced,
dedicated to making a specific antibody. Hybridoma supernatants are easy to produce, espe-
cially for large numbers of different monoclonal antibodies, but are relatively low in monoclonal
antibody concentration. mRNA is isolated from a hybridoma producing an antibody of inter-
est and used as a template for PCR amplification of V regions. Variable regions were initially
obtained by genomic cloning in bacteriophage [260], or cDNAs produced by standard tech-
niques [261]. Because of the difficulties involved with producing and screening bacteriophage
libraries, attention has increasingly focused on the use of polymerase chain reaction (PCR)
based approaches to obtain V regions for expression [262]. PCR approaches using degenerate
oligonucleotides as primers can result in cloning variable regions from antibody producing cells
(hybridomas) without any prior information about the antibody’s amino acid or nucleic acid
sequence [263, 264] . In order to clone V regions, primers must be designed for both 5’ and
3’ ends. Designing primers of the 3 prime end of the V region is relatively straightforward
since there are few different constant regions. However it is more difficult to design primers
for the 5 end. Two major approaches have been extensively used: primers designed to prime
in either the first framework region [264, 265], or in the leader peptide sequence [262, 263].
Although priming in the framework regions using conserved sequences can be used for V region
cloning, possible amino acid changes introduced into this region may have a negative impact
on antibody affinity [262]. Therefore, priming in the conserved hydrophobic leader sequence is
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generally a preferable strategy. Further examination of the murine sequences contained within
the Kabat database (collection and alignment of amino acid and nucleotide sequences of human
and mouse proteins of immunological interest) [266], have made possible the design of a family
of degenerate primers predicted to prime the majority of different variable regions [262].
1.3 Aim of the project
The primary aim of this project was to develop a gene-transfer vector for gene therapy of Motor
Neuron Diseases that will allow us to achieve minimal invasive administration of the vector by
targeting the peripheral sites of the neuromuscular synapse in order to reach the affected cells
located in the spinal cord. On this front the major aims of this project can be summarized as
follows:
I. Engineering and cloning of targeted lentiviral vectors with tropism to MNs via the NMJ by
incorporating antibodies against presynaptic terminal receptors Thy1.1, p75NTR and CAR.
II. Assess and prove the specificity of these new vectors in vitro on a number of cell lines and
primary motor neuron cultures.
III. In vitro assessment of retrograde axonal trafficking of targeted vectors in MN compart-
mented cultures.
IV. Assessment of transport into CNS via retrograde axonal pathway and MN transduction
upon in vivo peripheral muscle administration.
Chapter 2
Methods and Materials
2.1 Engineering membrane bound antibodies for target-
ing
The aim of this study was to generate a gene transfer vector that will allow us to achieve minimal
invasive administration of the vector by targeting the peripheral sites of neuromuscular synapse
in order to access the affected cells in the spinal cord. The antibodies chosen to be engineered
and used to produce targeted lentiviral vectors were against presynaptic terminal receptors
Thy1.1, p75NTR and CAR (coxsackievirus and adenovirus receptor). On this front cDNAs of
rat heavy and light chain variable regions of these antibodies had to be amplified and cloned
into the final expression cassette vector (pAbCD20) (Appendix A.1).
2.1.1 Identification of hybridoma producing mAb of interest
Hybridomas used in this study were: (1) the OX-7 (Thy1.1) obtained from ECACC (84112008).
OX-7 hybridoma clone was generated by the fusion of NS1 myeloma cells with BALB/c spleno-
cytes. The antibody which produces, Thy-1.1 (CD90), is a 2537 kDa GPI-anchored protein
found on the external leaflet of the lipid bilayer, localizing to lipid rafts and binds to thymo-
46
2.1. Engineering membrane bound antibodies for targeting 47
cytes expressing the Thy 1.1 determinant (specific for rat and AKR mouse) but not to those with
the Thy 1.2 determinant (BALB/c or CBA mouse); (2) the IgG192 (p75NTR) hybridoma cell
line (kindly provided by Professor Giampietro Schiavo, London Research Institute). Hybridoma
clone was generated by the fusion of Sp2/O-Agl4 myeloma cells with BALB/c splenocytes from
mice immunized with detergent-solubilized plasma membrane proteins of PC12 cells and se-
cretes a monoclonal antibody specific to rat surface protein p75NTR; and (3) the CAR (RmcB)
hybridoma cell line obtained from ATCC (CRL-2379), specific for mouse, rat and human.
OX-7 cells were cultured in RPMI-1640 (Sigma, UK) supplemented with 2 mM L-glutamine
and 10% Newborn Calf Serum (Heat Inactivated, Sigma, UK). 192 cells were cultured in RPMI-
1640 supplemented with 10% Fetal Calf Serum (FCS), 1% penicillin/streptomycin, 2 mM L-
glutamine and 1% sodium pyruvate. RmcB cells were cultured in RPMI-1640 (Gibco, UK),
supplemented with 10% newborn Calf Serum, 2 mM L-glutamine, 10 mM Hepes and 1 mM
sodium pyruvate.
Production of mAb from hybridoma cell line
Hybridoma supernatants are a major source of monoclonal antibodies and are easy to produce.
In order to examine whether these hybridomas produce Thy1.1 and p75NTR and CAR (RmcB)
antibodies respectively, a protocol was used, in which, the hybridoma is grown and split 1:10.
The cells are then grown for 3 days in complete growth medium supplemented with 10% fetal
calf serum, 2 days in serum free medium, 2 days in 1% fetal calf serum and finally 2 days in
serum free medium. The supernatant is then harvested (see Yokoyama et al). The specificity
of the antibodies produced by each hybridoma, was then tested by Western blot analysis and
immunohistochemisty studies.
2.1.2 Characterisation of mAb
The specificity of OX-7 and p75NTR(192) and CAR antibodies was tested by Western blot
analysis and Immunofluorescences on a panel of different cell lines and rat and mouse tissue
48 Chapter 2. Methods and Materials
lysates.
-Western blot analysis
Tissue Harvesting:
All procedures were performed according to the protocols approved (Animal Scientific Proce-
dures) Act of 1986 on animal research. Briefly rats were killed humanely by means of a lethal
injection of anaesthetic (Pentobarbital). Samples were harvested from the following tissues:
Brain, Cerebellum, Optic nerve, Eye bulb, Heart, Liver, Lungs, Kidney and Spleen.
Tissue lysis:
Tissues were weighed and then lysed in radioimmune precipitation assay lysis buffer (RIPA,
Pierce, USA) with a protease and phosphatase inhibitor cocktail (Pierce, USA). They were
homogenized, kept 10 min on ice and further processed with low intensity sonication in short
bursts for 1 minute to avoid heating of sample. The lysates were subsequently centrifuged at
10,000 g for 15 min at 4◦C, and the supernatant was collected and placed in a new tube. The
samples were aliquoted and stored at −80◦C until needed. The concentration of protein in
each sample was determined by the BCA Protein Assay method (Pierce, USA) carried out on
samples diluted 10, 50 and 100 times.
Western blot was performed to cell and tissue lysates to detect expression of receptors in target
cell lines. Antibodies and concentrations used in Western blot analysis are presented on Table
2.1
Table 2.1: Antibodies used in Western blot analysis for detection of target receptors
expressed on target cell lines
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
anti-rat Thy1.1 Produced by Mouse 1:2 Anti-mouse-HRP
(CD90) hybridoma in house Monoclonal 1:1000
anti-rat p75NTR Produced by Mouse 1:6 Anti-mouse-HRP
(MC192) hybridoma in house Monoclonal 1:1000
(unconcetrated)
- Immunofluorescence
Acid washed glass cover slips were prepared, and coated with Poly-d-lysine (0.1 mg/ml; SIGMA,
2.2. Construct preparation: Cloning of antibody V regions 49
UK), for for all cell lines, and double coated with Poly-d-lysine (0.1 mg/ml) and Collagen-IV
(0.01%; SIGMA, UK) for PC12 cells. Prior to seeding, coverlips were washed 3-times with
PBS. Once cells reached the desired confluence, they have been fixed with 2% PFA/PEM/MTS
for 30 min in room temperature. After fixation and prior to staining with primary antibodies,
non-specific binding of the antibody was reduced by incubating cells with blocking solution
(2% BSA in PBS) for 30min at RT. Cells were then incubated with antibodies presented on
Table 2.2, diluted in 2% BSA in PBS, at 4◦C overnight for primary antibody staining and 1 hr
RT for secondary antibody staining. Between primary and secondary antibody incubation, 3
washes with 2% BSA in PBS, were performed. Nuclear staining was achieved by adding DAPI
in Mowiol mounting solution (1:1000) and visualised with a Fluorescent inverted microscope
(NIKON TS100-i).
Table 2.2: Antibodies used for Immunofluorescent analysis for cell surface expression of
Thy1.1, p75NTR and CAR on targeted cell lines.
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
anti-rat Thy1.1 Produced by Mouse 500µl Anti-mouse-
(CD90) hybridoma in house Monoclonal in each well Alexa-Fluor 488
(unconcentrated) (1:1000 in 2% BSA/PBS)
anti-rat p75NTR Produced by Mouse 1:200 Anti-mouse-
(MC192) hybridoma in house Monoclonal in 2% BSA/PBS Alexa-Fluor 488
(concetrated) (1:1000 in 2% BSA/PBS)
anti-mouse/rat Abcam Rabbit 1:100 Anti-rabbit
p75NGF polyclonal in 2% BSA/PBS Alexa-Fluor 488
(1:1000 in 2% BSA/PBS)
anti-mouse/rat/human Produced by Mouse 500µl Anti-mouse
CAR (RmcB) hybridoma in house Monoclonal in each well Alexa-Fluor 488
(unconcetrated) (1:1000 in 2% BSA/PBS)
anti-mouse/rat/human Millipore Mouse 1:200 Anti-mouse
CAR (RmcB) Monoclonal in 2% BSA/PBS Alexa-Fluor 488
(1:1000 in 2% BSA/PBS)
2.2 Construct preparation: Cloning of antibody V re-
gions
The expression plasmids pαThy1.1, pαp75NTR and pαCAR, encoding for the chimeric mem-
brane bound antibodies for targeting were generated by amplification of heavy and light chain
variable regions of murine anti-Thy1.1, anti-p75NTR (clone MC-192) and anti-CAR (clone
RmcB) antibodies, as presented in Figure 2.1. RNA was extracted from using the RNeasy Mini
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Figure 2.1: Schematic presentation of cloning antibody variable regions. Schematic diagram
describing cloning of V regions of antibodies for targeting. RACE PCR amplification of heavy and light
chain variable regions from hybridoma cell lines and subsequent insertion upstream human constant
regions.
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Kit (QIAGEN, UK). First strand cDNA (RACE-ready cDNA) synthesis was performed using
a modified lock-docking oligo(dT) anti-sense primer and the SMARTer II A oligo (SMARTer
RACE cDNA Amplification Kit; Clontech). Heavy and light chain variable regions were PCR
amplified (5’RACE). First round 5’RACE was performed using UPM (universal Primer mix;
Clontech) and constant region degenerate Hvbw(deg) and Lvbw(deg) primers (Supplementary
Table 2). 5’ RACE PCR reactions were performed using the Advantage 2 Polymerase Mix
(Clontech) and RACE PCR products were cloned to pCR 2.1-TOPO (Invitrogen, UK) and
sequenced. Second round PCR amplification was performed with gene specific primers (Sup-
plementary Table 2) using the Platinum Pfx DNA Polymerase (Invitrogen, UK), and blunt-end
PCR products were cloned to pCR-Blunt II-Topo (Invitrogen, UK) and sequenced. Minipreps
were performed using the QIAprep Spin Miniprep Kit Using a microcentrifuge (QIAGEN, UK)
and then sequenced. For the sequencing reactions 1µl of M13 Sequencing primers (M13 Reverse
and M13 Forward (-20)) included in the kit were used at a concentration 3.2 pMoles/µl. A
minimum of 20 independent clones for each chain have been sequenced in order to identify
the consensus sequence of the antibody (MRC, CSC Genomics Laboratory). Primer sequences
used for amplification of heavy and light chains were designed to insert the coding sequences
for XhoI and NheI restriction enzymes (heavy chain) and HindIII and BsiWI restriction sites
(light chain) that will facilitate cloning. Final PCR products were cloned upstream human
heavy and light chain constant regions of the pαCD20 [93] plasmid (Appendix A.1). The re-
sulting constructs were designated as pαThy1.1, pαp75NTR and pαCAR. Constructs pαCD20,
pIgαβ (Appendix A.2), and pSINmu(SGN) (Appendix A.3) were kindly provided by Dr P.
Wang (University of Southern California, Los Angeles, CA 90089) [93].
2.2.1 Oligonucleotide primer design
Oligonucleotides used were designed based on Larrick et al [263] and Coloma et al [262]. To
clone the variable regions for sequence analysis, redundant primers hybridizing to the leader
sequence (5’ primer) and to the C constant region immediately downstream of the V-J region (3’
primer) were used in first round of PCR and 5’ RACE reactions. Primers had restriction sites
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chosen to facilitate cloning of the PCR product to the final expression cassette vector. In general
the amplified fragments of DNA were expected to be 400-500bp in length, corresponding to the
size of a V region with additional bases in the leader and 5’ portion of the constant regions and
restriction enzyme sites. Degenerate primers used in PCR reactions are presented on Tables
2.3-2.6.
Table 2.3: Degenerate Primers for Heavy chain Variable region amplification of mouse
Thy 1.1 (OX7/CD90) and mouse 192-IgG (p75)
Murine Immunoglobulin Heavy chain Variable Region PCR Primers
5’ End sense leader sequence
ie001Hvfw1(deg): 5’ GAGACTCGAGCACCATGRASTTSKGGYTMARCTKGRTT 3’
ie002Hvfw2(deg): 5’ GAGACTCGAGCACCATGRAATGSASCTGGGTYWTYCTCT 3’
ie003Hvfw3(deg): 5’ GAGACTCGAGCACCSAGGTGMAGCTCSWRSARYCSGGG 3’
(Coloma et al., 1992)
3’ End sense constant region
Hvbw(deg): 5’ GAGAGCTAGCAYCTCCACACACAGGRRCCAGTGGATAGAC 3’
(Larrick and Fry, 1991)
Table 2.4: Degenerate Primers for Light chain Variable region amplification of mouse Thy
1.1 (OX7/CD90) and mouse 192-IgG (p75)
Murine Immunoglobulin Light chain Variable Region PCR Primers
5’ End sense leader sequence
ie005LvFw1(deg): 5’ GAGAAAGCTTCACCATGGAGACAGACACACTCCTGCTAT 3’
ie006LvFw2(deg): 5’ GAGAAAGCTTCACCATGGATTTTCAAGTGCAGATTTTCAG 3’
ie007LvFw3(deg): 5’ GAGAAAGCTTCACCATGGAGWCACAKWCTCAGGTCTTTRTA 3’
ie008LvFw4(deg): 5’ GAGAAAGCTTCACCATGKCCCCWRCTCAGYTYCTKGT 3’
(Larrick and Fry, 1991)
3’ End sense constant region
Lvbw(deg): 5’ GAGACGTACGACTGGATGGTGGGAAGATGGA 3’
(Coloma et al., 1992)
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Table 2.5: Primers used in 5’RACE for Heavy Chain Variable region amplification.
Primers used in 5’Race reaction for the amplification of Heavy chain V regions
5’ End sense
Long Universal Primer Mix (Clontech)
3’End sense constant region
Hvbw(deg): 5’ GAGAGCTAGCAYCTCCACACACAGGRRCCAGTGGATAGAC 3’
(Larrick and Fry, 1991)
Table 2.6: Primers used in 5’RACE for Light Chain Variable region amplification.
Primers used in 5’Race reaction for the amplification of Light chain V regions
5’ End sense
Long Universal Primer Mix (Clontech)
3’End sense constant region
Lvbw(deg): 5’ GAGACGTACGACTGGATGGTGGGAAGATGGA 3’
(Coloma et al., 1992)
2.2.2 PCR amplification of V regions with Gene Specific Primers
(GSPs)
Gene specific primers were designed to specifically amplify the V regions including the leader
peptide and exactly the 3’ end immediately downstream of the V-J region (3’primer) (up to 9
residues following the W118 for the heavy chain and F118 for the light chain) and were used
during the second round of PCR reactions. Gene specific primers used in PCR reactions are
presented on Tables 2.7-2.12.
PCR reactions were performed in final volume of 50µl using 5µl of cDNA (obtained from
first strand cDNA synthesis), 0.5µl of Platinum Pfx, 10 µM of each primer, 150µM dNTPs
(Invitrogen, UK) and 50mM MgSO4 (Invitrogen, UK). PCR reactions were carried out for
30 cycles in a Thermal cycler (BIO-RAD) with: melting temperature 94◦C, for 15sec; primer
annealing at 55◦C, 30 sec; and primer extension at 68◦C, 1.5 min. 5’ RACE reactions were
performed in 50µl final volume using 1µl Advantage 2 Polymerase Mix (Clontech)and 10mM
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Table 2.7: Gene-specific primers for amplification of Heavy chain Variable region of mouse
anti-rat Thy1.1
Gene specific murine Immunoglobulin Heavy chain Variable Region PCR Primers
5’ End sense leader sequence
ie025HvfwOX7A 5’ GAGACTCGAGCACCATGGAATGG 3’ 58◦C
ie026HvfwOX7B 5’ GAGACTCGAGCACCATGGAATGGAG3’ 58◦C
HvfwThy1.1 5’ GAGACTCGAGCACCATGGGATGG 3’ 58◦C
(designed to hybridise to leader peptide as V region PCR product was cloned into TOPO vector )
3’ End sense variable region (9 residues after kabat W:118)
ie024Hvbw 5’ GAGAGCTAGCTGAGGAGACTGTGAGAGTGGTGC 3’ 58◦C
(primer re-designed to hybridise to residues 11 and 12 located 9 residues after W:118 of CDR3)
dNTP Mix (Clontech). The following Touch-down PCR reaction conditions (according to
manufacturer’s instructions)were used: melting temperature 94◦C, for 15 sec; primer annealing
at 68◦C, 30 sec; and primer extension at 68◦C, 1.5 min, for the first 5 cycles; primer annealing
temperature changed to 66◦C, 30 sec for the following 5 cycles and reduced finally to 63◦C, 30
sec for the remaining cycles.
2.2.3 Final expression vector
The construct encoding the membrane bound form of the human/mouse chimeric antibody
against human CD20 antigen (pαCD20) was kindly provided by P. Wang (University of South-
ern California, Los Angeles, CA 90089). This construct was generated after cDNAs for the
human kappa light chain constant region and the membrane bound human IgG1 constant
chain region were amplified and inserted downstream of the human CMV and EF1a promot-
ers respectively in the pBUdCD4.1 vector (Invitrogen, UK). This vector was used as our final
expression cassette vector [93] plasmid. Final PCR products were cloned upstream human
heavy and light chain constant regions in pαCD20 [93] plasmid in the place of heavy and light
chain V regions of anti-CD20 antibody. Cloning was facilitated by enzymatic digest reactions
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Table 2.8: Gene-specific primers for amplification of Light chain Variable region of mouse
anti-rat Thy1.1
Gene specific murine Immunoglobulin Light chain Variable Region PCR Primers
5’ End sense leader sequence
ie023Lvfw 5’ GAGAAAGCTTCACCATGGAGACAGA 3’ 58◦C
(designed to hybridise to leader peptide according to the PCR product generated by RACE PCR)
3’ End sense variable region (9 residues after kabat F:118)
ie022LvbwThy1.1 5’ GAGACGTACGTTTTATTTCCAGCTTGGTCCCCCCT 3’ 58◦C
(primer designed to hybridise to residues 11 and 12 located 9 residues after F:118 of CDR3)
Table 2.9: Gene-specific primers for amplification of Heavy chain Variable region of mouse
anti-rat 192-IgG (p75NTR)
Gene specific murine Immunoglobulin Heavy chain Variable Region PCR Primers
5’ End sense leader sequence
ie021Hvfwp75 5’ GAGACTCGAGCACCATGGATTGGCTGTGGAACTTGCTATTC 3’ 58◦C
(designed to hybridise to leader peptide according to the PCR product generated by RACE PCR)
3’ End sense variable region (9 residues after kabat W:118)
ie032Hvbwp75 5’ GAGAGCTAGCTGAGGAGACGGTGACTGAGGTTCC 3’ 58◦C
(primer designed to hybridise to residues 11 and 12 located 9 residues after W:118 of CDR3)
XhoI/NheI for heavy chain and BsiWI /HindIII for light chain variable region. The result-
ing constructs were designated as pαThy1.1 (Appendix A.4), pαp75NTR (Appendix A.5) and
pαCAR (Appendix A.6). Constructs pαCD20, pIgαβ, and pSINmu(SGN) were kindly pro-
vided by Dr P. Wang (University of Southern California, Los Angeles, CA 90089). Maps of all
constructs are presented at the Appendix section.
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Table 2.10: Gene-specific primers for amplification of Light chain Variable region of mouse
anti-rat 192-IgG (p75NTR)
Gene specific murine Immunoglobulin Light chain Variable Region PCR Primers
5’ End sense leader sequence
ie023Lvfw 5’ GAGAAAGCTTCACCATGGAGACAGA 3’ 58◦C
(designed to hybridise to leader peptide according to the PCR product generated by RACE PCR)
3’ End sense variable region (9 residues after kabat F:118)
ie027Lvbwp75 5’ GAGACGTACGTTTGATTTCCAGTTTGGTGCCTCCAC 3’ 58◦C
(primer designed to hybridise to residues 11 and 12 located 9 residues after F:118 of CDR3)
Table 2.11: Gene-specific primers for amplification of Heavy chain Variable region of mouse
anti-human/mouse/rat CAR(RmcB)
Gene specific murine Immunoglobulin Heavy chain Variable Region PCR Primers
5’ End sense leader sequence
HvfwCAR 5’ GAGACTCGAGCACCATGGATTCAC 3’ 58◦C
(designed to hybridise to leader peptide according to the PCR product generated by RACE PCR)
3’ End sense variable region (9 residues after kabat W:118)
HvbwCAR 5’ GAGAGCTAGCTGAGGAGACAGTGAGAGTGGTGC 3’ 58◦C
(primer designed to hybridise to residues 11 and 12 located 9 residues after W:118 of CDR3)
2.3 Construct preparation: Single chain antibodies and
human LP
2.3.1 ScCAR and Scp75NTR
Sequences of both CAR and p75NTR were designed in house and requested for gene synthesis
from Gene Art (Life Technologies, Invitrogen). Once final products were obtained they have
been subsequently cloned into pcDNA3 expression vector (Invitrogen, UK) with HindIII/NotI
double digest. Final constructs were designated as ScCAR(RmcB) and Scp75NTR and their
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Table 2.12: Gene-specific primers for amplification of Light chain Variable region of mouse
anti-human/mouse/rat CAR(RmcB)
Gene specific murine Immunoglobulin Light chain Variable Region PCR Primers
5’ End sense leader sequence
LvfwCAR 5’ GAGAAAGCTTCACCATGGATTCACAG 3’ 58◦C
(designed to hybridise to leader peptide according to the PCR product generated by RACE PCR)
3’ End sense variable region (9 residues after kabat F:118)
LvbwCAR 5’ GAGACGTACGTTTGATTTCCAGCTTGGTGCCTCC 3’ 58◦C
(primer designed to hybridise to residues 11 and 12 located 9 residues after F:118 of CDR3)
maps are presented on Appendix A.7 and A.8 respectively.
2.3.2 Human leader peptide-hLPp75NTR
Mouse leader peptide sequences found upstream heavy and light chain V regions of p75NTR
were substituted by Human leader peptide sequences which were used in anti-CD20 antibody
[93]. Sequences were designed in house and for time constraints were send for gene synthesis to
Gene Art (Life Technologies, Invitrogen). Once final products were obtained they have been
subsequently cloned into pαp75NTR expression vector, where heavy and light chain V regions
expressing a mouse leader peptide were substituted by the new ones expressing the human LP
by double digests XhoI/NheI (heavy chain) and HindIII/BsiWI (light chain). Final construct
was designated as hLPp75NTR.
2.4 Molecular Biology Techniques
2.4.1 Agarose gel electrophoresis
DNA samples were loaded onto a 1.5% agarose gel (1gr of agarose powder (Sigma, UK) dissolved
in 100ml of 1X TAE buffer by microwaving). 1µg/ml of ethidium bromide (EtBr, 10mg/ml,
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Sigma, UK) was added to the agarose gel which allowed visualization under the ultraviolet light
(UV). In each DNA sample was added appropriate volume of 6x DNA loading dye (NEB Inc)
to 1x final concentration. Gels were run at 90-100 Volts for approximately 30-40 mins. Images
of gels were acquired using a UVP transilluminator. The fragment size was confirmed with a
standard 2-log DNA Ladder (0.1 kb 10 kb, NEB Inc).
2.4.2 Gel extraction-Purification
DNA fragments were extracted from agaroze gels and purified using the QIAquick gel extraction
kit (QIAGEN, UK) according to manufacturer’s instructions. DNA was eluted in 40µl of the
provided elution buffer.
2.4.3 Ligation
Ligation reactions were performed using T4-DNA-ligase (Invitrogen, UK) and the appropriate
buffer at 1x final concentration (10x concentrated stock) in 20µl final volume. 100ng of vector
samples were used with the molar ratio of vector to insert set at 1:4, 1:6 and 1:8, respectively.
Reactions were always incubated at room temperature (22◦C) for 1 hr and 3µl of ligated mixture
was used in transformation reactions of chemically competent bacterial cells.
2.4.4 TOPO cloning
pCRII-Blunt-TOPO vector was used to perform TOPO cloning reactions of blunt-end PCR
products with the Zero Blunt TOPO PCR cloning kit according to the manufacturers instruc-
tions, while pCR 2.1-TOPO vector was used for TOPO cloning reactions of PCR products
bearing TA overhangs.
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2.4.5 Transformation of chemically competent cells
One vial of SOC medium (Invitrogen, UK) was pre-warmed to 37◦C and the water bath was
balanced to 42◦C. Chemo-competent E.coli DH5α cells (NEB, UK) and plasmids were thawed
on ice. 500ng of each plasmid-DNA sample were added to competent E.coli DH5 cells under
sterile conditions. Tubes were incubated on ice for 30 min. The cells were then heat shocked
at 42◦C for 30 seconds and tranfered back on ice for 2 min prior to addition of 250µl of pre-
warmed SOC medium was added to each tube under sterile conditions, followed by incubation
at 37◦C for 30 mins. Under sterile conditions, 1/10 and 9/10 of the of each culture were spread
on two individual pre-warmed agar plates containing the appropriate antibiotic for selection,
using a sterile spreader. A negative control of non-transformed competent DH5 cells was also
included. Plates were incubated overnight at 37◦C. Single colony of transformed bacteria were
picked and grown in 5 ml of LB medium containing 50µg/ml of antibiotic. The mini-cultures
were incubated for 8 hrs at 37◦C, in a shaking incubator at 250 rpm.
2.4.6 Restriction Enzyme Digests
Restriction Enzyme Digest reactions were performed utilizing enzymes and appropriate buffers
from NEB (New England Biolabs, UK). Reactions were performed in final volume of 20µl for
diagnostic digests and in 40µl for subcloning processes. In all cases buffers were used in 1X
final concentration (from a 10X concentrated stock) and the required enzyme in a volume of
maximun 1/10 of the final volume. 1X BSA (from a 10X concentrated stock) was added when
required. Plasmid DNA used in these reactions was at a concentration of 500 ng/µl. Higher
concentrations of plasmid DNAs were used in digests for cloning purposes. Reactions were
performed in appropriate temperature according to manufacturer’s instructions supplied with
each enzyme. All enzymes were heat inactivated (according to manufacturer’s instruction) prior
to further use in cloning procedures.
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2.4.7 Plasmid purification
All DNA plasmids used in this project were purified using QIAGEN DNA purification kits
for both Mini and Mega-preps (QIAGEN, UK). Mini-preps were used to assess the identity of
the plasmid DNA and confirm successful cloning while Mega-preps (Endo-Free MEGA prep,
QIAGEN, UK) were used for production of higher quality and concentration of DNA plasmids
required for lentiviral production.
2.4.8 Determination of DNA concentration
Spectrophotometry The total concentration of purified plasmid DNA was initially deter-
mined by spectrophotometry. DNA was diluted 1:300 in TE buffer and absorbance measured
at 260 nm (Glomax Multi Detection System, Promega, USA). To determine the quality of
DNA, the ratio of absorbance at 260 nm and 280 nm (Proteins and RNA) was calculated. A
ratio between 1.8 and 2.0 was indicative of high purity DNA. Each DNA concentration reading
was performed in duplicate to ensure consistence measurement.
Super-coiled DNA gel quantification
The amount of super-coiled DNA was quantified by DNA gel electrophoresis, in order to be
used for subsequent transfections and lentiviral production. Serial dilutions of each DNA sample
were prepared (< 1 mg/ml 1:10 dilution, between 1-4 mg/ml 1:100 dilution and > 4 mg/ml
1:200 dilution) prior to gel quantification. The diluted DNA samples were analyzed by gel
electrophoresis, running increasing concentrations of each sample alongside equally increasing
concentrations of 1 kb DNA ladder (NEB, UK). The band intensity of each DNA sample was
analyzed by Silicon software to determine its super-coiled DNA concentration by comparing to
the band intensity of standard 1 kb DNA ladder. The procedure is described in detail on figure
2.2.
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Figure 2.2: Super-coiled DNA gel quantification (A) Schematic presentation of DNA dilutions
and loading of agaroze gel. (B) Example of gel image obtained from quantification of pMD-RVGCVS24
B2c. a) NEB 1kb ladder key; b) Increasing concentrations of ladder and plasmid (0.5-2.0 µl) were
used to generate an average. Supercoiled DNA (green box) is aligned to the closest ladder band (here
3 kb) and DNA concentration is quantified by densitometry using equivalent mass (ng) of the selected
ladder band (here 125 ng). Non-supercoiled/relaxed DNA is omitted.
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2.5 Western blot analysis
Sodium Dodecyl Sulfate PolyAcrylamide Gel electrophoresis (SDS-PAGE)
Polyacrylamide gels composed of 12% resolving gel and 5% stacking gel were set up. In detail,
resolving gel solution was immediately added on to the gel tray (BioRad ,UK) and filled up
with water saturated butanol to flatten the gel top. Once the gel was polymerized, butanol was
removed and washed with dH2O. The stacking gel solution was added onto top of resolving gel
and the appropriate combs were inserted.
Loading control
p24 values (Table 2.13) were used to confirm equal loading of viral samples on the SDS page.
Loading was normalised to p24 (ng/ml) concentration of each lentiviral preparation in order
to ensure loading of equal ciral particles. 20µl of viral samples were mixed with 5µl of SDS
staining dye and boiled at 100◦C for 10 minutes. 10µl of pre-stained protein ladder (Novex
sharp prestained, UK) was used. Samples were run at 50V and when bands migrated into
resolving gel power was switched to 150V.
Table 2.13: Antibody used for Loading control in Western blot analysis
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
Anti-HIV Abcam Rabbit 1:2,000 Anti-rabbit-HRP
(p55+p24+p17) 1:25,000
Upon gel electophoresis, gels were transferred onto a nitrocellulose membrane (Hybond-ECL,
GE healthcare, Chalfont St Giles, UK) by transfer sandwich kit and tank transfer system
running at 100V for 1 hour. Upon transfer, membrane was carfully removed and blocked
overnight in 5% Marvel skimmed milk Sigma, UK) solution in 1xPBS-Tween (0.1% v/v) (Sigma,
UK). Next day, primary and secondary antibodies (when needed, unconjugated antibodies) were
diluted in 0.5% Marvel in 1xPBS and membranes were incubated for 2 hrs RT and 1 hr RT
respectively. Between primary and secondary antibody incubation three 20 min washes were
performed with 5% Marvel in PBS-Tween (0.1% v/v). Finally, membranes were incubated with
3ml of ECL substrate (Pierce, Rockford, IL, USA) for 5 min and added to X-ray films (Kodak)
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and developed in the dark room.
The protein blots were re-probed by stripping using restore western stripping buffer (Pierce,
UK) for 15 minutes, then washed with 1xPBS-Tween (0.1% v/v) for 15 minutes, re-blocked
with 5% milk solution in 1xPBS-Tween (0.1%v/v) for 1 hour and finally incubated with new
primary antibody, such as with anti-HIV-1 gag (p55+p24+p17) antibody (Ab63917, Abcam).
Table 2.14: Antibodies used in Western blot analysis for detection of molecules expressed
on the lentiviral surface
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
Anti-HA-HRP Myltenyi Biotec Mouse 1:10,000
Monoclonal
AntihumanIgG Abcam Mouse 1:700 Anti-mouse-HRP
(L) Monoclonal 1:1000
2.6 Production and Purification of Lentiviral Vectors
Over the last decade lentiviral vectors have emerged and developed as a powerful tool for
transgene delivery. Lentiviral vectors have been used in several applications in neurosciences,
hematology, stem cell/ biology, transgenesis and developmental biology, while in several cases
are also been used in ongoing human clinical trials. The method described in this section
outlines improved procedures to produce, concentrate and titrate lentiviral vectors based on
Human Immunodeficiency Virus (HIV-1).
Production of recombinant non-replicative HIV-1 based lentiviral vectors was achieved by tran-
sient co-transfection of human embryonic kidney (HEK 293T) cells using high concentrations
of four different plasmids. These are: (i) the lentiviral expression plasmid (transfer plasmid)
which encodes the transgene of interest flanked by all cis-acting viral sequences required for
packaging of RNA genome, (ii) one or two packaging plasmids which encode the viral structural
and functional proteins and (iii) the pseudotyping (envelope) plasmid which encodes for the
glycoprotein responsible for receptor recognition. For production of targeted lentiviral vectors
two additional plasmids were required. A plasmid encoding for human Ig|alpha and Igbeta
(designated as pαIgαβ), two immunoglobulin associated proteins that are required for sur-
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face expression of antibodies and either pαThy1.1, pαp75NTR or pαCAR encoding for chimeric
membrane bound antibodies used for targeting.
2.6.1 Propagation, passaging and preservation of packaging cell line
HEK 293T
Successful lentiviral vector production resulting in high titers is tightly connecting to the state
of HEK293T cells used. It is critical to use healthy cells at low passage numbers and actively
replicating. Thus, early passage HEK 293T cells were used and grown and passaged as described
below. 293T were grown at 37◦C in a humidified 5% CO2 incubator. Cells were never allowed to
reach 90% confluency. It was found to be vital for high titer lentiviral production to maintain
cell density at maximum 80% at all times. During subculturing, complete DMEM media
was aspirated from from a T175 cm2 tissue culture flask when the cells have reached 75-80%
confluency. Cells were then washed once with 25 ml of PBS and trypsinized with 2.5 ml of
1x trypsin-EDTA and incubate at 37◦C for 2-3 min. Upon trypsinization 7.5 ml of complete
DMEM media was added to the cells and cells were detached by gently pipetting, creating
single-cell suspension. Cells were usually subcultured in 1:10 ratio and flasks were filled with
complete growth medium to final volume of 25 ml. Three days prior to transfection suitable
number of T175 cm2 flasks with HEK 293T cells was prepared to achieve suitable number
of cells required for viral production. The night before seeding cells for lentiviral production
medium was fully renewed.
2.6.2 Lentiviral prodution
Reagents:
TVM1: In a T75 flask, make up 100 ml serum free DMEM-H without sodium bicarbonate by
the addition of 1.38 g DMEM-H powder (Sigma UK, D5648-SL) to 100 ml sterile tissue culture
water (Sigma UK, W3500). Add 2.5 ml 1 M HEPES (Sigma UK, H3537) and then transfer the
flask to the magnetic stirrer and add a small clean stir bar to the flask. Stir until all powder
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has dissolved then adjust the pH 7.10 by addition of 1 M NaOH. Sterilise by filtration using a
0.20µm syringe filter and store at 4◦C.
TVM2: In a clean autoclaved 500 ml duran bottle or T175 flask, make up 400 ml complete
DMEM-H by the addition of 5.52 g DMEM-H powder (Sigma UK, D5648-SL) to 350ml sterile
tissue culture water (Sigma UK, W3500) while swirling gently. Add 19.72 ml 7.5% sodium
bicarbonate solution (Sigma UK, S8761) and make up to 400 ml using sterile tissue culture
water. Add 10% FBS, 1X Pen-Strep (Penicillin 10,000 U/ml; Streptomycin 10,000 µg/ml,
Sigma UK) and 10 ml 1M HEPES (Sigma UK, H3537). Adjust to pH 7.9, whilst stirring with
magnetic stirrer, by addition of 1M NaOH. Sterilise by filtration using 1 L capacity 0.2 µm
filter (Nalgene, 161-0020) and store at 4◦C.
Procedure:
Recombinant non-replicative HIV-1-based LV vectors were produced using a modified transient
calcium phosphate transfection protocol of HEK293T cells (Olsen’s, personal communication
with Professor Mazarakis). Briefly, twelve 150 mm tissue culture dishes were seeded with
1.4x107 293T cells per dish. 24 hours later 293T cells at 80% confluence, were transfected
as described. Three hours prior to transfection fresh TVM1 and TVM2 media were made
and warmed to room temperature. Immediately before transfection four 50ml Falcon tubes
(VWR, 525-0156) were prepared each containing three times (one tubes for three plates in to-
tal 12 plates) the following: 5µg vector plasmid (326-pRRLsincppt-CMV-eGFPWPRE kindly
provided together with HIV packaging plasmids by Professor James Uney, University of Bris-
tol, Bristol, UK)(Appendix A.9), 2.5 µg of each of the packaging vector plasmids expressing
the HIV-1 gag/pol gene (289-pMD2-LgpRRE; Appendix A.10), HIV-1 Rev (288-pRSV-Rev;
Appendix A.11) together with 2.5µg of each of pαIgαβ (encodes human Igα and Igβ) two
immunoglobulin associated proteins that are required for surface expression of antibodies),
pSINmu and either pαThy1.1, pαp75 or pαCAR (encoding mouse/human chimeric anti-Thy1.1,
anti-p75NTR and anti-CAR antibodies respectively). The 5 plasmid control was generated as
above but lacking the plasmids encoding for the antibodies. Each tube was made up to a final
volume of 8 ml by the addition of TVM1 before addition of 410µl 1 M CaCl2 in two stages; first
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dropwise (5-6 drops) mixing by flicking, then the remainder quickly with no mixing; the reaction
mixtures were subsequently incubated at room temperature for 10 minutes. The media was
removed from the HEK 293-T cells and 32.8 ml TVM2 was added to each falcon tube, mixed by
pipetting up and down. Immediately after mixing, 13.5 ml of the DNA/TVM1/TVM2 mixture
was added to each plate taking care not to dislodge cells. Plates were returned to the incubator
(37◦C, 5% CO2) in stacks of no more than six. 16 h post transfection medium was replaced
with fresh low serum (2%) media supplemented with 10 mM sodium butyrate (ALDRICH,
UK). Thirty-six hours after sodium butyrate induction, the viral supernatant was collected and
filtered through a 45 µm pore size filter. The VSVG (Appendix A.12), 5pl (non-targeted control
vector lacking the membrane bound antibody on it’s surface) and αCD20 pseudotyped vectors
were used throughout as controls. Large-scale preparations were concentrated by centrifugation
at 6000 r.p.m. for 12-16 h at 4◦C (Beckman Coulter Avanti J-E, F500 rotor, Beckman Coulter,
High Wycombe, UK). The pellet was resuspended in ice-cold phosphate-buffered saline (PBS),
and was further concentrated by ultracentrifugation for 90 min at 20,000 r.p.m., 10◦C (Beckman
Coulter Optima L-80XP). The pellet was resuspended in 50µl ice-cold TSSM formulation buffer
(20 mM Tromethamine, 100 mM NaCl, 10 mg/ml sucrose and 10 mg/ml mannitol) every 15
min for 3 h and then centrifuged at 8,000 r.p.m. for 30 s. The supernatant was stored overnight
at 4◦C and the pellet was resuspended with a further 50 µl in ice-cold TSSM and stored under
the same conditions. 16 hrs later the pellet was centrifuged at 8,000 r.p.m. for 30 s and the
two supernatants were pooled, giving a final volume of 100µl (2000-fold concentration). Vector
preparations were stored at -80◦C.
2.6.3 Single plate Lentiviral production
For screening of the fusogenic molecule (SINmu) and the membrane bound antibody (human-
IgG) by western blot analysis, for single particle imaging analysis and for fixed imaging and
live imaging trafficking studies, lentiviral vector particles were generated by single plate 6 plas-
mid co-transfection of 293T cells by a calcium phosphate precipitation method. Transfections
were performed as described above with small differences during the concentration procedures.
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Thirty-six hours post induction viral supernatant from each plate was collected in a falcon
tube and centrifuged for 5 min at 750 rpm to remove viral and cell debris. Upon centrifugation
the viral supernatant was filtered through a 0.45 µm pore size and the viral supernatant was
transferred into a sterile polypropylene ultra-centrifugation tube. A sucrose cushion was cre-
ated by underlying to the bottom of the tube 2 ml of 20% sucrose solution. The preparations
were purified/concentrated by ultracentrifugation for 2 hrs at 81,949g at 4◦C (Beckman Coulter
Optima L-80XP) and the pellet was left to dissolve overnight at 4◦C in 50 µl ice-cold TSSM
formulation buffer and next day aliquoted into single-use cryovials and stored at -80◦C.
Particles produced for single particle analysis and labeled with lypophilic dyes (for trafficking
studies) bear a LacZ reporter gene instead of an eGFP.
2.6.4 Labeling lentiviral particles with lypophilic dyes
To label the particles with lipophilic dye (Vybrant DiO, Invitrogen, UK), an additional step
was added. 16 hours post-transfection media were replaced with Opti-Mem (Invitrogen, UK)
containing 3.7 mM Vybrant dye and incubated at 37◦C for 2 hours before replacing with media
containing sodium butyrate as above. A diagram of labeling of lentiviral particles is presented
on Figure 2.3.
2.6.5 Fluorescent labeling of single lentiviral particles
For detection of individual viral particles, fresh viral supernatant was overlaid upon Poly-D-
Lysine (Sigma, UK) coated coverslips in 24-well culture plate, bound for 2 hrs at RT and fixed
with 2 %PFA for 15 min at RT. A previous attempt to stain vectors CMV-eGFP resulted,
during confocal analysis, in detection with the 488 nm laser of strong backround signal from
unstained vector particles. Thus the experiment was repeated with vectors bearing CMV-LacZ
transfer plasmid. Coverslips were rinsed with PBS and particles were immunostained for the
presence of SINmu fusogen and membrane bound antibody with antibodies presented on Table
2.15. To confirm the presence of virions an anti-p24 antibody was used. Fluorescent images
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Figure 2.3: Lipophilic labeling of lentiviral vectors. 16 hours post transfection media is replaced
with opti-MEM containing DiO Vybrant dye and incubated at 37◦C for 2 hours before replacing with
media containing sodium butyrate. Labeling of the envelope with lypophilic dyes allows highly efficient
labeling of the viral vectors without affecting the biological titer of the vectors. DiO fluoresces in the
green spectrum.
were acquired using a Leica SP5 II confocal microscope (Leica Microsystem, Germany). Three
independent images of each viral preparation, were used for quantification. On each image 5
10x10 µm field were randomly selected, using custom macro in ImageJ (Rasband WS, ImageJ,
U.S. National Institutes of Health, USA. http://imagej.nih.gov/ij/), and used to quantify/count
the number of particles in each of the three channels were counted manually. The percentage
of triple positive particles was calculated.
Table 2.15: Antibodies used in single particle analysis
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
Anti-HA-FITC Myltenyi Biotec Mouse 1:15
Monoclonal in PBS
Invitrogen goat 1:300 Alexa-Fluor-594
in PBS anti-human IgG
(1:300 in PBS)
anti-HIV p24 Abcam Mouse 1:300 anti-mouse-
Monoclonal in PBS Alexa-Fluor-633
(1:1000 in PBS)
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2.7 Titration of lentiviral vectors
2.7.1 Lentiviral Titration by flow cytometry (FACS)
Day 1-Plate set up
24 hrs prior to transduction 1.5x105 of HEK 293 T cells per well were seeded in a 12 well plate
(Nunc, Demark) in final volume of 1 ml DMEM (Sigma,UK) and incubated overnight at 37◦C
and 5% CO2 incubator.
Day 2-Transduction
On the day of transduction cells were observed and confluency was estimated at 60-70%. The
number of cells was counted in two representative wells using a hemocytometer, the average was
calculated and the final number calculated was saved to be used for lentiviral titer calculation.
Serial dilutions of the unconcentrated and concentrated viral stocks were prepared in complete
growth medium containing 8 µg/ml polybrene. Plate set up and recommended preparation of
dilutions and are presented on Figure 2.4.
450 µl of the dilutions prepared in Figure 2.4B were applied to each well according to the 12
well plate schematic diagram (2.4A). Cells were incubated with lentiviral preparations for 6
hours at 37◦C, 5% CO2, when medium was fully replaced with 1 ml fresh complete medium.
Cells were incubated for additional 72hrs at 37◦C, 5% CO2.
Day 5- Preparation to analyse the expression of the eGFP, by flow cytometry.
Medium was carefully removed from each well, cells were washed with 1 ml 1xPBS (Gibco,UK)
and removed carefully. Cells were harvested by adding 250 µl of 1x Trypsin-EDTA (Sigma,
UK). Once cells were detached 750 µl of complete graowth medium were added cell suspension
was collected into a pre-labeled 1.5 ml eppendorf tube. Cells were spun at 2,000 rpm for 6
minutes, supernatant was carefully discarded and tubes were taped to loosen the cell pellet.
To fix the cells, 200l of 4% paraformaldehyde (Sigma,UK) were added for 15 minutes at room
temperature. Cells were then spun at 2,000 rpm for 6 minutes again, followed by removal of
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Figure 2.4: Lentiviral titration by FACS. (A) Schematic presentation of 12 well plate set up for
lentiviral vector titration. (B) Recommended serial dilution scheme for titration of lentiviral vectors
by FACS analysis. Dilutions can be extended if preparation is highly concentrated.
paraformaldehyde. Cell pellet was resuspended in 400 µl of 1x PBS (Gibco, UK), pH 7.4.
Finally, expression of fluorescent (transduced) cells was analysed by flow cytometry (FACS).
During FACS analysis the amount of gated cells in negative control should be set to be less
than 0.1%.
Viral titers were calculated using the following formula:
Transduction units (TU/ml)= (percentage of fluorescent positive cells/100) x (num-
ber of cells per well on day of transdcution) x (vector dilution factor) per µl of
vector. Here vector dilution factor is µl of vector= 1000 µl/450 µl= 2.2 per ml.
(450 µl were added)
The titer was calculated using a percentage of fluorescent positive cells within the range of
1-20%. Choosing values in this range diminishes the possibility of underestimating titer due to
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analysis of cells containing multiple vector copies (assume there is only one viral particle per
cell).
Note 1: It was observed that viral titers varied depending on the cell line used for titration.
When using HEK 293T cells titers for concentrated preps were expected to be within the range
of 1x109-1010 TU/ml. In our lab, with the production method described here, we managed to
achieve titers of up to x1011 TU/ml. When using Hela cells for titration (ie for αCAR targeted
vectors) titers are generally 10-fold lower (108). In all times, if the titer of a concentrated stock
was less than 1x108 TU/ml, it was discarded and never used for subsequent experiments.
Note 2: Lentiviral preparations baring the LacZ reporter gene were titered as follows: LacZ
expression detected using the β-Gal Staining kit (Invitrogen, K1465-01). Positive cells were
then manually counted to determine the number of transducing units per ml.
2.7.2 p24 ELISA
The HIV-1 p24 antigen ELISA RETROtek kit (ZeptoMetrix Corporation, Buffalo, NY, USA)
was used to determine the p24 levels of vector samples. Serial dilutions of the vector samples
were prepared and assay was performed according the manufacturers instructions. For uncon-
certrated samples dilutions were from 10−4 to 10−6, while for concentrated ones from 10−6 to
10−8 [267]. Titration based on p24 ELISA, determines the amount of p24 (viral capsid protein
encoded by the gag gene) in the viral supernatant, which is proportional to the amount of
lentiviral vectors. Again, it must be kept in mind that although assays based on measurement
of p24 (expressed in ng/µl) is a practical way of quantifying a lentiviral vectors, though they
do not reflect functional vector titers. More specifically this method tends to overestimate the
physical vector titer as within the p24 pool which is quantified the method does not distinguish
between free p24 and p24 from non-functional lentiviral particles.
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2.7.3 Quantitative PCR (real time qPCR)
To accurately determine transducing titers of lentiviral vectors produced, when flow cytometry
or other detection methods are not possible, qRT-PCR assays that have been developed, were
used.
qPCR titration of the lentiviral stocks was performed with Lenti-XqRT-PCR Titration Kit
(Clontech) which employs a quick RNA purification step and determines viral RNA genome
content using qRT-PCR and SYBR technologies. Reactions were performed according to the
manuals of the kits used (LEnti-X qRT-PCR Titration Kit; Viral RNA Isolation kit; Clontech).
The kit allows target cell infection with vector preparations harvested on the same day. Thus
freeze-thaw cycles that reduce the vector infectivity can be avoided. Though in this study
vectors that have already been frozen were titered in order to have a realistic titer of the vector
preparation since all vector stocks are preserved at -80◦C. In this assay, viral supernatant
is collected from virus producing cells (unconcentrated and concentrated viral preparations).
Concentrated viral vector are diluted 200-300 fold with cell culture medium (i.e., mix 1µl
of concentrated vector stock and 199 µl of medium) and using a viral RNA purification kit,
genomic viral RNA is purified. A DNAse treatment removes any residual plasmid DNA that
may have been carried over from the transient transfection of 293T cells during production.
Serial dilutions of the viral RNA are prepared and subjected to qRT-PCR to determine the
threshold (Ct) values for each dilution. Samples are amplified alongside a RNA standard to
correct for low level transcriptase activity. A standard curve is generated from serial dilutions
of an RNA control template. The copy number that corresponds to its Ct value on the standard
curve is used to calculate the RNA genome copy number in a sample.
When a functional titer by FACS (TU/ml) is determined it is possible to establish a relationship
between the two values. A titration ratio (copies/TU) can be calculated based on correlation
of these two values FACS (TU/ml) and qRT-PCR (copies/ml). When more similarly produced
virus preparations are prepared, this titration ratio can be used as a reference value to determine
relative TU value for these preparations [268]. Relative TU values were calculated especially for
2.8. Cell lines 73
vector preparations that a functional titration is not possible since the tropism of the vector is
not compatible with the cell line used for titration. This resulted in more accurate calculation
of titer.
2.8 Cell lines
HEK 293T cells, obtained from ATCC, were maintained in a 5% CO2 environment in Dulbec-
cos modified Eagles medium (Sigma, UK), with 10% Newborn Calf Serum (Heat Inactivated,
Sigma, UK), 1% penicillin/streptomycin (Sigma, UK) and 1% L-glutamine (Sigma, UK). S-16
were obtained from ATCC (CRL-2941) and cultured in Dulbeccos Modified Eagles Medium
supplemented with 4 mM L-glutamine; PC-12 cells were obtained from ECACC (88022401)
and cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% Horse Serum
(Gibco) and 5% Newborn Calf Serum in flasks which were pre-coated with 0.01% collagen type
IV (Sigma C5533). L6.C11 were obtained from ECACC and cultured in Dulbeccos Modified
Eagles Medium supplemented with 10% Fetal calf serum, 1% penicillin/streptomycin, 2 mM L-
glutamine. HeLa cells were obtained from ECACC (930210113) and cultured in EMEM (EBSS)
supplemented with 2 mM L-glutamine, 1% Non-Essential Amino Acid (NEAA) and 15% New-
born Calf Serum. SH-SY5Y were obtained from ECACC (9430304) and cultured in Hams F12:
EMEM (EBSS) (1:1) supplemented with 2 mM L-glutamine, 1% NEAA (Sigma UK) and 10%
Newborn Calf Serum. The mouse neuroblastoma cell line NSC-34 was obtained from Pro-
fessor Pam Shaw (University of Sheffield) and was maintained in DMEM supplemented with
10% FBS, 1% essential amino acids (Sigma, UK) and 1% penicillin/streptomycin and routinely
passaged every 72-96 hours.
2.9 In vitro transduction of target cells
Transduction of target cell lines with lentiviral preparations was performed using a suitable
multiplicity of infection (MOI). In the experiments presented in this study MOIs used were
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usually MOI 10, 25, 50 and in rare occasions such as Granta cells MOI 90. MOI is defined as
the number of transduction units per target cell. It correlates with the number of integration
events and subsequently with the expression of the gene of interst. MOI is usually calculated
through the following simple formula:
MOI= [(titer of your lentiviral vector preparation) x (the volume of lentiviral
vector in ml)]/ (number of cells to be transduced)
The MOI required to achieve efficient transduction depends on the cell line used (there are many
cell lines refractory to transduction, ie Granta-519) and the titration method. Transduction
process can be affected by various factors such as, vector volume, target cell number and
type, vector stability and length of period of the vector adsorption to target cells. Generally,
expression levels increase within increasing MOI. Though upon a certain limit it has been
observed that increasing MOI does not affect the expression levels. MOIs typically used in
transduction experiments are usually within the range 0-32. In the experiments described in
this study, transductions were performed at MOI 0, 5, 10, 25 and 50. Moreover vectors were
normalised for RNA and p24 values prior to transduction.
Briefly, target cells (2.5x105) were seeded in a 24-well well plate (Nunc, Demark) and spin
infected with concentrated targeted vectors and contols for 90 min at 2,500 rpm at 37◦C.Upon
spin infection cells were incubated for additional 2 hrs at 37◦C, 5% CO2, when medium was fully
replaced and cells were incubated for additional 72 hrs at 37◦C, 5% CO2. FACS analysis was
performed to determine the percentage of EGFP expressing cells, as described in the section
above. Human HeLa, SH-SY5Y and mouse NSC-34 cells (1.5x105) were plated in a 24-well
culture dish and infected with concentrated targeted vector αCAR and 5pl control for 6 hrs at
37◦C with 5% CO2 without spin infection.
2.9.1 Effect of soluble blocking antibody on targeted transduction
In the competion assays performed to further assess the specificity if the targeted vectors and to
demonstrate that specificity is determined by the membrane bound antibody incorporated on
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the LV surface, target cells (rat S-16, L6 and PC-12; human SH-SY5Y) (2.5x105) were infected
with targeted vectors for 6 hrs in presence of increasing concentrations of soluble blocking
antibody.
More specifically, for each of the anti-p75-192 (Abcam), anti-Thy1.1 (Abcam) and anti-CAR
(RmcB) (Millipore) antibodies, three different concentrations were prepared in 300 µl final
volume in complete growth medium. Concentrations prepared were 0 µ/ml, 3 µg/ml and 9
µg/ml. In the same tube, in presence of the antibody, appropriate amount of lentiviral vector
was added (based on MOI used) in presence of 3 µl (8 µg/ml) of polybrene. Mixture was
applied to cells and transduction proceeded as described above. The effect of blocking antibody
on transduction efficiency of targeted vectors and control was assessed through FACS analysis,
72 hrs post transduction as previously described.
2.10 Flow cytometry analysis
Flow cytometry was performed to quantify trasduction efficiency. Transduced EGFP expressing
cells were detected with FL1 laser. Data where obtained with the (FACS machine) and analyzed
with the FlowJo 8.7 software. Each FACS analysis was based on at least 10,000 events. Gates
were set in a way that they contained less than 1% of the cells from the negative control cell
population, which were untransduced cells for quantification of EGFP+ cells. To determine the
titer of vector particles, cells transduced with serial dilutions of vector particles, as described
above, were analysed for EGFP expression.
2.11 Primary Motor Neuron (MNs) culture preparation
2.11.1 Preparations of slides
All cells were plated on to culture vessels treated overnight with 5 mg/ml poly-L-Ornithin
(Sigma, UK). Next day, culture vessels were washed 3 times with cell culture water and air-
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dried before coating with laminin (3 mg/ml diluted in Neurobasal medium) for at least 2 hrs at
37◦C prior to cell seeding. Cells were plated in eight-well chambered slides (Lab-Tek Chambered
slide system, Nalge Nunc international, Rochester, NY, USA) and for fixed and live imaging
were plated in glass bottom dishes (Willco Wells, MBSt-5040).
2.11.2 Purification and preparation of primary MNs
All animal procedures were approved by the local Ethical Committee and performed in accor-
dance with United Kingdom Animals Scientific Procedures Act (1986) and associated guide-
lines. All efforts were made to minimize the number of animals used and the suffering. The
animals were housed under a 12 hrs light/dark cycle (light phase, 19:00-07:00 hours) with food
and water available ad libitum. Animals were supplied by Charles River, UK. Timed pregnant
female Wistar rats (E14.5) and C57BL/6 mice (E13.5), and were used. The animals were killed
by intraperitoneal injection of 200 mg/kg of sodium pentobarbitone and the embryos were
immediately removed and kept in modified Hanks balanced salt solution (HBSS, Ca+2 and
Mg+2 free, Sigma-Aldrich). Under sterile conditions each embryo was transferred into a Petri
dish (Duroplan, Wertheim, Germany) containing fresh HBSS for the dissection. Six ventral
portions of spinal cords were pooled in 1ml HBSS and chopped to small pieces with a sterile
scalpel. They were subsequently digested with 0.025% of trypsin (Sigma, UK) for 10 min at
37◦C. After digestion, 100 ml DNase (1 mg/ml in L-15 medium (Invitrogen, Gibco, Paisley,
UK), 100 ml bovine serum albumin (BSA) fraction V (Sigma-Aldrich, 4% in L-15 medium) and
800 ml L-15 medium were added to the tube, mechanically dissociating the clumps with a 1
ml tip and let to settle for 3 min at room temperature. The supernatant was then collected
into a clean tube. Twenty microlitres of DNAse, 100 ml BSA and 900 ml L-15 medium were
added to the remaining tissues and triturated again before letting to settle down for another
3 min. All three supernatants were pooled together and centrifuged through a BSA cushion
(4% in L-15 medium) (1500 r.p.m. for 5 min) followed by further purification based on motor
neurons relative large size and subsequent flotation on an Optiprep (Sigma, UK) gradient. To
achieve this, the pellet was resuspended in 2 ml L-15 medium (phenol red-free) and divided
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in two separate tubes, where 1ml layer of 10.5% Optiprep (Sigma, UK) in L-15 medium (with
phenol red) was applied to the bottom. A second centrifugation was performed at 760 g for 15
min. The interface (MN containing) were collected with 1 ml pipette and pooled into together
in 1 ml of complete MN growth medium (complete Neurobasel medium). Before seeding the
cells, laminin was removed and wells were washed with PBS and half of MN complete growth
medium was added. Cells were then seeded at a density of 100,000 cells per well (1 cm+2) in
the eight-well chambered slides and cultured at 37◦C in humidified atmosphere containing 5%
CO2. Half of the growth medium was changed after 24 hrs and subsequently every 3 days. For
live imaging studies cells were seeded in microfluidic chambers (MFCs) at a density of 200,000
cells per chamber and cultured as above.
Complete Neurobasel Medium: Neurobasal medium (Invitrogen Gibco) supplemented with
with: 2% B-27 serum free supplement (Invitrogen, Gibco), 2% Horse serum, heat inactivated
(Invitrogen, Gibco), 0.5 mM L-Glutamine (Sigma-Aldrich), Penicillin and strepromycin (Invit-
rogen), 25 µM β-mercaptoethanol (Invitrogen Gibco), 0.5 ng/ml rat cilliary neurotrophic factor
(rCNTF) (Alomone labs, Israel), 0.1 ng/ml human brain derived neurotrophic factor (hBDNF)
(Alomone labs), 0.1 ng/ml human glial-derived neurotrophic factor (hGDNF) (Alomone labs).
2.12 Imaging of MNs in chambered slides
2.12.1 Characterisation of primary MN cultures by immunostaining
Primary MN cells were fixed with 2% paraformaldehyde (Sigma) diluted in PEM/microtubules
stabilization buffer (0.2 M PIPES, 10 mM MgCl2, 10 mM EGTA, pH 7.2) for 20 min in the
dark, washed with PBS and permeabilised with PBS containing 2% BSA and 0.1% of Triton-X
100 (Sigma, UK) for 810 minutes. Blocking of nonspecific binding sites was achieved by 1
hour incubation in PBS with 2% BSA. Primary antibodies were diluted in the same buffer and
applied to the wells for 2hr at room temperature. Following incubation with primary antibody,
cells were washed 3 times with 1xPBS and were incubated for 3 hours at room temperature with
78 Chapter 2. Methods and Materials
secondary antibodies. Following washes with PBS the wells walls were removed from the slides
and mounted using ProLong anti-fade aqueous mounting medium (Invitrogen, Paisley, UK).
Primary and secondary antibodies used for characterization of primary MNs are presented on
table 2.16.
Table 2.16: Antibodies for characterization of primary MNs
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
anti-ChAT Millipore, UK goat n.d. donkey anti-goat
polyclonal (1:100 in 2%BSA/PBS) Alexa-Fluor-594 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-GFAP Invitrogen rabbit n.d. donkey anti-rabbit
polyclonal (1:1000 in 2%BSA/PBS) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-NeuN Millipore, UK mouse 1mg/ml donkey anti-mouse
monoclonal (1:100 in 2%BSA/PBS) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-Thy1.1 Abcam mouse 1mg/ml donkey anti-mouse
(CD90) monoclonal (1:200 in 2%BSA/PBS) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-Thy1.1 hybridoma mouse monoclonal n.d. donkey anti-mouse
(CD90) in house (500µl per well undiluted) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-p75 Abcam rabbit 1mg/ml donkey anti-rabbit
(NGF) polyclonal (1:200 in 2%BSA/PBS) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-p75 hybridoma mouse monoclonal n.d. donkey anti-mouse
(MC-192) in house (500µl per well undiluted) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-CAR Millipore, UK mouse 1mg/ml donkey anti-mouse
(RmcB) monoclonal (1:200 in 2%BSA/PBS) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
anti-CAR hybridoma mouse monoclonal n.d. donkey anti-mouse
(RmcB) in house (500µl per well undiluted) Alexa-Fluor-488 2mg/ml
(1:1000 in 2%BSA/PBS)
2.12.2 LV vector transduction of primary MNs
Rat and mouse primary cell cultures of MNs (1x105 cells per well) were plated in eight-well
chambered slides. Transduction of rat primary neurons was carried at DIV2 with concentrated
targeted and 5pl control vector preparations in absence of polybrene. MN cultures were
transduced at MOIs of 25 and 50. Transduction experiments were carried out in triplicate for
each MOI for all LV preparations. Primary neuronal cultures were incubated with vector stocks
in 300 ml conditioned culture medium for 6 hours at 37◦C in humidified atmosphere containing
5% CO2. After 6 hrs, medium was replaced with 300 ml of fresh conditioned cultured medium
and cells were incubated for a further 3 days at 37◦C with 5% CO2.
Cells were fixed with 2% paraformaldehyde (Sigma) diluted in PEM/microtubules stabilization
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buffer (0.2M PIPES, 10mM MgCl2, 10mM EGTA, pH 7.2) for 20 min in the dark, washed with
PBS and permeabilised with PBS containing 2% BSA and 0.1% of Triton-X 100 (Sigma, UK)
for 810 minutes. Blocking of nonspecific binding sites was achieved by 1 hour incubation in PBS
with 2% BSA. Antibodies to GFAP (1:800, MAB360, Millipore) and ChAT (1:100, AB144P,
Millipore) were diluted in the same buffer and applied to the wells overnight at 4◦C. After 30
min blocking, cells were incubated for 3 hrs at room temperature with secondary either donkey
or goat anti-mouse and anti-rabbit antibodies, conjugated with alexafluor 594 or 647 (1:1000,
Invitrogen, Paisley, UK). Following washes with PBS the wells walls were removed from the
slides and mounted using ProLong anti-fade aqueous mounting medium (Invitrogen, Paisley,
UK).
2.13 Imaging of MNs in microfluidic chambers (MFCs)
2.13.1 Preparation of MFCs
MFCs were prepared upon consultation and valuable help of Dr Michael Parkinson and Prof
GIampietro Schiavo (London Research Institute) as described below:
-Preparation of silicone inserts
PDMS Sylgard 184 base is mixed together with the curing agent (VWR) in a plastic cup and
stirred vigorously with wooden tongue depressor to ensure proper mixing. This introduces a lot
of air bubbles, which is normal and not an issue. Components should be weighted and mixed
in a 10 parts base for 1 part curing agent). Usually approximately 30 g makes enough for 12
chambers. Mixture is placed under a vacuum in a dessicator for 30-60 mins, or until the bubbles
are removed. It is important to ensure the epoxy master moulds (prepared and provided by
London Research Institute) are clean and dust free. PDMS is poored into the moulds; allow
PDMS to fill the corners of the mould, tilting occasionally to encourage this. Pop any small
air bubbles that remain with a needle. Moulds are transferred to an oven and left at 65-70◦C
for 1 h to harden. PDMS piece is then removed from the mould with a razorblade along edges
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to separate and lift the PDMS piece (or forceps if that is easier). PDMS piece is carefully
detached, making extra care not to scratch the epoxy master mould. Inserts are stored in dish
to prevent gathering dust until ready to be taken to London Research Institute for plasma
cleaning.
-Assembly of PDMS onto glass bottomed cell culture dishes
PDMS insert are cut into the desired shape, removing any ragged edges. Four well holes are
punched into the PDMS. All required materials are brought into a chemical hood (PDMS
pieces, glass bottomed dishes, magic tape, glass working surface). Both surfaces of the PDMS
piece are cleaned with magic tape. PDMS pieces and open glass bottom dish are put onto the
Plasma Cleaner Tray with the surface to be cleaned facing up (i.e. grooves at the top). Tray
is placed in the plasma cleaner and samples are irradiated two times for 30 sec. Immediately
after cleaning PDMS pieces are placed onto the glass bottom dish (grooves onto the glass),
using forceps to seal the PDMS to the glass by gently pushing down and removing air. All the
dishes (lids now on) are transfered into the oven and heat to 65-70◦C for 5-30 mins. Chambers
are coated with sterile ddH2O to prevent the chambers drying out.
-Coating of Microfluidics Chambers
Day 1 4% BSA in L15 media is made up, filtered sterilized (0.2 µm) and frozen in -20◦C for
stocks. For coating this has to be diluted to final concentration of 0.8% BSA in L15 media.
MFCs are coated by adding 250 µl 0.8% BSA into the somatic chamber and 200 µl into the
axonal chamber (was only added to 1 well on each side and was allowed to fill the two chambers
by capillary action). Chambers are tilted to create a flow from the somatic chamber to the
axonal chamber and placed like this overnight at 37◦C.
Day 2 BSA is removed from the chambers and poly-L-ornithine (3 µg/ml in ddH2O) is added.
Again 250 µl into the somatic chamber and 200 µl into the axonal chamber, left overnight at
room temperature. Chambers can be wrapped in parafilm and then stored at 4◦C if required.
Day 3 Poly-L-ornithine is aspirated and washed twice with ddH2O. Laminin in made up in L15
media (1/100 of stock) and as for BSA, add 250 µl laminin into the somatic chamber and 200
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µl into the axonal chamber. Again slides are tilted to encourage flow from somatic to axonal
and left like this for >2 hours at 3◦C (or until dissection is done). Prior to seeding primary
cells, chambers were washed with Neurobasal medium. Motor neurons were purified as usual
(Subsection 2.11.2). After BSA cushion the unpurified cells can were plated directly. Cells
from 6 spinal cords are enough for seeding 20 dishes. Alternatively if protocol was continued
with optiprep gradient, upon collection of cells from interface optiprep were diluted 1/10 and
spin through a second BSA cushion. Final pellet was resuspended in 150 µl of neurobasal
and recounted. After purification of MNs, cells were resuspended in Complete Neurobasel
media at 100,000-200,000 cells in 10 µl. Wash with neurobasel was asspirated from the somatic
compartment and 10 µl of cells (150,000-200,000) were added directly to the somatic channel.
MFCs were left for 2 hrs at 37◦C, when somatic compartment was filled with 250 µl and the
axonal compartment with 200 µl of complete neurobasel media. Half of the media were replaced
with fresh media 24 hrs after plating and then fed every other day.
2.13.2 Fixed imaging in MFCs
Rat and mouse MNs were purified as above and plated at 200,000 cells per dish into prepared
and coated microfluidic chambers [212]. Primary motor neurons 7 days post plating in MFCs
were incubated with either DiO labels αp75NTR or αThy1.1 and αCAR with TeNT-555 (kindly
provided by Prof Giampietro Schiavo, London Research Institute and used as 1µl undiluted
antibody per channel) and anti-p75NTR-AF647 (kindly provided by Prof Giampietro Schiavo,
London Research Institute and used as 1 µl per channel from 1:100 dilution) for 2 hrs at 37◦C
before fixing and imaging by confocal microscopy. Cells were fixed with 2% paraformaldehyde
(Sigma) diluted in PEM/microtubules stabilization buffer (0.2 M PIPES, 10 mM MgCl2, 10 mM
EGTA, pH 7.2) for 20 min in the dark and then quenched in PBS with 100 mM glycine, washed
with PBS and mounted using ProLong anti-fade aqueous mounting medium (Invitrogen, Paisley,
UK). Imaging was performed in a region of axon >200 µm from the axonal compartment.
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2.13.3 Live imaging in MFCs
Live imaging was performed as described in Salinas et al., [210]. 7 days post plating, an excess
of viral particles (10,000) were added to the axonal chamber with or without Alexa-647-labelled
anti-p75NTR (kindly provided by Prof Giampietro Schiavo, London Research Institute and used
as 1 µl per channel from 1:100 dilution) as described before [212] and incubated for 20 min at
37◦C before the chamber was filled with complete Neurobasal media, and left for a further 40
minutes, prior to imaging in an environmental chamber. Dishes were then imaged using a TCS
SP5 II confocal microscope with environmental chamber. Imaging was performed in a region
of axon >200 µm from the axonal compartment. Images were taken every 5 sec using the 488
nm laser, with the photo multiplier tube detection range of 500-550 nm, as DiO fluoresces in
the green spectrum. Images were processed using ImageJ and images enhanced using a 2.0
pixel median filter and brightness/contrast, and particle analysis performed using MTrackJ
and multiple Kymograph plugins. Images were then rendered and pseudocoloured using GIMP
(GNU Image Manipulation Programme; http://www.gimp.org).
2.13.4 Transduction in MFCs
For transduction of motor neurons in microfluidic chambers, EGFP expressing vector particles
were added to the axonal chamber in 8 µl for 20 min, before chambers were filled with complete
neurobasal media and left for a total of 6 hrs to allow retrograde trafficking and transduction
to occur. Medium was replaced 6 hrs post transduction. 72 hrs post transduction, neurons
were fixed in 4% PFA diluted in PEM/microtubules stabilization buffer (0.2 M PIPES, 10 mM
MgCl2, 10 mM EGTA, pH 7.2) for 20 min in the dark, then quenched in PBS with 100 mM
glycine, before permeabilisation in PBS plus 2% BSA and 0.1% Triton-X 100, and then stained
with antibodies against EGFP (1:1000, ab290, abcam), ChAT (1:100, AB144P, Millipore) and
SMI32 (1:1000, Covance, E11 CF00693). Cells were then imaged using a Leica SP5 II confocal
microscope and processed using ImageJ and images enhanced using a 1.0 pixel median filter and
brightness/contrast, and were then rendered and pseudocoloured using photoshop (Adobe).
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2.14 Immunostaining and microscopy
2.14.1 Fluorescent labeling of single lentiviral particles
For detection of individual viral particles, fresh viral supernatant from single plate preparation
was overlaid upon Poly-D-Lysine (Sigma, UK) coated coverslips in 24-well culture plate and
allowed to bind for 2 hrs at room temperature. The coverslips were rinsed with cold PBS
and adherent viruses were fixed with 2% PFA for 15 min at room temperature. Coverlips
were rinsed with cold PBS twice and particles were immunostained for the presence of SINmu
fusogen (anti-HA-FITC, 1:15, Miltenyi Biotech), αThy1.1/αp75NTR and αCAR human light
chain (AlexaFluor 594 anti-human IgG, 1:300, Invitrogen) and HIV p24 (1:300, abcam, using
an AlexaFluor 633 secondary). Fluorescent images were aquired using a Leica SP5 II confocal
microscope (Leica Microsystem, Gemany). Three independent images of each viral prep, were
used for quantification. On each image five 10x10µm fields were randomly selected, using
custom macro in ImageJ (Rasband WS, ImageJ, U.S. National Institutes of Health, USA.
http://imagej.nih.gov/ij/), and used to quantify/count the number of particles present. The
number of positive particles in each of the three channels (SINmu(SGN), anti-IgG and p24)
were counted manually. The percentage of triple positive particles was calculated.
2.15 In vivo targeted transduction
All animal procedures were approved by the local ethical committee and performed in ac-
cordance with the United Kingdom Animals Scientific Procedures Act (1986) and associated
guidelines. All efforts were made to minimize the suffering and the number of animals used.
The animals were housed under a 12 hrs light/dark cycle (dark phase, 19:00 to 07:00 hours)
with food and water available ad libitum. Animals were supplied by Harlan (Blackthorn, UK).
For all intramuscular injections performed in this study male C57/BL6 mice and FvB mice
20-25 gr and Wistar Rats 250 gr were used. Prior to any invasive procedure, all animals were
deeply anesthetized by inhalation of a mixture of 3L oxygen and 3.5% isoflurane (Merial, Par-
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ramata, NSW, Australia) and then received systemic analgesia. The anaesthetic mixture was
changed to 1 L oxygen and 2.2% isoflurane for the remaining of the operation.
2.15.1 Intramuscular injections
A small incision in hind limb was performed to expose gastrocnemius muscle or tibialis anterior
(TA) muscle. All injections were performed unilaterally in the right muscle.
Gastrocnemius muscle was injected at multiple sites where a total of 12-40 µl of pseudotyped LV
vectors was delivered with a 26G beveled needle using an infusion pump (UltramicropumpIII
and Micro4 Controller, World Precision Instruments, USA) at a stable flow rate of 1 µl/min
over the time required. Tibialis anterior muscle injection in C57BL/6 mice were performed via
single injection with a 26G hypodermic needle.
Upon delivery, needle was allowed to remain on site for an additional 1 minute before retraction
to prevent vector leakeage. At the completion of surgery, the skin was sutured and animals
were transfered to a recovery chamber to allow proper recovery to take place.
2.15.2 Intrastriatal injections
In vivo applications of targeted vectors and controls in CNS was performed to examine the
neurotropism of the lentiviral preparations. In all in vivo intrastriatal applications male Wistar
rats, weighing 200-250 gr were used. Procedure proceeded as described in detail below:
Animals were placed in a stereotactic frame (Taxic-6000, World Precision Instruments, USA)
with the nose bar set at -3.3 mm. The anaesthetic mixture was changed to 1 L oxygen and
2.2% isoflurane for the remaining of the operation. The scalp was cut and retracted to expose
the skull. Craniotomy was performed by drilling directly above the target region, to expose
the pial surface. One single injection was directed into the right striatum using the stereotactic
coordinates relative to bregma: anteroposterior, 0.5 mm; mediolateral, 3.0 mm; dorsoventral,
5.0 mm. Animals usually received 4.0 µl of pseudotyped LV vectors with a biological titre within
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the scale of 1x109 TU/ml via a 32G blunt needle using an infusion pump (UltramicropumpIII
and Micro4 Controller, World Precision Instruments, USA) at a stable flow rate of 0.2 µl/min
over 20 minutes. Upon delivery, needle was allowed to remain on site for additional 5 minutes
before slow retraction. At the completion of surgery, the skin is sutured and animals were
transfered to a recovery chamber to allow propery recovery to take place.
2.16 Tissue harvesting and preservation
In the present study, tissues (brain, spinal cords, TA and GS muscles) were harvested and
processed for analysis 3 weeks post injection.
All animals were euthanized by intraperitoneal injection of an 200 mg/kg of sodium pentobar-
bitone, transcardially perfused with 50 ml saline (0.9% w/v NaCl) plus heparin, followed by 250
ml of 4% PFA in PBS. Tissues were removed and post-fixed for 4 hrs in 4% PFA (kept at 4◦C),
followed by cryoprotection in 10% glycerol and 20% sucrose in PBS for at least 72 hrs. Tis-
sues were subsequently embedded and frozen in OCT (SUrgipath FSC22, Leica Microsystems,
Wetzlar, Germany).
2.16.1 Tissue processing and immunohistochemistry of spinal cord
and muscle sections
Fifty µm coronal sections from the sacral towards the lumbar part of spinal cord were cut using
a cryostat (Leica Microsystems), mounted on collagen coated slides and stored at -20◦C. For
muscle, twentyµm thick longitudinal sections were cut and mounted as before.
Immunohistochemistry was performed on slide mounted tissue sections. Tissue was perme-
abilised and blocked for 1 hour with PBS containing 10% serum and 0.1% Triton-X100. Pri-
mary antibodies were diluted in the same buffer and applied on sections as described below
and presented on table 2.17:
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Spinal cord tissues were incubated with antibodies to ChAT (1:50, Millipore, UK) and to
EGFP (1:500, Abcam, UK) for 72hrs at 4◦C. Incubation for 72 hrs was critical to achieve
specific staining with anti-ChAT antibody.
Muscle tissues were incubated with Alexa-FLuor-594-α-bungarotoxin (1:500, B134423, Invitro-
gen) and anti-Synaptophysin (1:250, 18-0130, Invitrogen). Synaptophysin staining required ON
staining at room temperature, followed by second ON at 4◦C. For triple staining Synaptophysin
was first added to the section and incubated ON at room temperature, next day Alexa-FLuor-
594-α-bungarotoxin and anti-EGFP (1:500, Abcam, UK) were added and incubated ON at
4◦C.
Upon primary antibody incubation sections were washed 3 times with PBS for 10 min shaking
and blocked for 30 min prior to incubating for 3 hrs at room temperature with secondary
fluorescently labeled antibodies. Sections were cover-slipped with ProLong anti-fade aqueous
mounting medium (Invitrogen, Paisley, UK) in presence of DAPI (0.05 µg/ml, Sigma, UK) to
label nuclear DNA.
Table 2.17: Antibodies used for immunohistochemistry of spinal cord and muscle sections
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
anti-ChAT AB114P, Millipore, UK goat n.d. donkey anti-goat
polyclonal (1:50 in 2%BSA/PBS) Alexa-Fluor-594 2mg/ml
(1:500 in 2%BSA/PBS)
anti-EGFP Abcam rabbit n.d. donkey anti-rabbit
polyclonal (1:500 in 2%BSA/PBS) Alexa-Fluor-488 2mg/ml
(1:500 in 2%BSA/PBS)
Alexa-Fluor-594 Invitrogen, UK n.s
α-bungarotoxin (B13423) (1:500 in 2%BSA/PBS)
anti-Synaptophysin Invitrogen rabbit donkey anti-rabbit
monoclonal (1:250 in 2%BSA/PBS) Alexa-Fluor-633 2mg/ml
(1:500 in 2%BSA/PBS)
2.16.2 Tissue processing and immunohistochemistry of brain sec-
tions
30µm coronal sections from the olfactory bulb(OB), through the entire striatum, globus pallidus
and substantia nigra (SN) were cut using a cryostat (Leica Microsystems), mounted on poly-L-
lysine coated slides and stored at -20◦C. Immunohistochemistry was performed on slide mounted
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brain sections. Tissue was permeabilised and blocked for 1 hour with PBS containing 10%
donkey serum and 0.1% Triton-X100. Primary antibodies to eGFP (1:500, ab290, Abcam),
NeuN (1:100, MAB377, Millipore, Watford, UK) and GFAP (1:400, ¡ MAB360, Millipore) were
diluted in the same buffer and applied on sections for 48 hrs at 4◦C (Table2.18). Sections were
then washed 3 times with PBS for 10 min shaking and blocked for 30 min prior to incubating
for 3 hrs at room temperature with secondary fluorescently labeled antibodies (Table2.18).
Sections were cover-slipped with ProLong anti-fade aqueous mounting medium (Invitrogen,
Paisley, UK) in presence of DAPI (0.05 µg/ml, Sigma) to label nuclear DNA.
Table 2.18: Antibodies used for immunohistochemistry of brain sections
Antibody
Supplier Species Concentration/ 2ry Antibody
Dilutions
anti-NeuN MAB377, Millipore, UK mouse n.d. donkey anti-mouse
monoclonal (1:100 in 2%BSA/PBS) Alexa-Fluor-594 2mg/ml
(1:500 in 2%BSA/PBS)
anti-EGFP ab290, abcam rabbit n.d. donkey anti-rabbit
polyclonal (1:500 in 2%BSA/PBS) Alexa-Fluor-488 2mg/ml
(1:500 in 2%BSA/PBS)
anti-GFAP MAB360, Millipore goat donkey anti-goat
polyclonal (1:400 in 2%BSA/PBS) Alexa-Fluor-647 2mg/ml
(1:500 in 2%BSA/PBS)
2.17 In vivo bioluminescence (BLI) imaging
Concentrated targeted and 5pl control luciferase (firefly luciferase) expressing lentiviral prepa-
rations were injected unilaterally in C57BL/6 mouse right gastrocnemius or tibialis anterior
muscle. Prior to imaging, mice were injected intraperitoneally with 150mg of D-luciferin (Gold
Biotechnology, St. Luis, USA). Expression was imaged at days 7, 14 and 21 post injection using
a bioluminescence imaging system (IVIS Spectrum/200, Perkin Elmer). At final time point (21
days) animals were subjected to terminal anaesthesia. Images were analysed by Living Image
4.3.1 software.
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2.18 Densitometry
Three independent western blot exposed film images were scanned and analyzed by ImageJ soft-
ware. The integrated density was determined as described from the web link. http://lukemiller.org/index.php/2010/11/analyzing-
gels-and-western-blots-with-image-j/
2.19 Statistical analysis
Analysis of variance (ANOVA) was used for statistical comparisons. Post hoc analysis was
Tukey’s Honestly Significant Difference. Analyses were carried out using GraphPad Prism 5
software. Data are expressed as MEAN±SEM or MEAN±SD values (n=3 or n=4).
2.20 Bioinformatics
2.20.1 IMGT/V-QUEST and IMGT/ Junction analysis Tool
Analyses of all immunoglobulin variable regions obtained with methods described above were
done with IMGT tools. IMGT (ImMunoGeneTics Information System) is a high-quality knowl-
edge resource and integrated information system that specialises in immunoglobulin (IG), T-
cell-receptor (TR) major histocompatibility complex (MHC) of human and other vertebrates.
V-QUEST analyses is an input of immunoglobulin germline or rearranged variable nucleotide
sequences. The results obtained from using V-QUEST comprise the identification of the V,
D, and J genes and alleles and the nucleotide alignment by comparison with sequences from
IMGT reference directory, the numbering according to Kabat [76], the definitions of CDRs,
the protein translation of the input, the identification of the JUNCTION and the 2-D Collier
de perles representation of the V-region. It also distinguishes aberrant results for pseudogenes
with DNA insertions or deletions, sequences resulting in stop codons due to wrong or partial re-
arrangements. IMGT/Junction analysis is a tool complementary to V-QUEST, which provides
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a thorough analysis of the V-J and V-D-J junction of IgG rearranged genes.
2.20.2 Leader Peptide Analysis
The presence and location of signal peptide cleavage sites in the amino acid sequences from
heavy and light chain V regions of Thy1.1, p75NMR and CAR antibodies were investigated
using TargetP and SignalP3 [269]. Amino acid sequences were uploaded in FASTA format and
analysed.
2.20.3 DNA analysis tools
All cloning strategy design and sequence analyses have been performed using the DNADYnamo
software (Blue Tractor software). Sequencing analyses results were processed with Chromas
(Applied Biosystems) and DNADynamo, while for protein translation online Expasy Translate
tool (Swiss Institute of Bioinformatics) was used.
Chapter 3
Engineering membrane bound
antibodies for targeting
Normal serum contains 1016 antibody molecules per milliliter. These antibodies can be har-
vested from experimental animals and have long been an important tool of investigators in their
attempts to identify or label molecules or cells and to separate molecules or cells from mixtures.
A limiting factor, however, has always been the variability of antisera. The development of hy-
bridization techniques opened a new field for the production of one kind of specific antibody
by immortalized antibody producing cells. Antibodies of a single idiotype produced by immor-
talized B cells are called monoclonal antibodies. Though, normal antibody-secreting cells are
end cells of a differentiation series, thus cannot be maintained in culture. In contrast myeloma
cells are immortal, but still limitations exist to their use since their antigen specificity is usually
unknown and is difficult to establish antigen specific myelomas. In 1975, George Kohler and
Cesar Milstein managed to fuse antibody-secreting cells (one specificity) with myeloma cells.
The resulting clone of cells is a hybrid -myeloma or hybridoma [270]. Hybridoma cells com-
bining the lymphocyte’s property of specific -antibody production and the immortality of the
myeloma cell are the source of monoclonal antibodies of predefined antigen specificity. Most
monoclonal antibodies to mouse have been derived from rat spleen-mouse myeloma fusions.
Hybridomas can be used further as valuable source not only of Ig protein but also Ig mRNA that
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can be used in further applications (fusion with other enzymes, reporters, toxins and antigens,
incorporation into viral vectors, transgenesis) and in combination with several recombinant
DNA techniques can serve as a source to engineer tailored-made hybrid, chimeric monoclonal
antibodies. Antibody engineering, the construction of ’designed antibodies’, is one of the fastest
growing fields in molecular biology. This involves cloning of antibody variable regions which re-
quires isolation of mRNA from a hybridoma that produces an antibody of the desired specificity
which is subsequently used as a template for cDNA synthesis with antibody-specific primers.
In this study the OX-7, p75-192 and CAR (RmcB) hybridoma cell lines were used to generate
mouse-human chimeric antibodies for targeting presynaptic terminal receptors.
3.1 Identification of hybridoma cell lines producing an-
tibody of interest
Prior to antibody engineering, these hybridomas were tested in order to confirm they produce
the antibodies of interest. Crude supernatants containing the secreted antibodies were isolated
and their specificity was then examined by western blot and Immunohistochemical analysis on
a panel of tissue and cell lines.
3.1.1 Identification of OX7 hybridoma producing mouse anti-rat
Thy1.1 (CD90) antibody
The antibody produced by OX7 hybridoma, recognizes rat Thy1.1 (CD90), a 25-37 kDa gly-
cosyiphosphatidylinositol (GPI)- anchored glycoprotein found on the external leaflet of the lipid
bilayer, localizing to lipid rafts [225]. There are two alleles of Thy-1 in mice which code for
Thy-1.1/CD90.1 and Thy-1.2/CD90.2 and differ in one amino acid. Anti-Thy1.1 (OX7) binds
to thymocytes expressing the Thy 1.1 determinant but not to those with the Thy 1.2 determi-
nant. Thy-1 has many immunologic and nonimmunologic functions which indicate that is an
important regulator of cell-cell and cell-matrix interactions. Thy 1.1 was identified originally
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as a thymocyte differentiation marker in mice, expressed in organs like thymus and lymphoid
tissues, particularly of the spleen. The Tuffin’s et al. study of Thy1.1 revealed a very high
expression of Thy1.1 in rat brain cortex, striatum and thymus [228] [271]. Moderate levels were
observed in kidney, lung tissue and spleen while no expression was detected in liver and heart.
Thy-1 has also been detected in the rat in spinal cord, the retina and the optic nerve [223]. In
cells lines Thy-1.1 is expressed in rat PC12 cells [272].
Based on these observations, western blot and immunofluorescent analyses of Thy1.1 (CD90)
with the antibody produced from hybridoma OX-7, were performed on a panel of cell lines
and tissues in order examine its specificity. Western blot analysis confirmed the detection
of this molecule (physiological ligand or counter receptor for murine Thy-1 in the lymphoid
compartment has not yet been identified [221]), as presented on Figure 3.1. Absence of protein
in the thymus is possibly a result of unsuccessful protein extraction. The antibody used in
western blot analysis was harvested from OX7 hybridoma, which was cultured in house. Thy1.1
antibody itself was examined by Western blot analysis to confirm the presence of heavy and
light chains, representative of a functional antibody (Figure 3.1A first line).
The anti-Thy1.1(CD90) antibody was further characterised by immunohistochemistry on PC12
cells, a positive control cell line [272].
3.1.2 Identification of p75-MC192 hybridoma producing mouse anti-
rat p75 (192) antibody
The initial description of monoclonal antibody 192-IgG established its effect of increasing the
affinity of NGF binding to the NGF receptor of PC12 cells, and demonstrated that 192-IgG
binds to the same number of sites as NGF does and that it does not bind NGF [237]. Later,
Taniucki and Johnson 1985, confirmed the specific binding of NGF receptor, both in vitro and
in vivo [271]). The 192-hybridoma clone was obtained by fusing Sp2/0-Ag14 myeloma cells
with splenocytes from Balb/C mice [237]. Immunohistochemical analysis of p75-192 antibody
on rat S-16, PC12 cells, C6 cells and L6 cells (all positive controls for rat p75 expression
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Figure 3.1: Characterisation of Thy1.1 antibody on tissue and cell lysates. Equal amounts
of tissue and cells lysates were western blotted with mouse monoclonal anti-Thy1.1 receptor antibody
produced by OX-7 hybridoma. (A) Bands were mainly observed in nervous tissues where prominent
band at 28 kDa likely corresponds to rat Thy1.1 in thymus, bands were not observed due to lack of
protein. This can be attributed to the activity of a bigger amount of protease than in other tissues,
scarcely inhibited by the same amount of protease inhibitors. On the first lane, where the antibody
supernatant was loaded, are presented the heavy (58 kDa) and light (30 kDa) chains of the Thy1.1
antibody. Blot is representative of several experiments. (B) A band at 28 kDa corresponding to Thy-
1 receptor was observed in PC12 cells, which served as a possitive control cell line. No bands were
observed, as expected, in mouse NSC-34 and human Hela and HEK 293T cells. Blot is representative
of several experiments.
[237, 273, 274]), as presented on Figure 3.3, revealed a strong specific signal on the surface
of these cells, while no signal was observed on the negative control mouse muscle cell line
C2C12, suggesting no expression of rat p75NTR in these cells and no cross reactivity of the rat
anti-p75-192 IgG monoclonal antibody with mouse and human cell types.
These results confirmed that the 192-hybridoma produces the mouse monoclonal MC-192 anti-
body specific for p75NTR. Interestingly, it was observed, that when incubated with p75 MC-192
antibody, dividing (M-phase) PC-12 cells were positive (Figure 3.3). This finding correlates
with previous reports for cell cycle phase-specific surface expression of p75NTR on PC12 cells
[233]. All target cell lines were also stained with a commercially available mouse monoclonal
192-IgG antibody, of the same specificity for a direct comparison with the one harvested from
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anti-Thy1.1 from OX7 hybridoma secondary only control 
Rat PC-12 cells
A. B.
Figure 3.2: Characterization of anti-Th1.1(CD90) antibody on rat PC-12 cells by immuno-
histochemistry. Thy1.1 distribution in vitro was assesed on PC-12 cells by immunohistochemistry.
Fluorescent microscope images presenting staining with (A) mouse anti-Thy1.1 antibody produced
from OX7 hybridoma and (B) negative control presenting absence of staining when primary antibody
is omitted. Cell nuclei are counter stained with DAPI (blue). Scale bars: 50µm.
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Figure 3.3: Characterisation of anti-p75-192 antibody.p75NTR distribution in vitro was ass-
esed on a panel of cell lines by immunohistochemistry. Fluorescent microscope images presenting
staining with mouse anti-p75-192 antibody: commercially available (top row) and produced from 192-
hybridoma (second row). Bottom row: negative control presenting absence of staining when primary
antibody is omitted. Last column: negative control presenting absence of expression on the negative
cell line mouse C2C12. Cell nuclei are counter stained with DAPI (blue). Scale bars: 50µm.
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192-hybridoma. Immunohistochemistry results obtained, showed for all cell lines, similar pat-
tern to the one obtained with hybridoma derived antibody.
The specificity of p75 MC-192 antibody produced from the 192-hybridoma was assessed in rat
tissue lysates (p75NTR positive) by western blot analysis. Unfortunately the antibody appeared
not to be specific for this application (even commercial p75 MC-192 was not recommended for
western blotting, according to manufacturer’s instructions) (Figure 3.4).
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Figure 3.4: Characterisation of p75 MC-192 antibody on tissue and cell lysates. Equal
amounts of tissue and cell lysates were western blotted with either rabbit polyclonal anti p75-LNGFR
receptor antibody (Abcam) or mouse monoclonal anti-p75 MC192 LNGFR antibody produced by MC
192 hybridoma). Bands were only detected with the polyclonal antibody. Prominent band at 75 kDa
likely corresponds to p75 NGF receptor. Blot is representative of several experiments.
3.1.3 Identification of CAR (RmcB) hybridoma producing mouse
anti-CAR (RmcB) antibody
The third antibody chosen to be incorporated on the lentiviral surface will be against the cox-
sackie virus and adenovirus receptor (CAR), a widely expressed cell adhesion protein involved
in tight junction formation in epithelial cells, and highly expressed in the developing brain.
It has been shown that Canine adenovirus serotype 2 (CAV-2) interaction with the neuronal
membrane correlates with CAR surface expression, followed by endocytosis involving clathrin
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Figure 3.5: In vitro characterisation of mouse anti-CAR (RmcB) antibody. CAR distribution
in vitro was assesed on a panel of cell lines by immunohistochemistry. Fluorescent microscope images
presenting staining with mouse anti-CAR antibody: commercially available (top row) and produced
from hybridoma (second row). Bottom row: negative control presenting absence of staining when
primary antibody is omitted. Last column: negative control presenting absence of expression on
the negative cell line NIH-3T3. (dif: differentiated; undif: undifferentiated). Cell nuclei are counter
stained with DAPI (blue). Scale bars: 20µm.
[210]. Furthermore CAV-2 preferentiallly transduces neurons and undergoes efficient retrograde
axonal transport following injection into the mouse gastrocnemius.
Anti-CAR (RmcB) monoclonal antibody secreted from hybridoma was harvested and its speci-
ficity was tested, by immunofluorescence, on a panel of cell lines. Antibody was tested alongside
with antibody of same specificity, purchased from Millipore (anti-CAR RmcB). Both antibodies
were tested on human HeLa, SH-SY5Y cells (positive control), mouse NIH-3T3 (negative con-
trol) and NSC-34 (Figure 3.5). Western blot analysis for anti-CAR (RmcB) was not performed.
3.2 Cloning of membrane bound antibodies for targeting
Genetic engineering and expression provide powerful tools for analysing antibody function
and for producing antibodies with selected functional properties. The availability of a cloned
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variable (V) region of appropriate specificity facilitates many operations. Cloned V regions can
be expressed joined to any constant (C) region, from either the same or a different species.
The resulting antibodies will have the desired effector functions. Chimeric antibodies that
are obtained by joining murine V regions to human C regions are expected to have decreased
immunogenicity in humans.
A major part of this project was dedicated to the construction of membrane bound antibodies
for targeting, which involved the amplification of heavy and light chain variable regions of the
mouse antibodies anti-CD90(Thy1.1), anti-p75 IgG192 and anti-CAR(RmcB) from hybridoma
cDNA and proceeding with cloning into upstream human constant regions to obtain mouse-
human chimeric antibodies.
Obtaining V regions for expression has primarily been focused on the use of polymerase chain
reaction (PCR)-based approaches. The PCR-based cloning strategy takes advantage of the
conservation of sequences seen for both the framework and leader segments of the V regions.
Although priming within the framework regions using conserved sequences can be employed
for V region cloning, amino acid changes introduced into the framework regions may have a
negative impact on antigen binding: therefore priming within the conserved hydrophobic leader
sequences is the preferred strategy. Here, both approaches have been tested in the attempt of
cloning the V regions of these three candidate antibodies for targeting.
Redundant PCR primers specific for both the leader sequence and the joining (J) regions can be
used; however, although this approach allows direct cloning of V regions without any sequence
information, it can potentially introduce sequence changes into the resulting antibody molecule.
Therefore the preferred approach to V region cloning and the one followed here proceeds in
two steps: first, redundant primers hybridizing to the leader sequence (5’ primer) and to the C
region immediately downstream of the V-J region (3’ primer) are used to clone the V regions
for sequence analysis of the J regions. Then, using the sequence information generated, primers
matching the 3’ end of the V regions are synthesized with the appropriate restriction sites in
order to facilitate cloning of V region in frame into the expression vector. Thus a second round
of amplification is carried out using appropriate leader and J region primers.
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Opposite to this direct way, there are also cases, as it will be presented here, where the use
of redundant primers does not lead to successful PCR amplification of V regions. In this
case RACE PCR technology can overcome this problem and be extremely useful providing full
information regarding the target sequence. Oligonucleotides used in the present study were
designed based on Larrick and Coloma [263, 262]. To clone the variable regions for sequence
analysis, redundant primers hybridizing to the leader sequence (5’primer) and to the C constant
region immediately downstream of the V-J region (3’primer) were used in the first round of
PCR and 5’ RACE reactions, respectively. The sequence of primers have restriction sites chosen
to facilitate cloning of the PCR product to the final expression cassette vector.
Figure 3.6 outlines the steps involved in cloning of immunoglobulin V regions.
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Figure 3.6: Engineering membrane bound antibodies. Schematic diagram describing cloning
of V regions of antibodies for targeting. RNA extraction followed by 5’ RACE PCR amplification
of heavy and light chain variable regions from hybridoma cell lines and subsequent cloning upstream
from the human constant region.
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Figure 3.7: PCR amplification of Thy1.1 (CD90) heavy and light chain V regions.(A) RNA
extracted from OX7 hybridoma was subsequently used as a template for cDNA synthesis and ampli-
fication of V regions. (B) First round of PCR amplification of heavy and light chain V regions using
redundant primers. lanes 1 and 10: 2 log DNA ladder; lanes 2-9: PCR amplification using 8 different
primers for heavy chain V region. Positive PCR reactions generated products at around 500bp, cor-
responding to heavy chain V region, as shown in lanes 3 and 5; lanes 11-14: PCR amplification using
4 different primers for light chain V region. Positive PCR reactions generated a product at around
450bp, corresponding to light chain V region, as shown in lane 11. (C) Control PCR reactions. cDNA
template was omitted from the reaction in order to access possible contamination. Agarose gel: 1.5%.
3.2.1 Cloning of variable regions of Thy1.1 (CD90) antibody
mRNA was isolated from OX7 hybridoma (ECACC 84112008) and used as a template for
cDNA synthesis as described in Section 2.2, using the SMARTer RACE cDNA amplification
kit. During first round of amplification, cDNA was amplified by PCR using degenerate primers
presented on tables 2.3 and 2.4. The Variable region for the light chain was obtained during
the 1st round of PCR (Figure 3.7), using the degenerate primers presented on Table 2.4.
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Positive, blunt end, PCR products obtained from first round of amplification (Figure 3.7) were
gel extracted and cloned into the sequencing vector pCR-Blunt II-TOPO vector in order to be
sequenced.
All four candidates for heavy chain, and twelve for light chain were sequenced. Nucleotide
sequence was translated and amino acid sequence was aligned for V-J-D and V-, J-GENE,
junction analysis and allele identification respectively. Sequences were uploaded and analysed
by the International Immunogenetics Information System (IMGT). PCR product was identified
by sequencing as productive IGH rearranged sequence with no stop codons and in frame junc-
tion for the heavy chain and productive IGK rearranged sequence for the light chain. Below
representative sequences for both heavy and light chain candidates are presented.
For heavy chain V region, as it is presented in Figure 3.8, two candidates were identified
appearing with the same frequency. The sequences differed in an amino acid which in version
A was an Isoleucine (I) while in version B was a phenylalanine (F). These amino acids are
marked in red in the Figure 3.8 (A). For light chain all twelve candidates were the same.
The sequences for both heavy and light chain V regions generated with redundant primers are
presented on figure 3.8.
Based on sequence information, second round of PCR was performed with gene specific primers
presented on table 2.7. Gene specific primers were designed to specifically amplify the V regions
including the leader peptide sequence and exactly the 3’ end immediately downstream of the
V-J region (3’primer) (up to 9 residues following the W118 for the heavy chain and F118 for
the light chain). These sites are marked in red in Figure 3.8B. Primer sequences included
the XhoI and NheI restriction sites for heavy chain and HindIII and BsiWI sites for light
chain, required for directional cloning in the final expression vector (Appendix A.1). It is
important to mention that for heavy chain V regions because both candidates appeared with
the same frequency in the number of clones scanned, both were considered. For this reason,
engineering anti-Thy1.1 antibody proceeded with cloning two constructs one for each version
of heavy chain V region, designated as anti-Thy1.1 A and anti-Thy1.1 B. In the figures below
final cloning steps of anti-Thy1.1 are presented. During second round of amplification with
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Figure 3.8: Thy1.1(CD90) Heavy and light chain variable region sequences obtained with
redundant primers(A) Thy1.1 heavy and light chain V regions are highlighted. CDR1, CDR2
and CDR3 are highlighted with yellow, green and pink respectively. Red boxes mark the differences
generated in heavy chain V regions due to degeneracy of primers used for amplification. (B) Protein
sequence of heavy and light chain variable regions of Thy1.1. Leader peptide sequences for heavy and
light chain are highlighted with yellow. Red boxes: a. mark W and F residues 118 according to Kabat
numbering indicative of the end of CDR3 for heavy chain and light chain respectively. b. indicate the
sites where the BW gene specific primers will be designed to bind. These are designed to be 9 residues
following W118 and F118 respectively with restriction sites placed on residues 11 and 12, which are
residues A and K for heavy chain and R and A for light chain.
gene specific primers (Figure 3.9A), miniprep DNA from TOPO cloning reactions were used
as templates. Positive samples were properly diluted (1:500) and appropriate volume (1µl
and 5µl) was used in the PCR reactions. As presented on Figure 3.9, both heavy and light
chain V regions were successfully amplified under both conditions. PCR products were gel
extracted and purified and digested with appropriate enzymes to facilitate direct cloning to
final expression vector. Upon digest and prior to cloning upstream the constant regions in
the final expression vector (Appendix A.1), samples were heated to 80◦C in order to heat
inactive enzymes and were gel purified once more. The quality of vector (pαCD20/XhoI/NheI;
pαCD20/HindIII/BsiWI) and inserts (Thy1.1 heavy chain V region A and B /XhoI/NheI;
Thy1.1 light chain V region/HindIII/BsiWI) was assessed on an 1.5% agaroze gel.
Cloning proceeded by first cloning the Thy1.1 light chain V region upstream of human constant
region was confirmed with double enzymatic digest HindIII/BsiWI to sites used prior to cloning
(Figure 3.10A). Following confirmation of cloning of light chain, heavy chain V regions A and
B were cloned upstream of the human constant region. Once more, successful cloning was
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Figure 3.9: Cloning of Thy1.1. (A) PCR products generated from second round of amplification
using gene specific primers. Lanes 2-4: PCR reactions performed with 0.4 ng of DNA template; Lanes
5-7: PCR reactions performed with 2 ng DNA template; Lanes 8-10: control PCR reactions from
which DNA template is omitted; Lanes 1 and 11: 2-log DNA ladder. Red boxes mark final PCR
products of Thy1.1 heavy chain V region A and B and light chain V region which will be used for
engineering chimeric antibody.(B) Thy1.1 (left) heavy chain V region A and B at 430bp and (right)
light chain V region at 403bp before extraction and purification. (C) Assessment of Vector and Insert
after digest and gel purification, before cloning to final expression vector. Lane 1: purified vector
pαCD20/XhoI/NheI; Lanes 2-3: purified Thy1.1 heavy chain V regions A and B/XhoI/NheI; Lane
4: 2-log DNA ladder; Lane 5: purified vector pαCD20/HindIII/BsiWI; Lane 6: purified Thy1.1 light
chain V region/HindIII/BsiWI. Agaroze gel: 1.5%.
confirmed with restriction enzyme digest to restriction sites used for cloning (Figure 3.10B).
Final construct pαThy1.1 was assessed with double digest BamHI/PstI and maxi-prep DNA
was checked before sequencing analysis. Enzymes used to assess integrity of constructs were
chosen to cut at cloning sites and within the V regions (Figure 3.10C).
Once cloning was confirmed with restriction enzyme digests, sequencing reactions were set up
to confirm that the sequence of the chimeric antibody generated is the expected one. Primers
used for sequencing are listed on table. Figure 3.11 presents the final protein sequence of
mouse/human chimeric anti-Thy1.1 antibody.
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Figure 3.10: Cloning of pαThy1.1 (A) Confirmation of cloning of light chain V region upstream
human constant region in final expression vector with HindIII/BsiWI restriction enzyme digest. (B)
Confirmation of successful cloning of heavy chain V region in final expression vector in miniprep
DNA preparations. Top: restriction enzyme digest with XhoI/NheI confirming successful cloning
of heavy chain V region in final expression vector. Bottom: Assessment of final construct with
BamH/PstI restrictin enzymatic digest. (C) Assessment of final construct pαThy1.1 in maxiprep
DNA preparations. HindIII/BsiWI, XhoI/NheI, XhoI/EcoRV and BamHI/PstI digests performed to
confirm the integrity of constructs pαThy1.1A and B. Pattern shown in the gel matches the expected
band size. Lanes 1-4: constructs with heavy chain V region A; Lanes 6-7: constructs with heavy chain
V region B. Agarose gel: 1.5%.
In the final sequence of anti-Thy1.1 antibody presented on Figure 3.11 is emphasized that
Thy1.1 heavy chain variable regions differ in one amino acid in their leader peptide. In version
A an Isoleucine (I) is found at the position where in version B a Phenyalanine (F) is observed,
both neutral, non-polar amino acids. This difference is a result of PCR amplification with
degenerate primers. As mentioned, clones for each version appeared with the same frequency
which was not conclusive regarding the identification of the consensus sequence and highlighted
the limitations of this approach. Using degenerate primers for the amplification, has proven
to be tricky in this particular case. Although this difference is not expected to affect the final
product, as leader peptide is cleaved and not present in mature antibody, concerns were raised
regarding the production and secretion of the antibody. Thus access to the actual leader peptide
sequence, as expressed in the mouse hybridoma from which RNA has originally been extracted
is critical. To achieve this an alternative approach was used. In this case first round of PCR was
not performed with degenerate forward primers. A 5’ RACE PCR amplification was performed
instead. In this reaction, forward redundant primer was replaced by UPM (Universal Primer
Mix) while C region primer used was the same with the one used in previous reactions. PCR
reactions were performed using the Advantage 2 Polymerase Mix (Clontech). Controls were
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Figure 3.11: Sequence of anti-Thy1.1 antibody. Protein sequence of heavy and light chain of
mouse/human chimeric anti-Thy1.1 antibody. Mouse leader peptide sequences are highlighted with
yellow. Within leader peptide sequences red ellipses mark the difference between heavy chain A and
B. Red boxes highlight the site where variable region was cloned. Protein sequence that follows is
human light and heavy chain constant region respectively.
set up to ensure specificity and exclude possible cross contamination. 5’RACE PCR generated
products were gel extracted and purified before proceeding with cloning to sequencing vector
pCR 2.1-TOPO (TOPO TA cloning) (Figures 3.12 and 3.13).
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Figure 3.12: RACE PCR amplification of Thy1.1 Variable regions. (A) First round 5’RACE
PCR amplification of heavy and light chain V region using UPM and C region primers. Lanes1-5:
Control PCR reactions. Lane 1: PCR reaction with UPM primers only. Lanes 2 and 3: PCR reaction
with heavy and light chain constant region primers only. Lanes 4 and 5: cDNA was omitted from
reaction to access possible contamination and specificity. Lanes 7 and 8: 5’RACE PCR products for
Thy1.1 heavy and light chain V regions respectively. (B) Gel extraction/ purification of heavy and
light chain V region 5’RACE PCR generated products. (C) Thy1.1 heavy and light chain V region
PCR products upon purification and prior to TOPO TA cloning. Agarose gel: 1.5%.
All ten candidates for heavy chain, and twelve for light chain have been TOPO TA (Figure 3.13)
cloned and sequenced. Nucleotide sequence was translated and amino acid sequence was aligned
for V-J-D and V-, J-GENE, junction analysis and allele identification respectively. Sequences
were uploaded and analysed by the International Immunogenetics Information System (IMGT).
PCR product were identified by sequencing as productive IGH rearranged sequence with no stop
codons and in frame junction for the heavy chain and productive IGK rearranged sequence for
the light one. Sequence analysis revealed, as presented below, the actual sequence for both heavy
and light chain V regions. By performing the first round of amplification with 5’RACE reaction
we have excluded the possibility of artificial base pair alterations in the leader peptide sequence,
due to the presence of degenerate primers. As presented below (Figure 3.14), all ten candidates
for heavy chain V region had exactly the same sequence. No difference was observed in the
leader peptide sequence as previously reported for Thy1.1 heavy chain V region. All clones
corresponded to the consensus sequence. Regarding the light chain V region the consensus
sequence identified by 5’RACE was the same with the one reported previously as result of PCR
amplification with degenerate/ redundant primers.
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Figure 3.13: TOPO TA cloning of pαThy1.1. A. EcoRI restriction enzyme digest performed
to access successful TOPO TA cloning of heavy chain V region. 10 positive candidates for heavy
chain V region were analysed by sequencing. B. EcoRI restriction enzyme digest performed to access
successful TOPO TA cloning of light chain V region. 12 positive candidates for light chain V region
were analysed by sequencing. Agarose gel: 1.5%.
Based on sequence information generated from 5’RACE reactions for Thy1.1 heavy and light
chain V regions, second round of PCR with gene specific primers was performed only for heavy
chain as light chain V region sequence was the same with the one reported previously. Once
more, gene specific primers were designed to specifically amplify the V regions including the
leader peptide sequence and exactly the 3’ end immediately downstream of the V-J region
(3’primer) (up to 9 residues following the W118 for the heavy chain). These sites are marked in
red in Figure 3.14A). Primer sequences included the XhoI and NheI restriction sites, required
for directional cloning to final expression vector. Cloning of anti-Thy1.1 antibody proceeded
simply by substituting the heavy chain V region from either of the constructs engineered before
with the heavy chain V region generated with 5’RACE. In the figures below the cloning of
Thy1.1 heavy chain V region is presented in detail. During second round of amplification with
gene specific primers (Figure 3.15A), miniprep DNA from TOPO-TA cloning reactions were
used as templates. Positive samples were properly diluted (1:500) and appropriate volume
(1µl and 5µl) was used in the PCR reactions. As presented on (Figure 3.15A), heavy chain
V regions were successfully amplified under both conditions. Blunt end PCR products were
gel extracted/purified and TOPO cloned to be sequenced for final time. Upon confirmation
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Figure 3.14: Thy1.1(CD90) Heavy and light chain variable region sequences obtained with
5’RACE. (A) Thy1.1 heavy chain V region is highlighted. CDR1, CDR2 and CDR3 are highlighted
with yellow, green and pink respectively. (B) Comparison of protein sequence of heavy chain variable
regions of Thy1.1 generated with 5’RACE and with degenerate primers. Leader peptide sequences
are highlighted with yellow. Red ellipses: mark the difference in residues in leader peptide sequence
generated due to the use of degenerate primers. (C) Thy1.1 light chain V region is highlighted.
CDR1, CDR2 and CDR3 are highlighted with yellow, green and pink respectively. (D) Comparison of
protein sequence of light chain variable regions of Thy1.1 generated with 5’RACE and with degenerate
primers. Leader peptide sequences are highlighted with yellow. Red boxes: a. mark W and F residues
118 according to Kabat numbering indicative of the end of CDR3 for heavy chain and light chain
respectively. b. indicate the sites where the BW gene specific primers will be designed to bind. These
are designed to be 9 residues following W118 and F118 respectively with restriction sites placed on
residues 11 and 12, which are residues A and K for heavy chain and R and A for light chain.
of the sequence, samples were digested with appropriate enzymes to facilitate direct cloning
to final expression vector, and prior to cloning upstream constant regions in final expression
vector, were heated to 80◦C in order to heat inactive enzymes and were gel purified once more
(Figure 3.15C). The quality of vector (pαThy1.1/XhoI/NheI) and insert (Thy1.1 heavy chain
V region/XhoI/NheI) has been assessed on an agarose gel (Figure 3.15C). Successful cloning of
Thy1.1 heavy chain V region was confirmed with XhoI/NheI restriction enzyme digest (Figure
3.15D) and sequencing with primers presented on Appendix A.1. Final construct is presented
on Appendix A.4.
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Figure 3.15: Cloning of Thy1.1 heavy chain Variable region. (A) PCR products generated
from second round amplification using gene specific primers. Lanes 2 and 3: PCR reactions performed
with 0.4 ng and 2 ng of DNA template respectively; Lanes 3: control PCR reaction from which DNA
template is omitted. Red box marks final PCR products of Thy1.1 heavy chain V region at 430bp which
will be used for engineering chimeric antibody. (B) Restriction Enzyme digest to access successful
TOPO cloning prior to proceeding with sequence analysis in order to confirm specific amplification
with GSPs. (C) Gel extracted and purified insert (Thy1.1 heavyV region/XhoI/NheI) and vector
(pαThy1.1/XhoI/NheI) prior to proceeding with cloning of new heavy chain to final expression vector.
(D) Assessment of final construct pαThy1.1 in maxiprep DNA preparations. XhoI/NheI restriction
enzyme digest performed to confirm the integrity of constructs pαThy1.1. Pattern shown in the gel
matches the expected band size. Agarose gel: 1.5%.
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3.2.2 Cloning of variable regions of p75 (192) antibody.
mRNA was isolated from 192 hybridoma (Kindly provided by Prof. Giamptietro Schiavo,
London Research Institute) and used as a template for cDNA synthesis as described in section
2, using the SMARTer RACE cDNA amplification kit. During first round of amplification
cDNA was amplified by PCR using degenerate primers presented on tables 2.3 and 2.4.
Results obtained from first round PCR amplification are presented on Figure 3.16.
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Figure 3.16: PCR amplification of p75(192) heavy and light chain V regions. (A) RNA
extracted from 192 hybridoma was subsequently used as a template for cDNA synthesis and amplifi-
cation of V regions. (B) First round of PCR amplification of heavy and light chain V regions using
redundant primers. lanes 1 and 11: 2-log DNA ladder; lanes 2-6: PCR amplification using 5 different
forward primers for heavy chain V region. No PCR products was generated with any combination;
lanes 7-10: PCR amplification using 4 different primers for light chain V region. Possitive PCR reac-
tion generated a product at around 450bp, corresponding to light chain V region, as presented in lane
7; lanes 12-20: Control PCR reactions. cDNA template was omitted from each reaction in order to
access possible contamination. (C) RACE PCR generated Light chain V region product prior to gel
extraction/ purification and TOPO cloning. (D) HindIII/BsiWI restriction enzyme digest performed
to assess successful TOPO cloning. Expected band size: 3224 bp, 500 bp (approximately, correspond-
ing to p75 light chain V region), 235 bp and 60 bp. Positive samples 2-16 were analysed by sequencing.
Agarose gel: 1.5%.
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PCR product at the expected size of 500 bp was only observed for light chain V region. The
product was generated with the same pair of primers as the ones successfully used to obtain
Thy1.1 light chain V region. Positive, blunt end, PCR product obtained from first round of
amplification has been gel extracted, purified and cloned into the sequencing vector pCR-Blunt
II-TOPO vector in order to be sequenced.
No product was observed for heavy chain V region (Figure 3.16B lanes 2-6). None of the 5
different combinations of forward and reverse primers succeeded in amplifying heavy chain V
region. This could, to a certain extend, be attributed to poor compatibility of the forward,
degenerate primer to the heavy chain V region leader peptide sequence. Reverse primer is
expected to hybridize, as it binds to constant region, the sequence of which is highly conserved.
All 15 candidates for light chain have been sequenced. Nucleotide sequence was translated
and amino acid sequence was aligned for V-J-D and V-,J-GENE, junction analysis and allele
identification respectively. Sequences were uploaded and analysed by the International Im-
munogenetics Information System (IMGT). 5 out of 15 clones were identified by sequencing as
productive IGK rearranged sequence with no stop codons and in frame junction. The rest were
corresponding to unproductive IGK rearranged sequence with premature stop codon resulting
from a reading frame shift in the V-J recombination site. This non-functional rearranged vari-
able regions are often obtained by PCR of hybridoma cDNA, when antibody variable regions
(VL or VH) are cloned from hybridoma cells lines. The origin of these sequences can be traced
to the myeloma cell lines originally utilized for the fusion during establishment of hybridoma
cell lines. The Sp210-Ag14 myeloma cell line originally used for 192 hybridoma [237], has been
reported as a non-secretor cell line. In many cases these hybridoma cells not only transcribe
the desired monoclonal antibody DNA, but also bear high levels of non-functionally rearranged
mRNAs that represent pseudogenes and can greatly exceed the level of normal antibody RNA.
Below is presented a representative productive sequence for light chain (Figure 3.17). All 5
productive light chain V region candidates were identical.
Amplification of p75NTR heavy chain V region with the same combination of primers was
attempted two more times altering the conditions of PCR reaction. Different annealing tem-
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Figure 3.17: p75(192) light chain variable region sequence obtained with redundant
primers Top: p75 light chain V region is highlighted. CDR1, CDR2 and CDR3 are highlighted
with yellow, green and pink respectively. Bottom: Protein sequence light chain variable region of p75.
Leader peptide sequence is highlighted with yellow. Red boxes: a. mark F residue 118 according to
Kabat numbering indicative of the end of CDR3 for light chain. b. indicate the sites where the BW
gene specific primer will be designed to bind. This is designed to be 9 residues following F118 with
restriction site placed on residues 11 and 12, which are residues R and A.
peratures were assessed, though no PCR product was generated with this approach. This could
be attributed, as mentioned above, to the fact that the degeneracy of the forward primers could
not match the sequence of the leader peptide for heavy chain. Thus strategy for achieving am-
plification of p75NTR heavy chain V region had to be changed. Since the problem appeared to
be the forward primers, 5’RACE PCR amplification could be an ideal approach. In 5’RACE,
forward redundant primers were replaced by UPM while backward primer used is designed
to hybridize to constant region, the sequence of which is highly conserved and known. This
reaction is expected to amplify the heavy chain sequence from the C region, where primers
hybridize, up to the total leader peptide sequence. Then gene specific primers can be used to
amplify only the V region. 5’RACE was performed for both heavy and light chain v region
amplification. This could confirm that the sequence obtained for light chain with degenerate
primers is the correct one and no base pair alteration were introduced to the leader peptide
sequence due to the primer sequence, as previously observed for Thy1.1 amplification. Controls
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Figure 3.18: RACE PCR amplification of p75NTR Variable regions.(A) First round 5’RACE
PCR amplification of heavy and light chain V region using UPM and C region primers. Lanes 1 and
2: 5’RACE PCR products for p75 heavy and light chain V regions respectively. Lanes 4-8: Control
PCR reactions. Lane 4: PCR reaction with UPM primers only. Lanes 5 and 6: PCR reaction with
heavy and light chain constant region primers only. Lanes 7 and 8: cDNA was omitted from reaction
to access possible contamination and specificity of reaction. (B) Gel extraction/ purification of heavy
and light chain V region 5’RACE PCR generated products. (C) TOPO TA cloning of p75NTR heavy
and light chain V region PCR products upon purification and prior to TOPO TA cloning. EcoRI
restriction enzyme digest performed to access successful TOPO TA cloning of heavy chain V region.
20 positive candidates for heavy chain V region and 11 for light were analysed by sequencing. Agarose
gel: 1.5%.
were set up to ensure specificity and exclude possible cross contamination. 5’ RACE PCR gen-
erated products were gel extracted and purified before proceeding with cloning to sequencing
vector pCR 2.1-TOPO (TOPO TA cloning) (Figure 3.18).
All 20 candidates for heavy chain, and 11 for light chain have been TOPO TA cloned and
sequenced. Nucleotide sequence was translated and amino acid sequence was aligned for V-
J-D and V-,J-GENE, junction analysis and allele identification respectively. Sequences were
uploaded and analysed by the International Immunogenetics Information System (IMGT). For
heavy chain, 13 out of 20 clones were identified by sequencing as productive IGH rearranged
sequence with no stop codons and in frame junction. For light chain 6 out of 11 clones were
identified as productive IGK rearranged sequence with no stop codons and in frame junction
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and the rest corresponded to unproductive chain. The sequence of all productive L chain clones
was identical to the one generated previously with degenerate primers. Thus for light chain a
total of 26 clones have been analysed, from which 11 corresponded to the same productive IGK
rearranged sequence. Below (Figure 3.19) the consensus sequence for both p75NTR heavy and
light chain V regions were presented.
Figure 3.19: p75(192) Heavy and light chain variable region sequences obtained with
5’RACE. (A) Top: p75 heavy chain V region is highlighted. CDR1, CDR2 and CDR3 are high-
lighted with yellow, green and pink respectively. Bottom: Protein sequence of heavy chain variable
region. Leader peptide sequence is highlighted with yellow. (B) Top: p75 light chain V region is high-
lighted. CDR1, CDR2 and CDR3 are highlighted with yellow, green and pink respectively. Bottom:
Protein sequence of light chain variable regions. Leader peptide sequence is highlighted with yellow.
Red boxes: a. mark W and F residues 118 according to Kabat numbering indicative of the end of
CDR3 for heavy chain and light chain respectively. b. indicate the sites where the BW gene specific
primers will be designed to hybridize. These are designed to be 9 residues following W118 and F118
respectively with restriction sites placed on residues 11 and 12, which are residues A and K for heavy
chain and R and A for light chain.
Based on sequence information generated from 5’ RACE reactions for p75NTR heavy and light
chain V regions, second round of PCR with gene specific primers was performed. Once more,
gene specific primers were designed to specifically amplify the V regions including the leader
peptide sequence and exactly the 3’ end immediately downstream of the V-J region (3’ primer)
(up to 9 residues following the W118 for the heavy chain). These sites are marked in red in
Figure 3.19. Primer sequences included the XhoI and NheI restriction sites for heavy chain and
HindIII and BsiWI sites for light chain, required for directional cloning to final expression vector.
Cloning of anti-p75NTR antibody proceeded simply by sequential cloning of p75 V regions to
the pαCD20 expression vector. In the figure below amplification with GSP and cloning is
presented in detail. During second round of amplification with gene specific primers (Figure
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3.20A), miniprep DNA from TOPO-TA cloning reactions were used as templates. Positive
samples were properly diluted (1:500) and appropriate volume (1µl and 5µl) was used in the
PCR reactions. As presented on Figure 3.20A, heavy and light chain V region were successfully
amplified under both conditions. Blunt end PCR products were gel extracted/purified and
TOPO cloned to be sequenced for final time. Upon confirmation of the sequence samples were
digested with appropriate enzymes to facilitate direct cloning to final expression vector, and
prior to cloning upstream constant regions in final expression vector, were heated to 80◦C in
order to heat inactive enzymes and were followed by additional gel purification. Successful
cloning of p75NTR light chain V region was confirmed with HindIII/BsiWI restriction enzyme
digest (Figure 3.20E).
Cloning proceeded, as presented above, by first cloning the p75NTR light chain V region up-
stream human constant region which was confirmed with double enzymatic digest HindIII/BsiWI
to sites used for cloning (Figure 3.20). Following confirmation of cloning of light chain, heavy
chain V regions was cloned upstream human constant region (Figure 3.21). p75NTR heavy chain
V region was gel extracted/purified, heated to 80◦C to heat inactive enzymes and assessed prior
to proceeding with cloning upstream of human heavy C region. Once more, successful cloning
was confirmed with restriction enzyme digest to sites used for cloning (Figure 3.21C). Final con-
struct pαp75NTR was assessed with double digest XhoI/BglII and maxi-prep DNA preparations
were prepared and checked before sequencing analysis (Figure 3.21 D).
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Figure 3.20: Cloning of p75NTR variable regions. (A) PCR products generated from second
round amplification using gene specific primers. Lanes 1 and 2: PCR reactions performed with 0.4 ng
and 2 ng of heavy chain DNA template respectively; Lane 3:2-log DNA ladder; Lane 4 control PCR
reaction from which DNA template is omitted. Lanes 6 and 7:PCR reactions performed with 0.4 ng
and 2 ng of light chain DNA template respectively. Red boxes mark final PCR products of p75NTR
heavy chain V region at 430 bp and light chain V region at 403 bp, which will be used for engineering
chimeric antibody. (B and C) Restriction Enzyme digest to access successful TOPO cloning of Light
chain (B) and heavy chain (C) prior to proceeding with sequence analysis in order to confirm specific
amplification with GSPs. (D) Gel extracted and purified insert (p75 lightV region HindIII/BsiWI)
prior to proceeding with cloning of light chain to final expression vector. (E) Assessment of cloning of
p75NTR light chain V region upstream human constant region in the final expression vector (Appendix
A.1). HindIII/BsiWI restriction enzyme digest performed to confirm cloning of light chain V region
(403 bp). Pattern shown in the gel matches the expected band size. Agarose gel: 1.5%.
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Figure 3.21: Cloning of p75NTR heavy chain Variable region. (A) Vector (Lp75 in pαCD20
and insert (p75NTR heavyV region/XhoI/NheI) samples before (A) and after (B) gel extrac-
tion/purification and prior to proceeding with cloning of heavy chain to final expression vector. (C)
Assessment of successful cloning of p75NTR heavy chain with XhoI/NheI restriction enzyme digest.
Expected band size: 6547 bp and 430 bp. (D) Assessment of final construct pα75NTR with XhoI/BgII
restriction enzyme digest in maxiprep DNA preparations. XhoI/NheI restriction enzyme digest per-
formed to confirm the integrity of constructs pαThy1.1. Pattern shown in the gel matches the expected
band size of 5283 bp, 1553 bp and 120 bp. Band at 120 bp was to faint to be captured. Agarose gel:
1.5%.
Once cloning was confirmed with restriction enzyme digests, sequencing reactions were set up
to confirm that the sequence of the chimeric antibody generated is the expected one. Primers
used for sequencing are presented on Appendix section (Appendix A.1). Below is presented
the final protein sequence of mouse/human chimeric anti-p75NTR antibody (Figure 3.22). A
schematic diagram of the final construct is presented on Appendix A.5.
3.2.3 Cloning of variable regions of CAR (RmcB) antibody
To generate the antibody against CAR antigen, we tested and RACE PCR amplified the light
and heavy chain variable regions from the CAR (RmcB) hybridoma cell line (ATCC CRL-
2379). Anti-CAR (RmcB) mRNA was isolated from RmcB hybridoma (ATCC CRL-2379) and
used as a template for cDNA synthesis as described in section 2, using the SMARTer RACE
cDNA amplification kit. During first round of amplification cDNA was amplified by 5’RACE
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Figure 3.22: Sequence of p75(192) antibody. Protein sequence of heavy and light chain of
mouse/human chimeric anti-p75 antibody. Mouse leader peptide sequences are highlighted with yel-
low. Red boxes highlight the sites where variable regions were cloned. Protein sequence that follows
is human light and heavy chain constant region respectively.
PCR with UPM and constant region reverse primers presented on tables 2.3 and 2.4.
Results obtained from first round PCR amplification are presented on the figure below.
Because the number of positive clones for both heavy and light chain positive clones was small
(Figure 3.23D and E) compared to ones used in previous analysis (Thy1.1 and p75) more
TOPO-TA clones were analysed. In total 14 clones for heavy and 18 for light chain were
analysed. All 14 candidates for heavy chain, and 18 for light chain were sequenced. Nucleotide
sequence was translated and amino acid sequence was aligned for V-J-D and V-, J-GENE,
junction analysis and allele identification respectively. Sequences were uploaded and analysed
by the International Immunogenetics Information System (IMGT). For heavy chain, 12 out
of 14 clones were identified by sequencing as productive IGH rearranged sequence with no
stop codons and in frame junction (Figure 3.24A). For light chain 11 out of 18 clones were
identified as productive IGK rearranged sequence with no stop codons and in frame junction
(Figure 3.24B) and the rest corresponded to unproductive IGH and IGK rearranged sequence
with premature stop codon resulting from a reading frame shift in the V-J recombination site.
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Figure 3.23: PCR amplification of CAR(RmcB) heavy and light chain V regions. (A)
RNA extracted from RmcB hybridoma was subsequently used as a template for cDNA synthesis and
amplification of V regions. (B) First round 5’RACE PCR amplification of heavy and light chain V
region using UPM and C region primers. Lanes 2 and 3: 5’RACE PCR products for CAR heavy and
light chain V regions respectively. Lanes 4-9: Control PCR reactions. Lanes 4 and 5: PCR reaction
with UPM primers only. Lanes 6 and 7: PCR reactions with heavy and light chain constant region
primers only. Lanes 8 and 9: cDNA was omitted from reaction to access possible contamination and
specificity. (C) Left: Gel extraction/ purification of heavy and light chain V region 5’RACE PCR
generated products prior to TOPO cloning. Right: heavy and light chain V region PCR products upon
purification and prior to TOPO TA cloning. (D) EcoRI restriction enzyme digest performed to assess
successful TOPO-TA cloning of CAR heavy chain 5’RACE product. Expected band size: 3224 bp, 550
bp (approximately, corresponding to CAR heavy chain V region), Possitive samples 2-16 were sent for
sequencing analysis. (E) EcoRI restriction enzyme digest performed to assess successful TOPO-TA
cloning of CAR light chain 5’RACE product. Expected band size: 3224 bp, 550 bp (approximately,
corresponding to CAR light chain V region). 4 positive candidates for heavy chain V region and 8 for
light were analysed by sequencing. Agarose gel: 1.5%.
Below are presented the consensus sequence for both p75 heavy and light chain V regions.
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Figure 3.24: CAR(RmcB) Heavy and light chain variable region sequences obtained with
5’RACE. textbf(A) Top: CAR heavy chain V region is highlighted. CDR1, CDR2 and CDR3 are
highlighted with yellow, green and pink respectively. Bottom: Protein sequence of heavy chain variable
region. Leader peptide sequence is highlighted with yellow. (B) Top: CAR light chain V region
is highlighted. CDR1, CDR2 and CDR3 are highlighted with yellow, green and pink respectively.
Bottom: Protein sequence of light chain variable region. Leader peptide sequence is highlighted with
yellow. Red boxes: a. mark W and F residues 118 according to Kabat numbering indicative of the
end of CDR3 for heavy chain and light chain respectively. b. indicate the sites where the BW gene
specific primers will be designed to bind. These are designed to be 9 residues following W118 and
F118 respectively with restriction sites placed on residues 11 and 12, which are residues A and K for
heavy chain and R and A for light chain.
Based on sequence information generated from 5’RACE reactions for CAR heavy and light
chain V regions, second round of PCR amplification with gene specific primers was performed.
Once more, gene specific primers were designed to specifically amplify the V regions including
the leader peptide sequence and exactly the 3’ end immediately downstream of the V-J region
(3’primer) (up to 9 residues following the W118 for the heavy chain). These sites are marked in
red in Figure 3.24. Primer sequences included the XhoI and NheI restriction sites for heavy chain
and HindIII and BsiWI sites for light chain, required for directional cloning to final expression
vector. Cloning of anti-CAR antibody proceeded simply by sequential cloning of CAR V
regions to the pαCD20 expression vector (Appendix A.1). In the figure below amplification
with GSP and cloning is presented in detail. During second round of amplification with gene
specific primers (Figure 3.25A), miniprep DNA from TOPO-TA cloning reactions were used
as templates. Positive samples were properly diluted (1:500) and appropriate volume (1µl and
5µl) was used in the PCR reactions. As presented on figure 3.25A, heavy and light chain
V regions were successfully amplified under both conditions. Blunt end PCR products were
gel extracted/purified and TOPO cloned to be sequenced for final time. Upon confirmation
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of the sequence samples were digested with appropriate enzymes to facilitate direct cloning
to final expression vector, and prior to cloning upstream constant regions in final expression
vector, were heated to 80◦C in order to heat inactive enzymes and were gel purified once more.
Successful cloning of CAR heavy chain V region was confirmed with XhoI/NheI restriction
enzyme digest (Figure 3.25D).
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Figure 3.25: Cloning of CAR variable regions. (A) PCR products generated from second round
amplification using gene specific primers; Lanes 1 and 4: 2-log DNA ladder; Lanes 2 and 3: PCR
reactions performed with 0.4 ng and 2 ng of heavy chain DNA template respectively; Lanes 5 and
6: PCR reactions performed with 0.4 ng and 2 ng of light chain DNA template respectively; Lanes
7 and 8: control PCR reaction from which DNA template is omitted. Red boxes mark final PCR
products of CAR heavy chain V region at 430 bp and light chain V region at 403 bp, which will be
used for engineering chimeric antibody. (B) Restriction Enzyme digest to access successful TOPO
cloning of heavy and light chain prior to proceeding with sequence analysis in order to confirm specific
amplification with GSPs. (C) Gel extracted and purified insert (CAR heavy V region XhoI/NheI)
and vector (pαpCD20/XhoI/NheI) prior to proceeding with cloning of light chain to final expression
vector. (D) Assessment of cloning of CAR heavy chain V region upstream human constant region
in the final expression vector. XhoI/NheI and EcoRI/PstI restriction enzyme digests performed to
confirm cloning of heavy chain V region (430 bp). Pattern shown in the gel matches the expected
band size. Agarose gel: 1.5%.
Cloning proceeded, as presented above, by first cloning the CAR heavy chain V region upstream
human constant region which was confirmed with double enzymatic digests XhoI/NheI and
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EcoRI/PstI (Figure 3.25D). Following confirmation of cloning of heavy chain, light chain V
region was cloned upstream human constant region (Figure 3.26A and B). CAR light chain V
region was gel extracted/purified, heated to 80◦C to heat inactive enzymes and assessed prior
to proceeding with cloning upstream human heavy C region. Once more, successful cloning
was confirmed with SacI/BsiWI restriction enzyme digest (Figure 3.26C).
 6628bp
HCAR in 
pCD20/
HindIII/BsiWI
 403bp
LCAR/
HindIII/BsiWI
 
403bp
Light 
CAR 
 6628bp
430bp
HC20 
           
B.A. C.
pαCAR(RmcB)/SacI/BsiWI
   1  2   3   4  5   6   7  8  9  10   
Figure 3.26: Cloning of CAR light chain Variable region. (A) Vector (HCAR in pαCD20 and in-
sert (CAR light V region/HindIII/BsiWI) samples before (A) and after (B) gel extraction/purification
and prior to proceeding with cloning of light chain to final expression vector. (C) Assessment of suc-
cessful cloning of CAR light chain with SacI/BsiWI restriction enzyme digest. Pattern shown in the
gel matches the expected band size. Agarose gel: 1.5%.
Once cloning was confirmed with restriction enzyme digests, sequencing reactions were set up to
confirm that the sequence of the chimeric antibody generated is the expected one. Primers used
for sequencing are listed on Appendix A.1. Below the final protein sequence of mouse/human
chimeric anti-CAR antibody is presented (Figure 3.27).
3.2.4 Characterisation of leader peptide sequences.
Locating proteins in the cell
In 1999, the Nobel prize in Physiology or Medicine was awarded to Gunther Blobel for the
discovery that proteins have intrinsic signals that govern their transport and localisation in
the cell. Since determining the subcellular localisation of a protein is an important clue to its
function, the characterization and prediction of N-terminal sequence motifs (intrinsic signals)
that direct proteins within a cell is of major importance. The best known ”intrinsic signal” is the
secretory signal peptide (SP), which in antibody sequences is known as leader peptide (LP).
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Figure 3.27: Sequence of CAR(RmcB) antibody. Protein sequence of heavy and light chain
of mouse/human chimeric anti-CAR antibody. Mouse leader peptide sequences are highlighted with
yellow. Red boxes highlight the sites where variable regions were cloned. Protein sequence that follows
is human light and heavy chain constant region respectively.
It targets proteins for translocation across the plasma membrane in prokaryotes and across
the endoplasmic reticulum (ER) in eukaryotes [275]. It is an N-terminal peptide, typically
15-30 amino acids long, which is cleaved off during translocation of the protein across the
membrane, thus it is not present in the mature protein. A simple consensus sequence for SPs is
not available, though three distinct compositional domains are typically found: an N-terminal
region which normally contains positively charged residues, a hydrophobic region (usually 6
residues long) and finally a C-terminal region comprised mainly of polar uncharged residues
with some conservation at the positions relative to the cleavage site [276]. Emanuelsson et al.,
have described the amino-acid sequence-based predictors TargtetP and SignalP [276]. These
subcellular localization predictors exclusively use the amino-acid sequence of the protein as the
only input information to locate proteins within the cell.
Engineeering the membrane bound antibodies for targeting involved, as described above, cloning
of heavy and light chain variable regions. Based on the methodology followed and the primers
used for amplification of variable regions the final products included the sequence of the leader
peptide for each one of them. The nucleotide sequence corresponding to the mature protein
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sequence subsequently form the template for gene specific primer design and cloning into final
plasmid vectors. For all three antibodies generated, the leader peptide sequence amplified
was a mouse leader peptide sequence, since these antibodies were expressed and secreted from
mouse hybridoma cell lines. Part of characterizing and comprehending the antibody protein
sequences cloned, involved identification and characterization of the leader peptide sequence.
In order to generate a targeted vector with the antibody of preference expressed on its surface
it is essential that during vector production in 293T cells, the antibody protein sequence is
secreted and processed to a fully mature antibody molecule, that will be incorporated on the
viral surface. For this reason it was of high importance to be able to define the presence of
an SP and determine the subcellular localisation of these antibody protein sequences, simply
based only on the amino acid sequence amplified.
The presence and location of signal peptide cleavage sites in the amino acid sequences of
both heavy and light chain variable regions of anti-Thy1.1, anti-p75 and anti-CAR engineered
antibodies was investigated using Target P1.1 [277] and SignalP 3.0 [269]. For every submitted
protein, Target P reports a prediction score for the three possible outcomes regarding the kind
of N-terminal sorting signal existing in the sequence being analysed: secretory signal peptide
(SP), chloroplast transit peptide (cTP) or mitochondrial targeting peptide (mTP) and assigns a
dedicated localisation in the ”Loc” column: (C)hloro[last, (M)itochondrial, (S)ignal or ”other”
localisations. Based on the scores, TargetP provides a reliability coefficient, RC, which is a
measure of how confident is the prediction. The RC ranges from 1 (very reliable prediction) to
5 (not reliable prediction; false possitive detected). When TargetP predicts, as presented below,
an SP then SignalP 3.0 analysis is required in order to have a detail prediction of the Signal
peptide and its cleavage site, important information regarding the mature protein. SignalP
predicts signal peptidase I cleavage sites based on a combination of neural network and hidden
Markov model (HMM) algorithms. The HMM calculates the probability of the presence of a
signal peptide to differentiate between secreted and non-secreted whilst the NN detects the
site of cleavage by assigning different scores to amino acids indicating if they are part of the
signal sequence and if they are adjacent to a cleavage site. More specifically, the two major
SignalP-NN scores appear in the report as S-score and C-score. The S-score can be interpreted
124 Chapter 3. Engineering membrane bound antibodies for targeting
as an estimate of the likelihood of the position belonging to the SP, whereas the C-score can be
interpreted as an estimate of the likelihood of the position being the first in the mature protein
(position +1 relative to the cleavage site). If there are several C-score peaks of comparable
strength, the true cleavage site predicted by Y-score, which is a geometric average of the C-
score and a smoothed slope of the S-score (as seen in graphical outputs of the figures). The
Y-score gives the best estimate of where the SP is cleaved. Upon checking graphical output
of SignalP it is recommended to further assess the sequence in order to distinguish between
a signal peptide (S) and a signal anchor (A). A signal anchor is just like an SP but it is not
cleaved. Instead it remains as a transmembrane α-helix in the membrane and anchors protein
to the membrane in an N-in/C-out orientation, called type II membrane protein [278]. To
avoid misinterpretation of the results all sequences were assessed for probability of being a
signal anchor. In the figures below are presented the results of TargetP and SignalP analysis
of amino acid sequences of all three antibodies.
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TargetP 1.1 for Thy1.1 light chain TargetP 1.1 for Thy1.1 heavy 
SignalP 3.0 for Thy1.1 light chain
SignalP 3.0 for Thy1.1 heavy chain
Figure 3.28: TargetP and SignalP analysis for Thy1.1(CD90) antibody leader peptide
sequences. TargetP output contains at ”Loc” column the prediction ”S” for secretory for both
heavy and light chain V region leader peptides. SignalP-NN graphical output showing C-, S- and
Y-score for both sequences. The cleavage site is predicted to be at the position of maximal Y-score.
SignalP-HMM score, showing probabilities for signal and anchor peptides and cleavage site. For both
heavy and light chain the prediction is for signal peptide with cleavage site between positions 20 and
21 for light chain leader peptide and positions 19 and 20 for heavy chain leader peptide.
The graphical output of TargetP and SignalP analysis of the amino acid sequence corresponding
to leader peptide for heavy and chain V regions of Thy1.1 antibody, as presented on figure 3.28
has predicted that the sequence amplified is a secretory signal. The ”Loc” column of TargetP
analysis contains the prediction ”S” for secretory with ”RC” value 1 defining a very reliable
prediction for both leader peptide sequences. SignalP-NN and SignalP-HMM analysis has
shown C-, S-, and Y scores. The cleavage site is predicted to be at the position of maximal Y-
score which correlates with the highest peaks presented on the graphs. The HMM algorithm,
further confirmed the prediction for a secretory signal excluding the possibility of being an
anchor protein and calculated a high probability for cleavage site between positions 20 and 21
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(residues G/DI) for light chain peptide and between positions 19 and 20 (residues S/EI) for
heavy chain peptide.
TargetP 1.1 for p75 light chain TargetP 1.1 for p75 heavy chain
SignalP 3.0 for p75 light chain
SignalP 3.0 for p75 heavy chain
Figure 3.29: TargetP and SignalP analysis for p75(192) antibody leader peptide sequences.
TargetP output contains at ”Loc” column the prediction ”S” for secretory for both heavy and light
chain V region leader peptides. SignalP-NN graphical output showing C-, S- and Y-score for both
sequences. The cleavage site is predicted to be at the position of maximal Y-score. SignalP-HMM
score, showing probabilities for signal and anchor peptides and cleavage site. For both heavy and light
chain the prediction is for signal peptide with cleavage site between positions 20 and 21 for light chain
leader peptide and positions 19 and 20 for heavy chain leader peptide.
The graphical output of TargetP and SignalP analysis of leader peptide sequences for heavy
and chain V regions of p75 antibody, as presented on figure 3.29 has predicted that the sequence
amplified is a secretory signal. TargetP analysis contains the prediction ”S” for secretory with
”RC” value 1 defining a very reliable prediction for both leader peptide sequences. SignalP-NN
and SignalP-HMM analysis has shown C-, S-, and Y scores. The cleavage site predicted by
Y-score correlates with the highest peaks presented on the graphs. HMM algorithm analysis
further confirmed the prediction for a secretory signal excluding the possibility of being an
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anchor protein and calculated a high probability for cleavage site between positions 20 and 21
(residues G/DI) for light chain peptide and between positions 19 and 20 (residues A/QI) for
heavy chain peptide.
TargetP 1.1 for CAR light chain
SignalP 3.0 for CAR light chain
TargetP 1.1 for CAR heavy chain
SignalP 3.0 for CAR heavy chain
Figure 3.30: TargetP and SignalP analysis for CAR(RmcB) antibody leader peptide se-
quences. TargetP output contains at ”Loc” column the prediction ”S” for secretory for both heavy
and light chain V region leader peptides. SignalP-NN graphical output showing C-, S- and Y-
score for both sequences. The cleavage site is predicted to be at the position of maximal Y-score.
SignalP-HMM score, showing probabilities for signal and anchor peptides and cleavage site. For both
heavy and light chain the prediction is for signal peptide with cleavage site between positions 20 and
21 for light chain leader peptide and positions 19 and 20 for heavy chain leader peptide.
Similarly to analysis for Thy1.1 and p75, the graphical output of TargetP and SignalP analysis
of leader peptide sequences for heavy and chain V regions of p75 antibody, as presented on
figure 3.30 predicted that the sequence amplified is a secretory signal. TargetP analysis con-
tains the prediction ”S” with ”RC” value 1 defining a very reliable prediction for both leader
peptide sequences. HMM algorithm analysis, further confirmed the prediction for a secretory
signal excluding the possibility of being an anchor protein and calculated a high probability for
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cleavage site between positions 20 and 21 (residues G/DI) for light chain peptide and between
positions 19 and 20 (residues S/QV) for heavy chain peptide.
According to von Heijne [279], the most common amino acids expected at position -1 of cleavage
site are alanine (A), glysine (G), serine (S), cystein (C), glutamine (Q) and threonine (T).
Taking this into account the predicted cleavage sites between amino acids 20-21 for light chain
and 19-20 for heavy chain leader peptide sequences, for all three antibodies, were considered
as accurate predictions and were used as reference for substituting leader peptide sequences as
presented later on this study.
3.2.5 Discussion
In this chapter, three mouse human chimeric membrane bound antibodies have been engineered.
This involved PCR amplification and cloning of the heavy and light chain variable regions for
all three antibodies. mRNA was isolated from OX7, 192 and CAR (RmcB) hybridoma and used
as a template for cDNA synthesis with a panel of primers. Several attempts were concentrated
on amplifying heavy and light chain V regions using degenerate PCR primers predicited to
prime the majority of different variable (V) regions [262]. The sequence of these primers was
primarily based on murine leader sequences contained within the database compiled by Kabat
et al. [280]. Similar families of redudant primers that have been published for both human and
murine V regions [263, 262], were also tried in this study. Degenerate oligonucleotides can be
used as primers for PCR -based approaches to clone V regions from antibody producing cells
without any prior information about the amino acid or nucleotide sequence of the antibody.
Hybridization of redundant reverse primers to the C region, 20 base pairs immediately down-
stream of V-J region (3’primer), was particularly useful and at all times primers hybridized
successfully. Redundant primers hybridizing to the leader sequence (5’primer) although prefer-
able to priming within the framework regions (FRs) (since amino acid changes introduced into
the FRs may have a negative impact on antigen binding) did not work at all times. In some
cases, primers that successfully hybridized within the leader sequence of an antibody and lead
to successful amplification of that V region (i.e. Thy1.1 heavy chain V region; Figure 3.7B),
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failed to hybridize in the same region of another antibody (i.e. p75 heavy chain V region;
Figure 3.16A) due to lack of homology between different leader peptide sequences. In another
instance, as reported for Thy1.1 heavy chain V region (Figures 3.8A and 3.11), primers intro-
duced amino acid substitutions which resulted in the amplification of V region with differences
in the leader peptide sequence which appeared with the same frequency in all clones analysed.
Although, these substitutions introduced into the leader sequences by imprecise priming do not
have any impact on antigen recognition by the antibody molecule, since the leader sequence
is not part of the functional antibody molecule, concerns regarding the possible impairment of
secretion of heavy and light chains led to altering the method used for PCR amplification of V
regions. Thus first round of amplification with degenerate/redundant primers was substituted
by 5’RACE PCR technology where the forward degenerate primers were replaced by UPM
(universal primer mix) that proved to be extremely useful providing full information regarding
the target sequence and lead to successful amplification of both heavy and light chain V re-
gions for all three engineered antibodies (anti-Thy1.1, anti-p75 and anti-CAR). Successful PCR
amplification of the heavy and light chain V regions should yield products of approximately
420 bp and 390 bp respectively. Failure to observe these products may reflect problems with
the primers being used, the quality of the cDNA or the reaction conditions used. The primers
and methodology used in this study were carefully designed and PCR conditions described in
(methods) were optimal and lead to successful amplification of both heavy and light chain V
regions for all three antibodies. Successfully amplified PCR products were TOPO cloned into
sequencing vectors and a minimum of 20-25 independent clones per heavy and light chain can-
didates were carefully analysed in order to identify the consensus sequence corresponding to a
functional antibody. Two problems have so far been reported to frequently arise when PCR
amplifying V regions. One problem originates from the error-prone nature of Taq DNA poly-
merase, often used in these studies, where it is not uncommon to trace nucleotide substitutions
in the V region which can lead to amino acid changes. To avoid this, Pfx polymerase was used
in all PCR reactions performed in this study. While for 5’RACE Advantage 2 polymerase mix
(high proof reading Taq polymerase was highly recommended by the manufacturers) was used
and no substitutions were observed, as confirmed by sequencing reactions. Another problem
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that can arise and was also identified in this study came from the fact that non-producing
myelomas used to generate the majority of all murine hybridoma cell lines contain an aber-
rant transcript [281]. This transcript contains a single-base pair deletion which results into a
frameshift and premature stop codon thus not encoding a functional L chain protein. Often the
non-secretor cell line P3-X63-Ag8.653 (and other cell lines derived from MOPC 21) which is
used for establishment of hybridoma cells does bear high levels of non-functionally rearranged
mRNAs. If this problem arises, there are certain methods available to use in order to avoid such
transcripts. It is possible to solve this problem by using a specific RNase H digestion of the
pseudogene mRNA. By designing an antisense oligonucleotide that can only bind to pseudogene
mRNA, RNase H can be used for specific digestion of the RNA in the resulting double-stranded
RNA-DNA hybrid [282]. Since these non-secretor cell lines are used for establishment of the
hybridomas used in this study, all positive clones from PCR reactions were carefully scanned
for the presence of these aberrant transcripts. Although pseudogenes were observed in all cases
during V region amplification reactions in this study, the percentage of these transcripts was
low compared to the functional products amplified. Wherever necessary, more clones have been
scanned in order to have adequate number of functional V region candidates corresponding to
the consensus sequence. Moreover all possible heavy and light chain V region candidates were
uploaded to IMGT and examined through IMGT/V-QUEST junctional analysis to confirm
the presence of productive IGH and IGK rearranged sequences (no stop codons and in-frame
junction). DNA from clones with desired sequences was reamplified by PCR using gene specific
primers appropriate for leader and J-region sequences, sequenced and finally cloned into expres-
sion vectors upstream human constant regions. Successful cloning was in all cases confirmed
with appropriate restriction enzyme digest. If all steps regarding amplification and analysis of
PCR products are performed as described above it is highly unlikely that a cloned V region
does not correspond a functional antibody sequence.
Signal peptides are cleavable sequences at the N-terminal of the protein which are responsible
for activating the translocation machinery for protein secretion across the cytoplamic inner
membrane and into the periplasm. Here, since the secretion of the both heavy and light chain
V regions are important for assembly and functional display of the chimeric antibody, V region
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sequences generated by PCR amplification were examined for the presence and exact cleavage
site of signal peptides to determine the sequence of the mature protein. The presence and
location of signal peptide cleavage sites in the amino acid sequences from heavy and light chain
V regions of Thy1.1, p75 and CAR antibodies were investigated using TargetP and SignalP3
[269]. As presented on figures 3.28-3.30, signal peptide cleavage sites were successfully predicted
for all three antibodies and were in agreement with previous reports [279].
Chapter 4
Lentiviral particle production.
Over the last decade lentiviral vectors have emerged and developed as a powerful tool for
transgene delivery. As described in the introduction, lentiviral vectors have been used in several
applications in neurosciences, heamatology, stem cell/ biology, transgenesis and developmental
biology, while in several cases are also been used in ongoing human clinical trials. The lentiviral
vectors designed, engineered and produced in this study are based on Human Immunodeficiency
Virus (HIV-1).
Production of lentiviral vectors is routinely achieved by transient co-transfection of human em-
bryonic kidney (HEK 293T) cells using high concentrations of three or four different plasmids.
These are: 1) the lentiviral expression plasmid (transfer plasmid) which encodes the transgene
of interest flanked by all cis-acting viral sequences required for packaging of RNA genome, 2)
one or two packaging plasmids which encode the viral structural and functional proteins and 3)
the pseudotyping (envelope) plasmid which encodes the glycoprotein responsible for receptor
recognition. The most commonly used glycoprotein is the one derived from vesicular stomatitis
virus (VSV-G). Viruses are obtained by collecting supernatants from the transfected packag-
ing cells. Typical titers of lentiviral vectors pseudotyped with VSV-G range form 106 to 107
transducing units per milliliter. Increased viral titers can be achieved by physical concentration
using ultracentrifugation. Lentiviral vectors pseudotyped with VSV-G have proven to be stable
and able to withstand concentration by ultracentrifugation required for their clinical use [283]
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without this having an affect to their titer. High concentrated viral preparations are required
for in vivo applications. Their broad cell tropism, however, do not make VSV-G pseudotyped
vectors amenable for targeting gene delivery to specific disease sites as they lack the ability to
access difficult to reach areas (such as the central nervous system) without invasive delivery
methods. Viral containing supernatants are concentrated and stored at -80◦C for future use. It
is preferable that viral supernatants are used fresh due to concerns of loss of viral titer resulting
from freeze-thaw cycle.
It is clear that restricting infection to specific cells, known as ’targeted transduction’, is critical
when it comes to safe and efficient in vivo gene delivery and it may be a possible way of enhanc-
ing therapy, reducing side effects and lowering the amount of vector required. An alternative
to pseudotyping with existing envelopes could be the modification of the viral surface through
genetic engineering. Targeting lentiviral vectors to specific cell types has so far proven to be
challenging. Several attempts have been made to alter the receptor attachment function in the
envelope protein without affecting membrane fusion. Yang et al. [93] have introduced an effi-
cient method to target lentiviral vector mediated gene transduction to a desired cell type. This
engineering approach involves the incorporation of a targeting antibody and pH-dependent fu-
sogenic protein as two distinct molecules onto the lentiviral surface. A binding deficient version
of the alphavirus Sindbis glycoprotein was used to pseudotype lentiviral vectors and mediate
fusion of viral membrane and endosomal membrane [284, 94]. The specificity of such a lentiviral
vector is solely determined by the antibody chosen to recognize a specific surface receptor of
the desired cell type. This methodology is flexible and can be extended to other forms of cell
type-specific recognition to mediate targeting. The only requirement is that the antibody must
be endocytosed after interaction with its cell-surface binding determinant as many enveloped
viruses enter their host cells via receptor mediated endocytosis.
In the previous chapter were described in detail the engineering and cloning of the membrane
bound antibodies chosen to be incorporated on the surface of the lentiviral vectors that will be
produced in this study. In this chapter generation of targeted vectors is described and targeted
vectors are characterised in detail regarding the molecular constituents that will determine their
targeting specificity.
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4.1 Production of recombinant targeted lentiviral vec-
tors and controls
The production of targeted lentiviruses enveloped with both membrane bound antibodies (anti-
p75; anti-Thy1.1 and anti-CAR) and fusogenic molecule was demanding and challenging. It
involved co-transfection of 293T cells with 6 different plasmids: plasmids encoding the viral
gag, pol and rev genes (289-pMD2-LgpRRE and 288-pRSV-REV), the lentiviral expression
plasmid (326-pRRL-sincppt-CMV-eGFP-WPRE genome plasmid) that carries the human cy-
tomegalovirus promoter (CMV) driving a reporter gene, plasmids encoding for the membrane
bound antibodies for targeting (pαThy1.1, pαp75 and pαCAR), the pIgαβ plasmid (cDNAs of
human Igα and Igβ in expression plasmid required for expression of surface antibody) and the
envelope plasmid SINmu (mutant Sindbis envelope).
During targeted vector production the amount of plasmids used for transfecting 293T cells was
adjusted to the requirements of a 6 plasmid co-transfection protocol. Various plasmid concen-
trations were assessed before concluding to the optimum combination which resulted to high
titer lentiviral preparations. Thus 293T cells were transfected with 5 µg vector plasmid (326-
pRRL-sincppt-CMV-eGFP-WPRE), 2.5 µg of each of the packaging vector plasmids expressing
the HIV-1 gag/pol gene (289-pMD2-LgpRRE), HIV-1 Rev (288-pRSV-REV) together with 2.5
µg of each of pIgαβ, pSINmu and either pαThy1.1, pαp75 or αCAR.
Upon production, for each lentiviral preparation biological activity of lentiviral vectors carrying
the EGFP reporter gene was determined by flow cytometry. For vectors expressing the LacZ
gene, titer was determined using β-Gal assay. The number of physical LV particles present in a
preparation was estimated using a HIV-1 p24 antigen ELISA, while the relative vector particle
numbers based on virion RNA were determined by one-step qRT-PCR. Titers and yields of
various preparations are listed in tables along the text.
12 plate concentrated and single plate concentrated 6 plasmid lentiviral vector preparations
expressing the following were produced using the Olsen modified calcium phosphate method
and purification through sucrose cushion.
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• α Thy1.1 (CD90) IgG pseudotyped targeted vector
• αp75NTR IgG pseudotyped targeted vector
• αCAR (RmcB) IgG pseudotyped targeted vetor
• 5 plasmid control, which was used as non-targeted control lacking the construct encoding
for the membrane bound antibody
• VSVG, 4 plasmid non-IgG pseudotyped control vector
• αCD20 IgG pseudotyped targeted vector, which was used as a negative control for targeted
transduction
Controls were used in studies described below for examining (1) incorporation of the engineered
membrane bound antibody into the lentiviral surface, (2) antibody directed binding to target
receptors and (3) targeted transduction efficiency. A diagram of production of targeted vectors
and controls is presented on figure 4.1.
4.2 Characterisation of targeted vectors.
4.2.1 Co-expression of Fusogen and Antibody molecules on Lentivi-
ral preparations.
In order to examine whether the engineered antibodies (αCD20; αThy1.1; αp75NTR; αCAR)
and fusogenic molecule (SINmu) were incorporated into the lentiviral preparations, western
blot analysis of the lentiviral concentrated preps both 12 and single plate preps has been
performed. αCD20, 5 plasmid control and VSV-G preps were included as controls. Antibodies
were carefully chosen in order to detect both SINmu and the engineered antibody. According
to Yang et al [93], a 10-residue HA-tag sequence (MYPYDVPDYA) is inserted between amino
acids 71 and 74 of the E2 glycoprotein of SINmu, for which exists a monoclonal antibody
that allows monitoring of SINmu expression. Expression of αCD20; αThy1.1; αp75; αCAR
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Figure 4.1: Generation of αThy1.1, αp75NTR and αCAR targeted lentivectors and controls.
Lentiviral vectors were generated by transfecting HEK293T cells using a modified calcium phosphate
precipitation method. Targeted vectors were generated by 6 plasmid co-transfection using the following
expression plasmids: 1) pαThy1.1/pαp75NTR/pαCAR and 2) pIgαβ plasmids required for surface
expression of antibody molecules, 3) SINmu(SGN) envelope plasmid, the 4) 326-pRRL-sincppt-CMV-
eGFP-WPRE genome plasmid and the 289-pMD2-LgpRRE and 288-pRSV-REV packaging plasmids
(not shown). αCD20, 5pl and VSVg vectors were used as controls
and HAmu will be detected by using an anti-human IgG antibody and an anti-tag antibody
respectively. As presented on Figure 4.2, western blot analysis for detection of SINmu (anti-
HA-HRP antibody) on the 6 lentiviral preps mentioned above revealed a strong band running
at approximately 64 kDa, which is the expected size, in all αCD20, αThy1.1, αp75 and the
5 plasmid control lentiviral preparations. No band was observed in the VSVG preparation,
which was used as a negative control in this experiment, since SINmu plasmid was not used
in the 4 plasmid transfection protocol for VSV-G. The signal observed in αCD20 correlates
with previous findings, demonstrating the incorporation of SINmu molecule on the lentiviral
preparation. Same blot has been stripped off and re-blotted for the engineered antibodies
(anti-human-IgG). Signal corresponding to human light IgG was observed in all preparations
except VSV-G. In the control pαCD20 samples, a 26 kDa band, representative of human L
chain was observed. For the engineered αThy1.1 and αp75NTR preps, a band at around 27-
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28 kDa revealed the presence of a human light IgG. The difference in the size between these
engineered vectors and the control pαCD20 was possibly due to the presence of two additional
glycosylation sites in the light chain V region of anti-p75NTR and anti-Thy1.1 compared to
CD20. Same findings were observed for αCAR preparations, as presented on figure 4.2B. For
all lentiviral preparations used in this experiments physical titer was determined (Table 4.1),
and were normalised to p24 concentration prior to loading on SDS-page gel and western blot
analysis. Membranes were stripped off and incubated with loading control rabbit pAb to α-HIV
proteins p55+p24+p17 which confirmed that equal amount of lentiviral preparation assessed
have been subjected to western blot analysis.
Table 4.1: Titers of single plate lentiviral preparations used in Western blot analysis
Vector
p24 concentration
Application
(ng/ml)
αVSVG Western Blot Analysis
(CMVeGFP)
Batch 1.50× 104
αCD20 Western Blot Analysis
(CMVeGFP)
Batch 2.86× 104
αThy1.1 Western Blot Analysis
(CMVeGFP)
Batch 2.04× 104
αp75NTR Western Blot Analysis
(CMVeGFP)
Batch 5.87× 104
αCAR Western Blot Analysis
(CMVeGFP)
Batch 1.43× 104
α5pl Western Blot Analysis
(CMVeGFP)
Batch 1.62× 104
Results obtained from western blot analysis presented on figure 4.2 confirmed that the SINmu
and membrane bound antibody molecules are being incorporated on the lentiviral preparations
generated.
4.2.2 Co-incorporation of antibody and fusogen molecules on the
same lentiviral vector.
Co-display of the anti-Thy1.1, anti-p75(MC192), anti-CAR (RmcB) and a fusogenic protein
(here SINmu SGN) on the same virion is essential for these engineered lentiviruses to enter
their target cells. To determine whether α75NTR (anti-p75(MC192)), αThy1.1 (anti-Thy1.1).
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Figure 4.2: Characterisation of targeted lentiviral preparations. (A, B) Western blot analysis
of targeted lentiviral preparations and controls to determine the expression of fusogenic protein and
antibody molecule. Top: Western blot analysis for detection of fusogenic protein with anti-HA-HRP
(1:10,000, Miltenyi Biotec). Fusogenic protein was as expected, detected in all preparations apart
from VSVg. Middle: Western Blot analysis for detection of antibody molecule with anti-human
IgG (L) 1:700, Abcam. Antibody molecule was as expected, detected only in (A) αCD20, αThy1.1
and αp75NTR and in (B) αCAR lentiviral preparations. Bottom: Western blot analysis of viral
preparations with loading control rabbit pAb to α-HIV proteins p55+p24+ p17.
αCAR and SINmuSGN (fusogenic molecule) were incorporated on the same virion and define
the percentage of the virions within a viral preparation that bear both components, virions
were immunofluorescently stained by a triple labeling method. In order to define the exper-
imental conditions and optimise the staining conditions αCD20 single plate viral preparation
was produced and incorporated into the experiment as positive control. This triple staining
method has previously been attempted for αCD20 in Lei et al. [94]. Vector particles were
bound onto poly-D-lysine coated coverslips. In order to avoid any autofluorescence or detection
of background signal originating from eGFP expressing vector particles, all vector preparations
produced for single particle analysis were expressing LacZ reporter gene. To assure that similar
number of particles was bound between different coverslips amounts loaded were normalised
based on p24 values, based on the physical titer calculated (Table 4.2).
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Table 4.2: Titers of single plate lentiviral preparations used in Single Particle Imaging
Vector
p24 concentration
Application
(ng/ml)
VSVG Single Particle Imaging
(CMVLacZ)
Batch 1 1.63× 104
Batch 2 1.40× 103
Batch 3 5.36× 103
αCD20 Single Particle Imaging
(CMVLacZ)
Batch1 2.86× 104
Batch 2
Batch 3
αThy1.1 Single Particle Imaging
(CMVLacZ)
Batch 1 1.54× 104
Batch 2 1.91× 103
Batch 3 8.19× 103
αp75NTR Single Particle Imaging
(CMVLacZ)
Batch 1 3.07× 104
Batch 2 1.72× 103
Batch 3 8.14× 103
αCAR Single Particle Imaging
(CMVLacZ)
Batch 1 9.59× 103
Batch 2 1.13× 104
Batch 3 6.19× 103
5pl Single Particle Imaging
(CMVLacZ)
Batch 1 1.54× 104
Batch 2 1.91× 103
Batch 3 8.19× 103
Prior to triple staining, single staining with each one of the antibodies chosen for this experi-
ment, was performed to assess the specificity of the staining and the possibility of crosstalk be-
tween the different channels during confocal analysis. As the the aim was to stain for molecules
on the surface of the particle, the step of permeabilisastion was eliminated in these experiments.
Images captured from control single particle analysis of the positive control vector αCD20 and
single staining with each one of the antibodies used in this experiments are presented on figure
4.3.
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Figure 4.3: Control single particle analysis. (A) Single particle analysis performed on positive
control vector αCD20. αCD20 particles were overlaid upon coverslips and stained for the presence
of SGN fusogen (anti-HA-FITC), αCD20 (Alexa 594 anti-human IgG) and HIV p24 (anti-p24). Co-
localizing pixels are indicated by a white signal. (B) Control staining. Particles were overlaid upon
coverslips and stained separately for the presence of SGN fusogen (anti-HA-FITC), antibody (Alexa
594 anti-human IgG) and HIV p24 (anti-p24) molecules. No cross talk is observed between the three
channels as particles labelled with only one of the markers did not give a signal for the other ones.
Scale bars: 5µm.
Once staining conditions were defined, single particle analysis was performed for the three
engineered targeted vectors (αp75NTR, αThy1.1 and αCAR). Single plate viral preparations
were made for each of the targeted αThy1.1, αp75NTR and αCAR. As controls, were included
the non-targeted vector (5pl contol) which bears the fusogenic molecule but not the antibody
molecule and a VSVG which lacks both the antibody and fusogen molecules. Particles positive
for HIVp24, surface antibodies (anti-p75NTR, anti-Thy1.1 and anti-CAR) and SGN fusogen were
present in the αp75NTR, αThy1.1 and αCAR samples along with particles positive for one or
two of the markers. The SGN +ve IgG+ve particles seen could represent non-vector exosomes.
There was no cross talk between the three channels as particles possessing only one of the
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markers did not give a signal for the other ones. Three independent images of each viral prep,
were used for quantification. On each image, five 10x10µm fields were randomly selected, using
Macrosrandom/ROI in ImageJ, and used to quantify/count the number of particles present.
The number of positive particles in each of the three channels (SINmu(SGN), anti-IgG and p24)
were counted manually. The percentage of triple positive particles was calculated. Upon quan-
tification was found that for αp75-CMV-SGN 49.8% of particles were triple positive, while for
αThy1.1-CMV-SGN 31% and for αCAR-CMV-SGN 53% of particles co-displayed the desired
features. In all cases were observed SGN/IgG only positive structures which were excluded
from counting (Figure 4.4).
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Figure 4.4: Coincorporation of antibody and fusogenic protein on the single lentivirus par-
ticle. (A) Schematic representation of the virus staining method for visualizing individual particles.
(B) αp75, αThy1.1, αCAR, 5pl, and VSVg particles were overlaid upon coverslips and stained for the
presence of SGN fusogen (anti-HA-FITC), αp75NTR / αThy1.1/ αCAR (Alexa 594 anti-human IgG)
and HIV p24 (anti-p24). The insert shows zoomed in view of the indicated region. Co-localizing pixels
are indicated by a white signal. (C) Quantification of triple positive particles. For αp75NTR 49.8% of
particles co-display antibody and fusogen molecule, while for αThy1.1 and for αCAR 31% and 53% of
total particles are respectively triple positive. Inserts show zoomed in view of the indicated regions.
Co-localizing pixels are indicated by a white signal. Scale bars: 10µm.
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4.3 Discussion
Producing targeted lentiviral vectors pseudotyped with membrane bound antibodies, although
it was initially considered to be challenging it proved to be possible. Various plasmid con-
centrations have been tried in order to define the optimal concentrations required. Plasmid
ratios assessed were based on previous reports [94, 95], though these did not increase either
the titer nor the transduction efficiency of the resulting lentiviral preparations. For this reason
in all lentiviral preparations presented in this study, the ratio of plasmids used in 6 plas-
mid co-transfection was the one initially reported in [93]. Overcoming the difficulties involved
in a six-plasmid co-transfection production protocol, it was possible to consistently generate
lentiviral vectors with high titer values (within the range of x1010 TU/ml) and comparable to
standard 4 plasmid co-transfection VSVG controls (biological titer ranging between 1010-1011
TU/ml). All lentiviral preparations were constantly assessed further to assess the quality of
lentiviral preparations produced each time. Utilizing labelling techniques it was possible, as
previously described [284], to fluorescently label the two key components of the system and vi-
sualize individual vector particles. Single particle imagine required the production of lentiviral
preparations expressing the LacZ reporter gene instead of EGFP. In preliminary experiments,
where EGFP expressing lentiviral particles were used, signal originating from EGFP expressing
vector particles was interfering when 488 laser was used to identify SINmu through HA tag.
In order to avoid this possible crosstalk all vector preparations produced for single particle
analysis were expressing LacZ reporter gene.
Despite the high titer values reported, it is noteworthy to consider that only 40-50% of the
particles produced co-display the two key molecules required for targeted cell transduction.
This is lower compared to previous reports of Joo et al [284] regarding the labeling of αCD20,
where 70% of lentiviral particles co-displayed these two molecules. As this percentage was
representative of three experiments performed with different vector batches differences in co-
display could not be attributed to production method. The only difference between these
targeted vectors is the presence of a human leader peptide sequence in heavy and light chain
V region of anti-C20 antibody instead of a murine leader peptide sequence found in heavy
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and light chain V region of all three engineered antibodies anti-Thy1.1, anti-p75 and anti-CAR.
This could partially explain the differences observed in co-incorporation levels since it is possible
that the use of a signal peptide sequence that matches the origin of the producer cell line can
lead to increase in secretion of mature antibody sequence which will subsequently increase the
incorporation levels of the antibody on the lentiviral surface.
Chapter 5
Improving targeted vector production
Based on preliminary results obtained from transduction experiments on PC12 and S-16 cells
with both αThy1.1 and αp75NTR targeted vectors, experiments proceeded with optimizing these
vectors in order to improve their transduction efficiency. Since it was shown, by preliminary
binding assay experiments, that both αThy1.1 and αp75NTR targeted vectors are binding to
their target cells, then the low transduction efficiency initially reported could partially be
explained by two facts. The vectors are indeed binding to their target receptors but either they
are not being internalised or vector internalisation does normally occur with the vector brought
into an endosome and either is being released too early from it or too late or is not released
at all and tagged to degradation. Based on these hypothesis, the strategy followed towards
optimisation of the targeting system was concentrated on the folowing points:
• endosomal escape
• improving expression
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5.1 Improving Transduction efficiency: non-spin VS spin
infection
The first attempt towards improving transduction efficiency was to improve the transduction
protocol followed so far. In the transduction experiments performed up to now, vectors were
applied to cells at a certain MOI, based on both the target cell number and the biological titer
of the vector, incubated for 6 hours at 37◦C, 5%CO2, with subsequent medium replacement,
which marked the end of transduction. Transduction experiments reported by other groups, in
whose work the experiments of this study were partially based on, in vitro targeted transduction
experiments were instead performed by spin-infection of the target cells with viral supernatants
[93, 284, 94]. Spin infection is usually performed for cells that are in suspension, such as B-cells,
in order to bring in contact the vector particles with the surface of the target cell, assisting
the first step towards transduction. In the present study, in order to improve the transduction
efficiency of targeted vectors αThy1.1 and αp75NTR, and refine our transduction protocol, in
vitro transduction experiments were performed and compared under both spin and non-spin
conditions. In an attempt to replicate spin infection transduction results reported previously
[93] with αCD20 targeted vectors in CD20 expressing cells, the transduction protocol was set
up and initially performed in CD20 expressing cells. Two target cell lines were used, BL31
and Granta-519 which both express CD20 receptor. Concentrated lentiviral vector αCD20 and
controls αThy1.1, VSV-G and 5pl were produced and applied to target cell lines at MOI 50.
Unfortunately transduction levels reported were too low and thus experiments were repeated
at higher MOI. Transduction of both cell lines was difficult. Descent transduction efficiency
with specificity was reported only in Granta 519 cells at MOI 90, where αCD20 targeted vector
transduced target cells at 2.54% ±0.44 (mean±s.d.; n=2 experiments), levels similar to the
onces achieved even with VSV-G, while transduction reported from control vectors αThy1.1
and 5pl was consistently at low background levels. In the case of BL31 cells transduction was
achieved only with VSV-G vector. Transduction levels reported from αCD20 targeted vectors
was low, at the same levels as negative targeted control αThy1.1 and non targeted 5pl vectors,
and thus considered as background. Below (Figure 5.1) are presented representative FACS
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plots of Granta 519 and BL31 cells infected with these vectors. It is clear that spin infection,
in the case of B cells which are in suspension is critical in order to achieve transduction. In the
lower panel there is a graphical representation of transduction achieved in Granta 519 (n=2
experiments). Titers of lentiviral preparations used are presented on Table 5.1.
Table 5.1: Titers of lentiviral preparations used for in vitro transduction of Granta 519
and BL31 cells
Viral Vector
Biological Titer RNA titer
(t.u./ml) (RNA copies/ml)
VSVG
(CMVeGFP)
Batch 1 1.83× 1011 4.96× 1010
Batch 2
αCD20
(CMVeGFP)
Batch1 3.13× 1010 8.48× 109
Batch 2
αThy1.1
(CMVeGFP)
Batch 1 1.12× 1011 3.02× 1010
Batch 2
5pl
(CMVeGFP)
Batch 1 4.08× 1010 1.11× 1010
Batch 2
In general, replication of transduction of B-cells (CD20 expressing) with targeted αCD20 vectors
were not that successful, and levels achieved where low compared to the ones initially reported
[93]. Since spin infection protocol was established, experiments to follow were extended to
αThy1.1 and αp75NTR targeted vectors.
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Figure 5.1: Transduction of B cells with αCD20 targeted vector. (A) Representative FACS
plots of non-spin and spin ininfection of Granta 519 and BL31 target cells. (B) Graphical representa-
tion of transduction resulted from spin infection of Granta 519 cells with targeted vector αCD20 and
controls αThy1.1, 5pl and VSV-G. (n=2 experiments)
Concentrated lentivral preparation of both targeted vectors and controls were prepared and
applied to target cells at MOI 50. Target cells were incubated with viral supernatants and
either spin infected (as described at section 2) or infection proceeded as before. 72 hrs post
infection, transduction efficiency was assessed through eGFP expression via FACS analysis.
Initially, spin infection experiments were performed on PC12 cells, where VSV-G and αThy1.1
and 5pl control vectors were applied at two different MOIs (MOI 25 and 50). Below (Figure 5.2)
are presented representative FACS plots from transduction experiments comparing infection to
spin infection of PC12 with targeted vectors and controls. Spin infection has resulted, as shown,
in increase in transduction efficiency. Transduction achieved with α Thy1.1 vector was 10 times
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higher compared to transduction resulting from normal infection. Increase in transduction was
observed also for 5pl control, though still at backgroungd levels.
Table 5.2: Titers of lentiviral preparations used for spin VS non-spin infection comparison
Viral Vector
Biological Titer RNA titer
(t.u./ml) (RNA copies/ml)
VSVG
(CMVeGFP)
Batch 1 2.17× 109 1.10× 1010
αCD20
(CMVeGFP)
Batch1 4.72× 109 4.73× 1010
Batch 2 9.28× 109 4.43× 1010
αThy1.1
(CMVeGFP)
Batch 1 1.39× 109 1.53× 1010
Batch 2 1.76× 109 9.77× 1010
αp75NTR
(CMVeGFP)
Batch 1 3.49× 1010 1.53× 1010
Batch 2 2.23× 109 1.24× 1011
5pl
(CMVeGFP)
Batch 1 4.14× 109 2.15× 1010
Batch 2 7.28× 109 2.92× 1010
Once spin infection protocol was established transduction experiments were extended to S-16
and L6 cells with both the αThy1.1 and αp75NTR targeted vectors. 5pl was used as non-
targeted control and αCD20 as IgG pseudotyped control with different specificity in order to
assess the specificity of the engineered vectors. 12 15cm2 (1.4x107) plate concentrated lentiviral
preparations were prepared and titered. Titer values are presented on Table 5.3. As presented
on figure 5.3, transduction achieved upon spin infections was, at all times, significantly higher
compared to the levels reported when lentiviral supernatants were simply applied onto to the
target cells.
Based on these observations, optimisation of tranduction efficiency of the engineered vectors
extended to the properties of the fusogen used for pseudotyping these targeted vectors.
5.2 Improving transduction efficiency: comparison of dif-
ferent fusogenic molecules
Lei et al. [94], have reported that by introducing specific mutations to SINmu, have generated a
lentiviral vector which exhibited 8-17 fold enhanced transduction efficiency compared to those
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Figure 5.2: Comparision of infection method in PC12 cells. 5x105 PC12 cells were infected
with targeted vector αThy1.1 and VSV-G, and 5pl control at MOI 50 and transduction effciency was
assessed through eGFP expression via FACS 72 hrs post infection. Percentage of eGFP expressing
cells, respresentative of transduction efficiency resulting from ordinary infection (top row) and spin
infection (bottom row) of PC12 cells with targeted vector and controls. Transduction efficiency is
improved upon spin infection.
bearing the parental SINmu [93]. Based on Lu et al. [193] studies on cholesterol dependency
of the Sindbis virus glycoprotein, which have shown that mutations on E1 domain at region
266 resulted in viruses less dependent on cholesterol for transduction, Lei and co-workers in-
corporated these mutations into SINmu and engineered different FMs designated as SGM and
SGN. A series of neutralization and pH dependent vector transduction assays revealed that
engineered FM had a broader pH range and subsequently enhanced transduction ability [94].
Using these new engineered SINmu, we attempted to improve the transduction efficiency of
our targeted vectors. On this front, concentrated lentiviral preparations bearing all versions
of engineered FMs were produced for each of the targeted αThy1.1 and αp75NTR vector and
controls 5pl. In total 6 concentrated lentiviral preparations were produced in order to asses the
effect of the fusogenic molecule in transduction efficiency.
Once these lentiviral stocks were produced, they were titered with qRT-PCR, and the viral
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RNA genome content for each prep was determined. We have used the qRT-PCR titration value
as a reference to determine a relative IFU value for the supernatant of the lentiviral vectors
produced, and then, the MOI for the subsequent infection experiments. This was achieved by
independent means, via FACS, for the VSV-G vector preparation, through which we obtained
a biological titre value and subsequently we established a relationship between the two values.
Below are presented the qRT-PCR values of these preps and the correlation between the RNA
titre with infectivity. Finally all vectors were applied to targeted cells at MOI 25 for PC12 and
S-16 cells and at MOI 50 for L6 cells. Below (Figure 5.4A.) are presented representative FACS
plots of spin infection experiments performed with targeted vectors and controls pseudotyped
with each of the different fusogenic molecules. Comparison of spin infection experiments was
based on the effect that each of the three different fusogenic molecules used had on transduction
efficiency. In all cases, as presented on Figure 5.4B, pseudotyping targeted lentiviral vectors
with SIN(mu) SGN version of fusogenic molecule, resulted in improvement of transduction
efficiency.
Table 5.3: Titers of lentiviral preparations pseudotyped with different fusogens.
Viral Vector
SIN SGN SGM
fusogen fusogen fusogen
αThy1.1
(CMVeGFP)
t.u./ml 3.49× 1010 1.12× 1011 6.90× 1010
αp75NTR
(CMVeGFP)
t.u./ml 1.50× 1010 2.57× 109 2.70× 1011
5pl
(CMVeGFP)
t.u./ml 1.10× 1011 4.08× 1010 1.04× 1011
5.3 Discussion
In the current chapter were presented the experiments performed aiming to improve trans-
duction efficiency of the targeted vectors. The strategy followed towards optimisation of the
targeting system was concentrated on two points: refinement of infection process and improve-
ment of fusogenicity.
Replication of the original experiment [93], on various B cell lines, as a proof of concept prior
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to assessing the newly engineered vectors, was proven to be difficult. Many experiments were
performed in which infection conditions were adapted to match the original ones (spin-infection
of B-cells CD20+ with similar titer αCD20 virus), to finally achieve transduction in Granta-510
cells (Figure 5.1). Unfortunately the maximum transduction achieved (2.9%) was considerably
low compared to the one reported by Yang et al., , where 52% of target cells were transduced.
This observation raised concerns regarding the ability to reproduce the method in our lab.
Despite the difficulty, it had to be taken into account than in the original study the target cell
line was 293T cells modified to stably express CD20 receptor (293T/CD20), while in the target
cell line used here CD20 receptor was naturally expressed.
Incorporating spin infection in these experiments was proven to be beneficial for enhancing
the transduction efficiency of the targeted vectors, though it was observed that it differentially
affected transduction, depending on the cell line (more or less refractory to transduction) and
the targeted vector used. It could be claimed that through spin-infection there is a possibility
of forcing the system to work. However this was not the case, as in transduction experiments
where normal infection (without spinning) was used instead (presented in Chapter 6), efficient
transduction was also observed. In an attempt to improve fusogenicity, and possibly enhance
endosomal escape, a panel of different versions of the fusogenic molecule SINmu were assessed.
Lei et al., have introduced specific mutations into the fusion domain of the binding-deficient
SINmu to generate several FMs which were reported to have a broader pH range that resulted
in increase in transduction efficiency [94]. Three different versions of SINmu were assessed
(Figure 5.4) and the one resulting in higher transduction was chosen to be used for subsequent
experiments. Results obtained from transduction experiments performed in this study allowed
to conclude to the final version of the targeted vectors produced, which were pseudotyped
with SINmu (SGN). This mutant version of SINmu was among the two most efficient fusogenic
molecules originally reported in the engineering studies of Lei et al., [94]. The other one was
SINmu(AGM) which did not prove to be that efficient in our studies.
Based on these resulted it was decided that all subsequent transduction experiments were
performed with lentiviral vectors pseudotyped with SIN(mu)SGN and by spin infection.
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Figure 5.3: Comparison of infection in PC12, S-16 and L6 cells with targeted vectors
αThy1.1 and αp75NTR. αThy1.1 and αp75NTR targeted vectors and controls were applied on
5x105 (A) PC12, (B) S-16 and (C) L6 cells with or without spin infection. Transduction efficiency
upon spin and non-spin infection was assessed through eGFP expression via FACS. On the left are
shown representative FACS plots comparing non-spin and spin infection. On the right are shown
graphical presentations of the transduction efficiency achieved upon infection of each cell line with
the vectors. In all cases transduction efficiency was improved upon spin infection as the percentage
of transduced cells was significantly increased for targeted vectors. Transduction observed with non-
targeted and αCD20 control vectors remained at low background levels. (±s.d., n=2 experiments with
individual lentiviral preparations; ∗∗p< 0.05, ∗∗∗p<0.001)
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Figure 5.4: Comparison of transduction of engineered lentiviral vectors bearing all three
different mutants of fusogenic molecule. PC12, S-16 and L6 cells were spin infected with con-
centrated lentiviral preparations. Transduction efficiency was assessed 3 days post infection through
eGFP expression via FACS. (A) Representative FACS plotes of PC12 and S-16 cells spin infected at
MOI 25 and L6 cells spin infected at MOI 50. (B) Graphical representation of transduction efficiency
achieved in target cell lines with lentiviral vectors pseudotyped with all three FMs. Pseudotyping
lentiviral vecrtors with SGN resulted in higher transduction. (±s.d., n=2 experiments; ∗∗p< 0.05,
∗∗∗p<0.001).
Chapter 6
Targeted transduction of cells in vitro
6.1 Targeted transduction of cells in vitro
As a first attempt to evaluate the targeting potential of these vectors rat, mouse and human
cell lines expressing the targeted receptors were used. Concentrated lentiviral preparations
expressing eGFP for both targeted vectors and controls were produced and titers are presented
on table 6.1. Spin infection, as introduced in previous chapter, was used only for transduction
of PC-12 cells. For all other cell lines and primary cultures (described on chapters 7 and 8)
viral infection was attempted by direct application of the vector onto the target cells.
Target cell lines were incubated with target vectors and controls at MOI 25. EGFP expres-
sion was used to measure the transduction efficiency. Four days post-transduction, EGFP
expression was detected by fluorescent microscopy and quantified by flow cytometric analysis
(fluorescence-activated cell sorting (FACS)). Rat S-16 Schwann cells were used as targeted cell
line for αp75NTR targeted vector as they express p75 low-affinity nerve growth factor receptor
(LNGFR) but not Thy1.1 or CD20 receptors. When S-16 cells were infected with αp75NTR
vector and αThy1.1, αCD20 and 5pl control vectors, efficient transduction was observed only
for αp75NTR-targeted vector. Transduction levels observed for αp75NTR vector were as high
as 57.93% ± 11.16% (mean ± s.d.; n=3 experiments with different vector batches), whereas
transduction observed from αThy1.1-, αCD20-targeted and 5pl non-targeted control vectors
154
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Table 6.1: Titer of lentiviral vectors used for in vitro targeted transduction.
Vector
Titer p24 concentration RNA titer
Application
(t.u./ml) (ng/ml) (RNA copies/ml)
αp75NTR Transduction of
(CMV eGFP) cell lines
Batch 1 1.95× 1010 1.27× 107 6.87× 1010
Batch 2 2.17× 1010 9.78× 104 6.36× 1010
Batch 3 2.16× 1010 1.64× 105 1.82× 1011
αThy1.1 Transduction of
(CMVeGFP) cell lines
Batch 1 6.36× 1010 8.46× 107 2.29× 1010
Batch 2 2.47× 109 3.23× 104 1.20× 1010
Batch 3 3.29× 109 2.42× 105 2.76× 1010
αCAR Transduction of
(CMVeGFP) cell lines
Batch 1 8.34× 109 9.46× 104 7.00× 1010
Batch 2 9.95× 109 1.46× 105 8.35× 1010
Batch 3 1.09× 1010 2.40× 105 4.70× 1010
5pl Transduction of
(CMVeGFP) cell lines
Batch 1 6.28× 1010 3.69× 104 2.26× 1010
Batch 2 1.37× 1010 2.48× 106 4.00× 1010
Batch 3 3.62× 1010 8.08× 104 1.56× 1011
was consistently below 5% and thus considered as background (Figure 6.1A). αThy1.1- and
αCD20- targeted vectors were used as controls to assess the specificity of the antibody ex-
pressed by the αp75NTR vector. These control vectors differ from the αp75NTR in the antibody
chosen to be incorporated on their surface, thus differences observed in transduction were de-
termined by the antibody’s specificity. Rat pheochromocytoma PC-12 and muscle L6 cells,
both expressing only p75(LNGFR) and Thy1.1 target receptors were infected with αp75NTR-
and αThy1.1-targeted vectors and controls (αCD20 and 5pl) as before. Whereas the αCD20-
targeted and 5pl non-targeted control vectors resulted in low-level background transduction
(below 0.5 % and 2% respectively), the αThy1.1- and αp75NTR -targeted vectors efficiently
transduced the target cell lines (Figure 6.1A). αThy1.1-targeted vector transduced PC-12 cells
at low levels (3.8% ± 1.52%; mean ± s.d., n=3 experiments with different vector batches),
while higher transduction efficiency was consistently reported for L6 cells (23.25% ± 8.55%;
mean ± s.d., n=3 experiments). Similarly αp75NTR vector transduced both PC-12 and L6 cells,
which express the p75 (LNGFR), at different transduction levels (4.91% ± 0.38% for PC-12
and 8.20% ± 0.43% for L6). Consistently, no off-target transduction was detected when target
cell lines were transduced with αCD20 and 5pl vectors.
When αCAR targeted vector was applied to its target cells human HeLa and SH-SY5Y and
mouse NSC-34 cells, (MOI 25) it transduced all cell lines. Efficiency of transduction var-
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Figure 6.1: Selective and efficient transduction of rat, human and mouse cell lines by
αp75NTR, αThy1.1 and αCAR. (A) Rat Schwan cells S-16 (p75-192 positive), muscle L6 (p75-192
and Thy1.1 positive) and pheochromocytoma PC12 (p75-192 and Thy1.1 positive) were spin infected
with αp75 and αTh1.1 at an MOI of 25. 5pl and αCD20 vectors were included as non-targeted control
vectors to assess the specificity of targeting. 72 hrs post transduction, FACS analysis was conducted
to analyze the percentage of EGFP expressing cells. Mean values are presented in the graphs: S-16,
57.93% ±11.16 for αp75; PC-12, 3.8% ±1.52% for αThy1.1, 4.91% ±0.38% for αp75; L6, 23.25%
±8.55% for αThy1.1, 8.20% ±0.43% for αp75 (±s.d., n=3 experiments with different vector batches).
(B) Human HeLa and SH-SY5Y cells and mouse NSC-34 cells were transduced with |alphaCAR
vector at MOI 25 and 50 respectively. 5pl vector was included as non-targeted control vector to assess
the specificity of targeting. 72 hrs post transduction, FACS analysis was conducted to analyze the
percentage of EGFP expressing cells. Mean values were: HeLa, 8.00% ± 0.52% for αCAR; SH-SY5Y,
34.91% ± 4.79% for αCAR; NSC-34, 4.16% ± 1.59% (± s.d., n=3 experiments with different vector
batches).
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ied between different cell lines for the targeted vector, though transduction resulting from
non-targeted 5pl control was near background levels (Figure 6.1B). For NSC-34, transduction
experiments were performed using MOI 25 (data not shown) and MOI 50. NSC-34 were dif-
ficult to transduce. Interestingly, when MOI was increased from 25 to 50 in order to achieve
significant levels of transduction with the αCAR-targeted vector, transduction observed from
5pl control remained below background levels (Figure 6.1B). Representative FACS plots are
presented on Figure 6.2.
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Figure 6.2: FACS analysis of transduced cell lines. The transduced cells presented on figure
6.1 were detached and fixed. Transduction efficiency of each of the targeted lentiviral vectors and
controls, on these cells, was assessed through EGFP expression and quantified by FACS analysis. All
cell lines were infected at MOI 25 apart form NSC 34 that were infected at MOI 50.
Next, it was attempted to determine whether the specificity of transduction observed was a
consequence of antibody-target receptor interaction. To achieve this, a series of competition
assays were performed. Target cell lines, were transduced in the presence of increasing concen-
trations of soluble anti-p75 (192), anti-Thy1.1(CD90) or anti-CAR (RmcB) blocking antibodies.
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Gene transfer to target cell lines, mediated by targeted vectors could be blocked with p75 (MC
192), Thy1.1 (CD90) and CAR (RmcB) antibodies, respectively (Figure 6.3). Titers of lentivi-
ral preparations used are presented on table 6.1. Figure 6.3 presents the effect of blocking
antibody and isotype control in the transduction achieved by the αp75NTR , αThy1.1 and
αCAR targeted vectors (n=3 individual spin infection experiments averaging the transduction
obtained from each one). Error bars are indicative of the variability observed between indi-
vidual experiments. The average transduction efficiency of targeted αp75NTR vector decreased
in the presence of soluble blocking antibody (anti-p75 MC 192), while it remained unaffected
in presence of isotype control (anti-Thy1.1). Transduction efficiency of the targeted αp75NTR
vector on S-16 was, on average, decreased by 62.5% when spin infection was performed in pres-
ence of 9 µg/ml of anti-p75 MC192, while it was slightly affected (15% decrease) when soluble
anti-Thy1.1 (9µg/ml) was used (Figure 6.3A bottom row). Additionally, similar results were
obtained when competition was performed on L6 cells, where an average of 33.8% decrease was
observed when spin infection was performed in presence of blocking antibody. Efficiency was
reduced by 6.2% in presence of isotype control. The specificity was further confirmed by includ-
ing in the competition assay the non-targeted 5plasmid control vector (Figure 6.4). In culture
of L6 and PC-12 cells (Figure 6.3A top row), the average transduction efficiency of targeted
αThy1.1 was decreased by 45.6% and 63.3% respectively when spin infection was performed in
the presence of 9 µg/ml of blocking antibody. When isotype control of the same concentration
was present, transduction levels of the targeted vector were slightly affected (9.5% and 16%
in L6 and PC-12 cells, respectively). αCAR specificity has further been assessed on cultures
of human SH-SY5Y cells (Figure 6.3B). Similarly to previous observations for αp75NTR and
αThy1.1, transduction efficiency in presence of soluble blocking antibody was decreased on
average by 60.22% and only 9% in presence of isotype control. The specificity was further
confirmed by including in the competition assay the non-targeted 5pl control vector for which
transduction efficiency remained unaffected at background levels (Figure 6.3B right). In all
cases, the presence of blocking antibody affected, as expected, the binding of targeted vectors
to the receptor of target cells. Thus the specificity observed indicates interaction between the
antibody expressed on the surface of the lentiviral vectors and the receptor expressed on the
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surface of the target cell.
6.2 Modifying the vehicle: Can it be more efficient?
In the previous chapter it has been shown that by applying SGN mutation to the binding defec-
tive Sindbis glycoprotein [94] and combining it with spin infection of target cells, transduction
efficiency can further be enhanced. Although production of these vectors proved to be challeng-
ing, since it involved 6 plasmid co-transfection, the biological titers achieved were constantly
high (within the range of ×1010 TU/ml) and comparable to 4-plasmid co-tranfection VSVG
controls (biological titer ×1010 − 1011 TU/ml). Despite the high titer values reported, it has
to be considered that (according to results obtained from single particle analysis Figure 4.4),
within a targeted lentiviral vector preparation only 40-50% of the particles produced co-display
the two key molecules required for targeted cell transduction.
6.2.1 Changing the leader peptide
To address this issue, first attempts concentrated on altering the signal peptide sequence of the
antibodies used for targeting, to match the origin of the producer cell line (human 293T cells).
It is expected that since the producer cell line is human, a human leader peptide sequence could
lead to better expression, secretion and cellular localization of the antibody molecule. Thus
resulting in more efficient incorporation on the lentiviral surface which as a consequence could
improve both the percentage of particles co-displaying the antibody and fusogen molecules
and the downstream transduction efficiency of a given targeted lentiviral preparation. On this
front, leader peptide substitution, was initially attempted for αp75NTR-targeted vector, where
the mouse leader peptide used in all previous reported studies was altered to a human leader
peptide. The human leader peptide used in this optimisation study was the one reported in
αCD20 targeted vectors used in previous studies [93, 284, 94]. Due to absence of a restriction
site that would allowed easy substitution of the mouse leader peptide with the PCR generated
human leader peptide via cloning, and due to time constrains that splice overlap extension
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Figure 6.3: Targeting specificity of αp75NTR , αThy1.1 and αCAR lentiviral vectors. (A)
2,5x105 L6, PC-12, and S-16 cells were incubated for 30 min at 37◦C with increasing concentrations of
soluble antibodies anti-p75-192 (Abcam) and anti-Thy1.1 (Abcam) which recognize the same epitopes
as αp75 and αThy1.1 lentiviral vectors respectively. Following antibody incubation, the cells were
spin-transduced with αp75 or αThy1.1 targeted vectors at an MOI of 25. Cells were analysed for
EGFP expression 72hrs post transduction. For both αThy1.1 (first row) and αp75NTR (second row)
transduction efficiency was decreased in presence of soluble blocking antibody anti-Thy1.1 and anti-
p75-192 respectively. Transduction levels remained unaffected in presence of soluble antibody with
specificity different from that of the targeted vector. (± s.d.; n=3 experiments with different vector
batches). (B) 2,5x105 SH-SY5Y cells were incubated for 30 min at 37C with increasing concentrations
of soluble antibody anti-CAR-RmcB (Millipore) which recognize the same epitopes as αCAR lentiviral
vector. Following antibody incubation, the cells were transduced with αCAR or 5pl vectors at an MOI
of 25. Cells were analysed for EGFP expression 72 hrs post transduction. 5pl vector was used as non-
targeted control. For αCAR (left column) transduction efficiency was decreased in presence of soluble
blocking antibody anti-CAR-RmcB. Transduction levels remained unaffected in presence of soluble
antibody with specificity different from that of the targeted vector and when non-targeted control
vector was used. (± s.d.; n=3 experiments with different vector batches).
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Figure 6.4: Targeting specificity of αp75NTR and αThy1.1 lentiviral vectors. 2,5x105 L6,
PC-12, and S-16 cells were incubated for 30 min at 37◦C with increasing concentrations of soluble
antibody anti-p75-192 (Abcam) and anti-Thy1.1 (Abcam) which recognize the same epitopes as αp75
and αThy1.1 lentiviral vectors respectively. Following antibody incubation, the cells were spin infected
with αp75NTR or αThy1.1 targeted vectors and 5pl control at an MOI of 25. Cells were analysed for
EGFP expression 72 hrs post transduction. For both αThy1.1 (first row) and αp75NTR (second row)
transduction efficiency was decreased in presence of soluble blocking antibody anti-Thy1.1 and anti-
p75-192 respectively. Background transduction levels of 5pl control remained unaffected (± s.d.; n=3
experiments with different vector batches).
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PCR and cloning of this sequence involves, constructs encoding for anti-p75NTR heavy and
light chain variable regions bearing human leader peptide sequences have been designed in
house and constructed by GeneArt. Fragments were designed in order to include XhoI/NheI
(heavy chain) and HindIII/BsiWI (light chain) restriction sites which allowed direct cloning
upstream human constant regions as previously described. The final construct was designated
as hLPαp75NTR. In Figure 6.5 both mouse (used) and new human leader peptide sequences are
shown. Mouse leader peptide sequence are highlighted in purple while human leader peptide
sequences are highlighted in green.
To generate hLPαp75NTR vector, cloning proceed as follows and described in detail on Figure
6.6. 12AAVLQP plasmid has been digested with XhoI/NheI to extract the humanLPαp75NTR
heavy V region product synthesized by GeneArt, gel purified and cloned to pαp75NTR/XhoI/NheI
upstream human heavy chain constant region. The same strategy was followed for humanLPαp75NTR
light V region which was extracted from 12AAVJPP with HindIII/BsiWI and gel extracted/purified
and cloned to pαp75NTR/HindIII/BsIWI. Cloning of both products and generation of hLPαp75NTR
construct was confirmed with appropriate restriction enzyme digests as presented on Figure 6.7.
6.2.2 Single chain antibodies
A limitation of the targeting vector system described here is the use of monoclonal membrane
bound antibodies. As a further improvement step it has been attempted to utilize single chain
antibodies (ScAb) to pair with SINmu(SGN) for targeting lentiviral vectors. ScAb have been
constructed for p75NTR and CAR based on the method described in [95]. Both ScAb are
composed of variable domains of the heavy and light chains of αp75NTR or αCAR, linked by a
GS linker and fused to a hinge-CH2-CH3 region of human IgG. To anchor the ScAb onto the
lentiviral surface, the ScAb is conjugated with HLA-A2 transmembrane domain. Thus in this
case, surface expression of the antibody does not require the presence of the accessory proteins
Igαβ, reducing the number of plasmids required for lentiviral production to five (5). Design
of αp75NTR and αCAR single chain antibody sequences as synthesised by GeneArt and their
cloning into pcDNA3 are presented on Figures 6.8-6.11.
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Figure 6.5: Design and cloning of hLPαp75NTR. (A) Amino acid sequence of anti-p75NTR heavy
and light chain variable regions. Mouse leader peptide sequences are highlighted in pink. Human
leader peptide sequences are highlighted in green. Full anti-p75NTR heavy and light chain variable
regions including a human leader peptide and XhoI/NheI (heavy chain) and HindIII/BsiWI (light
chain) restriction sites have been designed to be synthesized by GeneArt. (B) Plasmids 12AAVJQP
and 12AAVJPP encoding humanLP anti-p75NTR heavy and light chain V region respectively were
synthesized and provided by GeneArt. Fragments were excised with XhoI/NheI and HindIII/BsiWI
restriction enzyme digests in order to be cloned upstream of human constant regions in final expression
vector.
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Figure 6.6: Cloning of hLPαp75NTR (A) Vector: pαp75NTR/XhoI/NheI at 6502 bp (left) and
Insert: 12AAVLQP/XhoI/NheI at 429 bp (right) before extraction and purification. (B) Vector:
pαp75NTR/HindIII/BsiWI (left) and Insert: 12AAVJPP/HindIII/BsiWI at 403 bp (right) prior to
extraction and purification. Assessment of Vector and Insert upon digest and gel purification, prior
to cloning to final expression vector. Lane 1: purified vector pαp75NTR/XhoI/NheI; Lane 2: pu-
rified insert humanLPαp75NTR heavy V region; Lane 3: 2-log DNA ladder; lane 4: purified vector
pαp75NTR/HindIII/BsiWI; Lane 5: purified insert humanLPαp75NTR light V region. Agarose gel:
1.5%.
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Figure 6.7: Confirmation of hLPαp75NTR. Assessment of final construct hLPαp75NTR in maxi-
prep DNA preparations. (A) XhoI/NheI restriction enzyme digest to confirm cloning of heavy chain
V region. (B) HindIII/BsiWI restriction enzyme digest to confirm cloning of light chain V region.
Pattern presented in gels matches the expected band size. Agarose gel: 1.5%.
Once these constructs were cloned, the next step was to evaluate their targeting efficiency and
determine whether they were superior to the the original constructs. The same target cell
lines, as the ones used in Section 1.5 were used. Cell lines were incubated with different ver-
sion of target vectors and with 5pl control (MOI25). EGFP expression was used to measure
the transduction efficiency. Four days post-transduction, EGFP expression was detected by
fluorescent microscopy and quantified by flow cytometric analysis (fluorescence-activated cell
sorting (FACS)). Targeting efficiency of αp75NTR, hLPαp75NTR and Scαp75NTR was compared
in S-16 and L6 cells. As presented on Figure 6.12, when S-16 cells were infected with αp75NTR,
hLPαp75NTR, Scαp75NTR vectors and 5pl control, transduction levels reported were higher for
both modified versions compared to αp75NTR vector. More specifically, mean transduction was
increased by 51% when mouse leader peptide was subtituted with a human one in hLPαp75NTR
and by 27.5% when Scαp75NTR was used. Transduction observed from 5pl non-targeted control
vector was at background levels (Figure 6.12A). Similar results were obtained from transduction
experiments in L6 cells (Figure 6.12A). hLPαp75NTR and Scαp75NTR targeted vectors trans-
duced L6 cells with efficiency better than αp75NTR used so far. Transduction was increased by
48% for LPαp75NTR and doubled for Scαp75NTR. These results were promising and encourag-
ing for optimisation of the targeted vectors in future studies. Their specificity for the target
receptors had also to be assessed. On this front, a competition assay was performed where
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Figure 6.8: Scαp75NTR. The complete sequence (A) and schematic representation (B) of
Scαp75NTR. The different domains are indicated as follows: HLA leader peptide (yellow), GS linker
(dark blue) connecting variable domains of the heavy (green) and light (purple) chains of αp75NTR,
followed by hinge-CH2-CH3 region of human IgG (light blue) and HLA-A2 transbembrane domain
(white) used for anchoring the antibody onto the viral surface. (C) 12AAWK7P plasmid encoding
αScp75NTR antibody was synthesized and provided by GeneArt. HindIII and NotI sites were included
to facilitate cloning to pcDNA3 in order to achieve final construct pαScp75NTR.
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Figure 6.9: Cloning of Scαp75NTR. (A) HindIII/NotI restriction enzyme digest to extract
Scαp75NTR from 12AAWK7P GeneArt vector. (B) Gel extraction/purification of Insert: Scαp75NTR
and Vector: pcDNA3/HindIII/NotI. (C) Insert and vector upon gel extraction and prior to cloning.
(D) Restriction enzyme digest to confirm cloning of Scαp75NTR. Agarose gel: 1.5%.
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Figure 6.10: ScαCAR The complete sequence (A) and schematic representation (B) of ScαCAR.
The different domains are indicated as follows: HLA leader peptide (yellow), GS linker (dark blue)
connecting variable domains of the heavy (green) and light (purple) chains of αCAR, followed by
hinge-CH2-CH3 region of human IgG (light blue) and HLA-A2 transbembrane domain (white) used for
anchoring the antibody onto the viral surface.(C) 12AAZGVP plasmid encoding αScp75NTR antibody
was synthesized and provided by GeneArt. HindIII and NotI sites were included to facilitate cloning
to pcDNA3 in order to achieve final construct pαScp75NTR.
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Figure 6.11: Cloning of ScαCAR. (A) HindIII/NotI restriction enzyme digest to extract SCαCAR
from 12AAZGVP GeneArt vector. (B) HindII/NotI and PstI restriction enzyme digest confirming
cloning of ScαCAR in pcDNA3. Agarose gel: 1.5%.
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target cells were incubated with targeted vectors in presence of increasing concentrations of
anti-p75-(192) soluble blocking antibody. Surprisingly, the average transduction efficiency of
only targeted αp75NTR vector was considerably affected. hLPαp75NTR and Scαp75NTR vectors
were slightly affected, at levels reported previously for 5pl control (Figure 6.3).
On Figure 6.13 is presented the in vitro comparison of αCAR and ScαCAR targeted vector.
Transduction experiments, similar to the ones presented above, showed that both versions
transduced SH-SY5Y and NSC-34 with similar efficiency while higher ScαCAR vectors trans-
duced HeLa cells more efficient than αCAR. Specificity for both preparations was, once more
confirmed through competition assay (Figure 6.13B) where transduction for both vectors was
reduced in presence of soluble blocking antibody. These results are opposite to the ones re-
ported for Scαp75NTR targeted vector, which showed no response to the presence of blocking
antibody (Figure 6.12B).
In summary, human leader peptide driven αp75NTR and single chain antibodies for p75NTR
and CAR have been designed and successfully generated. In vitro assessment of these vectors
provided useful information regarding their specificity and transduction effciciency.
6.3 Discussion
In this chapter it was presented the ability of these newly engineered vectors to transduce
target cell lines. The transduction efficiency of each target vector was assessed on a panel of
target cell lines, expressing the target receptor. Off target effect of each vector was assessed by
incorporating in the transduction experiments negative control cell lines (that do not express
the target receptor). Unlike previous studies, where transduction efficiency was assessed in cell
lines generated to stable over-express the target receptors [93, 284, 98, 99, 285], in this study
the target cell lines used were naturally expressing the target cell-surface molecules. This by
necessity required the use of higher MOI. Transduction efficiency varied between different cell
lines possibly due to abundance of target receptors. The targeted vectors demonstrated at least
five to ten orders of magnitude lower transduction rates on off-target cells, demonstrating a
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Figure 6.12: In vitro comparison of αp75NTR, hLPαp75NTR and Scαp75NTR targeted
vectors (A) Rat Schwan S-16 and muscle L6 were spin infected with αp75NTR hLPαp75NTR and
Scαp75NTR and 5pl control at an MOI 25. 72 hrs post transduction, FACS analysis was conducted
to analyze the percentage of EGFP expressing cells. Mean values are presented in the graphs: S-
16, 50.3% ±4.5 for αp75NTR; 76.13% ±11.4% for hLPαp75NTR, 66.53% ±8.5% for Scαp75NTR ; L6,
19.29% ±7.01 for αp75NTR; 28.7% ±14.6% for hLPαp75NTR, 42.1% 8.1% for Scαp75NTR (±s.d., n=2
experiments with different vector batches). In both cases transduction efficiency of modified version
hLPαp75NTR and Scαp75NTR was better compared to the wt αp75NTR vector. (B) S-16 and L6
cells were incubated for 30 min at 37 C with increasing concentrations of anti-p75-192 soluble an-
tibody anti-p75-192 (Abcam). Following antibody incubation, the cells were spin-transduced with
αp75 hLPαp75NTR and Scαp75NTR targeted vectors at an MOI 25. (n=3 experiments with different
vector batches). (C) Comparison of coincorporation efficiency of αp75NTR and hLPαp75NTR vectors.
Quantification of triple positive particles revealed that a 12% increase when human leader peptide is
used. (For αp75 49.8% of particles co-display antibody and fusogen molecule, while for hLPαp75NTR
62% ).
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Figure 6.13: In vitro comparison of αCAR and ScαCAR targeted vectors (A) Human HeLa,
SH-SY5Y and mouse NSC-34 cells were infected with αCAR and ScαCAR and 5pl control at MOI
25. 72 hrs post transduction, FACS analysis was conducted to analyze the percentage of EGFP
expressing cells. Mean values are presented in the graphs: HeLa, 12.51% ±5% for αCAR; 3.46%
±1.6% for ScαCAR; SH-SY5Y, 33.46% ±2.5% for αCAR; 33.8% ±8.2% for ScαCAR; NSC-34, 3.15%
0.7% for αCAR and 1.56% ±0.7% for Scαp75NTR (±s.d., n=3). In all cases transduction efficiency was
similar between αCAR and ScαCAR vectors. (B) Competition assay on SH-SY5Y cells. Cells were
spin-transduced with αCAR and ScαCAR targeted vectors at an MOI 25 in presence of increasing
concentrations of coluble anti-CAR(RmcB) antibody. For both αCAR and ScαCAR transduction
efficiency was decreased in presence of soluble blocking antibody. (n=3 experiments with different
vector batches).
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high degree of gene transfer specificity (Figure 6.1). Consistently, no off-target transduction
was detected from control vectors that possess different or no specificity for the target receptor.
In an attempt to improve transduction efficiency different ratios for plasmids were tried during
the production of these targeted vectors, as stated on section 4.1, but this did not increase
either the titer or the transduction efficiency of these preparations. For this reason production
of targeted vectors and controls was carried out as described on Methods section.
Specificity was further confirmed through the competition assays presented above, where, sim-
ilar to other studies [93, 94, 97], the target cells lines were incubated with targeted vectors
and controls in presence of increasing concentration of soluble blocking antibodies and isotype
controls. A major difference between the competition assays performed in this study and the
ones in the previously publish reports [93, 94, 97], was that considerably higher concentration
of soluble blocking antibody was needed in order to observe efficient block in transduction.
This could be attributed to either the avidity of the antibodies used each time, or the abun-
dance of surface receptor which compared to stably expressing cell line, were less and thus the
competition effect did not affect the transduction immediately.
A limitation of the targeted vector system described and extensively assessed in this study was
the use of monoclonal membrane bound antibodies for targeting. As an attempt to further im-
prove the system for in vivo applications, Single chain antibody (ScAb) versions were utilised to
pair with SINmu(SGN). Based on previous reports [95], ScAb have been engineered for αp75NTR
and αCAR. Contrary to membrane bound antibodies, in ScAb incorporation and expression
of antibody molecule on the lentiviral surface, does not require the presence of accessory pro-
teins Igαβ, immediately reducing the number of plasmids required for vector production, and
possible increasing the percentage of effective particles. Indeed, an increase in transduction
efficiency was observed, though this was not significantly higher to the levels achieved before
with membrane bound antibodies (Figure 6.12) and varied according to the target cell line used.
Unlike to ScAb, replacement of murine leader peptide with a human one, significantly improved
both transduction efficiency (Figure 6.12 A) and surface incorporation of the antibody molecule
(Figure 6.12 C). Moreover when competition assay was performed for both hLPαp75NTR and
Scαp75NTR vectors, surprisingly, the average transduction efficiency of only targeted αp75NTR
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vector was considerably affected. hLPαp75NTR and Scαp75NTR vectors were slightly affected.
It seems that the presence of the blocking antibody at the given concentrations was not opti-
mum for these vectors to compete their transduction efficiency. It is possible that presence of
the blocking antibody at higher concentrations could efficiently block transduction. In studies
were similar competitions assays were used for assessing the efficiency of viruses pseudotyped
with single chain antibodies, the concentration of blocking antibody used was considerably
higher than the ones presented here. Indeed in [286], transduction was significantly affected
when the blocking antibody was used at concentrations ranging from 50-100 µg/ml. In the
future, it would be useful to perform bigger number of competition assay experiments where
the concentration of antibody will be gradually increased to reach the levels mentioned in [286]
in order to assess the efficiency of transduction through this way. Interestingly, when competi-
tion assay was performed to assess ScαCAR vector (Figure 6.13), transduction levels reported
were reduced at percentages similar to wt αCAR. For this reason it might also be useful to
repeat these experiments with fresh batch of lentiviral preparations. The possibility that the
modifications applied to αp75NTR vector to replace the leader peptide and generate the Scab
might have affected the conformation, thus the functionality of this antibody can be excluded.
Since the same strategy and methodology was used to generate ScαCAR vector, it is unlikely
that the outcome of the competition assays for hLPαp75NTR and Scαp75NTR vectors is linked
to the functionality of the antibody. In the future, production of new lentiviral preparations
for the modified versions of these vectors and repetition of the competition assays with higher
concentration of the blocking antibody could provide the essential information needed to draw
conclusions regarding the transduction efficiency and specificity of these vectors.
These observations suggested that there is room for improvements to be made in future, if
required. For time constrains, the assessment of all different versions both in vitro and in vivo,
was not possible to be accomplished in the context of this study.
Chapter 7
Targeted transduction of primary
Motor Neurons (MNs)
In vertebrates, skeletal muscle is composed of multinucleated cells forming fibers that are in-
nervated by MNs, which belong to CNS neurons. The cell bodies of MNs are located in the
brain-stem or the ventral horn of the spinal cord. MNS are also called cholinergic neurons,
because they use the neurotransmitter acetylcholine for signalling process. MNs have a sin-
gle axon with a myelin sheath that runs to muscles, where it branches and divides into many
unmyelinated terminal fibres to innervate myotubes, forming the motor unit. Based on their
function MNs are divided into three groups. The first are termed as somatic MNs that innervate
skeletal muscles; the second group are the special visceral MNs, which are related to branchial
muscle cells, and to the last group belong the general visceral MNs, that innervate smooth
muscles of the viscera indirectly [172, 173]. Signal transmission is based on the generation of
action potentials, which are created by a chemical gradient between intracellular and extra-
cellular plasma membranes, leading to a sudden change in cell voltage. This gradient is made
by ion channels in the cell membranes, some of which are voltage-gated and can be activated
by change in the voltage potential, and some are chemical channels and can be stimulated
by neurotransmitters. An action potential initiates at the axon hillock, which is the junction
between the cell body and the axon, and moves along the axon to the axon terminal, where
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it can transmit to the muscle cell through synapses termed Neuro Muscular Junction (NMJ)
(Ravula, 2006).
7.1 Establisment and characterisation of primary Motor
Neurons
Spinal motor neurons (MNs) have been the object of extensive study utilizing in vivo models,
though their detailed study in vitro has been hindered by the cellular complexity of spinal cord
and the difficulties involved in obtaining consistently pure motorneurons in culture. Since 1970s
different methods have been developed for identification, purification and enrichment of MN
culture. All these methods are primarily based on three major properties of the motoneuron: its
localisation in the ventral spinal cord, its relative large size and the fact that its axon projects
to the limb bud from early stages (reviewed in [287]). Each method has its advantages and
drawbacks: in general, methods that give a high degree of purification have relatively low yields.
The first technique, metrizamide density gradient centrifugation, was developed by Schnaar and
Schaffner [288], to enrich for large cells, and was further optimised by others [289, 290, 291].
The second approach involves immunopanning using antibodies to specific motoneuron cell
surface antigens, initially developed for chicken and rat motoneurons [287, 291, 292, 293]. Ig-
192 antibody to the p75 LNGFR used, is selectively expressed by motoneurons within ventral
spinal cord from E14 onwards [294]. In the present study a protocol based on density gradient
centrifugation was optimised and used.
Initially, healthy rat and mouse primary motor neuron cultures needed to be established and
characterised for surface expression of target molecules prior to proceeding with application
of targeted lentiviral vectors and assessment of targeted transduction. Primary MN culture
preparation protocol required optimisation at several steps including dissection, purification
and isolation and seeding of MN cells. Of high importance were the determination of the opti-
mal seeding density and the concentration of the reagents required for coating the chambered
slides, which both appeared to play a vital role in the survival and growth of MNs. Different
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plating densities were assessed. Starting from as low as 10,000 cells/cm2, cells plated at low
density were unable to survive for longer than 3 days, probably due to inefficient exchange of
growth factors and limited support. Since survival and growth of MNs are highly dependent on
seeding density and on secretion and exchange of essential factors through neighbouring cells,
gradually increasing seeding densities were examined before optimum concentrations were de-
fined and the final optimized protocol was established. In all the experiments presented in this
section, primary motor neurons were obtained and cultured as previously described in [295]
and presented in Chapter 2 (2.11.2).
7.2 Characterisation of MN cultures by immunohisto-
chemistry
Since the initial attempt was to obtain pure MNs cultures, to the extend that this was possible,
immunohistochemistry was required to characterise the composition of these cultures and to
analyse cell survival of MNs and glial cells. Various antibodies were assessed in order to achieve
a specific staining for these cells. Initially Islet-1 was used as a MN marker, however in the
present study staining was not specific and therefore was not suitable for characterisation of
MN cultures. Rabbit anti GFAP (astrocyte marker) and MAP2 (neuron specific antibody) an-
tibodies were also assessed, though staining achieved was not convincing for characterization of
these cultures. Final optimized immunohistochemistry protocol for efficient characterisation of
primary cultures involved double staining with goat anti-ChAT (selective marker for cholinergic
motor neurons in the ventral horn) and mouse anti-GFAP (astroglial marker) primary antibod-
ies assessed at 6 time points to characterise MN culture. Starting point was DIV1 (24 hours
post seeding) cultures were examined on days 3, 6, 9, 12, 14. Each time point was repeated in
triplicates (3 wells) and pictures for quantification were acquired from 5 random fields per well
using confocal microscopy. The ChAT- and GFAP-positive cells and the total number of DAPI-
stained nuclei were counted with ImageJ software and results were expressed as percentage of
total number of cells (DAPI+) (Figure 7.1). Analysis revealed that these cultures are enriched
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in neurons (about 86.4% at DIV1) but also contained astrocytes, which increase with time in
culture. More specifically GFAP+ cells starting from 13.60 % in cell culture at DIV1, increased
and eventually outnumbered the MNs by DIV14 (final time point). This was not surprising,
since, in contrast to MNs, astrocytes are dividing cells. By DIV 14, only 28.22% of the culture
was found to be MNs, while the rest were astrocytes. The composition of the cultures obtained
across the time points examined is reported on figure 7.1.
Specificity of ChAT labelling of MNs, presented above, was further confirmed with an additional
double staining of MN cultures with ChAT and NeuN (neuronal marker). Co-localisation of
green signal located at the MN cells nucleus (NeuN) and red (ChAT), as presented on figure
7.2, confirmed the specificity of ChAT staining in these cultures. Moreover, DAPI staining
indicated the presence of additional non-motor neuron cells, possibly atrocytes, since none of
the antibodies applied stained any of these cells.
7.3 Targeted transduction of primary motor neurons
Examination of the transduction efficiency of these targeted vectors in neuronal cells involved
direct comparison on embryonic primary motor neuron cultures. The expression of the targeted
receptors (rat Thy1.1 and p75NTRand mouse CAR) in rat and mouse primary motor neurons
in culture has been assessed and verified by immunohistochemistry prior to proceeding with
transduction experiments (Figures 7.3, 7.4).
Each type of virus was assessed with the same culture batch in order to compare the differences
in transduction levels. Titers of the lentiviral preparations used in these transduction experi-
ments are presented on Table 7.1. Once more 5pl vector was used as control for non-targeted
transduction. Generally, targeted lentiviral vectors, preferentially transduced motor neuron
cells as compared to non-targeted control shown to have no specificity between MNs and astro-
cytes (Figure 7.5). To quantitatively assess the three targeted vectors and compare them with
the non-targeted control, motor neuron marker ChAT was used, which revealed that 70.8 ±1.5%
of the EGFP+ cells transduced with αp75, 65.3± 2% with αThy1.1 and 66 ± 1.7% with αCAR
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Figure 7.1: Characterisation of rat primary MN cultures. (A) Graphical presentation of MN
and astrocytes ratio in rat primary MN cultures. The analysis was performed at 6 different time
points from DIV 1 to DIV 14 and results indicated that astrocytes with the initial percentage of 14%
overgrew in culture to 71 % of overall cell population by DIV 14, while MNs ratio decreased by 58%
within the same time. (B) Characterisation of rat primary MN cultures by immunostaining. MN
cells (ChAT-positive) are shown in red and glial cells (GFAP positive) are labelled in green. (A) DIV
1, (B) DIV 3, (C) DIV 6, (D) DIV 9, (E) DIV 12, (F) DIV 14. As illustrated, even though presence
of astrocytes during the first 24 hrs post seeding (DIV1) is minimum, it increases and astrocytes
outnumber MNs in 2 weeks time (DIV14).
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Figure 7.2: Confirmation of MN staining at DIV6. Immunolabeling of DIV6 MN cultures with
anti-ChAT (red) and anti-NeuN (green; MN nuclear staining). Co-localisation presented in yellow
indicates double positive staining of MN cells, which further confirms the specificity of ChAT antibody
for MN cells.
targeted vector (mean ± s.d.; in all cases n=3 experiments) were indeed motor neurons, whereas
only 12.52 ± 3.62% of the cells transduced with 5pl control were ChAT+. Glial fibrillary acidic
protein (GFAP) immunolabeling defined the percentage of astrocytes transduced by targeted
and non-targeted vectors. More specifically, at an MOI 25, αp75NTR-targeted vector was found
to transduce 23.15 ± 8.51% of ChAT+ cells and 8.2± 2.7% of GFAP+ cells, whereas at MOI 50
it transduced 27.34 ± 9% of ChAT+ cells and 9.8 ± 4.48% of GFAP+ cells. αThy1.1-targeted
vector transduced, at MOI 25, 27.85 ± 3.75% of ChAT+ cells and 5.64 ± 3.81% of GFAP+ cells,
whereas at MOI 50, this vector transduced 17.15 ± 3.31% of ChAT+ cells and 15.8 ± 9.7% of
GFAP+ cells. Finally αCAR-targeted vector, at MOI 25, transduced 47.08 ± 25% of ChAT+
cells and 15 ± 9% of GFAP+ cells, whereas at MOI 50, it transduced 43.2 ± 10.8% of ChAT+
cells and 18 ± 4.7% of GFAP+ cells. The non-targeted control at MOI 25, transduced 4.38 ±
1.27% of ChAT+ cells and 23.17 ± 7.7% of GFAP+ cells, whereas at MOI 50, it transduced
9.52 ± 3.48% of ChAT+ cells and 44.18 ± 7.8% of GFAP+ cells. Although, an increase in
the transduction levels of the motor neurons was observed, by increasing the MOI (from 25
to 50), the percentage of astrocytes being transduced has inevitably increased. At MOI 50 no
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significant difference in preference of the population being transduced by the targeted vectors
could be observed, although the non-targeted control still transduced astrocytes in preference
of motor neurons.
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Figure 7.3: Expression of target Thy1.1 and p75NTR receptors on primary MNs. Immunola-
beling of DIV2 rat MN cultures with antibodies anti-p75-192 and anti-Thy1.1 (green) either harvested
from hybridoma or obtained from commercial source. Cells are counterstained with DAPI. Scale bars,
50µm.
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Figure 7.4: Characterisation of target CAR on mouse and rat primary MN cultures.
Characterisation of CAR on mouse and rat primary motor neuron cultures with anti-CAR (RmcB)
antibody (A) harvested from hybridoma and (B) commercially available (CAR (RmcB), Millipore,
UK). (A) Double labelling of DIV2 MN cultures with anti-CAR (RmcB) antibody (harvested from
CAR hybridoma; green) and anti-ChAT (red). Co-localisation presented in yellow indicates double
positive staining of MN cells, which further confirms the specificity of CAR antibody for MN cells.
(B) Labelling of DIV2 MN cultures with anti-CAR (RmcB) antibody (Millipore; green). Expression
pattern matches the one identified with hybridoma antibody. Cell nuclei counterstained with DAPI.
Scale bars, 50µm.
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Figure 7.5: Gene transfer to primary motor neurons. EGFP expression in rat and mouse
embryonic CNS primary motor neuron cultures infected at MOI 25 and 50 with αp75-192, αThy1.1,
αCAR-RmcB and 5pl control pseudotyped HIV-1 lentiviral vectors. Cultures were fixed 4 days after
transduction and stained with antibodies to ChAT (Alexa594 secondary antibody staining motor
neuron) shown in red, and GFAP (Alexa647 secondary antibody staining astrocytes) shown in blue.
Graph shows the efficiency of gene transfer of pseudotyped vectors. Targeted vectors preferentially
transduce MNs as compared to 5pl control which showed no specificity between MNs and astrocytes.
The ratio EGFP+/ChAT+ relative to total ChAT+ cell number is plotted in black bars. The ratio of
EGFP+/GFAP+ cell number relative to GFAP+ cell number is plotted on white bars. The values are
expressed as mean± SD. ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.0001. Scale bars, 50 µm.
During the transduction experiments performed in primary motor neurons, extensive cell death
was observed upon application of the αp75NTR targeted lentiviral vector. Addition of αp75NTR
vector resulted in axonal retraction and eventually loss within the first 2 hours of incubation
(Figure 7.6, first row). The amount of transducing units (TU) applied did not seem to have a
direct correlation with this observation, as the same effect was observed when at MOI 25 and
MOI 50. This was restricted to the vector applied, as no cell death was observed when αThy1.1
targeted vector was applied to these cells at same MOI (Figure 7.6). Thus cell death observed
was initially attributed to αp75NTR binding to its target receptor p75NTR. This observation
further supported the specificity of this targeted vector for its target receptor, since it has
been reported in several studies that activation of p75 LNGFR in embryonic stages activates
apoptosis [236]. To further confirm this, rat primary motor neuron cultures were incubated
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Table 7.1: Titer of lentiviral vectors used for in vitro primary MN transduction.
Vector
Titer p24 concentration RNA titer
Application
(t.u./ml) (ng/ml) (RNA copies/ml)
αp75NTR Transduction of
(CMV eGFP) primary MNs
Batch 1 1.95× 1010 1.27× 107 6.87× 1010
Batch 2 2.17× 1010 9.78× 104 6.36× 1010
Batch 3 2.16× 1010 1.64× 105 1.82× 1011
αThy1.1 Transduction of
(CMVeGFP) primary MNs
Batch 1 6.36× 1010 8.46× 107 2.29× 1010
Batch 2 2.47× 109 3.23× 104 1.20× 1010
Batch 3 3.29× 109 2.42× 105 2.76× 1010
αCAR Transduction of
(CMVeGFP) primary MNs
Batch 1 8.34× 109 9.46× 104 7.00× 1010
Batch 2 9.95× 109 1.46× 105 8.35× 1010
Batch 3 1.09× 1010 2.40× 105 4.70× 1010
5pl Transduction of
(CMVeGFP) primary MNs
Batch 1 6.28× 1010 3.69× 104 2.26× 1010
Batch 2 1.37× 1010 2.48× 106 4.00× 1010
Batch 3 3.62× 1010 8.08× 104 1.56× 1011
with increasing concentrations of commercial available soluble anti-p75 MC-192 antibody and
with increasing doses of antibody secreted form 192 hybridoma which was used for engineering
αp75NTR targeted vector. Cells were incubated with these antibodies adjacent to cells incubated
with αp75NTR and images acquired at 2 hrs of incubations. As presented on Figure 7.6, in both
cases retraction and axonal loss was observed when an anti-p75NTR agent was applied to the
cells, whether this was a soluble antibody or a targeted lentiviral vector. These results, further
confirmed the specificity of the targeted vector. In order to avoid cell loss, the incubation time
for only the αp75NTR targeted vectors was limited to 2 hours, when the medium was fully
replaces with fresh complete growth medium. MOI was strictly kept at 25 in order to compare
transduction efficiency observed with all three targeted vectors.
7.4 Discussion
To extend transduction studies to a system that could mimic the in vivo scenario of motor
neurons, isolation and culture of rat and mouse primary motor neurons was attempted and de-
scribed in this section. Initially an optimized protocol for preparation and maintenance of rat
embryonic MNs culture was established. Isolation, purification and establishment of high stan-
dard primary motor neuron cultures required systematic and detailed optimisation. Different
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αThy1.1 αp75NTR MOI 25 αp75NTR MOI 50
anti-p75 MC-192 
1 μg/ml
anti-p75 MC-192 
2 μg/ml
anti-p75 MC-192 
5 μg/ml
anti-p75 MC-192 
10 μg/ml
hybridoma-192 
anti-p75NTR 1μl
hybridoma-192 
anti-p75NTR 5μl
hybridoma-192 
anti-p75NTR 10μl
hybridoma-192 
anti-p75NTR 15μl
2hrs post application of vector or antibody
Figure 7.6: Effect of application of αp75NTR in primary MN cultures. First row. Application
of αp75NTR to MNs resulted in extensive cell death at when examined at 2hrs. This was not the
case for αThy1.1. Second row. Application of anti-p75MC-192 (abcam) antibody in increasing
concentrations, resulted axonal retraction and cell death at 2hrs, as observed with αp75NTR. Bottom
row. Application of 192-hybridoma derived anti-p75NTR antibody in increasing amounts had similar
effects to ones observed with αp75NTR and anti-p75 MC-192. Scale bars: 100µm.
protocols were tested and various parameters had to be adjusted, to refine this technique. First
attempts of this study were concentrated on refining the method of isolating/dissecting spinal
cord from E14.5 embryos. Initially, a protocol for purification/ isolation of primary MN from
rat spinal cord had to be established and refined in order to obtain high quality MN cultures.
First attempts resulted in low yields of MNs cell from spinal cord tissue. Based on various
MN purification techniques that have been developed and reported over time [296, 297, 298]
preliminary experiments were performed and techniques combined. Since purification through
Optiprep gradient during the optimisation process was has found to gain higher cellular yield
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and purity [299], was the one chosen and adapted to the final protocol presented on Section
2.11. So far no purification method for MN cells resulting in 100% purity has been reported,
as it is normal that some other cell types e.g. astrocyte cells remain in the final supernatant
and in the culture consequently. At a certain extend, this can be evaluated as an advantage
since astrocytes can support primary neurons with a wide range of neurotrophic factors which
are required for neuron survival [298]. On the other hand, when astrocytes are present in a
high initial percentage in culture can overgrow and take over/outnumber MNs after a few days
in culture. It is of great importance to highlight that it is critical to identify and preserve the
balance between advantageous and adverse effects of astrocyte presence. For this reason, initial
purity of approximately 85% , as reported in nearly all of the preparations presented in this
section was satisfactory for the experiments performed and presented here.
Another challenge encountered during refinement of MN cultures was to find the optimal seeding
density of MN following extraction and purification steps. Several cell densities varying from
10,000-100,000 cells/cm2 were assessed. Upon extensive experimentation, healthy motor neuron
cultures were obtained at 100,000 MN per/cm2 seeding density.
For characterisation of MN cultures by immunohistochemistry, it was of interest to identify
and utilize an antibody with high specificity for rat MNs. A wide range of antibodies for
immunolabelling of different neuronal types is available, however although an antibody, specific
for the nuclear homeobox protein 9 (Hb9), and highly specific for motor neurons exists, a rat
specific one was not commercially available at the time. Thus alternative strategy was followed
in order to characterise these cultures. In the final protocol used in all of the experiments
presented in this section, double staining with goat anti-ChAT antibody for MN and mouse
anti-GFAP antibody for astrocytes was performed to characterise both primary cultures and
the specificity of transduction in the relevant experiments. Furthermore, modification of the
immunostaining protocol showed that incubation with the primary antibodies for 4 hrs at RT
yielded optimal results.
Several previous studies reported that 7 days post seeding only 20% of the cells in primary MN
culture are MNs [300]. To examine this and define the optimum time at which the lentiviral
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preparations should be applied, cell counting experiments were performed at 6 different time
points upon seeding. Cultures were fixed and stained percentages of MNs and astrocyte cells
in culture were determined. Results revealed that by DIV 6 still 64% of the cell population in
culture were MNs. Though, despite the low density of glial cells at the time of seeding (13%),
they eventually outnumbered MN cells. This can be attributed to the fact that are rapidly
dividing cells compared to MN that do not divide. Accordingly, by DIV 14 around 72% of the
cell population were astrocytes. Consequently, this limited the time span for the study on MNs,
setting an end point to 14 days in culture. Overall, the optimised protocol for MN isolation and
purification gave the possibility to produce high yields of MNs and long lasting healthy MN
cultures, which appeared to be useful for subsequent experiments with lentiviral preparations.
Since the primary aim of this section was to assess the transduction efficiency and specificity of
targeted lentiviral vectors and controls in primary MN cultures, the next step was to validate the
transduction of primary MN cultures with HIV-1 lentiviral vectors pseudotyped with different
envelop glycoproteins. Initially VSV-G and RV-G (B2C) pseudotyped lentiviral preparations
were assessed. This experiments were performed by a MSc student (Shilan Aslani) and results
(not shown here) reported that VSV-G lentiviral vectors shown non-cell specific despite the
high transduction efficiency of cells observed. On the other hand, transductions with RV-G
(B2C) vector revealed that, even though the percentage of transduction reported was lower
compared to VSVG, cells transduced were predominalty MNs confirming previous reports that
RV-G (B2C) pseudotyped lentiviral vectors were more neurotropic for MN than VSV-G ones.
Moreover transduction efficiency was not affected, irrespective of the time chosen to apply the
lentiviral preparations. From DIV1-DIV6 no difference was observed, suggesting that efficient
transduction could be achieved at any time point and without being related to the state of MN
cells. In this section, all transduction experiments were performed at DIV2, which facilitated
the study both in mater of purity but also in having a uniform starting population that will
also allow to perform neat immunolabeling studies.
In the transduction experiments performed in this study it was demonstrated that all three
targeted vectors selectively transduced motor neurons in presence of astrocytes (Figure 7.5),
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compared to 5pl-non-targeted control and previously reported VSV-G that showed no specificity
for these two cell populations. When the MOI was increased from 25 to 50, this specificity
was lost, due to over-saturation of the sample for the targeted vectors, though non-targeted
control still transduced astrocytes equally efficient. These results indicated that targeted vectors
presented an evident specificity for MN, possibly driven by the antibody incorporated on their
surface that recognised the target receptor on the surface of MN cells. Any transdcution
observed from 5pl control was considered as background and results from saturation of the
sample, since SINmu, which is the envelope used for pseudotyping of this vector, lacks the
ability to recognise its target receptor. It could be anticipated that the transduction observed
by targeted vectors could also be considered as backround. However, if this was the case
then it would be expected to observe similar transduction pattern to the one observed with
5pl and moreover the same result when MOI was increased from 25 to 50. Instead, targeted
vectors showed a clear preference for MN at standard MOI 25 which was lost due to saturation
when MOI was raised to 50. While transduction obtained from 5pl was still increasing for
astrocytes. Similar results were previously reported from our lab [295], where specificity for
MN and astrocytes observed for VEEV-G HIV-1 pseudotyped vectors compared to pantropic
VSV-G were at the same pattern to the one presented here for targeted vectors. Specificity
was further confirmed for αp75NTR targeted vector where the cell death observed in initial
experiments upon application of the vectors was attributed to activation of p75NTR [236].
Moreover, surface engineered lentiviral vectors were assessed on the primary motor neuron cul-
tures for the first time in this study. Targeting of p75NTR and Thy1.1 in primary cultures has not
been reported so far. Though targeting of CAR receptor has been reported in the past through
a different approach. Recently preferential neuronal transduction has been demonstrated by
canine adenovirus (CAV-2). This neuronal targeting assessed both in vitro, in primary neu-
ronal culture (MN examined as well) and in vivo was attributed to CAV-2 association with
CAR (coxsackie adenovirus receptor) expression on neuronal cells [249].
Despite the successful transduction of primary motor neurons by all three engineered targeted
lentiviral vectors, reported in this chapter, the site of the entry of the virions and their ability to
transport along the motor neuron axon could not be determined through this approach. Mass
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cultures presented here could only give an indication of transdution efficiency and specificity
without examining the ability of the engineered vectors to move retrogradely along the motor
neuron axon and achieve transduction of the soma. Additional labelling techniques, described
on Chapter 8, were used to visualize vector entry and trafficking.
Chapter 8
Retrogade trafficking of labeled vectors
in primary motor neuron cultures
8.1 Introduction
In the previous chapters it was demonstrated that all three engineered targeted vectors αThy1.1,
αp75NTR and αCAR could transduce target cell populations with high specificity. In this section
the primary goal was to determine whether retrograde trafficking of the targeted vectors can
occur in primary motor neurons.
Axonal transport is responsible for the long-distance movement (up to 1 meter in humans)
of signals and cargo between nerve termini and cell bodies. Thus is crucial for neuronal dif-
ferentiation and homeostastis. Rhabdoviruses such as rabies virus and VSV enter cells using
a well studied mechanism [196]. Following binding to a cell surface molecule (p75LNGFR,
NCAM or nAChR for RV), virus particles undergo endocytosis via clathrin coated pits. Upon
endocytosis, clathrin coated vesicles associate with the small GTPase Rab5, and is typically
accompanied by a decrease in endosomal pH. This is followed by a maturation of the endosome
and is characterised by a switch to Rab7 (rather than Rab5) and is accompanied by a further
decrease in pH, before the endosome finally fuses with the lysosome [197, 198]. The viral par-
ticles undergo endosomal escape before fusion with the lysosome, a process that is triggered by
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the acidic environment of the former [200]. This environment induces a conformational change
in the viral glycoprotein that mediates membrane fusion between the viral envelope and the
endosome membrane resulting in escape of the viral capsid through the subsequent fusion pore.
Extensive studies in motor neurons has revealed an elegant process by which proteins within
the extreme part of the axon can undergo retrograde trafficking to the soma, a process first
identified as a mechanism for allowing extracellular signals at the axon tip to be transmitted
to the cell body through these retrogradely trafficked signalling endosomes [301]. This process
has been best characterised for the p75NTR and as with many endosomal processes involves
the trafficking of the receptor through endosomes which undergo microtubule-mediated axonal
transport towards the cell soma, in a process driven by the microtubule motor myosin Va [195].
In addition to p75NTR, this pathway has been shown to mediate the transport of a number
of neurotoxins (botulinum, tetanus) [212] and the CAV and its receptor CAR [210], whose
internalization, similar to the one descibed above involved clathrin coated pits and association
with Rab5 and Rab7 GTPases. This pathway is utilised by tetanus neurotoxin (TeNT) and
enables these (and other) toxins to reach the neuron soma from the site of infection, the NMJ
[211, 208, 209, 207, 212, 210].
It is possible that the endocytic trafficking itinerary varies depending upon which part of the
axon the vector internalizes (e.g. only axon tips allow retrograde transport). To investigate if
this was the case and to unambiguously demonstrate that p75-, Thy1.1- and CAR- targeted
vectors enter the motor neurons via axon tip and retrograde traffic towards the soma, motor
neurons were grown in microfluidic chambers (MFCs) [302]. Additional labelling techniques
were used to visualize vector entry and trafficking into previously reported pathways. Labelling
of the envelope with lipophilic dyes aimed to allow highly efficient labelling of viral vectors
without affecting the biological titer of the vectors produced. Spread of virus upon infection
of the neurite portion of culture embryonic rat and mouse motor neurons was studied in com-
partmented culture and is presented in detail here.
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8.2 Preparation of microfluidics chambers
The experiments presented so far (Chapter 7) were performed using spinal cord preparations
enriched in motor neurons in mass cultures. Under these conditions, it is not always possible
to provide an unequivocal identification of the type of neuron imaged at any given time, nor to
assess the site of internalisation of the lentivector applied onto cells. To overcome these technical
shortcoming, we exploited a compartmentalised system based on microfluidic chambers (MFCs).
These silicone inserts allow culture of motor neurons so that they project axons through channels
to a second chamber, allowing separation of the soma, axon, and axon terminals and are suitable
for live imaging [303, 304] and biochemical analyses [304] (Figure 8.1).
The microfluidic neuron culture device provides a method to direct, isolate, lesion and biochem-
ically analyze CNS axons. Soft lithography uses replica molding to fabricate devices, resulting
in reproducible experiments [303]. Axonal and somatic compartments can be maintained flu-
idically isolated from each other by using a small hydrostatic pressure difference; this feature
can be used to localize soluble insults to one compartment for up to 20 h after each medium
change [303]. To maintain a fluidically isolated microenvironment in the axonal compartment,
the volume of the medium in the somatic (cell body) compartment was maintained at higher
levels at all times to ensure a laminar flow towards the axonal side. We used a volume difference
of 50 µl between the two compartments with lesser volume on the axonal side where the agent
(here the lentiviral vector) is to be localized. A small hydrostatic pressure difference results in
slow but continuous flow across the microgrooves, which counterbalances diffusion of species
(here lentiviral vectors) from the axonal to the somatic compartment.
Establishment of primary motor neuron cultures in microfluidic chambers (MFCs) and axon
growth from the somatic chamber, across the channels to the axonal chamber was challenging.
Survival and growth of MNs was highly dependant on preparation and cleaning of the silicone
inserts, coating of the surface and determination of the optimal seeding density of the cells.
Upon purification, neurons were seeded at 200,000 cells per dish into prepared and coated
microfluidic chambers. 7 to 8 days post seeding axon growth through the channels could be
observed with axon tips projecting to the axonal chamber side.
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Figure 8.1: Microfluidic chambers. Silicone inserts that allow culture of motor neurons so that
they project axons through channels to a second chamber, allowing separation of the soma, axon
and axon tip. Chambers were coated with poly-L-ornithine and laminin and MNs were plated at the
somatic chamber side at a density of 200,000 cells per dish. 7 days post seeding axons project through
the channels to the axonal chamber, resulting in separation of the soma, axon and axon tip. In all
trafficking studies targeted vectors and controls were applied to the axon tip and retrograde transport
across the channels to the soma was assessed.
Additional labelling techniques were used to visualize vector entry and trafficking. To determine
if the targeted lentiviral vectors undergo trafficking in certain reported pathways, lipid labelled
(DiO) targeted vectors and controls were applied to the axonal chamber at MOI 10 and also
alexa-647-labeled anti-p75NTR and alexa-555 anti-TeNT (tetanus neurotoxin) antibodies. Since
DiO fluoresces in the green channel, lentiviral preparations produced for this experiment were
carrying the LacZ reporter gene. Labelling of the envelope with lipophilic dyes allowed highly
efficient labelling of viral vectors without affecting the biological titer of the vectors produced.
Titers are presented in Table8.1. 7-8 days post seeding, an excess of viral particles (10,000) were
added to the axonal chamber with or without endosomal markers and processed for fixed and
live imaging studies. Based on the working principle of MFCs described above, any presence
of labelled vectors across the axons or transduction of soma upon application of the vectors to
the axonal compartment is expected to result only from lentiviral entry at the axonal terminal
and retrograde transport across the axon towards the soma which is located on the somatic
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compartment.
8.3 Retrograde trafficking of labeled vectors in MFCs
Transport was initially assessed in fixed cells. Fixed imaging of particles allowed extensive quan-
tification of particles undergoing trafficking and the endosomal pathway utilized. Under these
conditions multiple p75NTR positive endosomes were observed to undergo retrograde trafficking.
For αp75NTR-targeted vector, approximately 87% of the trafficked particles colocalised with the
tetanus neurotoxin and the majority of these, which was more than 60%, also colocalised with
p75NTR (Figure 8.2A and B). It has been reported that p75NTR internalizes upon activation
and undergoes retrograde trafficking, in neuronal cells, in specialized, non-acidic endosomal
compartments [207]. Similar trafficking results were also observed for αCAR-targeted vector
(Figure 8.2A and B). In the case of αThy1.1-targeted vector, as presented on Figure 8.2A and
B, a higher number of particles were predominantly colocalizing with the tetanus neurotoxin
(approximately 93% of which 30% were also colocalizing with the p75NTR). This further sup-
ports the specificity of αThy1.1 vector since Thy1 has been identified as a TeNT interacting
protein [219] and it has been shown that TeNT enters the axonal pathway and reaches the
soma of motor neurons located in the spinal cord [217, 216]. Importantly, these results were
reproducible in all replications of the trafficking studies, and data obtained from analysis of at
least 90 trafficking events per replication are shown here. For all three vectors, a small number
of particles not co-localizing with either marker was also observed. This was more frequently
observed for the non-targeted control vector (Figure 8.3). Using the same microfluidic culture
conditions, it was possible to define the percentage of background reported from non-targeted
control vector. Interestingly, non-targeted vector particles were also observed along the cham-
bers. Yet, careful examination of these events revealed that the majority of these particles were
not only non-associated with either marker but also detected outside the axon of the neuron,
on top or beneath the cells. A small percentage of these particles were also associated with
one or both of the markers. It is important to highlight that these events were maximum
10-20 in total, in the same number of axons assessed, each time, for trafficking as done for the
196 Chapter 8. Retrogade trafficking of labeled vectors in primary motor neuron cultures
targeted vectors. This suggests that these events were rare and considered as background sig-
nal. Retrograde trafficking of targeted vectors was further confirmed by applying HIV-1 vector
particles pseudotyped with VSVG to the same cultures. VSVG particles were used as negative
control for these trafficking studies, as VSVG is reported to have poor retrograde transport.
As expected, no VSVG vector particles were detected along the chambers (Figure 8.3C) which
further confirmed the validity of the results presented here.
8.4 Retrograde trafficking of labeled vectors in MFCs in
live primary motor neurons
To advance these trafficking studies, retrograde trafficking of these vectors was assessed in
live primary motor neurons. Time lapse confocal microscopy following co-application of either
of the targeted vectors and alexa-647 labeled anti-p75NTR for 60 min showed that retrograde
transport for all three targeted vectors was easily detectable (Figure 8.4, Supplementary Movies
1a, 2a, 3a ). Most of the vector trafficking occurred within the same endosomal compartment
as the p75NTR (Figure 8.4, Supplementary Movies 1b, 2b, 3b). Vectors colocalised with p75NTR
but not undergoing trafficking or vector non-associated with p75NTR but undergoing trafficking
were also observed. However, these events were rare compared to the majority of the moving
particles, which appeared to be associated with p75NTR at rates similar to those observed in
fixed cultures. Particle analysis of these vectors demonstrated that they were potent to undergo
extensive trafficking, often over 100 µm during the acquisition process. Speed and number of
events varied among the three vectors, with αCAR and αp75NTR vectors travelling along the
axons with similar efficiency.
Taken together these results reveal that all three targeted vectors are readily able to undergo
retrograde endosomal transport, upon application to the axon tip of the target motor neuron,
and that is most likely in the same pathway followed by TeNT and p75NTR [208]. Interestingly,
all three vectors appeared to have better trafficking characteristics than the ones observed for
RVG pseudotyped lentiviral vectors, compared to studies performed in our lab (Hislop et al.,
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Figure 8.2: Retrograde axonal transport of targeted vectors in fixed cells. (A) Primary motor
neurons plated in microfluidic chambers were incubated with either DiO labeled αp75 or αThy1.1 or
αCAR with TeNT-555 and anti-p75NTR-AF647 for 2 hours at 370C before fixing and imaging by
confocal microscopy. Shown are representative maximum projections of Z-stack images where white
circles show examples of colocalisation of vectors with both markers and yellow circles show examples
of colocalisation with just TeNT-AF555 and green circles show non-associated vectors. Scale bars,
20µm. (B) Shows quantification of colocalisation (n=3, 285 particles αp75, 160 particles αThy1.1
and 210 particles αCAR). Scale bars, 20 µm.
198 Chapter 8. Retrogade trafficking of labeled vectors in primary motor neuron cultures
Figure 8.3: Application of control vectors in fixed cells. Primary motor neurons were incubated
with either DiO labeled 5pl control or VSVG pseudotyped vectors and TeNT-555 and anti-p75NTR-
AF647 for 2 hours at 37◦C before fixing and imaging by confocal microscopy. Shown are representative
maximum projections of Z-stack images. Low background events are circled, often outside the neuron
(n=3, 15 particles for 5pl control and 19 particles for VSVG). Scale bars, 20 µm.
in review). Number of particles observed to traffic along the same number of axons assessed,
were on average 42 events for each repetition for RVG preparations of similar titer to any of
the targeted ones, where on average 90 events were observed for each repetition.
8.5 Retrograde trafficking of labelled vectors in MFCs
As presented above, endocytosed cargo undergoes a long journey along the axons, though
what happens when it reaches its target? Membrane fusion between the viral envelope and
the endosome membrane and subsequent escape of the virus core into the cytosol seems to be
highly dependent on the envelope used in this study, which is the mutated version of Sindbis
virus for efficient endosomal escape [95]. Targeted lentiviral vector particles, as shown, are
moving along the axons but do they reach the soma, and if so, does endosomal escape occurs
on time to achieve transduction of the target neuron?
To evaluate whether these targeted vectors have the potential to travel all the way along the
axon and transduce the soma of the motor neuron cells, EGFP expressing targeted vectors and
controls were applied to the axonal side and incubated for 6 hours followed by complete fresh
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Figure 8.4: Retrograde axonal transport of targeted vectors in live primary motor neurons.
Primary motor neurons were incubated with either DiO labeled αp75NTR or αThy1.1 or αCAR vectors
and anti-p75NTR-AF647 for 60 min before time-lapse confocal imaging of a region of axon >200 µm
from the axonal compartment. Representative image series of trafficking vectors particles showing
DiO vectors and p75NTR-AF647. Asterisks indicate examples of stationery particles. Scale bars, 10
µm.
200 Chapter 8. Retrogade trafficking of labeled vectors in primary motor neuron cultures
Figure 8.5: Merged image of retrograde axonal transport of targeted vectors in live pri-
mary motor neurons. Merge image series of trafficking vector particles (Figure 8.4) showing DiO
vectors and p75NTR-AF647. Asterisks indicate examples of stationery particles. Kymographs of the
same series. Scale bars, 10 µm.
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medium replacement. The medium was then renewed daily. 72 hours later transduction was as-
sessed through EGFP expression via immunostaining and confocal microscopy. Cells were fixed
and stained for GFP, motor neurons (anti-ChAT) and axonal marker (anti-SMI32). Examples
of transduced motor neuron axons, crossing the microgroove of the MCF and transduced soma,
positive for EGFP, SMI32 and ChAT are shown in Figure 8.6. Transduced motor neurons
were observed for all three targeted vectors. Axons belonging to a different type of neuron (or
a motor neuron not being transduced) not expressing EGFP are visible in adjacent parts of
the panels. Although transduction was observed for all of the targeted vectors, the analysis
of these data was only qualitative. Determination of MOI used was difficult, since at DIV7 it
was impossible to determine not only the number of axons grown along the microgrooves to
which the vectors were initially applied to, but also the soma of the neuron from which they
have originated. Transduction observed with targeted vectors was a result of vector entry at
the axonal terminal and retrograde transport across the axon towards the soma. Transduced
somata expressed EGFP 72 hrs later, which upon diffusion was easily detectable at the axonal
terminal located on the axonal compartment (Figure 8.6). EGFP expression detected on trans-
duced motor neuron axons crossing the microgroove was visualized with confocal microscope,
though is not clearly presented on the final projection images shown in Figure 8.6.
No transduction of the soma of motor neuron cells was observed when either 5pl control or
VSVG pseudotyped HIV1 vector particles were applied to the axonal side (Figure 8.7). As pre-
sented on Figure 8.7, eGFP expression, indicative of transduced soma upon retrograde transport
of the applied vector, was not detected neither at the soma nor at the axonal terminal of motor
neurons, upon incubation with 5pl or VSVG control vectors. These results further support that
only targeted vectors could traffic retrogradely upon axonal terminal internalisation and trans-
duce the soma of motor neurons which resulted in reported transgene expression and intense
labeling of both somata and axons. Once more all three targeted vectors appeared to have
retrograde transduction characteristics superior to wild type RVG-pseudotyped HIV lentiviral
vectors. Transduction experiments performed, in the same way, with wild type RVG-HIV-1,
where the same number of particles was applied to the axonal compartment, resulted in no or
extremely poor transduction, at background levels (Hislop et al., in review). Taken together
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these data indicate that these newly engineered targeted vectors are able to traffic retrogradely
and transduce their target. Interestingly the αThy1.1-, αp75NTR- and αCAR-targeted vectors
appeared to be more efficient than RVG pseudotyped HIV1 in trafficking and transduction of
primary motor neuron, in vitro.
Table 8.1: Titers of DiO labeled lentiviral preparations used in fixed and live imaging
studies in MFCs.
Vector
Titer p24 concentration RNA titer
Application
(t.u./ml) (ng/ml) (RNA copies/ml)
αCAR DiO Fixed and live imaging
(CMVLacZ) of MNs
Batch 1 6.42× 107 n.d. n.d.
Batch 2 9.45× 107 n.d. n.d.
Batch 3 1.20× 108 n.d. n.d.
αp75NTR DiO Fixed and live imaging
(CMVLacZ) of MNs
Batch 1 1.52× 108 n.d. n.d.
Batch 2 9.45× 107 n.d. n.d.
Batch 3 1.20× 108 n.d. n.d.
αThy1.1 DiO Fixed and live imaging
(CMVLacZ) of MNs
Batch 1 1.21× 108 n.d. n.d.
Batch 2 1.40× 108 n.d. n.d.
Batch 3 1.12× 108 n.d. n.d.
α5pl DiO Fixed and live imaging
(CMVLacZ) of MNs
Batch 1 1.10× 108 n.d. n.d.
Batch 2 7.73× 107 n.d. n.d.
Batch 3 1.20× 108 n.d. n.d.
αVSVG DiO Fixed and live imaging
(CMVLacZ) of MNs
Batch 1 4.75× 108 n.d. n.d.
Batch 2 3.10× 108 n.d. n.d.
Batch 3 4.10× 108 n.d. n.d.
8.6 Discussion
In this chapter it was attempted to determine whether retrograde trafficking of the targeted
vectors did occur in primary motor neurons. Initially motor neurons were grown in microflu-
idic chambers [302]. Thus preparation and growing of motor neurons in these chambers was
optimised and adjusted. Establishment of primary motor neuron cultures in microfluidic cham-
bers (MFCs) and axon growth from the somatic chamber, across the channels to the axonal
chamber was challenging. It appeared from preliminary optimisation experiments that survival
and growth of MNs was highly dependant on preparation and cleaning of the silicone inserts,
coating of the surface and determination of the optimal seeding density of the cells. Plasma
cleaning and accurate setting of the apparatus were proven to be possibly the most important
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Table 8.2: Titers of eGFP expressing lentiviral preparations used in transduction experi-
ments in MFCs.
Vector
Titer p24 concentration RNA titer
Application
(t.u./ml) (ng/ml) (RNA copies/ml)
αCAR Fixed and live imaging
(CMVeGFP) of MNs
Batch 1 8.34× 109 9.46× 104 7.00× 1010
Batch 2 9.95× 109 1.46× 105 8.35× 1010
Batch 3 1.09× 1010 2.40× 105 4.70× 1010
αp75NTR Fixed and live imaging
(CMVeGFP) of MNs
Batch 1 1.95× 1010 1.29× 107 6.87× 1010
Batch 2 2.17× 109 9.78× 104 6.36× 1010
Batch 3 2.16× 1010 1.64× 105 1.82× 1011
αThy1.1 Fixed and live imaging
(CMVeGFP) of MNs
Batch 1 6.36× 1010 8.46× 107 2.29× 1010
Batch 2 2.47× 109 3.23× 104 1.20× 1010
Batch 3 3.29× 109 2.42× 105 2.76× 1010
α5pl Fixed and live imaging
(CMVeGFP) of MNs
Batch 1 6.28× 1010 3.69× 1010 2.26× 1010
Batch 2 1.37× 1010 2.48× 106 4.00× 1010
Batch 3 3.62× 1010 8.08× 104 1.56× 1011
αVSVG Fixed and live imaging
(CMVeGFP) of MNs
Batch 1 6.28× 1010 3.69× 1010 2.26× 1010
Batch 2 1.37× 1010 2.48× 106 4.00× 1010
Batch 3 3.62× 1010 8.08× 104 1.56× 1011
step in the MFCs set up. It was observed that MNs could survive and project their axons along
the microgrooves only when plasma cleaning was performed properly. In occasions where the
standard settings of the apparatus where slightly changed, MN cells did not survive for more
than 24 hrs in culture. For this reason particular attention should be paid to achieve desirable
results. Once more seeding density had to be addressed. Upon extensive experimentation and
optimisation (together with Dr J Hislop) optimal seeding density was determined. Thus upon
purification, neurons were seeded at 200,000 cells per dish, density at which survival and growth
of primary MNs was supported. Microfluidic chambers were coated as previously described for
motor neurons. 7 to 8 days post seeding axon growth through the channels could be observed
with axon tips projecting to the axonal chamber side.
Additional labelling techniques were required to visualize vector entry and trafficking. This
was achieved by loading the production cells with dye (Vybrant DiO) following transfection
in the original transfection protocol. This protocol led to efficient labelling of vectors with no
apparent loss of the biological titer of the vectors produced. This was of major importance since
quality of the preparation should not be compromised for accurate assessment and comparison
to previous experiments.
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Experiments performed in this section show that all three targeted vectors, αp75NTR, αThy1.1
and αCAR upon interaction with their target receptors are retrogradely transported along mo-
tor neuron axons and transduced the soma of motor neuron cells. All three trafficking vectors
were located most of the times within the same endosomal compartment as the p75NTR. This
suggests that these vectors do indeed undergo retrograde trafficking in p75NTR endosomes to-
wards the soma. Interestingly, αThy1.1 was retrogradely transported mainly (>90%) in carriers
associated with TeNT HC. This further supports the specificity of this targeted vector, associ-
ating with Thy1 receptor, as Thy1 has been identified as a TeNT interacting protein[219]. In
contrast to CAR and p75NTR, internalisation and transport of Thy1 has not been demonstrated,
yet other adhesion molecules such a LgCAM and NCAM have been shown to internalise and
traffic in motor neurons [208, 214][305].
Both fixed and live imaging experiments performed proved that all three targeted vectors can
undergo retrograde transport, however, it is possible that this is a property of the HIV1 capsid
rather than the pseudotyping (surface engineering). This was assessed by imaging DiO-labelled
HIV1 lentiviral vectors pseudotyped with VSV-G which do not induce retrograde transduction
in vivo [82] and DiO-labelled 5pl non-targeted control. Lack of trafficking events both in fixed
and live imaging studies and absence of transduction with non-targeted 5pl control and VSVG
pseudotyped lentiviral vectors, further support the validity of these results and the specificity of
the system introduced here. For all three vectors, a small number of particles not colocalizing
with either marker were observed, which may be due to a slightly lower signal-to noise ratio,
or to diffusion occurred during medium replacement and washes of the chambers.
Interestingly it is reported that these targeted vectors appeared to be more efficient than wild
type RVG pseudotyped HIV viruses in trafficking and more specific in transduction of motor
neuron cells in vitro. Transduction of motor neuron soma upon application of the targeted
vectors to the axon was efficiently reported for all three targeted vectors. This could partially
be attributed to the envelope used for pseudotyping, which has been reported to allow efficient
endosomal escape [94].
Extensive studies performed in our lab investigating RVG pseudotyped HIV-1 vector trafficking
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and transduction in primary motor neuron cultures report that despite successful extensive
retrograde transport of vectors in both mass and compartmentalised cultures, it was not possible
to detect any transduction of neurons when incubated under the same conditions enabling
axonal retrograde transport (Hislop et al., in review). This was similar to data previously
observed with VEEV-G pseudotyped HIV vectors [295], which showed retrograde transport in
culture but very little retrograde transduction in vivo. However, this was not observed with
surface engineered targeted vectors presented here, which appeared to overcome these barriers
and efficiently transduce the soma of MNs upon retrograde trafficking. This suggests that
targeting for efficient retrograde axonal transport is not the only requirement for transduction
of motor neurons, and other post-trafficking factors are crucial for this process. These will
likely include the ability of the envelope to promote fusion when the endosome does reach the
soma, and the molecular processes that allow the transport of the capsid to the nucleus. It
is interesting that wild-type rabies virus is able to efficiently escape the endosome and get
transported to the nucleus. This is in part mediated by a direct interaction between the
capsid and cytoplasmic dynein [204, 203], but also suggests that the envelope glycoprotein
may not be the only requirement for efficient endosomal escape. Engineered targeted vectors
pseudotyped with a different, modified for better fusion envelope, were proven to efficiently
escape the endosome carrier upon arrival to the soma and transduce their target cell, overcoming
the barrier. This presented a clear advantage of the system used for targeting, not only in
the targeting side of it but also on the advantageous characteristic of a fusogenic molecule
operating completely separate from the antibody driving the vector. The advantage of the
system introduced and assessed here could possibly be attributed to the fact that receptor
recognition and fusion functions are completely uncoupled in this system. Based on this it could
be claimed that having the envelope protein determining both the tropism and the endosomal
escape might compromise one of the two properties of the lentiviral vector.
Finally the absence of both trafficking and transduction with VSVG and 5pl lentiviral vectors,
further validated the specificity of the system both in MFCs but also in mass cultures. These
results suggest that any transduction observed at least from non-targeted 5pl vector could not
be considered as a result of specific interaction with a receptor and transport to the nucleus,
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but instead a random event that points out the necessity of in vitro assessment of these vectors
in MFCs.
Hence for the first time here are reported the trafficking properties and efficiency of surface-
engineered vectors in a system mimicking the in vivo scenario and is shown that these targeted
vectors can be retrogradely transported and transduce the soma of motor neurons. Use of this in
vitro system strongly suggests that that the major block to efficient viral vector transduction is
at a stage following axonal transport, perhaps between endosomal escape and nuclear transport
of the vector capsid.
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Figure 8.6: Transduction of soma with targeted lentiviral vectors. Primary motor neurons
were incubated with EGFP expressing αp75NTR or αThy1.1 or αCAR vectors for 6 hours at 37◦C. 72
hours later, motor neurons were fixed, stained with antibodies against GFP, ChAT and SMI32 and
imaged by confocal microscopy to assess transduction of soma. Cell bodies are located on the left;
axons elongated through the microgrooves and reached the axonal compartment, located on the right.
The analysis shown is representative of three independent primary motor neuron cultures. Scale bars,
100 µm.
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Figure 8.7: Transdcution ifn MFCs with control samples. Primary motor neurons were incu-
bated with GFP expressing 5pl control or VSVG pseudotyped lentiviral vectors for 6 hours at 37◦C.
72 hrs later, motor neurons were fixed, stained with antibodies against EGFP, ChAT and SMI32 and
imaged by confocal microscopy to assess transduction of soma. Scale bars, 100 µm. Cell bodies are
located on the left; axons elongated through the microgrooves and reached the axonal compartment,
located on the right.
Chapter 9
Targeted gene transfer in vivo
The ultimate goal of this study was to develop a gene-transfer vector that will allow us to
achieve minimal invasive administration of the vector by targeting the peripheral sites of the
neuromuscular synapse in order to reach the affexted cells in the spinal cord.
It has previously been shown that transduction of spinal cord motor neurons with rabies virus
glycoprotein (RVG) pseudotyped lentiviral vectors can be achieved upon peripheral adminis-
tration to mouse and rat gastrocnemious muscle [82][86]. Though this is not motor neuron
specific since muscle and sensory neurons are transduced. Thus restricting infection to specific
cell types, known as targeted transduction, is crucial when it comes to in vivo applications.
In order to validate the promising in vitro results, presented in previous chapters, under the
complexity of an in vivo model, we proceeded with in vivo application to the muscle of the
three newly engineered targeted vectors.
9.1 In vivo intramuscular injections in rat gastrocne-
mius muscle
Our initial experiments were performed unilateraly in the right gastrocnemius muscle of adult
Wistar rats. Gastrocnemius muscle is a large compact muscle innervated by 300-400 motor
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neurons. Motor neurons that innervate this muscle are located at lumbar levels L4-L6 in the
spinal cord. For this reason, these parts of the spinal cord were examined following administra-
tion of the lentiviral vectors to examine retrograde delivery to the spinal motor neurons upon
peripheral muscle injection. In vivo grade (x2000 fold concentrated) lentiviral preparations
of αThy1.1 and αp75NTR targeted vectors and non-targeted 5pl control, each encoding EGFP
reporter gene were prepared for this purpose.
9.1.1 Retrograde tracer injections into rat and mouse gastrocne-
mius muscle
Prior to proceeding with initial injections and in order to confirm that upon peripheral in-
tramuscular delivery (gastrocnemious muscle) we can achieve retrograde labeling of the target
motor neurons cells located in the lumbar part of the spinal cord, injections of FASTBLUE
retrograde tracer (Polyscience Europe, Germany) [86] was attempted in 3 rats and 3 mice.
This experiment was performed in collaboration with Dr Antonio Trabalza who supervised and
significantly contributed to all in vivo experiments. Below are presented the results obtained
from analysis of mice spinal cords.
As presented on figure 9.1, labelled cells were observed in 50 µm spinal cord sections ipsilat-
erally to the injection site, in sections starting towards the end of the fourth lumbar segment
(L4) and spanning 1.92±0.62 mm through the fifth segment (L5), which was consistent with the
retrograde delivery and expression of the FASTBLUE retrograde tracer. Unfortunately FAST-
BLUE injections in rats did not results in labelling of motor neurons, only a few dendrites were
labelled which did not allow for proper quantification.
In these mouse spinal cord portions 44±26.8 labelled MNs were observed.
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Figure 9.1: In vivo intramuscular injection of FASTBLUE retrograde tracer in right gas-
trocnemius muscle of mice. Representative mice spinal cord sections from L4/L5, (10x Magnifi-
cation). Scale bars: 0.5 mm, insert 50 µm.
9.1.2 Injections of targeted lentiviral vectors into rat gastrocnemius
muscle
To examine the ability of the newly engineered targeted vectors to be retrogradely transported
and transduce spinal motor neurons upon peripheral muscle deliver the following in vivo ex-
periments were performed. In vivo grade (x2000 fold concentrated) lentiviral preparations of
αThy1.1 and αp75NTR targeted vectors and non-targeted 5pl control, each encoding EGFP re-
porter gene were prepared. 20µl (4x5µl) of each of the targeted vectors and control, presented
on Table 9.1 were injected at multiple locations into the gastrocnemius muscle of adult Wistar
rats (n=3 rats per group). αp75NTR targeted lentiviral preparations were prepared with both
versions of fusogenic protein (SIN and SGN) since in vitro results from transduction of cell lines
presented on Chapter 5. To accurately control the experiment 5pl-non-targeted control vector
was also prepared with both versions of fusogenic protein and injected to animals. The animals
were sacrificed five weeks post injection and spinal cord tissues were harvested to determine
EGFP expression levels in motor neurons. Also right gastrocnemius muscle (injection site) and
left gastrocnemius muscle (control site) were harvested to assess transduction of muscle fibers
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at the site of injection.
Table 9.1: Titers of eGFP expressing lentiviral preparations used in in vivo intramuscular
injections in adult Wistar rats.
Vector
RNA titer Titration ratio Titer
p24 concentration
(RNA copies/ml) (copies/t.u.) (t.u./ml) (ng/ml)
αp75NTR
(SGN-CMVeGFP) 6.87× 109 0.36 1.90× 1010 1.29× 107
αThy1.1
(SGN-CMVeGFP) 2.29× 1010 0.36 6.36× 1010 8.46× 107
5pl
(SGN-CMVeGFP) 2.26× 1010 0.36 6.28× 1010 3.69× 107
αp75NTR
(SIN-CMVeGFP) 9.53× 1009 0.36 2.64× 1010 1.06× 108
5pl
(SIN-CMVeGFP) 3.90× 1009 0.36 1.08× 1010 9.66× 107
Five weeks post injection the animals were sacrificed and spinal cord tissues were harvested
and examined for EGFP expression, indicative of retrograde delivery and expression of the
transgene by HIV-1 based targeted vector. 50µm of spinal cord sections were examined and
immunohistochemically stained with MN markers (anti-ChAT antibody) and anti-GFP anti-
body to enhance EGFP signal. Unfortunately, no EGFP was detected in any of the spinal cord
samples of the injected rats.
9.1.3 Assessment of muscle fibre transduction
Since no EGFP signal, indicative of retrograde transport, was observed in any of the animals
injected, assessment of the injection site followed. Viral transduction was observed with both
targeted vectors at the injection site, where GFP expressing muscle fibres were detected. Trans-
duced tissue was further examined for transduction near or at the NMJ. Right gastrocnemius
muscle (injection site) tissue samples were tested for transduction at NMJ. Thus, right gastroc-
nemious muscle was sectioned (20 µm Longitudinal sections) and immunohistochemistry was
performed for identification of NMJ utilizing post- and pre-synaptic markers. Initially, an anti-
body against synaptophysin (one of the 2 major protein components of membrane of synaptic
vesicles of presynaptic nerve ending) and alpha-bungarotoxin (snake venom toxin that binds
to the acetylcholine receptor α-subunits expressed at postsynaptic membrane) were tested on
control muscle samples (left gastrocnemious). In the figure presented below (Figure 9.2) post-
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Figure 9.2: Optimisation of pre- and post- synaptic labelling of NMJ in left gastrocnemius
muscle. Single staining of non-injected control muscle was performed using different dilutions of
either Alexa Fluor 594-α-bungarotoxin (Invitrogen B13423) (top row) or rabbit anti-synaptophysin
(Invitrogen 18-0130) (bottom row). Scale bars, 50µm.
and pre- synaptic parts of the NMJ were succesfully labeled. It is important to highlight that
no GFP expression was detected, as expected, in muscle fibers of left gastrocnemius muscle
further as this was the non-injected control site. Moreover EGFP expression in the injected
muscles was not uniform. There were areas with little or no expression, which suggests that
the distribution of the vector could be improved during muscle injections.
Upon successful testing, the optimal conditions of labelling pre-(synaptophysin) and post-(α-
bungarotoxin) synaptic parts of NMJ were determined. On this front, tissue sections expressing
GFP (indications of transduction), harvested from injected animals were assessed. In an at-
tempt to determine whether transduction was targeting the neuromuscular synapse, transduced
tissues were also stained for synaptophysin and α-bungarotoxin (pre- and post- synaptic mark-
ers).
In Figures 9.3 and 9.4, representative images of right gastrocnemious muscle sections are shown,
that were found to be transduced upon injection of either αThy1.1 or αp75NTR targeted vec-
tors. In both cases, it was observed that transduction of muscle fibers primarily occurred in
areas where α-bungarotoxin and synaptophysin were widely expressed. More specifically GFP
214 Chapter 9. Targeted gene transfer in vivo
 
Figure 9.3: Immunohistochemical analysis of right gastrocnemious muscle injected with
αThy1.1 targeted vector. Tissue samples transduced with αThy1.1 targeted vector were triple
stained for GFP (green), α-Bungarotoxin (red) and Synaptophysin (magenta). Transduced muscle
fibers were positive for the post-synaptic marker α-bungarotoxin. Scale bar, 50 µm.
positive cells were, in most of the cases, found to be positive for α-bungarotoxin or adjacent to
cells positive for α-bungarotoxin and synaptophysin.
Based on these findings it has been assumed at the time, that both targeted vectors were able to
transduce muscle fibers at the injection site, with preference to areas where the neuromuscular
synapse was identified. Though, so far there was no indication of retrograde transport and sub-
sequent motor neuron transduction upon in vivo application of these vectors. A limiting factor
for succeeding on this front could possibly be the volume of vector been injected. Given the size
of the rat gastrocnemius muscle and compared to previous studies performed in mice, where
20-25 µl of lentiviral vector of similar titer were intramuscularly injected to achieve retrograde
transport and transduction of spinal conrd MNs it was decided to proceed with additional set
of pilot in vivo experiments. This time the volume of the vector injected unilateraly in right
gastrocnemius muscle was increased to 40 µl per muscle.
Moreover, in vivo studies extended to intramuscular injections of lentiviral vectors expressing
not only EGFP but also LacZ and Luciferase (for live imaging experiments) reporter genes.
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Figure 9.4: Immunohistochemical analysis of right gastrocnemious muscle injected with
αp75NTR targeted vector. Tissue samples transduced with αp75NTR targeted vector were triple
stained for GFP (green), α-bungarotoxin (red) and Synaptophysin (magenta). Transduced muscle
fibers were positive for the post-synaptic marker α-bungarotoxin. Scale bar, 50 µm.
9.1.4 Intramuscular injection in rats of lentiviral vectors expressing
eGFP and LacZ reporter genes
Two sets of in vivo grade (x2000) lentiviral preparations of αThy1.1 and αp75NTR targeted
vectors non-targeted 5pl control, VSVG and RVG-B2c vectors each encoding either EGFP or
LacZ reporter genes were produced and titered. Details of lentiviral preparations used in the
subsequent in vivo experiments are presented on Tables 9.2 and 9.3 . 40µl (8x5 µl) of each
of the targeted vectors and controls, were unilaterally injected at multiple locations into the
right gastrocnemius muscle of adult Wistar rats (n=2 rats per group, in total of 5 groups per
reporter gene).
This time the animals were sacrificed three weeks post injection and spinal cords were harvested
to determine EGFP or LacZ expression levels in motor neurons. Prior to processing and staining
of spinal cord tissue samples for expression of either of the transgenes, a protocol for successful
identification of LacZ expression had to be established. In order to set up and assess for
successful enzymatic reaction, together with Dr Antonio Trabalza we have performed fixation,
sectioning and X-gal staining for detection of β -galactosidase activity in control spinal cord
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Table 9.2: Titers of eGFP expressing lentiviral preparations used in second set of in vivo
intramuscular injections in adult Wistar rats.
Vector
RNA titer Titration ratio Titer
p24 concentration
(RNA copies/ml) (copies/t.u.) (t.u./ml) (ng/ml)
B2c-CMVeGFP
1.21× 1011 4.12× 1010 1.51× 105
VSVg-CMVeGFP
4.68× 1010 2.92 1.60× 1010 5.65× 105
αThy1.1-CMVeGFP
1.09× 1011 3.73× 1010 6.10× 106
αp75NTR-CMVeGFP
6.36× 1010 2.17× 1010 9.78× 104
5pl-CMVeGFP
4.00× 1010 1.37× 1010 2.48× 106
Table 9.3: Titers of LacZ expressing lentiviral preparations used in second set of in vivo
intramuscular injections in adult Wistar rats.
Vector
RNA titer Titration ratio Titer
p24 concentration
(RNA copies/ml) (copies/t.u.) (t.u./ml) (ng/ml)
B2c-CMVLacZ
6.88× 1009 2.63× 1010 5.15× 1004
VSVg-CMVLacZ
9.78× 1009 2.60 1.60× 1009 5.15× 1004
αThy1.1-CMVLacZ
1.51× 1010 2.77× 1009 1.22× 1005
αp75-CMVLacZNTR
1.55× 1009 7.92× 1008 3.25× 104
5pl-CMVLacZ
4.31× 1009 1.65× 1009 9.85× 104
tissue samples. For this control experiment we have used spinal cord tissue extracted from
smad8 adult mice (kindly provided by Professor Vasso Episkopou), that endogenously express
β -galactosidase in the spinal cord. Following the staining protocol presented in Methods
section, we have been able to successfully identify expression of LacZ reporter gene. Also right
and left gastrocnemius muscle (injection site and control, respectively) were harvested to assess
possible transduction of muscle fibers at the site of injection.
Spinal cords harvested from rats injected with eGFP expressing vectors (Table 9.2) were sec-
tioned (50 µm) and immunohistochemically stained to examined EGFP expression, indicative
of retrograde delivery and expression of the transgene by the HIV-1 based targeted vector.
Immunostaining was also performed for the selective cholinergic motor neuron marker ChAT
(choline acetyl transferase), an enzyme that catalyses acetylcholine synthesis. Unfortunately,
no EGFP was detected in any of the spinal cord samples of the injected rats, not only for
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the targeted lentiviral vectors and 5pl control engineered in this study but also for RVG-B2c
pseudotyped HIV-1 lentiviral vector.
Analysis of the spinal cord tissues harvested from rats injected with HIV-1 vectors expressing
the LacZ reporter gene (Table 9.3) gave no indication of successful retrograde delivery as no
expression of β-gal was detected upon addition of X-Gal substrate.
Absence of transgene expression in any of the target spinal cord motor neurons gave no indica-
tion of the ability of these newly engineered targeted lentiviral vectors to undergo retrograde
transport and MN transduction upon in vivo application. Though this was not the case only
for the antibody pseudotyped vectors. However, no transduction was reported also for the
possitive control pseudotyped lentiviral vectors used in these two studies. Both EGFP and
LacZ expressing RVG-B2c pseudotyped lentiviral vectors failed to trasduce spinal cord motor
neurons. This was surprising as lentiviral vector pseudotyped with rabies-G (both EIAV and
HIV) have been shown to efficiently transduce spinal motor neurons upon peripheral muscle ad-
ministration to rat and mouse [82], [86]. However, it is necessary to report that in Mazarakis et
al., [82] experiments were performed by injecting rat gastrocnemius muscle with EIAV (equine
anemia virus) based vectors expressing LacZ reporter gene. While in Mentis et al., [86] mouse
muscles were injected with HIV-1 based vectors. In the studies presented above rat gastrocne-
mius muscles were transduced with HIV-1 based rabies-G (B2c) pseudoytped lentiviral vectors.
Moreover results obtained from in vitro studies in MFCs, presented in the previous chapter,
clearly demonstrated that both αThy1.1 and αp75NTR targeted lentiviral vectors were compe-
tent to be retrogradely transported along rat motor neuron axons and successfully transduce
the soma of target cells. And more specifically trafficking occurs in certain reported pathways
followed by TeNT and p75NTR. Lack of results to demonstrate this in vivo can have many
explanations and has been decided to be addressed systematically. Since all experiments de-
signed and presented on this study were based on HIV-1 based lentiviral vectors, shifting to
an EIAV based system was not recommended at this stage, although a direct EIAV/HIV-1
rabiesG pseudotyped lentiviral vector comparison was set up directly after these observations
(data will not be presented on this study). Thus, the size of the injected tissue was the next to
be addressed. Gastrocnemius muscle is a large compact muscle innervated by 300-400 motor
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neurons. Failure to report transduction could partially be attributed to the size of the muscle
and to the injection process itself. Multiple muscle injections cannot by principle be accurate
as far as the injection point and depth is concerned while leakage of the injected vector due to
repeated piercing of the injected muscle may also occur resulting in uneven distribution of the
vector. Based on previous successful intramuscular injections [86], which in contrast to the ones
presented above were performed to mouse muscles and in an attempt to address the muscle
size issue it was decided to proceed with the same injections into mice.
9.2 In vivo intramuscular injections of targeted lentivi-
ral vectors and controls in mice
Specificity of the αp75NTR and αThy1.1 targeted vectors was a limiting factor for proceeding
with application to mouse muscles. αp75NTR targeted vector recognised only rat p75NTR and not
mouse which blocked the progression of this vector to the mouse studies designed and presented
below. αThy1.1 targeted vector express anti-Thy1.1 antibody which recognises Thy1.1 receptor
expressed by rats. Fortunately it recognises and binds to Thy1.1 determinants expressed only by
some mouse strains (AKR/J, PL and FVB/NJ). On this front, in vivo studies were proceeded
with application of αThy1.1 targeted vector and controls in FVB/NJ mice. For the purpose
of this study the following lentiviral preparations were produced and titered (Tables 9.4 and
9.5). 24 µl (8x3 µl) of each of the targeted vectors and controls, were unilaterally injected at
multiple locations into the right gastrocnemius muscle of adult FVB/NJ mice (n=3 mice per
group). In these experiments the target MN population defined was the one determined from
initial FAST BLUE injections in mouse gastrocnemious muscle presented in section 9.1.1. We
did not perform separate injections of FAST BLUE retrograde tracer and subsequet assessment
of MN labelling in FVB/NJ mice, since we did not expect to observe any difference between
the same species regarding the intramuscular application of the tracer.
Animals were sacrificed three weeks post injection and spinal cords were harvested to determine
EGFP or LacZ expression levels in motor neurons. Once more, right and left gastrocnemius
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Table 9.4: Titer values of eGFP expressing lentiviral preparations injected in adult
FVB/NJ mice.
Vector
RNA titer Titration ratio Titer
(RNA copies/ml) (copies/t.u.) (t.u./ml)
B2c-CMVeGFP
3.72× 1010 2.59× 1009
VSVg-CMVeGFP
2.31× 1010 1.44 1.60× 1010
αThy1.1-CMVeGFP
1.58× 1011 1.09× 1010
5pl-CMVeGFP
2.26× 1009 1.56× 1009
Table 9.5: Titer values of LacZ expressing lentiviral preparations injected in adult FVB/NJ
mice.
Vector
RNA titer Titration ratio Titer
(RNA copies/ml) (copies/t.u.) (t.u./ml)
B2c-CMVLacZ
4.79× 1009 1.25× 1009
VSVg-CMVLacZ
9.78× 1009 2.60 3.75× 1009
αThy1.1-CMVLacZ
6.61× 1009 1.74× 1009
5pl-CMVLacZ
5.02× 1009 1.30× 1009
muscle (injection site and control respectively) were harvested to assess possible transduction
of muscle fibers at the site of injection.
Spinal cords harvested from mice injected with eGFP expressing vectors (Table 9.2) were sec-
tioned (50 µm) and immunohistochemically stained to examined EGFP expression, indicative
of retrograde delivery and expression of the transgene by the HIV-1 based targeted vector.
Sections were also stained for motor neuron marker ChAT. Unfortunately, no EGFP was de-
tected in any of the spinal cord samples of the injected mice, not only for αThy1.1 targeted
lentiviral vector and 5pl control engineered in this study but also for RVG-B2c pseudotyped
HIV-1 lentiviral vector.
9.3 In vivo bioluminescene imaging studies in mice
Understanding biological processes on the context of intact organ systems with fine temporal
resolution has required the development of imaging strategies that reveal cellular and molecular
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changes in the living body. Reporter genes that confer optical signatures on a given biological
process have been used more recently to investigate biological processes in living animal models
of human biology disease. The use of internal biological sources of light, luciferases, to tag cells,
pathogens, and genes has proven to be a versatile tool to provide in vivo indicators that can
be detected externally in live animals.
Bioluminescence is a naturally occurring enzyme reaction that occurs in a number of organisms.
In all cases luciferases require energy, oxygen and a specific substrate (commonly known as
luciferin), and may also require cofactors for production of light (reviewed in [306]). Among
the three luciferases cloned and characterized up to date the most widely used one is the one
from firefly (coleopterra) [307], [308]. The gene encoding firefly luciferase (Fluc) was cloned and
codon optimised for mammalian expression [309]. When cells expressing Luciferase are provided
with the substrate, luciferin, using as energy source cellular ATP, they emit a yellow-green light
with an emission peak at around 560 nm. Photons are both scattered and absorbed as they
pass through mammalian tissue. More specifically, blue and green light, which have shorter
wavelengths, are largely absorbed by tissues, while red light is affected less. The sensitivity
of detection, utilizing this system, for cells expressing luciferase near the body surface (e.g.
subcutaneously) is typically fairly high, however in animals with dark fur, the pigment, melanin,
absorbes light within the visible region of the spectrum which can attenuate and weaken the
signal. Thus in most of the studies the best subjects for in vivo imaging are nude mice.
In vivo imaging was first used to detect sites of bacterial replication in intact, living animals
in 1995 [310] and since then was proven to be efficiently used to monitor real time activity in
living animals. Among many applications, alphaviruses and inparticular Sindbis virus, has been
applied in an in vivo imaging protocol to monitor extend and location of viral replication. More
specifically, imaging of albino B6 mice intracerebrally (i.c.) injected with NSV-7-Luc allowed
detection of virus in brain and spinal cord [311].
Since all in vivo attempts so far, to demonstrate retrograde transport of the three newly engi-
neered targeted vectors, did not have a positive outcome, a new approach which possibly could
allow us to visualize the spatial and temporal distribution of the vector upon peripheral muscle
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application, was decided to be set up and monitored. To achieve this, initially a transfer vector
(HIV-1) plasmid encoding the luciferase (firefly) reporter gene was cloned by Dr Stuart Ellison
and targeted lentiviral vectors and controls expressing luciferase reporter gene were produced
and titered in order to be intramuscularly delivered in vivo to mice. While designing this study
several details that could affect the experiments were taken into consideration.
A limiting factor in this technique is the depth from which the light originates from. The
more tissue lies between the reporter and the detector, the more signal/light is lost resulting
from both absorption and scattering of light. Therefore, although rats have been used in BLI
imaging studies, their relatively larger size, compared to mice, hinders the detection of signal
originating from deep within the body (reviewed in [306]). And finally, not only the size of the
animal but also the depth at which the tissue examined is within the body may result in some
difficulties in signal detection. Clearly, the wavelength of transmitted light and the extend of
diffusion carry information that relates to the tissue depth of the source.
For these reasons and after careful consultation from Dr J Tremolenda (Biological Imaging Cen-
tre, Imperial College London), it has been decided to design and conduct imaging experiments
only in mouse. The major challenge of this study was the route of delivery under investigation.
To examine and determine whether transport to the CNS from peripheral muscle injection
sites could be visualized prior to 3 weeks, adult C57BL/6 and FVB/NJ mice were unilaterally
injected into right gastrocnemius muscle with luciferase expressing lentiviral preparations (Table
9.6). As a non-targeting control, 5pl control vector and VSVG were applied to mice in the same
way.
Initially 2 animals of each group were injected and subjected to imaging for each virus on days
7, 14 and 21 post injection. Prior to imaging, mice were injected subcutaneously with 150 mg of
luciferin per kg of body weight. The expression of the delivered reporter gene (firefly lyciferase,
Steady-Glo) was monitored and results are presented in the figures below. All animals were
left 5 min upon injection of the substrate (D-luciferin) prior to imaging to ensure expression of
transgene.
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Table 9.6: Titers of Luc expressing lentiviral preparations used in BLI studies.
Vector
RNA titer
p24 concentration
(RNA copies/ml) (ng/ml)
B2c-CMVLuc
2.76× 1010 8.67× 1006
VSVg-CMVLuc
1.42× 1010 1.98× 1005
αThy1.1-CMVLuc
5.21× 1009 1.21× 1005
αCAR-CMVLuc
1.62× 1010 4.07× 1004
5pl-CMVLuc
1.43× 1010 2.61× 1005
First group of animals subjected to live imaging experiment were injected with B2c-HIV-1-Luc
lentiviral vectors, which served as positive control in setting up the experiment. Animals were
monitored weekly up to day 21 (3 weeks) which was the terminal point at which the animals
were euthanised and tissue was collected. As presented in Figure 9.5, in both C57BL/6 and
FVB/NJ injected mice, strong signal was constantly observed throughout the study, originating
from transduced cells at the site of injection (right gastrocnemius muscle). No signal was
observed at the level of spinal cord, when animals were dorsally imaged. There was only one
case were a second signal, in supine view, originating from the equivalent level of the spinal
cord, was detected in C57BL/6 mice at day 7, which was unfortunately lost during subsequent
time points of acquisition. This could be evaluated as signal originating from transduced cells
at this level. For this reason tissue was harvested at day 21 for further processing and analysis.
When FVB/NJ mice were intramuscularly injected with αThy1.1 targeted vector, a second
signal at the level of the spinal cord was detectable at both mice at day 7 (Figure 9.6). Once
more, a week later the signal was lost. This time a more systematic approach was followed in
order to obtain vital information regarding the depth within the animal from which the second
signal originates, Dr Tremolenda advised and guided a FLIT 3D Reconstruction (Fluorescence
Tomography; Perkin Elmer) of a series of images acquired for each animal at day 21. The
resulting image as presented in Figure 9.6 (bottom panel) located the second signal centrally
in the animal body. From this analysis, the signal did not appear to be located in big depth,
though it had to be taken into consideration that the FLIT 3D Reconstruction is based on a
phantom shape of the animal which is not directly representative of the actual dimension/size
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Figure 9.5: Imaging of FVB/NJ and C57BL/6 mice 7, 14 and 21 days after i.m. injection
with B2c-HIV-1-Luc lentiviral vector. Viral transduction is determined by imaging the level of
firefly luciferase reporter gene expression. Prone and supine views show that virus is detectable at all
time points in the right leg (injection site). A strong signal originates from transduced cells at site of
injection. At day 7 in C57BL/6 mice a second signal is detectable in supine view.
of each animal. Thus the information regarding the location of the two signals which allow
to characterize them as separate are accurate, though the ones for depth at which the signal
comes from is only an estimate. For this reason, tissues were harvested and preserved for further
analysis.
In the next set of experiments, where C57BL/6 mice were injected with αCAR targeted vector,
a more invasive approach was decided to be followed in order to investigate the origin of the
second supine signal. Possible explanations for loss of supine signal during the last 2 weeks, or
complete absence of signal, could be the tissue thickness/depth, as well as the dark pigment, of
C57BL/6 or even silencing of the CMV promoter driving the expression of Luciferase gene. To
overcome these problems and come to a conclusion regarding the presence of signal originating
from transduced cells at the spinal cord, it has been decided that on day 21 animals will be
subjected to terminal anesthesia and imaged with their skin removed and cavity open to fully
expose the spinal cord tissue. This was a delicate procedure were animals have to be kept alive,
in deep anaesthesia during the whole imaging. Dr Antonio Trabalza, with whom the study
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Figure 9.6: Imaging of FVB/NJ mice 7, 14 and 21 days after i.m. injection with αThy1.1-
Luc targeted lentiviral vector. Viral transduction is determined by imaging the level of firefly
luciferase reporter gene expression. Prone and supine views show that virus is detectable at all time
points in the right leg (injection site). A strong signal originates from transduced cells at site of
injection. A second signal at day 7 is detectable in supine view. FLIT 3D Reconstruction of series of
images generate a representative view, locating the two signals one strong at the leg and a weak one
at the level of the spinal cord.
was conducted together, had removed the skin with extreme care to ensure that no bleeding
occurred, at all times, during analysis.
Live imaging of mice injected with αCAR targeted vector (Figure 9.7) detected at all time
points, a strong signal originated from transduced cells at the injection site. At day 21 upon reg-
ular imaging, animals were deeply anaesthetised and imaged with their skin removed. The aim
of this approach was to overcome possible limitations due to the dark skin colour of C57BL/6
9.3. In vivo bioluminescene imaging studies in mice 225
ms No1
prone supine
ms No2
D
a
y
 7
D
a
y
 1
4
D
a
y
 2
1
C57BL/6 mice injected with αCAR_CMVLuc
Day 21  skin removed and cavity opened
prone supine
lymph 
removed
Figure 9.7: Imaging of C57BL/6 mice 7, 14 and 21 days after i.m. injection with αCAR-
Luc targeted lentiviral vector. Viral transduction is determined by imaging the level of firefly
luciferase reporter gene expression. Prone and supine views show that virus is detectable at all time
points in the right leg (injection site). A strong signal originates from transduced cells at site of
injection. No additional signal was observed in any of the animals imaged. At day 21 animals were
deeply anaesthetised and skin was removed. When cavity was opened and spinal cord tissue was
directly exposed a strong signal was observed as a result of photons emitted from transduced cells
within the spinal cord. To avoid misinterpretation of the results, spinal cord signal was still detectable
when lymph nodes were removed.
mice which could prevent the light diffusion and weaken any possible signal from transduced
cells. The procedure was conducted under strict, well controlled and monitored conditions. An-
imals were kept under deep anaesthesia throughout imaging and tissue was regularly hydrated
with saline. Imaging with skin removed did not give any direct information. Signal detected at
the level of spinal cord only when leg was covered, to prevent camera saturation due to strong
signal from the leg (data not shown). Thus immediate exposure of the spinal cord, by opening
the cavity (no bleeding was reported at any time) revealed for the first time a strong second
signal originating from the spinal cord (Figure 9.7 bottom panel). This was the first time that
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a signal originating from the target tissue was directly observed. To avoid misinterpretation
of the results, lymph nodes were carefully removed and animals imaged for the last time. As
presented on figure 9.7 spinal cord signal was still detectable even upon removal of the lymph
nodes. In the far left picture of figure 9.7 the lymph node removed was placed on the side
of the animal and imaged at the same time. The reason for doing this was that initially it
was assumed that either the signal did not come from the spinal cord but from the lymph
node, or the spinal cord signal was too weak to be detected individually. For this reason the
node was removed and cavity opened wider to expose better the spinal cord. Photons emitted
from spinal cord of mice injected with CAR targeted vector indicated retrograde transport and
transduction of spinal cord cells with the targeted vector.
To validate these results, C57BL/6 and FVB/NJ mice were injected with non-targeted 5pl
control and VSVG vector. Moreover a group of non-injected animals was also imaged. Ad-
ministration of VSVG-Luc and non-targeted 5pl control generated bioluminescence signals only
specific to the injected muscle (Figures 9.8 and 9.9). Even when skin was removed and spinal
cord was directly exposed, no spinal cord signal was observed. Similarly to imaging for αCAR
injected animals, when the lymph node was removed and animals imaged, the only signals
detected were the ones originating from the right leg and the lymph node placed on the side
of the animal. Moreover 3-D tomography detected only one strong signal specific to the right
injected muscle at all times.
9.4 Targeted gene transfer in vivo in mouse
The ultimate goal of this study was to develop a gene-transfer targeted vector capable of direct
delivery sto spinal cord MNs via the NMJ. To this end, we proceeded, as presented above, with
several in vivo muscle injections. Lack of retrograde transport and transduction of spinal cord
motor neurons in all of the experiment presented above led to concentrate all efforts of this
study in application to mouse muscles. Results obtained from luciferase studies with αCAR
targeted vector on mouse gastrocnemius muscle were encouraging and efforts to optimise the
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Figure 9.8: Imaging of FVB/NJ and C57BL/6 mice 7, 14 and 21 days after i.m. injection
with VSVG-HIV-1-Luc lentiviral vector. Viral transduction is determined by imaging the level
of firefly luciferase reporter gene expression. Prone and supine views show that virus is detectable at
all time points in the right leg (injection site). A strong signal originates from transduced cells at site
of injection. No additional signal was observed in any of the animals imaged. At day 21 animals were
deeply anaesthetised and skin was removed. No signal originating from spinal cord was detected at
all times. When lymph was removed the only signals detectable were the ones from the leg and the
lymph. FLIT 3D reconstruction of series of images generate a representative view, locating only one
strong signal at the leg right leg.
vector and the delivery route continued. It has been shown that transduction of spinal cord
motor neurons with rabies virus glycoprotein (RVG) pseudotyped lentiviral vectors can be
achieved upon peripheral administration to gastrocnemious muscle [82].
A smaller muscle, the tibialis anterior (TA) was chosen to to be injected in the studies presented
in this section. It is a smaller, less complex muscle, innervated by 140 motor neurons [312]
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Figure 9.9: Imaging of FVB/NJ and C57BL/6 mice 7, 14 and 21 days after i.m. injection
with non-targeted 5pl-Luc lentiviral vector. Viral transduction is determined by imaging the
level of firefly luciferase reporter gene expression. Prone and supine views show that virus is detectable
at all time points in the right leg (injection site). A strong signal originates from transduced cells at
site of injection. No additional signal was observed in any of the animals imaged. At day 21 animals
were deeply anaesthetised and skin was removed. No signal originating from spinal cord was detected
at all times. When lymph was removed the only signals detectable were the ones from the leg and the
lymph.
compared to gastrocnemius, which as reported above, is a group of muscles innervated by
around 400 motor neurons. Motor neurons that innervate tibialis anterior are restricted to
columns ranging from L5 to L6 in the spinal cord [313]. Differences in development can be
appreciated among muscles, which are maintained for maturity. Pun and colleagues have
identified fast synapsin muscles as tibialis anterior and delayed-sunapsin muscles, as lateral
gastrocnemius during mouse myogenesis [314]. Thus TA muscle was considered as a ideal
alternative for muscle administration of the lentiviral preparations.
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Tibialis Anterior (TA)
A.
B.
Figure 9.10: C57bl/6 mouse Tibialis anterior injections. (A) Small incision in hind limb was
performed to expose tibialis anterior (TA) muscle, where FASTBLUE and targeted vectors will be
delivered through a single injection. (B) Representative cross section of mouse spinal cord where nuclei
of TA are retrogradely labeled by intramuscular injection of Fast Blue. 57.75±2.88 motor neurons in
average were traced per animal. Scale bar, 50µm.
Prior to injections with αCAR targeted lentiviral vector, peripheral intramuscular delivery
(TA) of FASTBLUE retrograde tracer confirmed successful retrograde labeling of lumbar MN
cells through this route. C57BL/6 mice (n=4) were unilaterally injected with 4 µl each of 2%
retrograde tracer FASTBLUE. Animals were sacrificed 8 days post TA injection and spinal cord
tissues were harvested and analysed for lumbar motor neuron labeling. A representative cross
section of the mouse spinal cord where nuclei of TA are retrogradely labeled by intramuscular
injection of Fast Blue are presented on Figure 9.10B. Average number of motor neurons traced
was 57.75±2.88.
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Since the target group of cells has been identified and access to it through the neuromuscular
route was confirmed studies proceeded with delivery of αCAR targeted vector expressing EGFP
reporter gene through a single injection into TA of mice. In vivo grade (x2000) lentiviral
preparations of αCAR targeted vector, 5pl non-targeted control and RVG-B2c vector were
produced. On table 9.7 are presented the details of lentiviral preparations applied to tibialis
anterior of mice.
Table 9.7: Titer values of eGFP expressing lentiviral preparations injected in TA of adult
C57BL/6 mice.
Vector
Titer [p24] RNA Titer
(t.u./ml) (ng/ml) (RNA copies/ml)
αCAR-CMVeGFP
1.09× 1009 2.40× 1005 4.70× 1010
B2c-CMVeGFP
2.94× 1009 1.56× 1005 1.13× 1010
5pl-CMVeGFP
3.62× 1009 4.48× 1005 2.00× 1010
The vectors presented on table 9.7 were unilaterally injected, through a single injection (25µl)
into right mouse TA (n=3 mice). Three weeks post injection the animals were sacrificed and
spinal cord tissues were harvested and examined for EGFP expression, indicative of retrograde
delivery and expression of the transgene by HIV-1 based targeted vector. Tissue processing
revealed that mice injected with control (both non-targeted and B2c-HIV-1) did not result in
any detectable transduction of spinal cord cells (Figure 9.11B). In contrast, EGFP transgene
expression was observed in neurons within the lumbar cord region of the spinal cord of mice
injected with αCAR-targeted vector (Figure 9.11). The insert of merge image shows a panel
of five EGFP-expressing motor neuron cells. Both the soma and motor neuron dendrites were
labeled with variable intensities. To identify these EGFP positive cells as motor neurons,
immunostaining was performed for ChAT, which allowed to follow transgene expression in
these motor neurons for a series of 5-6 sections (50 µm each). A total of 7, non-overlapping,
transduced motor neuron cells were identified in 6 sections. Viral transduction was also observed
with both vectors at the injection site (muscle fibers). Despite the successful transduction of
spinal motor neuron cells as a result of intramuscular injection of the CAR-targeted vector,
variability of transduction was observed between animals. Motor neuron transduction upon
peripheral muscle delivery of αCAR vectors was only observed in one out of three animals.
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Figure 9.11: In vivo intramuscular delivery of CAR-targeted vector. Tropism of αCAR
targeted lentiviral vector in the spinal cord following intramuscular TA delivery. Sections were double
stained using anti-EGFP antibody (AlexaFluor 488 secondary antibody enhancing the GFP signal)
shown in green, antibody to ChAT (AlexaFluor 594 secondary antibody staining MN) shown in red.
(A) Representative cross section of the spinal cord where TA motor neurons express EGFP encoded
by αCAR targeted vector. (B) Representative cross section of spinal cord from animals injected with
5pl non-targeted control (top row) where no TA motor neuron transduction was observed. While
intramuscular injection of αCAR-targeted vector resulted in TA motor neuron transduction. Insert
shows zoomed in optical sectioning images of three transduced TA MNs. Both soma and dentrites are
EGFP-positive. Scale bars, 250 µm for low magnification pictures, 50 µm for inserts.
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To examine and determine whether transport to the CNS from peripheral muscle injection sites
(TA) could be visualized prior to 3 weeks, adult C57BL/6 mice were unilaterally injected into
right TA with αCAR-targeted luciferase expressing vector). As a non-targeting control, 5pl
control vector was applied to mice in the same way.
Table 9.8: Titer values of luciferase expressing lentiviral preparations injected in TA of
adult C57BL/6 mice.
Vector
Titer [p24] RNA Titer
(t.u./ml) (ng/ml) (RNA copies/ml)
αCAR-CMVLuc
1.93× 1009 4.07× 1004 1.62× 1010
5pl-CMVLuc
2.13× 1009 4.20× 1004 1.43× 1010
5 animals of each group were subjected to imaging for each virus on days 7, 14 and 21 post
injection. The expression of the delivered reporter gene (firefly lyciferase, Steady-Glo) was mon-
itored and results are shown in Figure 9.12. In mice injected with the αCAR-targeted vector,
two strong bioluminescent signals generated by firefly luciferase expression were seen both at
the injection site (right TA) and at the level of the spinal cord. In contrast, administration of
non-targeted 5pl control generated bioluminescence signals only specific to the injected muscle.
In some cases stronger signal originating from the αCAR targeted injected leg was masking the
few photons emitted from spinal cord, and leg was covered to prevent camera saturation. This
was not observed when animals injected with non-targeting vector were covered in the same
way (Figure 9.12 bottom row). This further supported that the second signal observed in the
animals injected with the targeted vector does originate from photons emitted from transduced
cells at the level of spinal cord. These data demonstrated validation of the route in vivo, and
allowed observation of transport and expression of transgene dynamically upon muscle applica-
tion. However, contrary to injections of EGFP-expressing vectors (Figure 9.11), this approach
did not seem to allow, at any point, to prove transduction of spinal cord motor neurons at a
cellular level, instead it is a fast and non-invasive way of visualizing the spatial and temporal
distribution of this targeted vector.
Overall, in vivo intramuscular injection of CAR targeted vector was shown through this ap-
proach that can lead to transduction of corresponding motor neurons in lumbar spinal cord.
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Figure 9.12: In vivo bioluminescence imaging of mice intramuscularly injected with αCAR
expressing luciferase. αCAR-targeted luciferase-expressing vector and 5pl control were ulilateraly
injected into TA of adult C57BL/6 mice (n=5 animals/group). Virus infection at seven, fourteen and
twenty-one days later, was determined by imaging the level of firefly luciferase reporter gene expression.
In some cases stronger signal originating from the CAR-targeted injected leg was masking photons
emitted from spinal cord, and leg was covered to prevent camera saturation. This was not observed in
animals injected with non-targeting vector (bottom row), supporting that the signal observed on the
animals injected with the targeted vector originates from transduced cells at the level of spinal cord.
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Variability observed between animals could partially be attributed to the injection process it-
self, as muscle injection cannot by principle be accurate as far as the injection point and depth
is concerned, or even the strength of expression of the transgene itself, which is regulated by
an upstream CMV promoter. Despite the difficulties faced, the results presented in this section
are the first demonstration of in vivo CNS transport and transduction achieved with surface
engineered vectors upon peripheral muscle administration.
9.4.1 In vivo application to the rat brain
To further investigate the tropism of all three targeted vectors in vivo and investigate their
ability to be retrogradely transported, targeted vectors and controls were stereotaxically applied
to the rat striatum. This approach has proven to be of great importance regarding in vivo
retrograde transport of lentivral vectors tested in our lab, as it was successfully used many
times in the past to define tropism of a lentiviral preparation ([295], [315]). On this front,
application of these vectors to the rat brain would possibly give some information regarding
the tropism of especially the αThy1.1 and αp75NTR for which the only data of retrograde
transport and cell transduction have been obtained through in vitro experiments on rat cell
lines and primary motor neuron cultures. Details of the lentiviral preparations produced for
striatal injections are presented in Table 9.9. Prior to injection vectors were normalised to
vector infectivity values to ensure equal administration of potent lentiviral particles. All rats
received 4µl of appropriate lentiviral preparation diluted in formulation buffer (TSSM). 3 rats
were injected per group.
Three weeks post injection the animals were sacrificed and brains were harvested, sectioned and
examined for EGFP expression, indicative of retrograde delivery and expression of the transgene
by HIV-1 based targeted vector. Figure 9.13 shows that all vectors tested were able to efficiently
deliver the transgene to the site of injection. Differences in the tropism were observed among
the three targeted vectors (αCAR, αp75NTR, and αThy1.1). αCAR has shown considerable
affinity for neurons, though still transducing a small amount of astroglia. αp75NTR appeared to
transduce astroglia to the same extent as it transduced neurons. Interestingly αThy1.1 targeted
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vector appeared to be the most specific for striatal neurons giving only marginal transduction of
astroglia. The non-targeted control vector (lacking the targeting antibody but still pseudotyped
with neurotropic sindbis-G) did also transduce neurons albeit at lower efficacy. Moreover, all
three vectors also achieved retrograde transduction of mytral cells of the olfactory bulb, a
distal structure extensively connected to the striatum’s olfactory tubercle. Differences were,
once more, evident among the three vectors. αp75NTR appeared to be less effective in achieving
distal transduction compared to αCAR and αThy1.1-targeted vectors. Unfortunately none
of the vectors reported has shown significant transduction of dopaminergic neurons of pars
compacta of the substantia nigra, which have exclusively efferent projections to the striatum.
Table 9.9: Titer values of lentiviral preparations injected in the rat striatum.
Vector
Titer [p24] Vector Infectivity
(t.u./ml) (ng/ml) (t.u./ng p24)
αCAR-CMVeGFP
1.09× 1010 2.40× 1005 4.55× 1004
αp75NTR-CMVeGFP
4.13× 1009 7.32× 1004 5.64× 1004
αThy1.1-CMVeGFP
2.47× 1009 3.23× 1004 7.63× 1004
5pl-CMVeGFP
3.62× 1010 4.48× 1005 8.08× 1004
9.5 Discussion
The initial goal of this study was to develop a targeted gene transfer vector that will allow a less
neuroinvasive and specific transgene delivery into the nervous system following peripheral in-
tramuscular delivery, by targeting the peripheral sites of neuromuscular synapse. Based on lim-
itations in specificity of previous studies in which despite successful transduction of spinal cord
motor neurons upon intramuscular delivery of rabies virus glycoprotein pseudotyped lentiviral
vectors, sensory neurons and muscle got transduced [82][86], novel targeted lentiviral vectors
were designed and presented in this study. In previous chapter the targeting specificity, ret-
rograde trafficking and transduction efficiency of the three newly engineered targeted vectors
αThy1.1, αp75NTR and αCAR were extensively assessed. In this chapter specificity and traf-
ficking of these vectors are analysed under the complexity of an in vivo model. To study the
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Figure 9.13: Instrastriatal injections of targeted vectors. EGFP expression at the site of injec-
tion (striatum) and distal sites (olfactory bulb) injected with targeted pseudotyped HIV-1 lentiviral
vectors (single injection of 4 µl volume). 30/40 µm thick brain sections from n=12 rats harvested at
3 weeks post injection were obtained and stained with anti-EGFP antibody to enhance the EGFP
signal (shown in black). High magnification inserts corresponding to marked regions (dashed box) of
the panoramic section images indicate the transduction of cell bodies and fibres. Panoramic section
images were captured by epifluorescent microscope either with a 10x objective (olfactory bulb) or
4x objective (striatum). Color inserts were captured at site of injection with confocal microscope
equipped with a 40x objective. Sections were triple stained using anti-EGFP antibody (AlexaFluor
488 secondary antibody enhancing the EGFP signal) shown in green, antibody to NeuN (AlexaFluor
594 secondary antibody staining neuronal cells) shown in red, and antibody to GFAP (AlexaFluor 647
secondary antibody staining astrocytes) shown in magenta.Quantification (n=1) of vector tropism in
the striatum. Scale bars, 50 µm.
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in vivo gene transfer efficiency of these novel targeted lentiviral vectors, adult rats and mice
were injected in the gastrocnemius and tibialis anterior muscle, euthanized approximately 3
weeks post injection and transduction of spinal cord MNs indicative of retrograde delivery was
assessed by immunohistochemistry.
9.5.1 Identification of target cells
Careful experimental design of this study involved identification and labelling of the target cell
group. Motor neurons that activate a given muscle define a motor nucleus, a pool, and those
that serve the hind limb muscles are located in the lumbar spinal cord, along overlapping but
distinct segments of the cord. Intramuscular injections and retrograde transport of Fast Blue
dye, both in gastrocnemius muscle and tibialis anterior allowed the identification of the neurons
of a given pool and their organization in the spinal cord. In other words, provided information
regarding the efficiency and ability to assess the target cells following a specific delivery route.
For this reason, injections of Fast Blue dye were always performed prior to preceding with in
vivo application and retrograde assessment of the targeted vectors. Quantification of labelled
cells in animals injected with this dye defined the number of MNs that was accessible for
transduction, given the delivery route and injection method chosen and assessed in this study.
These experiments were of high importance, since they provided essential information regarding
the target and the feasibility of the delivery route assessed each time. Fast blue injections were
performed in gastrocnemius muscle of both mice and rats while in tibialis anterior only for
mice, since TA injections were only performed in mice.
9.5.2 In vivo intramuscular injections in rat gastrocnemius muscle
Efficient transgene delivery and balanced expression in motor neurons are central to the success
of gene therapy and the genetic manipulation of the motor system. Results obtained from
these first pilot in vivo experiments were not encouraging for utilising them as gene therapy
tools. Absence of transgene expression in any of the target spinal cord motor neurons gave
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no indication of the ability of these newly engineered targeted lentiviral vectors to undergo
retrograde transport and MN transduction upon in vivo application. A major part of this side
of the project was concentrated on defining the reasons and systematically improve the system
used, in order to resolve the issues resulting to poor or no transgene expression.
Absence of transgene expression was not observed only in animals injected with the targeted
antibody pseudotyped vectors but was also reported for the positive control pseudotyped lentivi-
ral vectors used in these two studies. Both EGFP and LacZ expressing RVG-B2c pseudotyped
lentiviral vectors failed to transduce spinal cord motor neurons. This was surprising for the
positive control vector utilized in these studies. Lentiviral vectors pseudotyped with rabies-G
(both EIAV and HIV) have previously been shown, both by us and others, to efficiently trans-
duce spinal motor neurons upon peripheral muscle administration to rat and mouse [82], [86].
Indeed, the specific targeting of neuronal cells reported with rabies-G EIAV progressed these
studies to lentiviral delivery of therapeutic transgenes or RNAi in murine models of ALS and
SMA which were proven to be effective in ameliorating symptoms of these diseases [51, 165, 90].
Transduction reported with these RVG-EIAV vectors resulted in stable and long term expres-
sion of either the reporter or therapeutic transgene (up to 12 months) [82, 316]. Compared
to the injections performed in this study, where the same muscle (gastrocnemius), injection
method (multiple injections per muscle) and titer of lentiviral preparation were used, RVG
pseudotyped lentiviral vectors successfully applied in [82, 51, 165, 90, 316] were based on EIAV
(equine infectious anemia virus) vectors expressing solely LacZ and not eGFP. This clearly
suggests that EIAV could be a superior to HIV as lentiviral vector system to be used in these
applications. The gagpol gene used in EIAV based lentiviral vectors is codon optimised and
independent of the rev for its expression thus facilitating lentiviral production by limiting the
number of plasmids utilized. Additionally, the LacZ reporter gene expression is driven by a
full enhancer-CMV promoter compared to the standard minimal-CMV promoter used in the
present study. These could possibly account for better quality of lentiviral preparation applied
in vivo and stronger transgene expression. However, no study involving direct in vivo com-
parison of these two systems has been reported so far. For this reason and in order to resolve
this a direct EIAV/HIV-1 rabies-G pseudotyped lentiviral vector comparison experiment was
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set up immediately upon these observations. Intrastriatal injections of both RVG pseudotyped
HIV-1 and EIAV vectors were performed and tissues are currently being analysed. Despite
this, repeating all in vitro and in vivo studies conducted so far and shifting to an EIAV based
system was not recommended at this stage mainly due to time constrains.
RVG-B2c pseudotype was used all way through as a positive control for assessment of retro-
grade transport in vivo, since RVG-EIAV vectors were the first proof of principle for retrograde
transport and delivery of therapy to MNs following intramuscular injection [82, 90, 51]. Absence
of transduction of spinal cord MN following intramuscular injection of RVG-B2c-HIV1 pseudo-
typed vectors in this study was particularly surprising. Results obtained from these experiments
differed from a previous study in the lab where successful MN transduction was reported. In
that study (conducted by Dr Stuart Ellison and Dr Antonio Trabalza), EGFP expressing HIV
vectors pseudotyped with either RVG (CVS-B2c strain) or hybrid (RVG/VSVg) envelope were
injected in the right gastrocnemious muscle of rats and mice (n=2 for each group). The titer
of the vectors injected was similar or a log lower to the ones used in the present study. More
specifically, 4 x 5 µl and 2 x 5 µl of vector (5.52 x 109 t.u./ml and 2.1 x 109 t.u./ml for CVS-B2c
and RVG/VSVg respectively) were injected in the right gastrocnemius muscle of rats and mice
respectively and EGFP expression was assessed in the lumbar part of spinal cords. EGFP
expression was detected only in a few sections of the RVG injected mice. More specifically 8
motors were transduced in the first animal while only 2 in the second one. However no EGFP
was detected in any of the RVG injected rats or in either of the hybrid injected rats following
immunohistochemical staining to enhance EGFP signal. This was the only study where we have
reported successful spinal cord MN transduction following intramuscular injection of RVG-B2c
pseudotyped HIV1 vector. Despite the success, MN transduction was observed only in mice
with the number of transduced motor neurons observed being considerably different between
the animals of the group. These results clearly indicated that variability exists within a group
of intramuscularly injected animals.
Taken these into consideration the total volume of the vector injected was the next to be
addressed. In the pilot experiments, presented here, in rat gastrocnemius muscle, a total of
24-25 µl of lentiviral preparation was initially delivered to single muscle. Three injections were
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performed per muscle and needle remained into the injection site for additional 1 min prior to
retraction, to avoid vector leakage. Despite the fact that the titer of the lentiviral preparations
injected in these experiments were within the same range as the ones used in the successful
studies metioned above (1 − 7x109 t.u./ml), the total volume injected was less, even half to
the one injected in these studies. Gastrocnemius muscle was injected with a total 50 µl (5x10
µ) in [82], which was raised to 90 µl and 120 µl (for both reporter and therapeutic trangenes)
injected in a group of muscles in functional studies [90, 165]. It is sensible that, the volumes
used in rescue experiments were by necessity large in order to treat multiple affected muscles
and reverse phenotype, but still the minimum volume reported in intramuscular delivery to rats
[82] was not less than 50 µl. Based on this, in the next set of in vivo experiments designed and
performed a total of 40 µl (8x5 µl) of both eGFP and LacZ expressing lentiviral preparations
were injected per gastrocnemius muscle.
Unfortunately, analysis of spinal cord tissue harvested from these animals did not reveal any
MN transduction indicative of retrograde delivery. At this point methodology followed for
tissue processing and immunolabeling was addressed. Absence of EGFP or LacZ expression,
indicative of MN transdcution, could be attributed to the fixation, staining/processing or vi-
sualization methods used in this study. Nevertheless, same fixation protocols and anti-EGFP
immunolabeling applied onto rat brain and spinal cord tissues harvested from rat injected with
VEEV-G pseudotyped lentiviral vector, in projects that were running at the same time in the
lab, resulted in successful labeling of transduced cells. Taken that the exact same protocol
was followed during tissue harvest, fixation, immunohistochemistry (same primary/secondary
antibodies adn dilutions), mounting and microscopy analyses, the possibility that failure to
detect transduction was due to poor experimental methodology had to be excluded.
Failure to report transduction could partially be attributed to the size of the muscle and to
the injection process itself. Gastrocnemius muscle is a large compact muscle. Additionally,
multiple muscle injections cannot by principle be accurate as far as the injection point and
depth is concerned while leakage of the injected vector due to possible piercing of the injected
muscle can also occur resulting in uneven distribution or even loss of the vector. In vitro
experiments in primary cell lines and MFCs have already confirmed the receptor specificity,
9.5. Discussion 241
internalization and retrograde trafficking of the targeted vectors. Moreover analyses of injected
gastrocnemius muscle tissue revealed transduction near or at the NMJ in an extent that affinity
for the neuromuscular junction could be claimed. It may however be possible that the vectors
are transducing muscle fibers near the injection site but due to the relatively big size of the
muscle, the amount of vector injected might not be sufficient to achieve desirable transduction
at the NMJ that will result in efficient motor neuron transduction. To address this and overcome
the relative big size of the rat gastrocnemius muscle, same in vivo studies preceded into mice.
9.5.3 In vivo intramuscular injections in mouse gastrocnemius mus-
cle
The specificity of the αp75NTR and αThy1.1 targeted vectors was a limiting factor in adapting
the injections into mouse gastrocnemius muscle. Since αp75NTR recognises and binds only to rat
p75NTR and not to mouse, it was not possible to proceed with any injections to mouse with this
vector. Fortunately, αThy1.1 targeted vector recognises and binds to Thy1.1 receptor, predom-
inantly expressed in rats, but also in some mouse strains among which is the FVB/NJ strain.
At this point αCAR was also incorporated into in vivo studies. Its broad species specificity
(recognises mouse, rat, human) makes this targeted vector the ideal candidate, though in order
to address the size and volume issue and refine the muscle delivery protocol followed in these
studies, its application was confined to mouse muscle. Total volume injected was kept stable at
24 µl per injected muscle, as in the previous studies, and transgenes assessed were for αThy1.1
and B2c-HIV-1 both EGFP and LacZ. Unfortunately, no transgene expression indicative of ret-
rograde delivery of these vectors to the spinal cord MNs was detected, for any of the lentiviral
preparations assessed (targeted vectors and positive controls). This was surprising especially
for the positive control vector B2c-HIV-1, which has been shown to transduce spinal cord mo-
tor neurons upon application to mouse hind limb muscles [86] and also to rat gastrocnemius
muscle (one study performed in our lab). More surprisingly, neither αCAR not CAV-2-GFP
(Canine adenovirus) vector (kindly provided by Prof. Eric J Kremer), resulted in motor neuron
transduction when applied to mouse gastrocnemius muscle at the same time. CAV-2 was con-
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sidered as positive control for validating the route of administration and receptor targeting, as
this vector has been proven to bind to CAR (coxsackie adenovirus receptor) [317, 318], traffic
retrogradely along MNs axons [210] and transduce spinal cord motor neurons upon application
to gastrocnemius muscle [249]. Since none of the positive control lentiviral vectors resulted in
any MN transduction, failure could not be attributed to the different pseudotyping approach
(utilizing surface engineering). It is evident that variability exists regarding the outcome of
intramuscular injections. It may however be possible that the vectors are transducing muscle
fibers near the injection site but have little binding affinity for the pre-synaptic terminals (as
has been reported for AAV vectors [319, 320]) to result in efficient motor neuron transduction.
According to the outcome of the trafficking experiments performed with all three targeted vec-
tors compared to non-targeted controls, this possibility can not be considered for the present
study. Results obtained from in vitro studies in MFCs, presented in previous chapter, clearly
demonstrated that all three αThy1.1 and αp75NTR and αCAR targeted lentiviral vectors were
competent to be retrogradely transported along rat motor neuron axons and successfully trans-
duce the soma of target cells upon binding to their target receptors located at the axon of the
motor neuron. More specifically it was shown that their trafficking occurs in certain reported
pathways followed by TeNT and p75NTR. Lack of results to demonstrate this in vivo can have
many explanations and has been decided to be addressed systematically.
9.5.4 In vivo bioluminescence (BLI) imaging in mice
To examine whether a possible transport of these targeted vectors and controls to CNS can be
detected and visualised in live mice a new approach that will allow visualisation of the spatial
and temporal distribution of the vector upon peripheral muscle application was set up at this
point. To achieve this, new lentiviral preparations, carrying the luciferase reporter gene were
prepared (Table 9.6) in order to be visualised in bioluminescence studies. In vivo imaging is a
widely used approach proven highly efficient to monitor real time activity of various substances,
including viral replication [312], in living animals. In the present study several factors that
could affect the experimental process had to be taken under careful consideration. Particular
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attention had to be paid regarding the depth from which the expected signal/light will originate
from. The wavelength of transmitted light/signal and the extend of diffusion, carry information
that correlates to the tissues depth of the the source. Therefore, although rats have been used
in several BLI studies, their relative large size, compared to mice, masks the detection of signal
originating from tissues deep within the body [306]. The major challenge of this study was
once more the route of delivery chosen to be examined. Although detection and monitoring
of signal at the level of the spinal cord has been reported before [311], there are no records of
any study attempting delivery through the neuromuscular junction to cells within the spinal
cord. Spinal cord tissue lies deep within the body which practically poses a difficulty regarding
the scattering of the light originating from any possible trangene expression by motor neurons
within the lumbar part of the spinal cord. For these reasons it has been decided to design
and perform the imaging experiment only in mice. Animals were injected similarly to previous
experiments and monitored weekly, in 3 time points. Injection of B2c-HIV-1-Luc vector in
both C75BL/6 and FVB/NJ mice (Figure 9.5) resulted in detection of a strong persisting
signal originating from transduced cells at the site of injection (right gastrocnemius muscle)
which persisted throughout the study. A signal originating from the equivalent level of the
spinal cord, was detected only in C57BL/6 mice when imaged supine. Interpretation of the
signals generated in this study was difficult, mainly due to lack of information around this novel
approach. Indeed, this study was the first to investigate this route of delivery in living animals.
Detection of this supine signal could partially be explained by the fact that the tissue laying
at the abdominal part of the animal is softer compared to the dorsal side. Additionally, the
skin colour on this side is lighter compared to the dorsal one. Both these reasons could affect
the scattering of the light originating from transduced cells deep in the body. However, the
strength of this signal was weak and non persistent, as it was not detected through out the study.
A possible reason could be either that expression in the tissue from which it originates is lost
overtime, or that the signal itself it too weak to be detected by the camera and/or is masked due
to camera saturation by the stronger signal originating from the injected hind limb muscle right
next to it. To address this, right leg was covered to prevent camera saturation. This approach
has previously been reported in other studies where a stronger signal originating from one
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site of the body was causing camera saturation and masking a weaker signal originating from
other tissues [311]. This adjustments allowed better view of the second signal, but still could
not give any information regarding its origin. Same signals (right gastrocnemius muscle and
a weaker in supine view) were observed in animals injected with the targeted vectors αThy1.1
(Figure 9.6) and αCAR (Figure 9.7). Application of FLIT 3-D reconstruction was particularly
useful in some cases (Figure 9.6), since it allowed clear distinction between the two signals and
localisation of the second one deep in the center of the body. Based on these observations
and due to lack of any background information, a more invasive approach was decided to be
followed in order to investigate the origin of the centrally located signal. In animals injected
with αCAR targeted vector, at day 21 (Figure 9.7) skin was removed and abdominal cavity
opened in order to directly expose the spinal cord. Imaging through this approach revealed
for the first time the presence of a signal originating from the spinal cord indicating presence
of transduced cells within the spinal cord as a result of retrograde delivery from the muscle.
Absence of spinal cord signal in animals injected with VSVG (Figure 9.8) and 5pl-non targeted
control (Figure 9.9) further enhanced the specificity of the signal detected in αCAR injected
mice. Surprisingly, in this study it was found that lymph nodes did also emit a signal, which
raised many questions regarding the distribution of the substrate (luciferin) and the possible
way by which molecules can be washed off through this route, as intramuscular delivery of the
virus could not account for transfer to this organ.
These results, demonstrated for the first time validation of the route in vivo and allowed the
observation and expression of the transgene dynamically upon muscle application. Despite the
success, this approach did not allow us to prove transduction of spinal cord MNs at a cellular
level, excluding possibility for quantification and thus limiting this study as a qualitative, non-
invasive approach of assessing the route followed upon muscle application of surface engineered
vectors.
Attempts to prove transduction at cellular level were made through immunohistochemistry
experiments. These experiments were proven to be extremely challenging as commercially
available antibodies against luciferase do not have the desired specificity. Moreover, luciferase
itself is not immunogenic and thus antibodies with high specificity are difficult to produce.
9.5. Discussion 245
The anti-luciferase antibodies used in this study (Rb anti-Luciferase, SIGMA; Rb pAb to
Firefly Luciferase, Abcam) were not proven to be specific. Protocols were modified in many
different ways. Different antibody dilutions were examined, Triton-X was excluded from the
permeabilization step (as over-permeabilization adversely affects staining), though non-specific
signal was observed in both positive and negative control tissue (right and left gastrocnemius
muscle respectively). Anti-luciferase staining was also attempted in non-fixed muscle tissue,
as it is reported that paraformaldehyde can diversely affect staining by over-cross-linking and
distortion of the tertiary structure of eGFP or luciferase proteins. Unfortunately attempts to
stain for luciferase failed once more.
Based on these observations this BLI approach was decided to be considered as a new, fast non-
invasive way of visualizing the spatial and temporal distribution of the vectors intramuscularly
injected.
9.5.5 Targeted gene transfer in vivo
Attempting gene delivery to the spinal cord via the NMJ has been a difficult process, primary
because of restriction posed regarding the route followed. In vitro experiments in primary
MN mass cultures and in MFCs, trying to mimic the in vivo scenario have proven highly
promising as all three targeted lentiviral vectors designed and engineered in this study were
able of specific retrograde trafficking and transduction of MN upon application to axonal tip
of these cells. Introducing novel properties for both surface engineered lentiviral vectors and
the receptors that they target. Despite the successful and promising in vitro results, the in
vivo application of this system has proven to be extremely challenging. Several adjustments
and optimizations were made in order address issues regarding the volume of vector injected,
the transgene used for detection of transduction and the size difference of the injected muscle
between species. Repeated in vivo applications leading to lack of retrograde transport and
transduction of spinal cord MNs led to concentrate all efforts of this study in application to
mouse muscles. In an attempt to further address the issues of the size of the injected muscle,
injections were attempted to a smaller muscle, the tibialis anterior (TA).
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TA is a smaller, less complex muscle, innervated by 140 motor neurons [312] compared to
gastrocnemius, which as reported above, is a group of muscles innervated by around 400 motor
neurons.
Differences in development, in terms of the neuromuscular junction and receptor clustering,
can be appreciated among muscles, which are maintained for maturity, and which, in this case,
could affect vector uptake. Some differences have been observed in the development of neuro-
muscular junctions and consequent alignment of presynaptic nerves with associated receptors
(i.e. acetylcholine receptor) during myogenesis [172]. Pun and colleagues have identified fast
synapsin muscles as tibialis anterior and delayed-synapsin muscles, as lateral gastrocnemius dur-
ing mouse myogenesis [314]. It therefore altering intramuscular delivery method and switching
to injection in TA muscle was considered as a better alternative for muscle administration of
the lentiviral preparations.
Application to smaller muscles has been reported in many studies [86]. In this study is reported
for the first time that application to the mouse TA of αCAR targeted lentiviral vector (Table
9.7) resulted in transduction of neurons within the lumbar cord region of the spinal cord (Figure
9.11). Co-labeling with ChAT identified these neurons as motor neurons and allowed to follow
transgene expression in MN cells for a series of 5-6 sections. A total of 7, non-overlapping, motor
neuron cells were found to be transduced within these sections. Unfortunately, variability
observed between animals, as spinal cord MN transduction was reported in only one out of
three mice injected with αCAR targeted vector, restricted these results to strictly qualitative
analysis. These results were by necessity qualitative as no quantification was possible. To an
extent it would be possible to calculate the percentage of transduction as a ratio for either the
maximum number of 140 TA motor neurons reported previously [312] or with the MN cells
labelled upon FASTBLUE injections. In the first instance the transduction achieved accounts
for 5% of the total MN population. In the second instance, taken that with FASTBLUE
upon TA intramuscular delivery (Figure 9.10), the number of MN labelled was 57.75±2.88,
and this defined the target population that can be accessed through that route, then the
percentage of transduced cells rises to approximately 11.6%. These results are comparable to
the one study reporting that gene transfer to mouse TA motor neurons with RVG-B2c-HIV-1
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lentiviral vector, upon TA muscle application resulted in 8-16% transduction of total TA motor
neurons [86]. Spinal cord motor neuron transduction observed and presented here, as a result of
CAR targeting and retrograde axonal transport upon intramusuclar application correlates with
studies involving CAR targeting. In these studies, where targeting of CAR was achieved via
CAV-2, retrograde transport and successful MN transduction was reported upon application to
gastrocnemius muscle [249].
Compared to the study presented here, Mentis et al., injected volumes ranging from 30 to
5 µl per muscle of similarly high titre Rabies-HIV-1 pseudotyped vectors. The important
difference from the current study is that always a combination of two muscles per mouse were
injected, each muscle at multiple sites, with various combinations of the following: quadriceps
and gastrocnemius, tibialis anterior and soleus muscles [86]. This can be taken into account
during optimization of αCAR vector for future applications.
There are several studies reporting successful retrograde gene therapy in rodents resulting from
combined muscle injections. These include studies in animal models of motor neuron diseases,
where delivery to combination of muscles is necessary to treat multiple affected muscles in order
to rescue or reverse the disease phenotype. More specifically, Wang et al., injected AAV vectors
into 4 limbs per rat, 2 gastrocnemius and 2 triceps brachii muscles for neuroprotective gene
therapy in ALS mice [321]; in another AAV study combination of triceps brachii, gastrocnemius
and muscles along the dorsal trunk were injected for neurotrophic gene therapy in ALS and
SMA mice [322, 323]. Moreover, Kaspar et al injected adenoviral vectors (AAV) into the
hindlimb quadriceps and intercostal muscles aiming to achieve IGF-1 gene therapy in ALS
mice [80]. Finally, as previously mentioned, a combination of muscles including hindlimb,
facial, diaphragm, intercostal and tongue muscles were injected with lentiviral vectors in many
studies for gene therapy of motor neuron disease in mouse models of motor neuron diseases
[90, 50, 51, 165]. It is thus clear that combined muscle application of lentiviral vector is needed
when it comes to in vivo gene therapy of disease models.
It has to be underlined that the current study focused on retrograde transport to motor neurons
and did not include the sensory neuronal pathway. This might require further investigation in
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the future, if absolute specificity to MNs needs to be confirmed. Transduction reported with
B2c-EIAV vectors was not MN specific as sensory neurons were also transduced [82], thus
assessment of sensory neuron transduction by αCAR will further validate the specificity of this
vector. Moreover in the current study, viral transduction was also observed at the injection
site (muscle fibers) with both αCAR targeted vector and 5pl non-trageted control, indicating
background transduction as a result of non-specific fusion of the envelope used in this study
(SINmu) with the muscle fibers (in the case of 5pl cotrol) or of interaction of the αCAR vector
with the CAR expressed on the surface of muscle cells. Expression of the viral transgene from
the CMV promoter in muscle fibers suggests that depending on future experimental objective
cell type-specific promoters may be required to limit transgene expression to certain cell types.
Though this was not the objective of this study.
EGFP, as an insert protein, can diffuse throughout the cell body but is unable to cross cellular
membranes to neighbouring cells. Absence of spinal cord MN transduction in the animals
injected with 5pl non-targeted control vector, ruled out the possibility of EGFP transport
from transduced muscle fibers (reported with both αCAR and 5pl at injection site) to motor
neurons. Studies of Kaspar et al, where VSVG pseudotyped lentiviral vectors were applied
to muscle, resulted only in efficient EGFP expression in the muscle (injection site) but not in
motor neurons [80]. Same was observed here with 5pl non-targeted control. Moreover, in vitro
assessment of retrograde transport and trafficking in MFCs revealed that only targeted vectors
can traffic retrogradely and transduce the soma of MNs (Figure 8.6), while no trafficking or
transduction is reported for 5pl or VSVG pseudotyped vectors (Figure 8.7). Therefore it can
be concluded that EGFP expression observed in motor neurons upon TA injections requires
the retrograde transport of the vector, which in this case is facilitated by the interaction of the
anti-CAR antibody with its target receptor CAR.
Regardless of the success, the transduction efficiency reported here, with αCAR targeted lentivi-
ral vector is lower compared to transduction resulting from retrograde transport of either B2c
pseudotyped-EIAV or AAV vectors. These observations, together with the absence of MN
transduction upon intramuscular delivery of B2c-HIV-1 lentiviral vectors and the variability
reported regarding the transgene expression in mice injected with αCAR targeted vector but
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also in mice injected with RVG-B2c-HIV-1 vectors (previous study Ellison and Trabalza), could
be attributed to the injection process itself and the route of administration. The possibility
that these vectors might have difficulty to access the neuromuscular junction when injected
intramuscularly (or at least at inadequate levels to produce a detectable signal) could be an
explanation for the variability observed between animals within the same group. The presence
of a potent barrier at the site of injection may prevent the uptake of these vectors. Indeed,
presence of a ’perisynaptic barrier’ is reported in several studies (reviewed in [324]). Cell bod-
ies and their dendrites of motor neurons and certain other subset of neurons (as GABAergic
interneurons) in the mature brain and spinal cord possess intensely negative charged perineu-
ronal or perisynaptic nets of proteoglycans which are linked by collagenous ligands to nerve
cell surface glycoproteins. These perineuronal proteoglycans may entrap tissue fluid, form-
ing a ”perisynaptic barrier”, a gel layer surrounding/protecting the synapses which are the
fundamental functional unit of the nervous system (reviewed in [324]). Degradation of the per-
ineuronal proteoglycans by treatment with chondroitinase ABC or hyaluronidase is reported
to reactivate the neuronal plasticity and promotes the functional recovery of a severed nervous
system (reviewed in [324]). It is therefore worthy to consider this approach in future attempts
to resolve/overcome the issues associated with application of our targeted vectors and controls
into the muscle. Nevertheless, there are always potential pitfalls associated with the in vivo
intracellular trafficking of the targeted vectors which can lead to negative results.
Another possible explanation could be the strength of the transgene’s expression, which in the
present study is regulated by an upstream minimum CMV promoter. Direct comparison of the
sequence of the CMV promoter utilised in the transfer vector HIV-1 plasmid used in this study
with the CMV promoter utilized in EIAV transfer plasmid in the successful studies mentioned
above [82, 90, 50, 51, 165] revealed an 500 bp difference, which correspond to the full sequence
of the enhancer used in these studies.
For this reason, the full enhancer CMV promoter (GenBank GQ872121.1) has been gener-
ated and cloned into the HIV-1 transfer vector plasmid utilised in the lab. Injections with
αCAR where transgene expression is driven by FULL enhancer CMV promoter are currently
in progress. Results that will be obtained will be useful for future functional experiments.
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9.5.6 In vivo application to the rat brain
Application of the targeted vectors and control into the rat brain was a relatively small part
of this study. Delivery of all three targeted vectors to the rat striatum was performed in an
additional attempt to further investigate their tropism in vivo and investigate their ability to
be retrogradely transported. Moreover this approach was considered a possible way to obtain
additional information regarding the tropism of especially αThy1.1 and αp75NTR targeted vec-
tors, for which retrograde trafficking has only been validated in vitro. Although the number
of animals injected per group were n=3, due to time constraints the results presented in this
study are the outcome of analysis from only 1 animal per group. For this reason, this study can
only be judged qualitatively and informative as low number of animals analysed did not allow
for proper quantitative analysis and making the proper conclusions. RVG and RVG derived
pseudotyped HIV-1 lentiviral vectors were the term of comparison in this study, to evaluate the
ability of retrograde transport for each of the three engineered vectors. Among the receptors
that the targeted vectors recognise and bind to was the p75NTR, which is a common target
for both RVG and αp75NTR vector. Transduced cells at the site of injection (striatum) were
observed for all three targeted vectors and non-targeted control. Intrastrial injections of this
targeted vector revealed that it transduced at the same extend both neurons and astroglia. This
might have accounted for poor pre-synaptic terminal targeting of SN dopaminergic neurons.
The same explanation could apply for αCAR which despite showing considerable affinity for
neurons, it still transduced a small amount of astroglia. Interestingly enough, αThy1.1-targeted
vector appeared to have the highest specificity for striatal dopaminergic neurons giving only
marginal astroglial transduction. Moreover despite the fact that all vectors achieved retrograde
transduction of mytral cells of the olfactory bulb (Figure 9.13), none of them has shown signifi-
cant transduction of dopaminergic neurons of pars compacta of the substantia nigra. Compared
to previous studies, anti-Thy1.1 antibody injections (the antibody that is used on the surface
of αThy1.1 vector for targeting) were shown to be axonally trasported both retro- and antero-
gradely upon injection to the caudate nucleus of the rat [229]. Given its wide distribution
throughout the brain (from olfactory bulb to brain stem) and predominantly in neurons [227],
it is not surprising that αThy1.1 vector was the one transducing SN dopaminergic neurons
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with high specificity compared to the rest. As far as αCAR is concerned, is has previously been
reported that CAV (which is binding to CAR), upon injection into the rat striatum, can be
transported throughout the striatum to afferent structures such as the cortex, the substantia
nigra, and thalamus [249]. Here, less extended distribution of αCAR, is difficult to be explained
given that results are derived from only one animal. The possibilities of either poor retrograde
transport of this vector in the brain or limitations posed by HIV-1 vectors used in this study
compared to adenovirus used in other studies, are areas that should be considered for further
investigation.
Noticeable transduction at the injection site was observed for 5pl-nontargeted vector, report-
ing once more (similar to the muscle injections) non-specific transduction with this mutated
envelope possibly as a result of application of a high-concentrated lentiviral preparation at the
injection site. In all cases definite conclusions regarding the tropism of these vectors in the rat
brain cannot be drawn given the small number of animals analysed by now. Total numbers of
animals from all groups in this study should be analysed and careful quantification is required
prior to determining the in vivo tropism of these vectors following striatum application.
Chapter 10
General Discussion
Gene therapy vectors developed from the Lentiviruses, and in particular Human Immunodefi-
ciency virus (HIV-1), have been shown to be efficient tools for the transduction of transgenes
into mammalian cells [325, 27]. Pseudotyping lentiviral vectors with specific viral glycoproteins
allows the targeting of these vectors to specific cell populations. Rabies virus glycoprotein pseu-
dotyping enables retrograde axonal transport and access to distal areas of the nervous system
after peripheral administration [82]. This makes lentiviruses a particularly attractive vector for
use in gene therapy of motor neuron disease, since it allows a non-invasive administration of
the vector by targeting the peripheral sites of neuromuscular synapses in order to ultimately
reach of the affected central nervous system. A barrier to the clinical use of RVG pseudotyped
lentivirus vectors though, is the relatively low efficiency of transduction displayed by these vec-
tors when applied in non-human primates (NHPs) (unpublished data). Recently, attempts to
improve this system-involved modification of the envelope proteins. In our lab and others have
shown that generation of hybrid enveloped vectors by fusing envelope glycoproteins composed
of parts of RVG and VSVG [315, 326], can confer higher rate of retrograde gene transfer extend-
ing the range of potential applications in the field of neuroscience. Despite several successful
in vitro viral vector systems designed and available up to date, absolute cell type specificity
has not been achieved, while the development of a targeting vector for efficient gene delivery
both in vitro and in vivo appears to be much more difficult [327, 328]. Over the last decade,
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cell-specific targeting strategies have concentrated on surface engineering of envelope proteins
by mutating the natural receptor sites and inserting cell-specific ligands (i.e. antibodies) into
the viral GP. Targeting systems available to date involve, among others, antibody-mediated
specific binding methods based on (i) molecular events of receptor binding and endocytosis fol-
lowed by fusogen induced pH dependent membrane fusion [93, 94, 95, 96] or (ii) active vector
and target cell membrane fusion [97, 98, 99].
The targeted lentiviral vectors developed during this study can be particularly useful for mini-
mally invasive administration of the vectors by targeting the peripheral sites of the neuromus-
cular synapse in order to ultimately reach the affected CNS. This study was based on incor-
porating membrane bound antibodies against presynaptic terminal receptors Thy1.1, p75NTR
and CAR on the surface of lentiviral vectors pseudotyped with modified Sindbis GP [94]. The
results presented in this study indicate that these newly engineered targeted lentiviral vectors
bear novel trafficking and transduction characteristics and specificity for MNs, superior to ones
observed with existing lentiviral vectors, which make them good candidates for non-invasive
CNS therapy for ALS.
10.1 Engineering targeted lentiviral vectors
In the present study mouse/human chimeric membrane bound antibodies against presynaptic
terminal receptors Thy1.1, p75NTR and CAR were engineered and incorporated on the surface
of lentiviral vectors to achieve targeting to NMJ. This involved PCR amplification and cloning
of heavy and light chain variable regions for all three antibodies used for targeting. Cloning of
antibody variable regions from antibody producing cells, without any prior information about
the amino acid or nucleotide sequence, has proven to be particularity challenging. Several
approaches were attempted to amplify V regions of these three antibodies. The most critical
part of these experiments was the selection and application of the right set of primers. PCR
amplification based on degenerate oligonucleotides, or on redundant primers hybridizing within
the leader sequence of the framework regions (FRs) at 5’ end of antibodies in combination
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with C region primers [280] was attempted several times. Issues commonly related with these
approaches involved amino acid changes within framework regions, which might diversely affect
antigen binding, or introduction of substitutions within the leader sequence that could affect
antibody processing and secretion. Extensive study and research around antibody V region am-
plification resulted in using an alternative approach based on 5’RACE PCR technology, where
the forward degenerate primers were replaced by a universal primer mix, which allowed success-
ful amplification of heavy and light chain V regions and provided full information regarding the
target sequence. A problem frequently encountered during V region PCR amplification was the
presence of aberrant transcripts, originating from the non-secretor partner of the hybridoma,
which resulted in non-functional L chain protein. There are certain methods available to use in
order to avoid this transcript. In the present study all positive clones from PCR reactions were
carefully scanned for presence of these aberrant transcripts. Successfully amplified, functional
V regions for all three antibodies were cloned upstream human constant regions in pαCD20 vec-
tor [93] to generate mouse/human chimeric anti-Thy1.1, anti-p75NTR and anti-CAR antibodies
used for targeting. Of high importance during cloning of antibody sequences is the careful
assessment of its signal peptide. The presence and location of signal peptide cleavage sites in
the amino acid sequence of the V regions of these three antibodies was confirmed upon analysis
with TargetP and SignalP3 tools [276]. Careful analysis of both signal peptides and antibody
V region sequences, and comparison with previously published sequences, amplified with the
same way [93], revealed the presence of a human in place of a mouse leader/signal peptide
sequence. Indeed in Yang et al., [93], the initially amplified mouse leader peptide, originating
from the hybridoma used in each study, was replaced by a human leader peptide, to achieve
better expression and secretion during lentiviral production in the human HEK 293T cell line.
However, direct comparison of human and mouse leader peptides and their downstream effect
in antibody production and secretion, has not been reported so far. In this study, the human
leader peptide sequence used in [93] was cloned upstream V region of anti-p75NTR sequence and
lentiviruses bearing either of the two versions of this antibody (with a mouse or a human leader
peptide) were compared. Comparison revealed an increase (around 12%) in incorporation of
membrane bound antibody molecules on the surface of lentiviral vectors (Figure 6.12 C) which
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subsequently led to an increase in transduction efficiency. During design for replacement of
leader peptide sequences attention should be paid in preserving the cleavage sites, essential for
proper processing and secretion of the mature antibody.
10.2 Targeted lentiviral particle production
Production of targeted lentiviral vectors pseudotyped with membrane bound antibodies was
proven to be challenging. Generation of these lentivectors is highly demanding since it involves
a six-plasmid co-transfection production protocol. Despite the difficulties and using upon exten-
sive experimentation the plasmid ratio reported in [93], it was possible to consistently produce
targeted lentiviral vectors with high titer values, ranging between x109-1010 t.u./ml, throughout
this study. High titer lentiviral preparation were proven to be particularly useful for both in
vitro and in vivo experiments. The quality of lentiviral preparations was constantly assessed.
Both western blot analysis and single particle imaging were proven informative regarding the
presence and distribution of the two key molecules (surface antibody and fusogenic protein)
within a given lentiviral preparation. Utilizing labeling techniques, it was possible, as previ-
ously described [284], to fluorescenlty label the two key components of the system and visualize
individual vector particles. A potential limitation to this analysis is the presence of viral aggre-
gates which upon fixation and immunolabeling are difficult to analyse. However, single plate
lentiviral preparations and extensive pipetting during viral resuspension can overcome this
problem during analysis. This approach allowed for determination of the percentage of virions
within a given lentiviral preparation, that co-express the antibody and the fusogen molecules.
Despite the high titer values reported, it had to be taken into account that within a targeted
lentiviral vector preparation only 40-50% of the particles produced had the potential to induce
targeted cell transduction. This was considerably lower to previous reports were around 70% of
the virions analysed co-displayed this two molecules [284]. However, in that study, given that
smaller fields were used for quantification and no description was given regarding the exact
quantification process, did not allow for direct comparison with the particles produced here.
Moreover it had to be taken into account that in these vectors, the constructs encoding for the
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membrane bound antibody had a human leader peptide sequence, compared the ones analysed
in this study which had a murine one. This could possibly account for better processing and
secretion during lentiviral production which possibly resulted in more efficient display of anti-
body molecules on the lentiviral surface. To address this, altering the murine signal peptide
sequence of the p75NTR antibody used for targeting, to match the origin of the producer cell
line (human leader peptide sequence) was attempted and shown to increase the incorporation
levels by 12% (Figure 6.12 C). This gives a possibility to further improve these vectors for
future studies. However, even with a small percentage of potent active lentiviruses (40-50% of
total particles) the in vitro targeted transduction reported by these vectors was considerably
efficient. This opens the possibility to further improve our system in future studies.
10.3 In vitro targeted transduction
Transduction efficiency of these vectors was initially assessed in vitro on a panel of target cell
lines. During optimisation and setting up of the transduction experiments, considerably diffi-
culty was faced during replication of experiments with αCD20 targeted vector [93]. Replication
of the original experiment [93], on various B cell lines, as a proof of concept prior to assessing
the newly engineered vectors, was proven to be difficult. Several experiments were performed
and infection conditions adapted to match the original ones (spin-infection of B-cells CD20+
with similar titer αCD20 virus), to finally achieve transduction in Granta-510 cells (Figure
5.1). Unfortunately the maximum transduction achieved (2.9%) was considerably low com-
pared to the one reported by Yang et al., , where 52% of target cells were transduced. This
observation raised questions regarding the ability to reproduce the method. Despite the diffi-
culty, it had to be taken into account than in the original study the target cell line was 293T
cells modified to stably express CD20 receptor (293T/CD20), while in the target cell line used
here CD20 receptor was naturally expressed. Transducion reported during initial experiments
with newly engineered targeted vectors was too low, thus considerable efforts were made to
enhance transduction efficiency of these lentiviruses. Improving the transduction efficiency of
these vectors concentrated on three fronts: optimisation of lentiviral production to achieve high
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titer lentiviral preparations, refinement of infection process and improvement of fusogenicity.
On this front, spin infection was proven to be beneficial for enhancing transduction efficiency,
though it was observed that depending on the cell line (more or less refractory to transduction)
and the targeted vector used, spin infection could be omitted (i.e. αCAR targeted vector).
It could be claimed that through spin-infection there is a possibility of forcing the system to
work. However this was not the case, as in transduction experiments where normal infection
(without spinning) was used instead, efficient transduction was also observed. In an attempt
to improve fusogenicity, and possibly enhance endosomal escape, a panel of different versions
of the fusogenic molecule SINmu were assessed. Lei et al., have introduced specific mutations
into the fusion domain of the binding-deficient SINmu to generate several FMs which were
reported to have a broader pH range that resulted in increase in transduction efficiency [94].
Three different versions of SINmu were assessed (Figure 5.4) and the one resulting in higher
transduction was chosen to be used for subsequent experiments. These experiments allowed to
conclude to the final version of the targeted vectors produced, which were pseudotyped with
SINmu (SGN).
Unlike previous studies, where transduction efficiency was assessed in cell lines generated to
stable over-express the target receptors [93, 284, 98, 99, 285], in this study the target cell lines
used were naturally expressing the target cell-surface molecules. This by necessity required the
use of higher MOI. Since the ultimate target were receptors expressed at the NMJ, target cells
used in in vitro transduction experiments were carefully selected to resemble partners of the
NMJ. Transduction efficiency varied between different cell lines possibly due to abundance of
target receptors. The targeted vectors demonstrated at least five to ten orders of magnitude
lower transduction rates on off-target cells, demonstrating a higher degree of gene transfer
specificity (Figure 6.1). Consistently, no off-target transduction was detected from control
vectors. Importantly, if the transduction observed was not the consequence of specific antibody-
antigen interaction, then it would have been expected to observe similar or at least comparable
levels of transduction with negative control vectors (αCD20 and 5pl), as they possess different
or no specificity for the target receptor.
Specificity was further confirmed through a series of competition assays where, similar to other
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studies [93, 94, 97], the target cells lines were incubated with targeted vectors and controls in
presence of increasing concentration of soluble blocking antibodies and isotype controls. It was
observed that in presence of soluble antibody with specificity same to the antibody expressed by
the targeted vector assessed each time, transduction efficiency was decreased, while was slightly
or not affected when isotype control was present (Figure 6.3). Effect of blocking antibody
on transduction efficiency was also assessed in comparison to non-targeted control (Figure
6.4), where presence of either blocking or isotype control antibody, at any concentration did
not affect the transdcuction observed by the non-targeted vector, which was at all times at
low background levels. A major difference between the competition assays performed in this
study and the ones in the previously publish reports [93, 94, 97], was that considerably higher
concentration of soluble blocking antibody was needed in order to observe efficient block in
transduction. This could be attributed to either the avidity of the antibodies used each time,
or the abundance of surface receptor which compared to stably expressing cell line, were less
and thus the competition effect did not affect the transduction immediately.
A limitation of the targeted vector system described and extensively assessed in this study was
the use of monoclonal membrane bound antibodies for targeting. As an attempt to further im-
prove the system for in vivo applications, ScAb version were utilised to pair with SINmu(SGN).
Based on previous reports [95], ScAb have been engineered for αp75NTR and αCAR. In this
system heavy and light chain variable regions are connected through a GS linker, fused to a
hinge region of human constant region and anchored on the lentiviral surface through a trans-
membrane domain. Thus, incorporation and expression of antibody molecule on the lentiviral
surface, does not require the presence of accessory proteins Igαβ, immediately reducing the
number of plasmids required for vector production, and possible increasing the percentage of
effective particles. The targeting specificity of these versions was evaluated. Indeed, an increase
in transduction efficiency was observed, though this was not significantly higher to the levels
achieved before with membrane bound antibodies (Figure 6.12) and varied according to the
target cell line used. Unlike to ScAb, replacement of murine leader peptide with a human one,
significantly improved both transduction efficiency (Figure 6.12 A) and surface incorporation
of the antibody molecule (Figure 6.12 C). These observations suggested that there is room for
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improvements to be made in future, if required. For time constrains, the assessment of all
different versions both in vitro and in vivo, was not possible to be accomplished in the context
of this study.
10.4 Targeted transduction of primary MNs
Spinal motor neurons (MNs) have been the object of extensive study utilizing in vivo models,
though their detailed study in vitro has been hindered by the cellular complexity of spinal cord
and the difficulties involved in obtaining consistently pure motorneurons in culture. Isolation
and successful maintenance of primary spinal cord motor neurons in culture can be utilized to
extend transduction studies to a system that could mimic the in vivo scenario of motor neurons.
Application of the three newly engineered vectors to these cultures provided useful information
regarding their tropism and targeting specificity in a state, resembling the in vivo arrangement
of the target cell population. Targeted vectors produced in this study, upon application to
MNs, were observed to selectively transduce MNs in presence of astrocytes (Figure7.5) in these
mixed cultures. Comparing the results from application of these surface engineered vectors to
mass cultures to previous application of VEEV and VSVG pseudotyped vector, performed in
our lab, [295] it is clear that their tropism to motor neurons is significantly higher compared
to the astrocytes. Surface engineered lentiviral vectors were assessed on the primary motor
neuron cultures for the first time in this study. Targeting of p75NTR and Thy1.1 receptors in
primary cultures has not been reported so far. Recently preferential neuronal transduction has
been demonstrated by canine adenovirus (CAV-2). This neuronal targeting assessed both in
vitro, in primary neuronal culture (MN examined as well) and in vivo was attributed to CAV-2
association with CAR (coxsackie adenovirus receptor) expression on neuronal cells [249].
However, application to mass cultures could only provide information regarding the transdution
efficiency and specificity of each preparation without examining the ability of the engineered
vectors to move retrogradely along the motor neuron axon and achieve transduction of the
soma. Studying trafficking of mature HIV-1 particles is a difficult process. The endocytic
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trafficking route followed by different pseudotyped virions may vary depending upon which
part of the axon the vector undergoes internalisation. Growing motor neurons in microfluidic
chambers (MFC)[212] is an efficient way of assessing this, as these inserts allow separation of
somas, axons and axon terminals. A number of complimentary labelling techniques can be
utilized to visualize receptor and vector entry and trafficking.
Extensive studies in motor neurons has revealed an elegant process by which proteins within the
extreme distal part of the axon can undergo retrograde trafficking to the soma, a process first
identified as a mechanism for allowing extracellular signals at the axon tip to be transmitted
to the cell body through these retrogradely trafficked signalling endosomes [301]. This process
has been best characterised for the p75NTR and as with many endosomal processes involves the
trafficking of the receptor through Rab5 positive endosomes and accumulation in Rab7 positive
endosomes [208]. These endosomes undergo microtubule-mediated axonal transport towards the
cell soma, in a process driven by the microtubule motor myosin Va [195]. In addition to p75NTR,
this pathway has been shown to mediate the transport of a number of adhesion molecules
(ALCAM, NCAM) [214], neurotoxins (botulinum, tetanus) [212], and viruses such as canine
adenovirus 2 (CAV2) and its receptor CAR [210]. Moreover, labelling with the recombinant
binding fragment of TeNT (HC) can be used to extensively monitor internalisation and axonal
retrograde transport in many neuronal types [206], allowing the quantitative analysis of these
trafficking processes both in vitro and in vivo [207, 305, 208].
In this study it was shown that, αp75NTR-, αThy1.1- and αCAR-targeted vectors upon inter-
action with their target receptors are retrogradely transported along motor neuron axons and
transduced the soma of MN cells. Trafficking was characterized and reported within carriers
associated with either one or both TeNT HC and p75NTR. In contrast to CAR and p75NTR,
internalisation and transport of Thy1 has not been demonstrated, yet other adhesion molecules
such as LgCAM and NCAM were shown to internalise and traffic in motor neurons [214]. Re-
sults obtained in these compartmentalized cultures were highly promising since they confirmed
the initial hypothesis that the vectors engineered, do target receptors, which internalise and
traffic along the motor neuron axon. Lack of trafficking events both in fixed and live imag-
ing studies and absence of transduction with non-targeted 5pl control and VSVG pseudotyped
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lentiviral vectors, further support the validity of our retrograde trafficking results for the tar-
geted vectors.
Interestingly, during these studies, these targeted vectors appeared to be more efficient than
wild type RVG-pseudotyped-HIV-1 viruses in trafficking and more specific in transduction of
MN cells in vitro. This could partially be attributed to the envelope used for pseudotyping,
which has been reported to allow efficient endosomal escape [94], as well as to the endosomal
compartment in which these vectors are travelling into. Studies performed in our lab investi-
gating RVG-pseudotyped-HIV-1 vector trafficking and transduction in primary MNs cultures
report inefficient transduction with this vector (Hislop et al., in review). In these studies it was
shown, through labelling for acidic endosomes (Lysotracker labelling, Hislop et al., in review),
that RV-G axonal transport is happening within non-acidic Rab7-positive endosomes. It is
likely that the neutral pH is instrumental in the transport of intact lentiviral vectors, since
acidic environment would trigger the conformational change in the RV-G mediating fusion of
the viral envelope with the membrane of the endosome, thus allowing endosomal escape of
the viral capsid [200]. As such, the neutral environment prevents endosomal escape, allowing
transport of the vectors to the soma, where fusion occurs and the capsid can enter the nucleus
and integrade into the genome. For RVG, it was constantly observed that although exten-
sive retrograde transport of vectors was detected both in mass and MFCs, no transduction of
neurons was detected when incubated under the same conditions enabling axonal retrograde
transport. These observations were similar to data previously observed with VEEV-G pseudo-
typed HIV vectors [295], which showed retrograde transport in culture but very little retrograde
transduction in vivo. This suggests that targeting for efficient retrograde transport is not the
only requirement for transduction of MNs, and other post-trafficking factors are crucial for this
process. These are more likely to include the ability of the envelope used for pseudotyping
to promote fusion when the endosome does reach the soma, and the molecular processes that
allow the transport of the capsid to the nucleus.
Observations for both RV-G and VEEV-G were opposite to the results presented here for
the three targeted vectors, where both retrograde trafficking and transduction of soma was
repeatedly reported. Trafficking studies initially performed for SINmu [284], shed some light
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on the endocytic mechanisms of these engineered lentiviruses regarding the virus-endosome
fusion and endosomal transport. Studies using endocytic markers suggested that transport and
maturation steps occurred into an intermediate endosome while the endosomal fusion of SINmu
enveloped viruses started at an early stage of the endocytic pathway. However virus-endosome
fusion occurred before microtubule-associated movement. Unlike the rabies virus, these vectors
do not interact directly with motor transport proteins (dynein), and is possible to be destroyed
by proteases if released too early. Moreover experiments on the fusion kinetics of this envelope
compared to VSV-G pseudotypes revealed that SINmu fusogen-mediated membrane fusion is a
long process, remarkably more slower than that of VSV-G, possibly attributed to the separation
of the functions of binding and fusion into two individual molecules in this system [284]. Further
engineering of the fusogen molecule, related to mutations in the E1 domain of the fusogenic
molecule, designated as SGN, SGM and AGM (which differ from the original SINmu by three
amino acids) was proven to result in broader pH range of these vectors, which allowed for better
and faster membrane fusion and consequenlty more efficient endosomal escape [94].
Application of surface engineered vectors pseudotyped with this fusogen, to neurons and assess-
ment of retrograde transport has not been attempted. Hence for the first time this study reports
the trafficking properties and efficiency of surface-engineered vectors in a system mimicking the
in vivo scenario and shows that these targeted vectors can be retrogradely transported and
transduce the soma of motor neurons. In the trafficking experiments, the mutated fusogen
chosen (SGN, [94]) resulted in enhanced transduction efficiency, compared to RV-G, both in
immortalised target cell lines in vitro and also in mass and MFCs primary MNs cultures, proba-
bly due to improved and more efficient endosomal escape upon transport to the soma. However,
association with endosomal (i.e.Rab5 and Rab7), or assessment of the endosomal compartment
(pH through lysotracker) have not been investigated in this study. These and other processes
will be an interesting area of future studies with the goal of understanding the differences
observed compared to other envelopes and improving efficacy of lentiviral gene therapy vectors.
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10.5 In vivo gene transfer
Theoretically, gene transfer to upper and lower motor neurons can be achieved either by di-
rect injection into the brain and spinal cord, remote delivery utilizing a vector that can be
retrogradely transported or by ex vivo gene transfer. To study the in vivo function of these
newly engineered vector, all three αThy1.1, αp75NTR and αCAR targeted vectors have been
intramuscularly injected into rat and mouse leg muscles.
Attempting gene delivery to the spinal cord via the NMJ has been a difficult process, primary
because of restriction posed regarding the route followed. Despite the successful and promising
in vitro results in MFCs, the in vivo application of this system has proven to be extremely
challenging. Several adjustments and optimisation were made in order to address issues re-
garding the injection method, the volume of vector injected, the transgene used for detection of
transduction and the size difference of the injected muscle between species. Repeated in vivo
applications leading to lack of retrograde transport and transduction of spinal cord MNs led to
concentrate all efforts of this study in application to mouse muscles. In an attempt to further
address the issues of the size of the injected muscle, injections were finally attempted to the
tibialis anterior (TA) a smaller, less complex muscle, innervated by 140 motor neurons [312].
Upon several in vivo attempts with all three targeted vectors, intramuscular injection of the
αCAR targeted vector into mouse tibialis anterior (TA) resulted in transduction of correspond-
ing motor neurons in lumbar spinal cord (Figure 9.11). A total of seven (7), non-overlapping
motor neuron cells were found to be transduced within 6 (50µm thick) sections. However, the
variability observed between animals, as spinal cord MN transduction was reported in only one
out of three mice injected with αCAR targeted vector, restricted these results to strictly qual-
itative analysis. To an extend it would be possible to calculate the percentage of transduction
found, which account for 5% of the total MN population, or to 11.6% of the number of MN
traced with FASTBLUE labelling. These results are comparable to the one study reporting
that gene transfer to mouse TA motor neurons with RVG-B2c-HIV-1 lentiviral vector, upon
TA muscle application resulted in 8-16% transduction of total TA motor neurons [86]. The dif-
ference from our study was not only that always a combination of two muscles per mouse were
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injected, each muscle at multiple sites, with various combinations of the following: quadriceps
and gastrocnemius, tibialis anterior and soleus muscles [86], but more importantly the age of
animals injected. In contrast to the single intramuscular injections of αCAR targeted vector
in TA muscles of adult mice performed here, all intramuscular injections reported in [86] were
performed on postnatal P12 mice. It is thus clear that delivery of similar volumes of vector
in considerably smaller muscles could be beneficial for muscle targeting and subsequent re-
strograde delivery of the vectors and transduction of spinal cord motor neurons. The results
presented in the current study provide a clear advantage of the system proposed here over RVG-
B2c-HIV-1 lentiviral vectors presented in [86], since similar transduction efficiency is reported
upon intramuscular administration of our targeted vectors in a single muscle (only TA) of adult
mice (not P12). Our results are promising and should be validated in a larger cohort of animals
and possibly in younger animals. Moreover spinal cord motor neuron transduction reported
with αCAR targeted vector, as a result of CAR targeting and retrograde axonal transport
upon intramusuclar application correlates with studies involving the same receptor, though
with CAV-2, where retrograde transport and MN transduction was shown upon application to
gastrocnemius muscle [249].
In the future, care should be taken regarding the intramuscular application of RVG-B2c-HIV
vectors. Retrograde transport and transduction of spinal cord motor neurons upon intramus-
cular delivery of RVG-B2c- pseudotyped-HIV-1 lentiviral was proven to be inconsistent in our
hands. All intramuscular delivery in vivo attempts performed in this study with this pseu-
dotype, both in rats and mice failed to report transduction of spinal cord motor neurons.
Regardless of the several efforts made to address possible barriers such as size of muscle in-
jected and volume of vector delivered per target muscle, as well as reporter gene utilised to
evaluate transduction, absence of MN transduction was reported at all times. Only in one
study performed in our lab where B2c-HIV-1 lentiviral vectors were intramuscularly delivered
to mouse gastrocnemius muscles, we were able to report around 13.64 ± 9.64 % transduction
of lumbar spinal cord motor neurons (Dr Antonio Trabalza and Dr Stuart Ellison). Given that
the titer of the lentiviral preparation utilized in that study was similar to the ones utilized in all
in vivo applications described here and that no modifications were made to either the protocol
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or plasmids used for production of these lentiviral preparations it is clear that high degree of
variability is associated with intramuscular injections. Variability was also reported regarding
the transgene expression within the same group of mice injected with αCAR targeted vector,
where MN transduction was observed in only one out of three animals. This could partially be
attributed to the injection process itself. Muscle injections can not by principle be that accurate
and precise as far as the injection point and depth is concerned. Despite the efforts made in this
study to refine the injection process in order to limit the variability introduced from multiple
muscle injections, differences in transgene expression within the same group of animals could
not be eliminated. This was more evident with applications into the gastrocnemius muscle,
where apart from one study, all other attempts did not result in MN transduction. Taking into
account that, as far as the RVG-B2c-HIV1 lentiviral vectors are concerned, retrograde transport
and transduction of distal cells has repeatedly been reported upon intrastriatal application of
these vectors [315], questions are raised regarding the efficiency of the route of administration
followed in this study. Moreover, in all intramuscular administrations of the targeted vectors
and the positive control vector RVG-B2c-HIV1, transduction of muscle fibres at the injection
site was always observed. Considering all these, it is possible that these vectors might have
difficulty to access the neuromuscular junction when injected intramuscularly (or at least at
inadequate levels to produce a detectable signal).
The presence of a potent barrier at the site of injection may prevent the uptake of these vec-
tors. Indeed, a ”perisynaptic barrier” is reported in several studies (reviewed in [324]). Cell
bodies and their dendrites of motor neurons and certain other subset of neurons (as GABAergic
interneurons) in the mature brain and spinal cord possess intensely negative charged perineu-
ronal or perisynaptic nets of proteoglycans which are linked by collagenous ligands to nerve
cell surface glycoproteins. These perineuronal proteoglycans may entrap tissue fluid, forming a
”perisynaptic barrier”, a gel layer surrounding/protecting the synapses which are the fundamen-
tal functional unit of the nervous system [329]. Degradation of the perineuronal proteoglycans
by treatment with chondroitinase ABC or hyaluronidase is reported to reactivate the neuronal
plasticity and to promote the functional recovery of a severed nervous system (reviewed in
[324]). Indeed, hyaloronidase has been reported to increase the biodistribution of acid α-1,4
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glucosidase in the muscle of Pompe disease mice [330]. Pompe disease (glycogen storage dis-
ease type II) is a glycogen storage disease caused by a deficiency of the lysosomal enzyme, acid
maltase/acid α-1,4 glucosidase (GAA). Enzyme replacement therapy (ERT), often is applied
to replace the deficient enzyme and to restore the lost function. However, enhancing the en-
zyme activity to the muscle following ERT is relative insufficient, possibly due to the resistant
nature of muscle fibers to therapy [331, 332]. Matalon et al., reported that intravenous (i.v.)
or intraperitoneal (i.p.) administration of hyaluronidase (hyase) into mice prior to GAA treat-
ment, increased GAA activity into several muscles (heart, diaphragm, quadriceps) compared to
untreated mice [330]. Hyaluronidase pretreatment has also been shown to significantly increase
gene transfer/plasmid uptake efficiency in skeletal muscle [333]. This was also reported in a
recent study, where transfer of CAG-driven plasmid (AAV2/7 based p.CAG.apoE3) into tibialis
anterior muscles, pretreated with hyaluronidase, of apoE−/− mice significantly enhanced local
intramuscular expression of apoE3 [334]. It is therefore worthy to consider the approach of
pretreatment with hyaluronidase in future attempts to resolve/overcome the issues associated
with application of our targeted vectors and controls into the muscle.
Regardless of the success, the transduction efficiency reported with αCAR-targeted lentiviral
vector is lower compared to previously reported MN transduction resulting from intramuscular
delivery and retrograde transport of either RVG-B2c pseudotyped-EIAV. Efficient spinal cord
motor neuron transduction upon peripheral muscle administration of RVG-B2c pseudotyped
EIAV vectors to rat gastrocnemius muscle has been achieved [82]. Indeed, the specific targeting
of neuronal cells reported with rabies-G EIAV progressed these studies to lentiviral delivery
of therapeutic transgenes or RNAi in murine models of ALS and SMA which were proven to
be effective in ameliorating symptoms of these diseases [51, 165, 90]. Transduction reported
with these RVG-EIAV vectors resulted in stable and long term expression of either the reporter
or therapeutic transgene in the spinal cord (up to 12 months) [82, 316]. Contrary to these
studies, in the injections performed here, all vectors utilised (targeted and control ones) were
HIV based. Could therefore be suggested that EIAV might be superior to HIV as a lentiviral
vector system to be used in intramuscular applications? Is it it’s smaller size that might be
beneficial for neuronal uptake and retrograde transport? Nonetheless, no study involving direct
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in vivo comparison of EIAV and HIV based vectors, has been reported so far. In future studies
it would be useful to directly compare these two systems in intramuscular delivery experiments.
Intramuscular delivery has extensively been utilised in several studies for gene based treatment
of motor neuron diseases. It is an attractive, minimally invasive approach which allows access
to affected cells located in the spinal cord by targeting the peripheral sites of neuromuscular
synapse. Intramuscular delivery of viral vectors derived from adenoviruses and adeno-associated
viruses (AAVs) has also been used with varying degrees of success for MN gene transfer in animal
models of MN diseases [335, 336, 80, 337]. Kahn et al., generated adenoviral vectors encoding
genes for various neurotrophic factors and presented axonal transport in spinal cord motor
neurons following intramuscular injection [338]. Recently, Wang et al., injected AAV-GDNF
vectors into 4 limbs per rat, 2 gastrocnemius and 2 triceps brachii muscles for neuroprotec-
tive gene therapy in ALS mice [321]; in another AAV study combination of triceps brachii,
gastrocnemius and muscles along the dorsal trunk were injected for neurotrophic gene therapy
in ALS and SMA mice [322, 323]. Moreover, Kaspar et al, when injected adenoviral vectors
AAV vectors encoding EGFP or insulin-like growth factor 1 (IGF-1) into the hindlimb quadri-
ceps and intercostal mouse muscles they reported transduction of more than 400 MNs in the
spinal cord (with eGFP vector) while achieved retrograde viral delivery and neuroprotective
effect in ALS mice [80] (with IGF-1 AAV). Recently, it was shown that intramuscular injection
of self-complementary (sc) AAV9 vectors expressing survival motor neuron (SMN) into SMA
mice mediated widespread gene delivery to MNs along the whole spinal cord (not only to the
ones connected to the injected muscle) and decreased disease severity [339]. According to these
studies the therapeutic benefits of intramuscular AAV vector delivery are greater than the ones
reported so far with EIAV vectors, though non restricted to MN connected to the injected
muscle. However the reasons that favour retrograde delivery to spinal cord upon intramuscular
application of AAVs compared to LVs remain unidentified.
Intramuscular administration is particularly attractive for human gene therapy because it is
non-invasive and easily accessible, nonetheless it faces difficult challenges in translation to
humans. Most importantly the muscle volume of humans vastly exceeds that of the mouse
and rat, requiring vector diffusion across long distances to achieve uptake at the NMJ. Given
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the low transduction efficiency reported in this study upon intramuscular application of these
newly engineered vectors to mice and rats, it has to be considered that an application to
human muscles would require large amounts of lentiviral vectors in order to achieve similar
or improved results. In a human application it is definite that clinical grade, much purer and
more concentrated lentiviral preparations will be used. Considering the large amount of vector
required to achieve efficient uptake at the NMJ and spinal cord motor neuron transduction, it
is of great importance to carefully examine all possible implications and complications of the
muscle physiology and release into the bloodstream that are involved in application of large
volumes of lentiviral preparations. Upon intramuscular injections of these vectors in mice and
rat muscles it has been observed in this study, that a great percentage of the virions applied
remains at the site of application, transducing muscle cells. This should also be carefully
considered and refined prior to human application.
Even if the volume issue can be overcome, human motor axons are extremely long for a vector to
”travel” efficiently. Both AAV and LVs have been applied to non-human primates. Despite their
success at alleviating symptoms and extending survival in murine models of ALS and SMA, a
barrier to clinical use of RVG-B2c pseudotyped lentivirus vectors is the relative low efficiency
of transduction displayed by these vectors when applied in non-human primates (unpublished
data). Recently, intramuscular application of rAAVs has been translated to nonhuman primates
[340]. Indeed, intramuscular injection of rAAV2/6 into the gastrocnemius muscle of African
green monkeys resulted in transgene delivery and expression in transverse sections between L4
and S2 of the spinal cord. It was also claimed that in some spinal cord sections transduction
achieved was more than 50%. However, low level of vector copies was also detected in the
contralateral side as well as in both sides at the thoracic level, which likely represents vascular
spread of the vector, described in another study upon intramuscular injection into non-human
primates [341]. Once more the reasons that allow retrograde delivery and more efficient MN
transduction upon intramuscular application of AAV vectors compared to LVs in non-human
primates remains unidentified. It is possible that their small size favours their application
through this route, though transgene expression in long term should be investigated to evaluate
the efficiency of this system prior to clinical application to humans.
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Problems commonly associated with intramuscular administration of vectors (also observed in
this study), are either high binding affinity for muscle and limited binding affinity at synap-
tic terminals which subsequently reduce the neuronal uptake and retrograde transport. To
avoid this problem of muscle binding and uptake, injections have been attempted directly into
peripheral nervous system. Intraneural delivery into sciatic nerve was reported to result in sig-
nificant higher adenoviral gene expression in spinal cord neurons compared with intramuscular
or subcutaneous injections [342]. Moreover remote AAV gene delivery to adult rat spinal cord
was achieved upon peripheral nerve injection [343]. Distal delivery has also been attempted
with EIAV, where RVG-EIAV gene expression in cervical spinal cord motor neurons of SOD1
mice was reported upon brachial plexus injection. Moreover, effective gene transfer upon di-
rect spinal cord injections has been demonstrated with adenoviral NGF vectors in normal rats
[344], AAV2 vectors and also with a rabies G pseudotyped EIAV vector in SOD-1 mice [71].
However, direct intraspinal injection into humans remains a daunting challenge with serious
potential morbidity.
In the context of remote delivery for gene therapy of MNDs intramuscular administration of the
vehicle carrying the therapy is evaluated as the ideal approach. Considering all the limitations
posed and challenges faced, that block the progression of the available systems to clinic for
translation to humans, targeted gene therapy seems to be the ideal strategy. Restricting infec-
tion to specific cell populations aims at increasing the specificity and safety of gene therapy,
avoiding diffusion of vector to non-desirable sides. Surface engineering of vectors can confer the
desired specificity. On this front, for targeted gene therapy for MNDs, the optimal goal is to
enhance vector uptake at the neuromuscular junction through increased motor neuron affinity
and limiting muscle affinity. Results obtained from engineering and assessment of the three
novel targeted lentiviral vectors presented in this study, αp75NTR, αThy1.1 and finally αCAR
provide compelling evidence that transport to CNS can be achieved with surface engineered
vectors upon targeting the peripheral neuromuscular synapse.
Although targeting the NMJ with this strategy appears promising, it is vital to consider the
efficiency of targeting in animals and humans with neurodegenerative disorders. There is con-
siderable evidence linking disruption of neural intracellular transport system (NIT) to various
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common and rare neurodegenerative diseases of the CNS. Problems with the microtubular
tracks, energy for the ATP-dependent motors, or problems connecting the motors to their
cargo have all been implicated in peripheral and central neurologic disorders. Indeed, studies
on (SOD)1 mutant mouse models of ALS have shown that axonal transport is disrupted early
in the disease [345], possibly through multiple mechanisms including mitochondrial damage,
excitotoxicity, inflammation responses, cargo phosphorylation (reviewed in [346]). Moreover,
abnormal intermediate filaments or neurofilament accumulation in the perikaryon and axon of
motor neurons may cause strangulation of axonal transport and cell death (reviewed in [347]).
It is clear that axonal transport may impaired in MND, preventing adequate delivery in symp-
tomatic cases. Since the targeting method introduced in this study is based on NMJ receptor
targeting and remote delivery, involving migration by retrograde transport along the axons to
the cell body of MNs, it is of great importance to account the possibility that defects observed
in ALS may limit the efficiency of the targeted viruses utilised in this approach. Despite the
difficulties, many groups, as the ones already described earlier, have achieved successful deliv-
ery through this route. Enhanced uptake and retrograde transport achieved through improving
vector pseudotyping with approaches as the ones described here as well as treatment at a pre-
symptomatic phase can be advantageous overcoming possible barriers/defects associated with
the onset and progress of the disease.
As detailed presented, the targeting method described in the current study, relies on receptor
targeting via antibody mediated endocytosis. All three targeted vectors recognise and bind to
presynaptic receptors expressed at the NMJ. Upon binding, the target receptor is internalized
and the vector traffics, within an endosome, along the axon to reach the soma of the neuron
where it delivers the transgene of interest. It has to be considered that the target receptors are
naturally expressed at NMJ involved in activation and regulation of many cellular pathways
important for normal physiology. Therefore it can be argued that by targeting these receptors it
is also possible to induce their downregulation and potentially disturb the physiology. In other
words, targeting of these receptors may reduce their abundance at the NMJ and therefore
ablate their important role in maintenance of a functional neuromuscular synapse. Despite
these concerns, application of these vectors to muscles of wt mice and rats had no adverse
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effect in their physiology. In all in vivo experiments presented in this study animals behaved
normal with any deficits observed during the time being monitored (3-5 weeks).
It has to be underlined that the current study focused on retrograde transport to motor neurons
and did not include the sensory neuronal pathway. This might require further investigation in
the future, if absolute specificity to MNs needs to be confirmed. Moreover, variability reported
could partially be attributed to the strength of expression of the transgene itself, which is
regulated by the an upstream CMV promoter. Most studies using lentiviral vectors have used
powerful constitutive promoters such as phospoglycerate kinase 1 (PGK1), cytomegalovirus
(CMV), combination of chicken β-actin and CMV (CAG), and elongation factor 1 alpha (EF1α)
[348]. Direct comparison of the sequence of the CMV promoter utilised in the transfer vector
HIV-1 plasmid used in this study with the CMV promoter utilized in EIAV transfer plasmid
in the successful studies mentioned above [82, 90, 50, 51, 165] revealed an 500 bp difference
indicating that the full sequence of the enhancer upstream CMV was absent from HIV-1 plasmid
used in this study, which could partially explain the variability observed in transgene expression
within the same group of animals. Aiming to improve expression for future studies and in vivo
applications, full enhancer CMV promoter was generated and cloned into the HIV-1 transfer
vector plasmid utilised in the lab. αCAR-targeted vector and control vectors were produced
and intramuscularly administrated. Results obtained from first set of pilot experiments are
encouraging, suggesting that there is room for improvement of the efficiency of this novel
system.
10.6 Conclusion: a wealth of achievements.
In the present study, aiming to overcome the limitations of viral vectors used up to date, and to
offer a safe, efficient and non-invasive therapeutic strategy novel lentiviral vectors with tropism
to motor neurons (MNs) via the neuromuscular junction (NMJ) were developed.
Antibodies against presynaptic terminal receptors were cloned and incorporated on the lentiviral
surface to generate the αThy1.1, αp75NTR and αCAR targeted vectors.
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Novel surface engineered targeted lentiviral vectors were proven to recognise and specifically
enter CAR, Thy1.1, and p75NTR expressing cells respectively. The specificity of these targeted
vectors is determined by the antibody incorporated on their surface.
It was further shown that these vectors preferentially transduce motor neurons, when applied to
primary motor neuron cultures and present enhanced trafficking, transduction and specificity
for MNs. Utilizing a microfluidic culture model it was shown that all three targeted lentiviral
vectore undergo retrograde axonal trafficking in carriers associated with TeNT-Hc and p75NTR.
Finally it has been shown that in vivo intramuscular delivery of CAR-targeted lentiviral vector
to mouse tibialis anterior results in transduction of motor neurons in lumbar spinal cord. This is
the first ever demonstration of surface engineering conferring novel trafficking and transduction
characteristics to lentiviral vectors.
Overall, the results presented in this study indicate that these newly engineered targeted vectors
bear novel trafficking and transduction characteristics and specificity for MNs, superior to ones
observed with existing lentiviral vectors, which make them good candidates for non-invasive
CNS-targeted therapeutics in MN diseases.
10.7 Future Work
These newly engineered targeted lentiviral vectors have the potential to be used as tools for
non-invasive CNS therapeutics. Identification of CAR as a target molecule that can lead to
retrograde transport of lentiviral vectors and transduction of spinal cord MNs, is a novel finding
that can eventually lead to successful delivery of therapeutic factors to models of MNDs with
the ultimate goal of translation to humans. On this front several modifications can be applied
to our system in order to overcome challenges and barriers faced during the initial applications
and will allow us to fully refine and improve its targeting efficiency.
In the future it would be beneficial to refine intramuscular application of these vectors. Work
is planned to improve the injection process and overcome possible barriers with the goal to en-
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hance vector uptake at the neuromuscular junction via limiting muscle affinity. Future studies
will involve injection of αCAR targeted vectors and RVG-B2c-HIV into mouse tibialis anterior
pretreated with hyaloronidase (hyase) and direct comparison of these vectors in untreated mus-
cule. As hyaluronidase pretreatment was shown to significantly increase gene transfer/plasmid
uptake efficiency in skeletal muscle through degradation of the perineuronal proteoglycan that
form a ”perisynaptic barrier” [333].
Moreover, efforts will concentrate on further improving the quality and efficiency of our lentiviral
preparations. Currently, a human codon optimised version of gag/pol plasmid (289-pMD2-
LgpRRE) is extensively assessed in the lab in order to define the optimum plasmid ratios at
which the transfection process will result in higher titer lentiviral preparations. Incorporating in
our studies a codon optimised gag/pol will reduce the number of plasmids required for lentiviral
production, as transfection will be rev independent and achieve more efficient expression during
production in HEK 293T cells. Through this application we aim to limit the number of plasmid
involved in our 6 plasmid transfection required for production of targeted vectors aiming to
achieve targeted lentiviral preparations with higher percentage of fucntional particles.
Intramuscular application of the novel α CAR-targeted lentiviral vector presented in this study,
was the first proof of principle of surface engineering conferring novel trafficking and transduc-
tion characteristics to lentiviral vectors. Nonetheless application of this vectors was highly as-
sociated with variability observed in transgene expression between animals of the same group.
Since variability reported could partially be attributed to the strength of expression of the
transgene itself, which is regulated by the an upstream minimum CMV promoter, incorpora-
tion and assessment of more powerful promoters should be explored. Already, a CMV promoter
with full enhancer sequence has been cloned and lentiviral vectors ultilizing it have been pro-
duced. In vitro and in vivo experiments of direct comparison of the two promoters have already
revealed an improvement in expression levels. First set of pilot in vivo experiments, with vec-
tors utilizing the full enhancer, reported enhanced levels of expression and also a slight increase
in the number of transduced spinal cord MNs upon intramuscular injections. Future work is
planned to examine different promoters and combinations in order to identify the one that will
be utilized for further fucntional studies. Most studies using lentiviral vectors have used power-
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ful constitutive promoters such as phospoglycerate kinase 1 (PGK1), cytomegalovirus (CMV),
combination of chicken β-actin and CMV (CAG), and elongation factor 1 alpha (EF1α) [348].
In vitro experiments involving assessment and comparison of lentiviral vectors utilizing mini-
mum CMV, full CMV and CAG promoter are currently ongoing and results obtained will be
evaluated for selection of the promoter utilized in the final version of the αCAR vector applied
in in vivo efficacy studies in the animal model of ALS.
The ultimate goal of this study is to improve efficacy and safety of gene therapy achieved to
date for ALS utilizing these NMJ targeted vectors. On this front αCAR targeted vector will be
used further in in vivo efficacy studies in a mouse model for ALS. αCAR will be retrogradely
transported and integrated in the genome of MNs where it will express its therapeutic cargo.
This cargo will be composed of combination of the Insulin-like Growth Factor 1 (IGF-1), which
has been shown to be neuroprotective for MNs [80], with the neuroprotective chaperone heat
shock protein 70 (hsp70). Hsps may prevent MN toxicity by facilitating disease protein degra-
dation/sequetsration or by blocking inappropriate protein interactions but also by altering the
downstream signalling events that lead to neuronal dysfunction and cell death [349]. Hsp70 has
been shown to confer neuroprotection and insufficient availability of Hsp70 may contribute to
MN’s susceptibility to death in ALS mice. It has been demonstrated that recombinant human
Hsp70 (rhHsp70) when intraperitoneally injected at P50 until the endstage, in G93A mutant
SOD1 (G93A SOD1) mice was effective at delaying symptom onset, preserving motor function,
increasing lifespan and prolonging MN survival [350]. In the same study, interestingly, injected
rhHsp70 localized to skeletal muscle and was not readily detected in the CNS. Treatment with
rhHsp70 also resulted in an increased number of innervated neuromuscular junctions compared
with control tissue.
As these human cDNAs are rather small (0.6-2.2 kb) the total length of these constructs will
not exceed 7 kb which is well within the cloning capacity of the transfer vectors utilised (8-10
kb) and as such we do not anticipate reduction in titer or instability issues [316]. Human codon
optimised version of both IGF-1 and hsp70 are already prepared and ready to cloned into the
final HIV transfer vector. To achieve expression of both genes simultaneously instead of utilizing
bicistronic or multicistronic vectors we will use a self cleaving 2A peptide. 2A is small peptide
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first identified by Ryan et al., [351] in the foot-and-mouth disease virus (FMDV), a member of
the picornavirus. 2A is a good candidate to replace IRES elements used in multicistronic vectors
because of its small size and high cleavage efficiency between genes upstream and downstream
of the 2A peptide. The average length of 2A peptides is 1822 amino acids. The 2A peptide
that will be used to link this two genes is the T2A, Thoseaasigna virus 2A.
The G93A SOD-1 model of ALS [146] which are industry standard models of these diseases,
will be utilised in these studies and delivery will be performed by injecting in multiple muscles
including legs (targeting movement), diaphragm and intercostals (targeting breathing) and
face/ tongue (targeting bulbar function and thus feeding) as described in Azzouz et al., [51, 90].
Efficacy will be determined by examining the effect of therapy (pre- and at onset of symptoms
for SOD1 mice) on prolongation of survival and amelioration of the neuromuscular symptoms
using a battery of disease specific tests such as weight, rotarod and stride length.
On this front we envisage to design and test the ability of αCAR-targeted vector that could
ameliorate the disease phenotype of ALS mouse model and which could form the preclinical
proof of principle experiments for progression of this novel gene therapy approach to clinical
trials for motor neuron diseases.
Supplementary Material
Supplementary information is provided in the electronic copy that accompanies this thesis and
includes movies related to live imaging studies presented on Section 8.4:
• Supplementary Movie 1: αp75NTR undergoes retrograde trafficking in p75NTR
positive endosomes in microfluidic chambers. Rat primary motor neurons were
incubated with DiO labelled αp75NTR particles and anti-p75NTR-AF647. (a) Acquisition
series of vector trafficking, with tracking data added in ImageJ, (b) shows the same series
with p75NTR labelling.
• Supplementary Movie 2: αCAR undergoes retrograde trafficking in p75NTR
positive endosomes in microfluidic chambers. Rat primary motor neurons were
incubated with DiO labelled αCAR particles and anti-p75NTR-AF647. (a) Acquisition
series of vector trafficking, with tracking data added in ImageJ, (b) shows the same series
with p75NTR labelling.
• Supplementary Movie 3: αThy1.1 undergoes retrograde trafficking in p75NTR
positive endosomes in microfluidic chambers. Rat primary motor neurons were
incubated with DiO labelled αThy1.1 particles and anti-p75NTR-AF647. (a) Acquisition
series of vector trafficking, with tracking data added in ImageJ, (b) shows the same series
with p75NTR labelling.
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319
Figure A.1: pαCD20. cDNAs of human κ light chain constant region and the membrane bound human
IgG1 constant region were amplified and inserted upstream of human CMV and EF1α promoters,
respectively, in the pBudCE4.1 vector (Invitrogen). Light and heavy chain variable regions from the
murine anti-CD20 antibody were cloned and inserted upstream the corresponding constant regions.
The construct was generated by Yang et al [93]. Restrictions sites used for inserting the variable
regions upstream constant regions are indicated.
320 Appendix A.
Figure A.2: pIgαβ. cDNAs of human Igα and Igβ were cloned by [93] into the pBudCE4.1 vector to
yield pIgαβ. This plasmid is required for surface expression of antibodies.
321
Figure A.3: pSINmu. SINmu was generated by [93] by replacing ZZ domain with HA tag on the SIN
vector generated by [96]. This version of SIN was designated as SINmu.
322 Appendix A.
Figure A.4: pαThy1.1. Light and heavy chain variable regions from the murine anti-Thy1.1 (CD90)
antibody were cloned and inserted upstream the corresponding constant regions. Restrictions sites
used for inserting the variable regions upstream constant regions are indicated.
323
Figure A.5: pαp75NTR. Light and heavy chain variable regions from the murine anti-p75 (MC192)
antibody were cloned and inserted upstream the corresponding constant regions. Restrictions sites
used for inserting the variable regions upstream constant regions are indicated.
324 Appendix A.
Figure A.6: pαCAR. Light and heavy chain variable regions from the murine anti-CAR (RmcB)
antibody were cloned and inserted upstream the corresponding constant regions. Restrictions sites
used for inserting the variable regions upstream constant regions are indicated.
325
Figure A.7: ScCAR (RmcB).
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Figure A.8: Scp75NTR.
327
Figure A.9: 326-pRRLsincppt-CMV-EGFPWPRE.
328 Appendix A.
Figure A.10: 289-pMD2-LgpRRE.
329
Figure A.11: 288-pRSV-Rev.
330 Appendix A.
Figure A.12: pMD2-VSVG.
331
Table A.1: Sequence of primers used for sequencing final constructs pαThy1.1, pαp75NTR
and pαCAR, pαCD20, pSINmu and pIgαβ
Primer Sequence 5’- 3’
ie033CMVfw CAA ATG GGC GGT AGG CGT G
ie034CMVbw GAT CCT CAA TAC TTT GCT GAC AGT AA
ie035ConstantLOX7fw CTG TCA GCA AAG TAT TGA GGA TCC
ie036Constant Lbw GTG ATG ATG ACC GGT ATG CAT ATT C
ie037EEa1fw TCAAGCCTCAGACAGTGGTTC
ie038EEa1OX7bw GAG TGG TGC CTT GGC CCC A
ie039ConstantHOX7fw1 CCG GGA GAT CAT GAG GGT GT
ie040Constant Hbw1 TCAAGCCTCAGACAGTGGTTC
ie041Constant Hfw2 CCG TCA GTC TTC CTC TTC CCC
ie042Constant Hbw2 CAC CTG TGG TTC TCG GGG C
ie043CMV p75bw CGG GAA GAT GAA GAC AGA TGG T
ie044Constant Lp75fw GCA ACC TAT TAC TGT CAG CAC AG
ie045EEa1 Hp75bw TTG AGG TTG TTG ATC TGC AAA TAG G
ie046Constant Hp75fw 1 GTC TCC TCA GCC AAA ACG ACA
ie047Constant Hfw3 GCCCCGAGAACCACAGGTG
ie048Constant Hbw3 GAC CGA GGA GAG GGT TAG GG
ie049 CMV CD20bw TGC AGC CAC CGT ACG TTT CA
ie050 ConstantLCD20fw ACG TTC GGT GCT GGG ACC A
ie051 EEa1CD20bw GGT CCC TGT GCC CCA GAC AT
ie052ConstantHCD20fw1 GTC TAT TTC TGT GCA AGA GTG GTG
ie053 CMV Igbw TGCC ATT GTC CTC AAA CCG GAT
ie054 Igb fw1 AAG GGC CGC ATG GAA GAG T
ie055 Igb bw1 GCA TAT TCA GAT CCT CTT CTG AGA
ie055 Igb bw1 GCA TAT TCA GAT CCT CTT CTG AGA
ie056EEa1 Iga bw CGC ACG CGG AGG TAG GT
ie057 Iga fw1 GGT CCA GGA GGG CAA CGA G
ie058 Iga bw1 GGT TAG GGA TAG GCT TAC CTT CG
ie059 SINmu fw1(E3) CCT TGC AGA AGT TGG TCG TGA
ie060 SINmu bw1(E3) AGT ATG GTG GCA GTA CGA GCA
ie061 SINmu fw2(E2) TAT TGC GGT GCG GAT CGT C
ie062 SINmu bw2(E2) GTG ATG TAG CCT GCA GTT GTA G
ie063 SINmu fw3(E2) GGG ACG GGA AAA ATA TGA TCT ACC T
ie064 SINmu bw3(E2) TCC GAC GAT CCA TTC AGT GGT
ie065 SINmu fw4(E2) GGA GAC TAG GGG CAA ACC CG
ie066 SINmu bw4(6K) AGG CAG GCA GCA GGA GC
ie067 SINmu fw5(6K) CTG CTC CTG CTG CCT GC
ie068 SINmu bw5(E1) CAC GTA CAC ATC TAG GAA ACT GGT
ie069 SINmu fw6(E1) GCG ATT AAG GTG CAC ACT GC
ie070 SINmu bw6(E1) ATG TCC TGA TAA AGG CAG CGT T
ie071 SINmu fw7(E1) CCGAGCGGTGGACTGTTCA
ie072 SINmu bw7(E1) GCA TTA ACC CTC ACT AAA GGG AAG
